{
    "1": {
        "title": "Full name",
        "short_title": "Full name",
        "type": "FreeText",
        "coefficient": 0,
        "tags": [
            "Section 0"
        ],
        "possible_answers": {},
        "actual_answers": {}
    },
    "2": {
        "title": "Email",
        "short_title": "Email",
        "type": "FreeText",
        "coefficient": 0,
        "tags": [
            "Section 0"
        ],
        "possible_answers": {},
        "actual_answers": {}
    },
    "3": {
        "title": "Country",
        "short_title": "Country",
        "type": "SingleChoice",
        "coefficient": 0,
        "tags": [
            "Section 0"
        ],
        "possible_answers": {
            "Austria": 0,
            "Belgium": 0,
            "Bulgaria": 0,
            "Croatia": 0,
            "Cyprus": 0,
            "Czechia": 0,
            "Denmark": 0,
            "Estonia": 0,
            "Finland": 0,
            "France": 0,
            "Germany": 0,
            "Greece": 0,
            "Hungary": 0,
            "Ireland": 0,
            "Italy": 0,
            "Latvia": 0,
            "Lithuania": 0,
            "Luxembourg": 0,
            "Malta": 0,
            "Netherlands": 0,
            "Poland": 0,
            "Portugal": 0,
            "Romania": 0,
            "Slovak Republic": 0,
            "Slovenia": 0,
            "Spain": 0,
            "Sweden": 0,
            "Norway": 0,
            "Ukraine": 0,
            "Iceland": 0
        },
        "actual_answers": {
            "Spain": "Spain",
            "Austria": "Austria",
            "Lithuania": "Lithuania",
            "Croatia": "Croatia",
            "Netherlands": "Netherlands",
            "Ireland": "Ireland",
            "Germany": "Germany",
            "Poland": "Poland",
            "Italy": "Italy",
            "Greece": "Greece",
            "France": "France",
            "Czechia": "Czechia",
            "Belgium": "Belgium",
            "Hungary": "Hungary",
            "Finland": "Finland",
            "Luxembourg": "Luxembourg",
            "Malta": "Malta",
            "Portugal": "Portugal",
            "Norway": "Norway",
            "Slovenia": "Slovenia",
            "Estonia": "Estonia",
            "Sweden": "Sweden",
            "Ukraine": "Ukraine",
            "Slovak Republic": "Slovak Republic",
            "Denmark": "Denmark",
            "Latvia": "Latvia",
            "Iceland": "Iceland",
            "Bulgaria": "Bulgaria"
        }
    },
    "4": {
        "title": "Institution",
        "short_title": "Institution",
        "type": "FreeText",
        "coefficient": 0,
        "tags": [
            "Section 0"
        ],
        "possible_answers": {},
        "actual_answers": {}
    },
    "5": {
        "title": "Type of institution",
        "short_title": "Type of institution",
        "type": "SingleChoice",
        "coefficient": 0,
        "tags": [
            "Section 0"
        ],
        "possible_answers": {
            "Ministry": 0,
            "National Public Health Agency": 0,
            "National reference/expert laboratory": 0,
            "Other": 0
        },
        "actual_answers": {}
    },
    "6.1": {
        "title": "Is there national guidance for empiric antibiotic treatment when the following infections are suspected? : Bloodstream infection",
        "short_title": "National guidance for empiric treatment - bloodstream infection?",
        "type": "SingleChoice",
        "coefficient": 0.167,
        "tags": [
            "National guidance",
            "Blood"
        ],
        "possible_answers": {
            "Yes": 1,
            "No": 0,
            "Do not know": "null"
        },
        "actual_answers": {
            "Spain": "No",
            "Austria": "No",
            "Lithuania": "No",
            "Croatia": "No",
            "Netherlands": "Yes",
            "Ireland": "No",
            "Germany": "Yes",
            "Poland": "Yes",
            "Italy": "Yes",
            "Greece": "Yes",
            "France": "Yes",
            "Czechia": "No",
            "Belgium": "Yes",
            "Hungary": "No",
            "Finland": "No",
            "Luxembourg": "Yes",
            "Malta": "Yes",
            "Portugal": "Yes",
            "Norway": "Yes",
            "Slovenia": "No",
            "Estonia": "Yes",
            "Sweden": "Yes",
            "Ukraine": "No",
            "Slovak Republic": "Do not know",
            "Denmark": "Yes",
            "Latvia": "Yes",
            "Iceland": "Yes",
            "Bulgaria": "Yes"
        }
    },
    "6.2": {
        "title": "Is there national guidance for empiric antibiotic treatment when the following infections are suspected? : Uncomplicated UTI",
        "short_title": "National guidance for empiric treatment - uncomplicated UTI?",
        "type": "SingleChoice",
        "coefficient": 0.167,
        "tags": [
            "National guidance",
            "Urine"
        ],
        "possible_answers": {
            "Yes": 1,
            "No": 0,
            "Do not know": "null"
        },
        "actual_answers": {
            "Spain": "Yes",
            "Austria": "No",
            "Lithuania": "Yes",
            "Croatia": "Yes",
            "Netherlands": "Yes",
            "Ireland": "Yes",
            "Germany": "Yes",
            "Poland": "Yes",
            "Italy": "Yes",
            "Greece": "Yes",
            "France": "Yes",
            "Czechia": "Yes",
            "Belgium": "Yes",
            "Hungary": "No",
            "Finland": "Yes",
            "Luxembourg": "Yes",
            "Malta": "Yes",
            "Portugal": "Yes",
            "Norway": "Yes",
            "Slovenia": "No",
            "Estonia": "Yes",
            "Sweden": "Yes",
            "Ukraine": "No",
            "Slovak Republic": "Do not know",
            "Denmark": "Yes",
            "Latvia": "Yes",
            "Iceland": "Yes",
            "Bulgaria": "Yes"
        }
    },
    "6.3": {
        "title": "Is there national guidance for empiric antibiotic treatment when the following infections are suspected? : Complicated UTI",
        "short_title": "National guidance for empiric treatment - complicated UTI?",
        "type": "SingleChoice",
        "coefficient": 0.167,
        "tags": [
            "National guidance",
            "Urine"
        ],
        "possible_answers": {
            "Yes": 1,
            "No": 0,
            "Do not know": "null"
        },
        "actual_answers": {
            "Spain": "Yes",
            "Austria": "No",
            "Lithuania": "Yes",
            "Croatia": "Yes",
            "Netherlands": "Yes",
            "Ireland": "No",
            "Germany": "Yes",
            "Poland": "Yes",
            "Italy": "Yes",
            "Greece": "Yes",
            "France": "Yes",
            "Czechia": "Yes",
            "Belgium": "Yes",
            "Hungary": "No",
            "Finland": "Yes",
            "Luxembourg": "Yes",
            "Malta": "Yes",
            "Portugal": "Yes",
            "Norway": "Yes",
            "Slovenia": "No",
            "Estonia": "Yes",
            "Sweden": "Yes",
            "Ukraine": "No",
            "Slovak Republic": "Do not know",
            "Denmark": "Yes",
            "Latvia": "Yes",
            "Iceland": "Yes",
            "Bulgaria": "Yes"
        }
    },
    "6.4": {
        "title": "Is there national guidance for empiric antibiotic treatment when the following infections are suspected? : Upper respiratory tract infection",
        "short_title": "National guidance for empiric treatment - upper respiratory tract infection?",
        "type": "SingleChoice",
        "coefficient": 0.167,
        "tags": [
            "National guidance",
            "Respiratory tract"
        ],
        "possible_answers": {
            "Yes": 1,
            "No": 0,
            "Do not know": "null"
        },
        "actual_answers": {
            "Spain": "Yes",
            "Austria": "No",
            "Lithuania": "Yes",
            "Croatia": "Yes",
            "Netherlands": "Yes",
            "Ireland": "Yes",
            "Germany": "Yes",
            "Poland": "Yes",
            "Italy": "Yes",
            "Greece": "Yes",
            "France": "Yes",
            "Czechia": "Yes",
            "Belgium": "Yes",
            "Hungary": "No",
            "Finland": "Yes",
            "Luxembourg": "Yes",
            "Malta": "Yes",
            "Portugal": "Yes",
            "Norway": "Yes",
            "Slovenia": "No",
            "Estonia": "Yes",
            "Sweden": "Yes",
            "Ukraine": "No",
            "Slovak Republic": "Do not know",
            "Denmark": "No",
            "Latvia": "Yes",
            "Iceland": "Yes",
            "Bulgaria": "Yes"
        }
    },
    "6.5": {
        "title": "Is there national guidance for empiric antibiotic treatment when the following infections are suspected? : Lower respiratory tract infection",
        "short_title": "National guidance for empiric treatment - lower respiratory tract infection?",
        "type": "SingleChoice",
        "coefficient": 0.167,
        "tags": [
            "National guidance",
            "Respiratory tract"
        ],
        "possible_answers": {
            "Yes": 1,
            "No": 0,
            "Do not know": "null"
        },
        "actual_answers": {
            "Spain": "Yes",
            "Austria": "No",
            "Lithuania": "Yes",
            "Croatia": "Yes",
            "Netherlands": "Yes",
            "Ireland": "Yes",
            "Germany": "Yes",
            "Poland": "Yes",
            "Italy": "Yes",
            "Greece": "Yes",
            "France": "Yes",
            "Czechia": "Yes",
            "Belgium": "Yes",
            "Hungary": "No",
            "Finland": "Yes",
            "Luxembourg": "Yes",
            "Malta": "Yes",
            "Portugal": "Yes",
            "Norway": "Yes",
            "Slovenia": "Yes",
            "Estonia": "Yes",
            "Sweden": "Yes",
            "Ukraine": "No",
            "Slovak Republic": "Do not know",
            "Denmark": "Yes",
            "Latvia": "Yes",
            "Iceland": "Yes",
            "Bulgaria": "Yes"
        }
    },
    "6.6": {
        "title": "Is there national guidance for empiric antibiotic treatment when the following infections are suspected? : Skin and soft tissue infection",
        "short_title": "National guidance for empiric treatment - soft tissue/skin infection?",
        "type": "SingleChoice",
        "coefficient": 0.167,
        "tags": [
            "National guidance",
            "Soft tissue"
        ],
        "possible_answers": {
            "Yes": 1,
            "No": 0,
            "Do not know": "null"
        },
        "actual_answers": {
            "Spain": "Yes",
            "Austria": "No",
            "Lithuania": "Yes",
            "Croatia": "No",
            "Netherlands": "Yes",
            "Ireland": "Yes",
            "Germany": "Yes",
            "Poland": "Yes",
            "Italy": "Yes",
            "Greece": "Yes",
            "France": "Yes",
            "Czechia": "Yes",
            "Belgium": "Yes",
            "Hungary": "No",
            "Finland": "Yes",
            "Luxembourg": "Yes",
            "Malta": "Yes",
            "Portugal": "Yes",
            "Norway": "Yes",
            "Slovenia": "No",
            "Estonia": "No",
            "Sweden": "Yes",
            "Ukraine": "No",
            "Slovak Republic": "Do not know",
            "Denmark": "Yes",
            "Latvia": "Yes",
            "Iceland": "Yes",
            "Bulgaria": "Yes"
        }
    },
    "7": {
        "title": "You answered \"yes national guidance for empiric antibiotic treatment\" for one or several infections in the question above. Which laboratory AST data are generally used when writing and/or reviewing the national treatment guidance? (Tick all that apply)",
        "short_title": "Laboratory AST data generally used for national treatment guidance",
        "type": "MultipleChoice",
        "coefficient": 1,
        "tags": [
            "National guidance"
        ],
        "possible_answers": {
            "Results from routine AST available in the national AMR surveillance system.": 1,
            "Results from the extended AST available in the national AMR surveillance system.": 1,
            "Results from AST data generated at the national reference/expert laboratory.": 1,
            "International guidance (e.g., European association of urology).": 0.5,
            "International AST data.": 0.5,
            "No AST data used; guidance based on other information.": 0.2,
            "Do not know.": "null",
            "Other": 0.2
        },
        "actual_answers": {
            "Spain": [
                "Other"
            ],
            "Austria": [
                ""
            ],
            "Lithuania": [
                "Results from AST data generated at the national reference/expert laboratory."
            ],
            "Croatia": [
                "Results from routine AST available in the national AMR surveillance system.",
                "Results from the extended AST available in the national AMR surveillance system.",
                "Results from AST data generated at the national reference/expert laboratory.",
                "International guidance (e.g., European association of urology)."
            ],
            "Netherlands": [
                "Results from routine AST available in the national AMR surveillance system.",
                "Results from the extended AST available in the national AMR surveillance system.",
                "Results from AST data generated at the national reference/expert laboratory.",
                "International guidance (e.g., European association of urology)."
            ],
            "Ireland": [
                "Results from routine AST available in the national AMR surveillance system.",
                "Results from AST data generated at the national reference/expert laboratory.",
                "International guidance (e.g., European association of urology).",
                "International AST data."
            ],
            "Germany": [
                "Results from routine AST available in the national AMR surveillance system.",
                "Results from the extended AST available in the national AMR surveillance system.",
                "Results from AST data generated at the national reference/expert laboratory.",
                "International guidance (e.g., European association of urology).",
                "International AST data.",
                "No AST data used; guidance based on other information."
            ],
            "Poland": [
                "Results from AST data generated at the national reference/expert laboratory.",
                "International guidance (e.g., European association of urology).",
                "International AST data."
            ],
            "Italy": [
                "Results from routine AST available in the national AMR surveillance system.",
                "International guidance (e.g., European association of urology).",
                "International AST data."
            ],
            "Greece": [
                "International AST data."
            ],
            "France": [
                "Results from routine AST available in the national AMR surveillance system."
            ],
            "Czechia": [
                "Results from routine AST available in the national AMR surveillance system.",
                "Results from AST data generated at the national reference/expert laboratory.",
                "International guidance (e.g., European association of urology)."
            ],
            "Belgium": [
                "Results from AST data generated at the national reference/expert laboratory.",
                "International guidance (e.g., European association of urology).",
                "Other"
            ],
            "Hungary": [
                ""
            ],
            "Finland": [
                "Results from routine AST available in the national AMR surveillance system.",
                "Results from the extended AST available in the national AMR surveillance system.",
                "Results from AST data generated at the national reference/expert laboratory."
            ],
            "Luxembourg": [
                "No AST data used; guidance based on other information."
            ],
            "Malta": [
                "Results from AST data generated at the national reference/expert laboratory."
            ],
            "Portugal": [
                "Results from routine AST available in the national AMR surveillance system.",
                "Results from the extended AST available in the national AMR surveillance system.",
                "Results from AST data generated at the national reference/expert laboratory.",
                "International guidance (e.g., European association of urology).",
                "International AST data."
            ],
            "Norway": [
                "Results from routine AST available in the national AMR surveillance system.",
                "Results from the extended AST available in the national AMR surveillance system.",
                "Results from AST data generated at the national reference/expert laboratory."
            ],
            "Slovenia": [
                "Results from routine AST available in the national AMR surveillance system."
            ],
            "Estonia": [
                "Results from routine AST available in the national AMR surveillance system.",
                "Results from the extended AST available in the national AMR surveillance system.",
                "International guidance (e.g., European association of urology).",
                "International AST data."
            ],
            "Sweden": [
                "Results from routine AST available in the national AMR surveillance system.",
                "Results from AST data generated at the national reference/expert laboratory.",
                "International guidance (e.g., European association of urology).",
                "Do not know."
            ],
            "Ukraine": [
                ""
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Results from routine AST available in the national AMR surveillance system.",
                "Results from the extended AST available in the national AMR surveillance system.",
                "Results from AST data generated at the national reference/expert laboratory.",
                "International guidance (e.g., European association of urology)."
            ],
            "Latvia": [
                "Results from AST data generated at the national reference/expert laboratory.",
                "Other"
            ],
            "Iceland": [
                "Results from routine AST available in the national AMR surveillance system.",
                "Results from the extended AST available in the national AMR surveillance system.",
                "Results from AST data generated at the national reference/expert laboratory.",
                "International guidance (e.g., European association of urology).",
                "International AST data."
            ],
            "Bulgaria": [
                "Results from routine AST available in the national AMR surveillance system."
            ]
        }
    },
    "8": {
        "title": "You answered \"no national guidance for empiric antibiotic treatment\" for one or several infections in the question above. Who or which institution(s) guide(s) and determine(s) empiric antibiotic treatment? (Tick all that apply)",
        "short_title": "If no national guidance, which institution(s) guide(s) and determine(s) empiric treatment? ",
        "type": "MultipleChoice",
        "coefficient": 1,
        "tags": [
            "National guidance"
        ],
        "possible_answers": {
            "Regional and/or local guidance (including two or more institutions).": 1,
            "The healthcare facility that treats the patient.": 0.5,
            "The treating physician(s).": 0.2,
            "Clinical microbiologist(s) at the healthcare facility/laboratory that treats the patient.": 0.2,
            "Do not know.": "null",
            "Other.": 0.2
        },
        "actual_answers": {
            "Spain": [
                "The healthcare facility that treats the patient."
            ],
            "Austria": [
                "The healthcare facility that treats the patient.",
                "The treating physician(s)."
            ],
            "Lithuania": [
                "The healthcare facility that treats the patient."
            ],
            "Croatia": [
                "Regional and/or local guidance (including two or more institutions).",
                "The healthcare facility that treats the patient.",
                "The treating physician(s).",
                "Clinical microbiologist(s) at the healthcare facility/laboratory that treats the patient.",
                "Other."
            ],
            "Netherlands": [
                ""
            ],
            "Ireland": [
                "Regional and/or local guidance (including two or more institutions)."
            ],
            "Germany": [
                ""
            ],
            "Poland": [
                ""
            ],
            "Italy": [
                ""
            ],
            "Greece": [
                ""
            ],
            "France": [
                ""
            ],
            "Czechia": [
                "Regional and/or local guidance (including two or more institutions).",
                "The treating physician(s).",
                "Clinical microbiologist(s) at the healthcare facility/laboratory that treats the patient."
            ],
            "Belgium": [
                ""
            ],
            "Hungary": [
                "The healthcare facility that treats the patient.",
                "The treating physician(s)."
            ],
            "Finland": [
                "Regional and/or local guidance (including two or more institutions).",
                "The healthcare facility that treats the patient.",
                "The treating physician(s)."
            ],
            "Luxembourg": [
                ""
            ],
            "Malta": [
                ""
            ],
            "Portugal": [
                ""
            ],
            "Norway": [
                ""
            ],
            "Slovenia": [
                "Regional and/or local guidance (including two or more institutions).",
                "The healthcare facility that treats the patient."
            ],
            "Estonia": [
                "The healthcare facility that treats the patient.",
                "The treating physician(s)."
            ],
            "Sweden": [
                ""
            ],
            "Ukraine": [
                "The healthcare facility that treats the patient.",
                "The treating physician(s).",
                "Clinical microbiologist(s) at the healthcare facility/laboratory that treats the patient."
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Regional and/or local guidance (including two or more institutions).",
                "The treating physician(s).",
                "Clinical microbiologist(s) at the healthcare facility/laboratory that treats the patient."
            ],
            "Latvia": [
                ""
            ],
            "Iceland": [
                ""
            ],
            "Bulgaria": [
                ""
            ]
        }
    },
    "9.1": {
        "title": "Is there national guidance on when to take samples for microbiological cultures and other analysis for the following suspected and/or confirmed infections? : Bloodstream infection",
        "short_title": "National guidance for sampling suspected/confirmed bloodstream infections?",
        "type": "SingleChoice",
        "coefficient": 0.167,
        "tags": [
            "National guidance",
            "Blood"
        ],
        "possible_answers": {
            "Yes": 1,
            "No": 0,
            "Do not know": "null"
        },
        "actual_answers": {
            "Spain": "Do not know",
            "Austria": "No",
            "Lithuania": "No",
            "Croatia": "Yes",
            "Netherlands": "Yes",
            "Ireland": "Yes",
            "Germany": "Yes",
            "Poland": "Yes",
            "Italy": "Yes",
            "Greece": "Yes",
            "France": "Yes",
            "Czechia": "Yes",
            "Belgium": "Yes",
            "Hungary": "No",
            "Finland": "No",
            "Luxembourg": "No",
            "Malta": "Yes",
            "Portugal": "Yes",
            "Norway": "Yes",
            "Slovenia": "Do not know",
            "Estonia": "Yes",
            "Sweden": "Yes",
            "Ukraine": "Yes",
            "Slovak Republic": "Do not know",
            "Denmark": "Yes",
            "Latvia": "Yes",
            "Iceland": "Yes",
            "Bulgaria": "No"
        }
    },
    "9.2": {
        "title": "Is there national guidance on when to take samples for microbiological cultures and other analysis for the following suspected and/or confirmed infections? : Uncomplicated UTI",
        "short_title": "National guidance for sampling suspected/confirmed uncomplicated UTI?",
        "type": "SingleChoice",
        "coefficient": 0.167,
        "tags": [
            "National guidance",
            "Urine"
        ],
        "possible_answers": {
            "Yes": 1,
            "No": 0,
            "Do not know": "null"
        },
        "actual_answers": {
            "Spain": "Yes",
            "Austria": "No",
            "Lithuania": "No",
            "Croatia": "Yes",
            "Netherlands": "Yes",
            "Ireland": "No",
            "Germany": "Yes",
            "Poland": "Yes",
            "Italy": "Yes",
            "Greece": "Yes",
            "France": "Yes",
            "Czechia": "Yes",
            "Belgium": "Yes",
            "Hungary": "No",
            "Finland": "Yes",
            "Luxembourg": "No",
            "Malta": "Yes",
            "Portugal": "Yes",
            "Norway": "Yes",
            "Slovenia": "Do not know",
            "Estonia": "Yes",
            "Sweden": "Yes",
            "Ukraine": "No",
            "Slovak Republic": "Do not know",
            "Denmark": "No",
            "Latvia": "No",
            "Iceland": "Yes",
            "Bulgaria": "No"
        }
    },
    "9.3": {
        "title": "Is there national guidance on when to take samples for microbiological cultures and other analysis for the following suspected and/or confirmed infections? : Complicated UTI",
        "short_title": "National guidance for sampling suspected/confirmed complicated UTI?",
        "type": "SingleChoice",
        "coefficient": 0.167,
        "tags": [
            "National guidance",
            "Urine"
        ],
        "possible_answers": {
            "Yes": 1,
            "No": 0,
            "Do not know": "null"
        },
        "actual_answers": {
            "Spain": "Yes",
            "Austria": "No",
            "Lithuania": "No",
            "Croatia": "Yes",
            "Netherlands": "Yes",
            "Ireland": "No",
            "Germany": "Yes",
            "Poland": "Yes",
            "Italy": "Yes",
            "Greece": "Yes",
            "France": "Yes",
            "Czechia": "Yes",
            "Belgium": "Yes",
            "Hungary": "No",
            "Finland": "Yes",
            "Luxembourg": "No",
            "Malta": "Yes",
            "Portugal": "Yes",
            "Norway": "Yes",
            "Slovenia": "Do not know",
            "Estonia": "Yes",
            "Sweden": "Yes",
            "Ukraine": "No",
            "Slovak Republic": "Do not know",
            "Denmark": "No",
            "Latvia": "No",
            "Iceland": "Yes",
            "Bulgaria": "No"
        }
    },
    "9.4": {
        "title": "Is there national guidance on when to take samples for microbiological cultures and other analysis for the following suspected and/or confirmed infections? : Upper respiratory tract infection",
        "short_title": "National guidance for sampling suspected/confirmed upper respiratory tract infection?",
        "type": "SingleChoice",
        "coefficient": 0.167,
        "tags": [
            "National guidance",
            "Respiratory tract"
        ],
        "possible_answers": {
            "Yes": 1,
            "No": 0,
            "Do not know": "null"
        },
        "actual_answers": {
            "Spain": "Yes",
            "Austria": "No",
            "Lithuania": "No",
            "Croatia": "Yes",
            "Netherlands": "Yes",
            "Ireland": "No",
            "Germany": "Yes",
            "Poland": "Yes",
            "Italy": "Yes",
            "Greece": "Yes",
            "France": "Yes",
            "Czechia": "Yes",
            "Belgium": "No",
            "Hungary": "No",
            "Finland": "Yes",
            "Luxembourg": "No",
            "Malta": "No",
            "Portugal": "Yes",
            "Norway": "Yes",
            "Slovenia": "Do not know",
            "Estonia": "Yes",
            "Sweden": "Yes",
            "Ukraine": "No",
            "Slovak Republic": "Do not know",
            "Denmark": "No",
            "Latvia": "No",
            "Iceland": "Yes",
            "Bulgaria": "No"
        }
    },
    "9.5": {
        "title": "Is there national guidance on when to take samples for microbiological cultures and other analysis for the following suspected and/or confirmed infections? : Lower respiratory tract infection",
        "short_title": "National guidance for sampling suspected/confirmed lower respiratory tract infection?",
        "type": "SingleChoice",
        "coefficient": 0.167,
        "tags": [
            "National guidance",
            "Respiratory tract"
        ],
        "possible_answers": {
            "Yes": 1,
            "No": 0,
            "Do not know": "null"
        },
        "actual_answers": {
            "Spain": "Yes",
            "Austria": "No",
            "Lithuania": "No",
            "Croatia": "Yes",
            "Netherlands": "Yes",
            "Ireland": "No",
            "Germany": "Yes",
            "Poland": "Yes",
            "Italy": "Yes",
            "Greece": "Yes",
            "France": "Yes",
            "Czechia": "Yes",
            "Belgium": "Yes",
            "Hungary": "No",
            "Finland": "Yes",
            "Luxembourg": "No",
            "Malta": "No",
            "Portugal": "Yes",
            "Norway": "Yes",
            "Slovenia": "Do not know",
            "Estonia": "Yes",
            "Sweden": "Yes",
            "Ukraine": "No",
            "Slovak Republic": "Do not know",
            "Denmark": "Yes",
            "Latvia": "No",
            "Iceland": "Yes",
            "Bulgaria": "No"
        }
    },
    "9.6": {
        "title": "Is there national guidance on when to take samples for microbiological cultures and other analysis for the following suspected and/or confirmed infections? : Skin and soft tissue infection",
        "short_title": "National guidance for sampling suspected/confirmed soft tissue/skin infection?",
        "type": "SingleChoice",
        "coefficient": 0.167,
        "tags": [
            "National guidance",
            "Soft tissue"
        ],
        "possible_answers": {
            "Yes": 1,
            "No": 0,
            "Do not know": "null"
        },
        "actual_answers": {
            "Spain": "Yes",
            "Austria": "No",
            "Lithuania": "No",
            "Croatia": "No",
            "Netherlands": "Yes",
            "Ireland": "No",
            "Germany": "Yes",
            "Poland": "Yes",
            "Italy": "Yes",
            "Greece": "Yes",
            "France": "Yes",
            "Czechia": "Yes",
            "Belgium": "Yes",
            "Hungary": "No",
            "Finland": "Yes",
            "Luxembourg": "No",
            "Malta": "No",
            "Portugal": "Yes",
            "Norway": "Yes",
            "Slovenia": "Do not know",
            "Estonia": "No",
            "Sweden": "Yes",
            "Ukraine": "Yes",
            "Slovak Republic": "Do not know",
            "Denmark": "Yes",
            "Latvia": "No",
            "Iceland": "Yes",
            "Bulgaria": "No"
        }
    },
    "10": {
        "title": "You answered \u201cno national guidance on when to take samples for microbiological cultures\u201d for one or several infections in the question above: Who or which institution(s) guide(s) and determine(s) when a sample should be taken for microbiological cultures? (Tick all that apply)",
        "short_title": "If no national guidance, which institution(s) guide(s) and determine(s) sampling?",
        "type": "MultipleChoice",
        "coefficient": 1,
        "tags": [
            "National guidance"
        ],
        "possible_answers": {
            "Regional and/or local guidance (including two or more institutions).": 1,
            "Guidance at each individual healthcare facility.": 0.5,
            "The treating physician(s).": 0.2,
            "Do not know.": "null",
            "Other.": 0.2
        },
        "actual_answers": {
            "Spain": [
                ""
            ],
            "Austria": [
                "Guidance at each individual healthcare facility.",
                "The treating physician(s)."
            ],
            "Lithuania": [
                "Guidance at each individual healthcare facility."
            ],
            "Croatia": [
                "Regional and/or local guidance (including two or more institutions).",
                "Guidance at each individual healthcare facility.",
                "The treating physician(s).",
                "Other."
            ],
            "Netherlands": [
                ""
            ],
            "Ireland": [
                "The treating physician(s)."
            ],
            "Germany": [
                ""
            ],
            "Poland": [
                ""
            ],
            "Italy": [
                ""
            ],
            "Greece": [
                ""
            ],
            "France": [
                ""
            ],
            "Czechia": [
                ""
            ],
            "Belgium": [
                "Regional and/or local guidance (including two or more institutions).",
                "Guidance at each individual healthcare facility.",
                "The treating physician(s)."
            ],
            "Hungary": [
                "Guidance at each individual healthcare facility.",
                "The treating physician(s)."
            ],
            "Finland": [
                "Regional and/or local guidance (including two or more institutions).",
                "Guidance at each individual healthcare facility.",
                "The treating physician(s)."
            ],
            "Luxembourg": [
                "Regional and/or local guidance (including two or more institutions)."
            ],
            "Malta": [
                "Guidance at each individual healthcare facility.",
                "The treating physician(s)."
            ],
            "Portugal": [
                ""
            ],
            "Norway": [
                ""
            ],
            "Slovenia": [
                ""
            ],
            "Estonia": [
                "Guidance at each individual healthcare facility.",
                "The treating physician(s)."
            ],
            "Sweden": [
                ""
            ],
            "Ukraine": [
                "The treating physician(s)."
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Regional and/or local guidance (including two or more institutions).",
                "The treating physician(s)."
            ],
            "Latvia": [
                "Regional and/or local guidance (including two or more institutions)."
            ],
            "Iceland": [
                ""
            ],
            "Bulgaria": [
                "Guidance at each individual healthcare facility."
            ]
        }
    },
    "11": {
        "title": "Is there national guidance outlining which antibiotics to include as a minimum in the routine AST?See list of all included pathogens in the introduction.",
        "short_title": "National guidance outlining antibiotics to include as minimum in routine AST? ",
        "type": "SingleChoice",
        "coefficient": 1,
        "tags": [
            "National guidance"
        ],
        "possible_answers": {
            "Yes, national guidance in place for all included pathogens (excluding C. difficile).": 1,
            "Yes, national guidance in place for some of the included pathogens.": 0.7,
            "No national guidance in place but it is currently being developed.": 0.3,
            "No national guidance in place for any included pathogens": 0
        },
        "actual_answers": {
            "Spain": "Yes, national guidance in place for some of the included pathogens.",
            "Austria": "No national guidance in place for any included pathogens",
            "Lithuania": "No national guidance in place for any included pathogens",
            "Croatia": "Yes, national guidance in place for all included pathogens (excluding C. difficile).",
            "Netherlands": "No national guidance in place for any included pathogens",
            "Ireland": "No national guidance in place for any included pathogens",
            "Germany": "No national guidance in place for any included pathogens",
            "Poland": "Yes, national guidance in place for all included pathogens (excluding C. difficile).",
            "Italy": "Yes, national guidance in place for all included pathogens (excluding C. difficile).",
            "Greece": "Yes, national guidance in place for all included pathogens (excluding C. difficile).",
            "France": "Yes, national guidance in place for all included pathogens (excluding C. difficile).",
            "Czechia": "No national guidance in place for any included pathogens",
            "Belgium": "Yes, national guidance in place for some of the included pathogens.",
            "Hungary": "Yes, national guidance in place for all included pathogens (excluding C. difficile).",
            "Finland": "No national guidance in place for any included pathogens",
            "Luxembourg": "No national guidance in place for any included pathogens",
            "Malta": "No national guidance in place for any included pathogens",
            "Portugal": "Yes, national guidance in place for all included pathogens (excluding C. difficile).",
            "Norway": "Yes, national guidance in place for all included pathogens (excluding C. difficile).",
            "Slovenia": "Yes, national guidance in place for all included pathogens (excluding C. difficile).",
            "Estonia": "Yes, national guidance in place for all included pathogens (excluding C. difficile).",
            "Sweden": "Yes, national guidance in place for all included pathogens (excluding C. difficile).",
            "Ukraine": "Yes, national guidance in place for all included pathogens (excluding C. difficile).",
            "Slovak Republic": "No national guidance in place for any included pathogens",
            "Denmark": "No national guidance in place for any included pathogens",
            "Latvia": "Yes, national guidance in place for some of the included pathogens.",
            "Iceland": "No national guidance in place for any included pathogens",
            "Bulgaria": "No national guidance in place for any included pathogens"
        }
    },
    "12": {
        "title": "You answered \"No national guidance outlining which antibiotics to include as a minimum in the routine AST\u201d. Who or which institution(s) generally guides and determines which antibiotics to include in the routine AST? (Tick all that apply)",
        "short_title": "If no national guidance, which institution(s) guide(s) and determine(s) minimum AST?",
        "type": "MultipleChoice",
        "coefficient": 1,
        "tags": [
            "National guidance"
        ],
        "possible_answers": {
            "Regional and/or local guidance (including two or more institutions).": 1,
            "National reference/expert laboratory": 1,
            "The clinical microbiological laboratory that performs the AST.": 0.8,
            "The healthcare facility where the sample was taken.": 0.5,
            "The treating physician(s)": 0.2,
            "Do not know": "null",
            "Other": 0.2
        },
        "actual_answers": {
            "Spain": [
                ""
            ],
            "Austria": [
                "The clinical microbiological laboratory that performs the AST."
            ],
            "Lithuania": [
                "The clinical microbiological laboratory that performs the AST.",
                "The healthcare facility where the sample was taken."
            ],
            "Croatia": [
                ""
            ],
            "Netherlands": [
                "The clinical microbiological laboratory that performs the AST.",
                "The treating physician(s)",
                "Other"
            ],
            "Ireland": [
                "The clinical microbiological laboratory that performs the AST."
            ],
            "Germany": [
                "The clinical microbiological laboratory that performs the AST.",
                "The healthcare facility where the sample was taken.",
                "The treating physician(s)"
            ],
            "Poland": [
                ""
            ],
            "Italy": [
                ""
            ],
            "Greece": [
                ""
            ],
            "France": [
                ""
            ],
            "Czechia": [
                "The clinical microbiological laboratory that performs the AST."
            ],
            "Belgium": [
                ""
            ],
            "Hungary": [
                ""
            ],
            "Finland": [
                "The clinical microbiological laboratory that performs the AST."
            ],
            "Luxembourg": [
                "Other"
            ],
            "Malta": [
                "The clinical microbiological laboratory that performs the AST."
            ],
            "Portugal": [
                ""
            ],
            "Norway": [
                ""
            ],
            "Slovenia": [
                ""
            ],
            "Estonia": [
                ""
            ],
            "Sweden": [
                ""
            ],
            "Ukraine": [
                ""
            ],
            "Slovak Republic": [
                "National reference/expert laboratory",
                "The clinical microbiological laboratory that performs the AST."
            ],
            "Denmark": [
                "The clinical microbiological laboratory that performs the AST."
            ],
            "Latvia": [
                ""
            ],
            "Iceland": [
                "National reference/expert laboratory"
            ],
            "Bulgaria": [
                "The clinical microbiological laboratory that performs the AST.",
                "The healthcare facility where the sample was taken."
            ]
        }
    },
    "13": {
        "title": "In your country, which laboratories perform the routine AST? (Tick all that apply)",
        "short_title": "Which laboratories perform the routine AST?",
        "type": "MultipleChoice",
        "coefficient": 1,
        "tags": [
            "National guidance"
        ],
        "possible_answers": {
            "All clinical microbiological laboratories.": 1,
            "A subset of clinical microbiological laboratories": 1,
            "National reference/expert laboratory": 1,
            "Do not know": "null",
            "Other": 0
        },
        "actual_answers": {
            "Spain": [
                "All clinical microbiological laboratories."
            ],
            "Austria": [
                "All clinical microbiological laboratories."
            ],
            "Lithuania": [
                "All clinical microbiological laboratories."
            ],
            "Croatia": [
                "All clinical microbiological laboratories."
            ],
            "Netherlands": [
                "All clinical microbiological laboratories."
            ],
            "Ireland": [
                "All clinical microbiological laboratories."
            ],
            "Germany": [
                "All clinical microbiological laboratories."
            ],
            "Poland": [
                "All clinical microbiological laboratories.",
                "National reference/expert laboratory"
            ],
            "Italy": [
                "All clinical microbiological laboratories."
            ],
            "Greece": [
                "All clinical microbiological laboratories."
            ],
            "France": [
                "All clinical microbiological laboratories."
            ],
            "Czechia": [
                "All clinical microbiological laboratories.",
                "National reference/expert laboratory"
            ],
            "Belgium": [
                "All clinical microbiological laboratories.",
                "A subset of clinical microbiological laboratories",
                "National reference/expert laboratory"
            ],
            "Hungary": [
                "All clinical microbiological laboratories.",
                "National reference/expert laboratory"
            ],
            "Finland": [
                "All clinical microbiological laboratories."
            ],
            "Luxembourg": [
                "All clinical microbiological laboratories."
            ],
            "Malta": [
                "All clinical microbiological laboratories."
            ],
            "Portugal": [
                "A subset of clinical microbiological laboratories"
            ],
            "Norway": [
                "All clinical microbiological laboratories."
            ],
            "Slovenia": [
                "All clinical microbiological laboratories."
            ],
            "Estonia": [
                "All clinical microbiological laboratories."
            ],
            "Sweden": [
                "All clinical microbiological laboratories."
            ],
            "Ukraine": [
                "All clinical microbiological laboratories."
            ],
            "Slovak Republic": [
                "All clinical microbiological laboratories.",
                "National reference/expert laboratory"
            ],
            "Denmark": [
                "All clinical microbiological laboratories."
            ],
            "Latvia": [
                "All clinical microbiological laboratories."
            ],
            "Iceland": [
                "A subset of clinical microbiological laboratories",
                "National reference/expert laboratory"
            ],
            "Bulgaria": [
                "All clinical microbiological laboratories.",
                "National reference/expert laboratory"
            ]
        }
    },
    "14": {
        "title": "Are there clinical microbiological laboratories that store routine AST data only in paper format?",
        "short_title": "Are there laboratories that store routine AST data only in paper format?",
        "type": "SingleChoice",
        "coefficient": 1,
        "tags": [
            "National guidance"
        ],
        "possible_answers": {
            "Yes.": 0,
            "No.": 1,
            "Do not know.": "null"
        },
        "actual_answers": {
            "Spain": "No.",
            "Austria": "Do not know.",
            "Lithuania": "Yes.",
            "Croatia": "Do not know.",
            "Netherlands": "No.",
            "Ireland": "No.",
            "Germany": "No.",
            "Poland": "Do not know.",
            "Italy": "No.",
            "Greece": "No.",
            "France": "No.",
            "Czechia": "No.",
            "Belgium": "Do not know.",
            "Hungary": "No.",
            "Finland": "No.",
            "Luxembourg": "No.",
            "Malta": "No.",
            "Portugal": "Yes.",
            "Norway": "No.",
            "Slovenia": "No.",
            "Estonia": "No.",
            "Sweden": "No.",
            "Ukraine": "Yes.",
            "Slovak Republic": "No.",
            "Denmark": "No.",
            "Latvia": "No.",
            "Iceland": "No.",
            "Bulgaria": "Do not know."
        }
    },
    "15": {
        "title": "Is there national guidance outlining which antibiotics to include in an extended AST?",
        "short_title": "National guidance outlining which antibiotics to include in an extended AST?",
        "type": "SingleChoice",
        "coefficient": 1,
        "tags": [
            "National guidance"
        ],
        "possible_answers": {
            "Yes, national guidance in place for all included pathogens.": 1,
            "Yes, national guidance in place for some of the included pathogens.": 0.7,
            "No national guidance in place but it is currently being developed.": 0.3,
            "No national guidance in place for any included pathogens.": 0,
            "Extended AST not used.": 0,
            "Do not know": "null"
        },
        "actual_answers": {
            "Spain": "Yes, national guidance in place for all included pathogens.",
            "Austria": "No national guidance in place for any included pathogens.",
            "Lithuania": "No national guidance in place for any included pathogens.",
            "Croatia": "Yes, national guidance in place for all included pathogens.",
            "Netherlands": "No national guidance in place for any included pathogens.",
            "Ireland": "No national guidance in place for any included pathogens.",
            "Germany": "No national guidance in place but it is currently being developed.",
            "Poland": "Yes, national guidance in place for all included pathogens.",
            "Italy": "Yes, national guidance in place for some of the included pathogens.",
            "Greece": "Yes, national guidance in place for some of the included pathogens.",
            "France": "Yes, national guidance in place for all included pathogens.",
            "Czechia": "No national guidance in place for any included pathogens.",
            "Belgium": "Do not know",
            "Hungary": "Yes, national guidance in place for all included pathogens.",
            "Finland": "Yes, national guidance in place for some of the included pathogens.",
            "Luxembourg": "No national guidance in place for any included pathogens.",
            "Malta": "No national guidance in place for any included pathogens.",
            "Portugal": "Yes, national guidance in place for some of the included pathogens.",
            "Norway": "Yes, national guidance in place for all included pathogens.",
            "Slovenia": "Yes, national guidance in place for all included pathogens.",
            "Estonia": "Yes, national guidance in place for all included pathogens.",
            "Sweden": "Yes, national guidance in place for some of the included pathogens.",
            "Ukraine": "Extended AST not used.",
            "Slovak Republic": "No national guidance in place for any included pathogens.",
            "Denmark": "No national guidance in place for any included pathogens.",
            "Latvia": "Yes, national guidance in place for some of the included pathogens.",
            "Iceland": "No national guidance in place for any included pathogens.",
            "Bulgaria": "No national guidance in place for any included pathogens."
        }
    },
    "16": {
        "title": "You answered \"No national guidance outlining which antibiotics to include in the extended AST\u201d. Who or which institution(s) generally guides and determines which antibiotics to include in the routine AST? (Tick all that apply)",
        "short_title": "If no national guidance, which institution(s) guide(s) and determine(s) extended AST?",
        "type": "MultipleChoice",
        "coefficient": 1,
        "tags": [
            "National guidance"
        ],
        "possible_answers": {
            "Regional and/or local guidance (including two or more institutions).": 1,
            "National reference/expert laboratory": 1,
            "The clinical microbiological laboratory that performs the AST": 0.4,
            "The healthcare facility where the sample was taken": 0.3,
            "The treating physician(s)": 0.2,
            "Do not know": "null",
            "Other": 0.2
        },
        "actual_answers": {
            "Spain": [
                ""
            ],
            "Austria": [
                "The clinical microbiological laboratory that performs the AST"
            ],
            "Lithuania": [
                "The clinical microbiological laboratory that performs the AST"
            ],
            "Croatia": [
                ""
            ],
            "Netherlands": [
                "The clinical microbiological laboratory that performs the AST",
                "The treating physician(s)",
                "Other"
            ],
            "Ireland": [
                "The clinical microbiological laboratory that performs the AST"
            ],
            "Germany": [
                "The clinical microbiological laboratory that performs the AST",
                "The healthcare facility where the sample was taken",
                "The treating physician(s)"
            ],
            "Poland": [
                ""
            ],
            "Italy": [
                ""
            ],
            "Greece": [
                ""
            ],
            "France": [
                ""
            ],
            "Czechia": [
                "National reference/expert laboratory",
                "The clinical microbiological laboratory that performs the AST"
            ],
            "Belgium": [
                ""
            ],
            "Hungary": [
                ""
            ],
            "Finland": [
                ""
            ],
            "Luxembourg": [
                "Other"
            ],
            "Malta": [
                "The clinical microbiological laboratory that performs the AST"
            ],
            "Portugal": [
                ""
            ],
            "Norway": [
                ""
            ],
            "Slovenia": [
                ""
            ],
            "Estonia": [
                ""
            ],
            "Sweden": [
                ""
            ],
            "Ukraine": [
                ""
            ],
            "Slovak Republic": [
                "National reference/expert laboratory",
                "The clinical microbiological laboratory that performs the AST"
            ],
            "Denmark": [
                "The clinical microbiological laboratory that performs the AST"
            ],
            "Latvia": [
                ""
            ],
            "Iceland": [
                "National reference/expert laboratory"
            ],
            "Bulgaria": [
                "National reference/expert laboratory",
                "The clinical microbiological laboratory that performs the AST",
                "The treating physician(s)"
            ]
        }
    },
    "17": {
        "title": "Which laboratories perform molecular typing of relevant resistance gene(s) in AMR isolates? (Tick all that apply)",
        "short_title": "Which laboratories perform molecular typing of relevant resistance gene(s)?",
        "type": "MultipleChoice",
        "coefficient": 1,
        "tags": [
            "National guidance"
        ],
        "possible_answers": {
            "All clinical microbiological laboratories.": 1,
            "A subset of clinical microbiological laboratories.": 1,
            "National reference/expert laboratory.": 1,
            "Do not know.": "null",
            "Other": 1
        },
        "actual_answers": {
            "Spain": [
                "A subset of clinical microbiological laboratories."
            ],
            "Austria": [
                "A subset of clinical microbiological laboratories."
            ],
            "Lithuania": [
                "National reference/expert laboratory."
            ],
            "Croatia": [
                "National reference/expert laboratory."
            ],
            "Netherlands": [
                "All clinical microbiological laboratories.",
                "National reference/expert laboratory."
            ],
            "Ireland": [
                "A subset of clinical microbiological laboratories."
            ],
            "Germany": [
                "A subset of clinical microbiological laboratories.",
                "National reference/expert laboratory."
            ],
            "Poland": [
                "A subset of clinical microbiological laboratories.",
                "National reference/expert laboratory."
            ],
            "Italy": [
                "A subset of clinical microbiological laboratories.",
                "National reference/expert laboratory."
            ],
            "Greece": [
                "A subset of clinical microbiological laboratories.",
                "National reference/expert laboratory."
            ],
            "France": [
                "A subset of clinical microbiological laboratories.",
                "National reference/expert laboratory."
            ],
            "Czechia": [
                "A subset of clinical microbiological laboratories.",
                "National reference/expert laboratory."
            ],
            "Belgium": [
                "A subset of clinical microbiological laboratories.",
                "National reference/expert laboratory."
            ],
            "Hungary": [
                "A subset of clinical microbiological laboratories.",
                "National reference/expert laboratory."
            ],
            "Finland": [
                "All clinical microbiological laboratories.",
                "National reference/expert laboratory."
            ],
            "Luxembourg": [
                "National reference/expert laboratory."
            ],
            "Malta": [
                "National reference/expert laboratory."
            ],
            "Portugal": [
                "A subset of clinical microbiological laboratories.",
                "National reference/expert laboratory."
            ],
            "Norway": [
                "A subset of clinical microbiological laboratories.",
                "National reference/expert laboratory."
            ],
            "Slovenia": [
                "Other"
            ],
            "Estonia": [
                "A subset of clinical microbiological laboratories.",
                "National reference/expert laboratory."
            ],
            "Sweden": [
                "All clinical microbiological laboratories."
            ],
            "Ukraine": [
                "A subset of clinical microbiological laboratories.",
                "National reference/expert laboratory."
            ],
            "Slovak Republic": [
                "National reference/expert laboratory."
            ],
            "Denmark": [
                "A subset of clinical microbiological laboratories.",
                "National reference/expert laboratory."
            ],
            "Latvia": [
                "A subset of clinical microbiological laboratories.",
                "National reference/expert laboratory."
            ],
            "Iceland": [
                "National reference/expert laboratory."
            ],
            "Bulgaria": [
                "A subset of clinical microbiological laboratories.",
                "National reference/expert laboratory."
            ]
        }
    },
    "18": {
        "title": "Is WGS and bioinformatic analysis performed in-house at the national reference/expert laboratory for some or all AMR bacteria under national surveillance?",
        "short_title": "WGS and bioinformatics performed inhouse at NRL?",
        "type": "SingleChoice",
        "coefficient": 1,
        "tags": [
            "National genomic surveillance"
        ],
        "possible_answers": {
            "Yes, both WGS and bioinformatics are performed in-house.": 1,
            "Yes, WGS is performed in-house but bioinformatics is outsourced.": 1,
            "Yes, WGS is outsourced but bioinformatics is performed in-house.": 1,
            "No, both WGS and bioinformatics are outsourced.": 1,
            "No, WGS is not used.": 0,
            "Other.": 0.2
        },
        "actual_answers": {
            "Spain": "Yes, both WGS and bioinformatics are performed in-house.",
            "Austria": "Yes, WGS is outsourced but bioinformatics is performed in-house.",
            "Lithuania": "Yes, both WGS and bioinformatics are performed in-house.",
            "Croatia": "Yes, WGS is outsourced but bioinformatics is performed in-house.",
            "Netherlands": "Yes, both WGS and bioinformatics are performed in-house.",
            "Ireland": "Yes, both WGS and bioinformatics are performed in-house.",
            "Germany": "Yes, both WGS and bioinformatics are performed in-house.",
            "Poland": "Yes, WGS is outsourced but bioinformatics is performed in-house.",
            "Italy": "Yes, both WGS and bioinformatics are performed in-house.",
            "Greece": "Yes, both WGS and bioinformatics are performed in-house.",
            "France": "Yes, WGS is outsourced but bioinformatics is performed in-house.",
            "Czechia": "Yes, both WGS and bioinformatics are performed in-house.",
            "Belgium": "Yes, both WGS and bioinformatics are performed in-house.",
            "Hungary": "Yes, both WGS and bioinformatics are performed in-house.",
            "Finland": "Yes, both WGS and bioinformatics are performed in-house.",
            "Luxembourg": "Yes, both WGS and bioinformatics are performed in-house.",
            "Malta": "Yes, both WGS and bioinformatics are performed in-house.",
            "Portugal": "Yes, both WGS and bioinformatics are performed in-house.",
            "Norway": "Yes, both WGS and bioinformatics are performed in-house.",
            "Slovenia": "Yes, both WGS and bioinformatics are performed in-house.",
            "Estonia": "Yes, both WGS and bioinformatics are performed in-house.",
            "Sweden": "Yes, both WGS and bioinformatics are performed in-house.",
            "Ukraine": "No, WGS is not used.",
            "Slovak Republic": "Yes, WGS is outsourced but bioinformatics is performed in-house.",
            "Denmark": "Yes, both WGS and bioinformatics are performed in-house.",
            "Latvia": "Yes, both WGS and bioinformatics are performed in-house.",
            "Iceland": "No, both WGS and bioinformatics are outsourced.",
            "Bulgaria": "Yes, both WGS and bioinformatics are performed in-house."
        }
    },
    "19.1": {
        "title": "Which of the following pathogens routinely undergo WGS as part of the national surveillance of AMR? : E. coli (carbapenem R and/or P) : WGS performed",
        "short_title": "E. coli (carbapenem R and/or P) - WGS as part of AMR surveillance?",
        "type": "SingleChoice",
        "coefficient": 0.077,
        "tags": [
            "National genomic surveillance",
            "E. coli",
            "Carbapenem"
        ],
        "possible_answers": {
            "Yes, all isolates sequenced.": 1,
            "Yes, for specific time periods and/or number of isolates.": 0.8,
            "Yes, when required/requested.": 0.8,
            "No, not sequenced.": 0
        },
        "actual_answers": {
            "Spain": "Yes, for specific time periods and/or number of isolates.",
            "Austria": "Yes, all isolates sequenced.",
            "Lithuania": "Yes, for specific time periods and/or number of isolates.",
            "Croatia": "Yes, for specific time periods and/or number of isolates.",
            "Netherlands": "Yes, all isolates sequenced.",
            "Ireland": "Yes, for specific time periods and/or number of isolates.",
            "Germany": "Yes, all isolates sequenced.",
            "Poland": "Yes, when required/requested.",
            "Italy": "Yes, when required/requested.",
            "Greece": "Yes, when required/requested.",
            "France": "Yes, all isolates sequenced.",
            "Czechia": "Yes, when required/requested.",
            "Belgium": "Yes, when required/requested.",
            "Hungary": "Yes, for specific time periods and/or number of isolates.",
            "Finland": "Yes, all isolates sequenced.",
            "Luxembourg": "Yes, when required/requested.",
            "Malta": "Yes, when required/requested.",
            "Portugal": "Yes, for specific time periods and/or number of isolates.",
            "Norway": "Yes, all isolates sequenced.",
            "Slovenia": "Yes, all isolates sequenced.",
            "Estonia": "Yes, all isolates sequenced.",
            "Sweden": "Yes, all isolates sequenced.",
            "Ukraine": "No, not sequenced.",
            "Slovak Republic": "Yes, when required/requested.",
            "Denmark": "Yes, all isolates sequenced.",
            "Latvia": "Yes, for specific time periods and/or number of isolates.",
            "Iceland": "Yes, all isolates sequenced.",
            "Bulgaria": "Yes, when required/requested."
        }
    },
    "19.2": {
        "title": "Which of the following pathogens routinely undergo WGS as part of the national surveillance of AMR? : E. coli (3GC- R and/or P) : WGS performed",
        "short_title": "E. coli (3GC- R and/or P) - WGS as part of AMR surveillance?",
        "type": "SingleChoice",
        "coefficient": 0.077,
        "tags": [
            "National genomic surveillance",
            "E. coli",
            "3rd-generation Cephalosporin"
        ],
        "possible_answers": {
            "Yes, all isolates sequenced.": 1,
            "Yes, for specific time periods and/or number of isolates.": 0.8,
            "Yes, when required/requested.": 0.8,
            "No, not sequenced.": 0
        },
        "actual_answers": {
            "Spain": "Yes, when required/requested.",
            "Austria": "Yes, when required/requested.",
            "Lithuania": "No, not sequenced.",
            "Croatia": "Yes, when required/requested.",
            "Netherlands": "No, not sequenced.",
            "Ireland": "Yes, when required/requested.",
            "Germany": "Yes, when required/requested.",
            "Poland": "Yes, when required/requested.",
            "Italy": "Yes, when required/requested.",
            "Greece": "Yes, when required/requested.",
            "France": "Yes, when required/requested.",
            "Czechia": "No, not sequenced.",
            "Belgium": "Yes, when required/requested.",
            "Hungary": "Yes, when required/requested.",
            "Finland": "Yes, when required/requested.",
            "Luxembourg": "Yes, when required/requested.",
            "Malta": "Yes, when required/requested.",
            "Portugal": "Yes, when required/requested.",
            "Norway": "Yes, when required/requested.",
            "Slovenia": "Yes, when required/requested.",
            "Estonia": "Yes, when required/requested.",
            "Sweden": "Yes, when required/requested.",
            "Ukraine": "No, not sequenced.",
            "Slovak Republic": "Yes, when required/requested.",
            "Denmark": "Yes, for specific time periods and/or number of isolates.",
            "Latvia": "Yes, for specific time periods and/or number of isolates.",
            "Iceland": "No, not sequenced.",
            "Bulgaria": "No, not sequenced."
        }
    },
    "19.3": {
        "title": "Which of the following pathogens routinely undergo WGS as part of the national surveillance of AMR? : E. coli (colistin R) : WGS performed",
        "short_title": "E. coli (colistin R) - WGS as part of AMR surveillance?",
        "type": "SingleChoice",
        "coefficient": 0.077,
        "tags": [
            "National genomic surveillance",
            "E. coli",
            "Colistin"
        ],
        "possible_answers": {
            "Yes, all isolates sequenced.": 1,
            "Yes, for specific time periods and/or number of isolates.": 0.8,
            "Yes, when required/requested.": 0.8,
            "No, not sequenced.": 0
        },
        "actual_answers": {
            "Spain": "Yes, when required/requested.",
            "Austria": "Yes, when required/requested.",
            "Lithuania": "No, not sequenced.",
            "Croatia": "Yes, when required/requested.",
            "Netherlands": "No, not sequenced.",
            "Ireland": "Yes, all isolates sequenced.",
            "Germany": "Yes, when required/requested.",
            "Poland": "Yes, when required/requested.",
            "Italy": "Yes, when required/requested.",
            "Greece": "Yes, when required/requested.",
            "France": "Yes, all isolates sequenced.",
            "Czechia": "Yes, when required/requested.",
            "Belgium": "Yes, when required/requested.",
            "Hungary": "Yes, when required/requested.",
            "Finland": "No, not sequenced.",
            "Luxembourg": "Yes, when required/requested.",
            "Malta": "Yes, when required/requested.",
            "Portugal": "Yes, for specific time periods and/or number of isolates.",
            "Norway": "Yes, all isolates sequenced.",
            "Slovenia": "Yes, when required/requested.",
            "Estonia": "Yes, all isolates sequenced.",
            "Sweden": "Yes, all isolates sequenced.",
            "Ukraine": "No, not sequenced.",
            "Slovak Republic": "Yes, when required/requested.",
            "Denmark": "Yes, all isolates sequenced.",
            "Latvia": "Yes, for specific time periods and/or number of isolates.",
            "Iceland": "Yes, all isolates sequenced.",
            "Bulgaria": "Yes, when required/requested."
        }
    },
    "19.4": {
        "title": "Which of the following pathogens routinely undergo WGS as part of the national surveillance of AMR? : K. pneumoniae (carbapenem R and/or P) : WGS performed",
        "short_title": "K. pneumoniae (carbapenem R and/or P) - WGS as part of AMR surveillance?",
        "type": "SingleChoice",
        "coefficient": 0.077,
        "tags": [
            "National genomic surveillance",
            "K. pneumoniae",
            "Carbapenem"
        ],
        "possible_answers": {
            "Yes, all isolates sequenced.": 1,
            "Yes, for specific time periods and/or number of isolates.": 0.8,
            "Yes, when required/requested.": 0.8,
            "No, not sequenced.": 0
        },
        "actual_answers": {
            "Spain": "Yes, for specific time periods and/or number of isolates.",
            "Austria": "Yes, all isolates sequenced.",
            "Lithuania": "Yes, for specific time periods and/or number of isolates.",
            "Croatia": "Yes, for specific time periods and/or number of isolates.",
            "Netherlands": "Yes, all isolates sequenced.",
            "Ireland": "Yes, for specific time periods and/or number of isolates.",
            "Germany": "Yes, all isolates sequenced.",
            "Poland": "Yes, when required/requested.",
            "Italy": "Yes, when required/requested.",
            "Greece": "Yes, for specific time periods and/or number of isolates.",
            "France": "Yes, all isolates sequenced.",
            "Czechia": "Yes, when required/requested.",
            "Belgium": "Yes, when required/requested.",
            "Hungary": "Yes, for specific time periods and/or number of isolates.",
            "Finland": "Yes, all isolates sequenced.",
            "Luxembourg": "Yes, when required/requested.",
            "Malta": "Yes, when required/requested.",
            "Portugal": "Yes, for specific time periods and/or number of isolates.",
            "Norway": "Yes, all isolates sequenced.",
            "Slovenia": "Yes, all isolates sequenced.",
            "Estonia": "Yes, all isolates sequenced.",
            "Sweden": "Yes, all isolates sequenced.",
            "Ukraine": "No, not sequenced.",
            "Slovak Republic": "Yes, when required/requested.",
            "Denmark": "Yes, all isolates sequenced.",
            "Latvia": "Yes, for specific time periods and/or number of isolates.",
            "Iceland": "Yes, all isolates sequenced.",
            "Bulgaria": "Yes, for specific time periods and/or number of isolates."
        }
    },
    "19.5": {
        "title": "Which of the following pathogens routinely undergo WGS as part of the national surveillance of AMR? : K. pneumoniae (3GC- R and/or P) : WGS performed",
        "short_title": "K. pneumoniae (3GC- R and/or P) - WGS as part of AMR surveillance? ",
        "type": "SingleChoice",
        "coefficient": 0.077,
        "tags": [
            "National genomic surveillance",
            "K. pneumoniae",
            "3rd-generation Cephalosporin"
        ],
        "possible_answers": {
            "Yes, all isolates sequenced.": 1,
            "Yes, for specific time periods and/or number of isolates.": 0.8,
            "Yes, when required/requested.": 0.8,
            "No, not sequenced.": 0
        },
        "actual_answers": {
            "Spain": "Yes, when required/requested.",
            "Austria": "Yes, when required/requested.",
            "Lithuania": "No, not sequenced.",
            "Croatia": "Yes, when required/requested.",
            "Netherlands": "No, not sequenced.",
            "Ireland": "Yes, when required/requested.",
            "Germany": "Yes, when required/requested.",
            "Poland": "Yes, when required/requested.",
            "Italy": "Yes, when required/requested.",
            "Greece": "Yes, when required/requested.",
            "France": "Yes, when required/requested.",
            "Czechia": "No, not sequenced.",
            "Belgium": "Yes, when required/requested.",
            "Hungary": "Yes, when required/requested.",
            "Finland": "Yes, when required/requested.",
            "Luxembourg": "Yes, when required/requested.",
            "Malta": "Yes, when required/requested.",
            "Portugal": "Yes, when required/requested.",
            "Norway": "Yes, when required/requested.",
            "Slovenia": "Yes, when required/requested.",
            "Estonia": "Yes, when required/requested.",
            "Sweden": "Yes, when required/requested.",
            "Ukraine": "No, not sequenced.",
            "Slovak Republic": "Yes, when required/requested.",
            "Denmark": "No, not sequenced.",
            "Latvia": "Yes, for specific time periods and/or number of isolates.",
            "Iceland": "No, not sequenced.",
            "Bulgaria": "No, not sequenced."
        }
    },
    "19.6": {
        "title": "Which of the following pathogens routinely undergo WGS as part of the national surveillance of AMR? : K. pneumoniae (colistin R) : WGS performed",
        "short_title": "K. pneumoniae (colistin R) - WGS as part of AMR surveillance?",
        "type": "SingleChoice",
        "coefficient": 0.077,
        "tags": [
            "National genomic surveillance",
            "K. pneumoniae",
            "Colistin"
        ],
        "possible_answers": {
            "Yes, all isolates sequenced.": 1,
            "Yes, for specific time periods and/or number of isolates.": 0.8,
            "Yes, when required/requested.": 0.8,
            "No, not sequenced.": 0
        },
        "actual_answers": {
            "Spain": "Yes, when required/requested.",
            "Austria": "Yes, when required/requested.",
            "Lithuania": "Yes, when required/requested.",
            "Croatia": "Yes, when required/requested.",
            "Netherlands": "No, not sequenced.",
            "Ireland": "Yes, all isolates sequenced.",
            "Germany": "Yes, when required/requested.",
            "Poland": "Yes, when required/requested.",
            "Italy": "Yes, when required/requested.",
            "Greece": "Yes, when required/requested.",
            "France": "Yes, all isolates sequenced.",
            "Czechia": "Yes, when required/requested.",
            "Belgium": "Yes, when required/requested.",
            "Hungary": "Yes, when required/requested.",
            "Finland": "No, not sequenced.",
            "Luxembourg": "Yes, when required/requested.",
            "Malta": "Yes, when required/requested.",
            "Portugal": "Yes, for specific time periods and/or number of isolates.",
            "Norway": "Yes, all isolates sequenced.",
            "Slovenia": "Yes, when required/requested.",
            "Estonia": "Yes, all isolates sequenced.",
            "Sweden": "Yes, all isolates sequenced.",
            "Ukraine": "No, not sequenced.",
            "Slovak Republic": "Yes, when required/requested.",
            "Denmark": "Yes, all isolates sequenced.",
            "Latvia": "Yes, for specific time periods and/or number of isolates.",
            "Iceland": "Yes, all isolates sequenced.",
            "Bulgaria": "Yes, for specific time periods and/or number of isolates."
        }
    },
    "19.7": {
        "title": "Which of the following pathogens routinely undergo WGS as part of the national surveillance of AMR? : P. aeruginosa (carbapenem R and/or P) : WGS performed",
        "short_title": "P. aeruginosa (carbapenem R and/or P) - WGS as part of AMR surveillance?",
        "type": "SingleChoice",
        "coefficient": 0.077,
        "tags": [
            "National genomic surveillance",
            "P. aeruginosa",
            "Carbapenem"
        ],
        "possible_answers": {
            "Yes, all isolates sequenced.": 1,
            "Yes, for specific time periods and/or number of isolates.": 0.8,
            "Yes, when required/requested.": 0.8,
            "No, not sequenced.": 0
        },
        "actual_answers": {
            "Spain": "Yes, for specific time periods and/or number of isolates.",
            "Austria": "Yes, all isolates sequenced.",
            "Lithuania": "No, not sequenced.",
            "Croatia": "Yes, for specific time periods and/or number of isolates.",
            "Netherlands": "Yes, all isolates sequenced.",
            "Ireland": "Yes, when required/requested.",
            "Germany": "Yes, when required/requested.",
            "Poland": "Yes, when required/requested.",
            "Italy": "Yes, when required/requested.",
            "Greece": "Yes, for specific time periods and/or number of isolates.",
            "France": "Yes, all isolates sequenced.",
            "Czechia": "Yes, when required/requested.",
            "Belgium": "Yes, when required/requested.",
            "Hungary": "Yes, when required/requested.",
            "Finland": "Yes, when required/requested.",
            "Luxembourg": "Yes, when required/requested.",
            "Malta": "Yes, when required/requested.",
            "Portugal": "Yes, when required/requested.",
            "Norway": "Yes, all isolates sequenced.",
            "Slovenia": "Yes, all isolates sequenced.",
            "Estonia": "Yes, all isolates sequenced.",
            "Sweden": "Yes, all isolates sequenced.",
            "Ukraine": "No, not sequenced.",
            "Slovak Republic": "Yes, when required/requested.",
            "Denmark": "Yes, all isolates sequenced.",
            "Latvia": "Yes, when required/requested.",
            "Iceland": "Yes, all isolates sequenced.",
            "Bulgaria": "Yes, for specific time periods and/or number of isolates."
        }
    },
    "19.8": {
        "title": "Which of the following pathogens routinely undergo WGS as part of the national surveillance of AMR? : A. baumanii (carbapenem R and/or P) : WGS performed",
        "short_title": "A. baumanii (carbapenem R and/or P) - WGS as part of AMR surveillance?",
        "type": "SingleChoice",
        "coefficient": 0.077,
        "tags": [
            "National genomic surveillance",
            "A. baumanii",
            "Carbapenem"
        ],
        "possible_answers": {
            "Yes, all isolates sequenced.": 1,
            "Yes, for specific time periods and/or number of isolates.": 0.8,
            "Yes, when required/requested.": 0.8,
            "No, not sequenced.": 0
        },
        "actual_answers": {
            "Spain": "Yes, for specific time periods and/or number of isolates.",
            "Austria": "Yes, all isolates sequenced.",
            "Lithuania": "Yes, when required/requested.",
            "Croatia": "Yes, for specific time periods and/or number of isolates.",
            "Netherlands": "Yes, all isolates sequenced.",
            "Ireland": "Yes, when required/requested.",
            "Germany": "Yes, when required/requested.",
            "Poland": "Yes, when required/requested.",
            "Italy": "Yes, when required/requested.",
            "Greece": "Yes, for specific time periods and/or number of isolates.",
            "France": "Yes, all isolates sequenced.",
            "Czechia": "Yes, when required/requested.",
            "Belgium": "No, not sequenced.",
            "Hungary": "Yes, for specific time periods and/or number of isolates.",
            "Finland": "Yes, when required/requested.",
            "Luxembourg": "Yes, when required/requested.",
            "Malta": "Yes, when required/requested.",
            "Portugal": "Yes, when required/requested.",
            "Norway": "Yes, all isolates sequenced.",
            "Slovenia": "Yes, all isolates sequenced.",
            "Estonia": "Yes, all isolates sequenced.",
            "Sweden": "Yes, all isolates sequenced.",
            "Ukraine": "No, not sequenced.",
            "Slovak Republic": "Yes, when required/requested.",
            "Denmark": "Yes, all isolates sequenced.",
            "Latvia": "Yes, when required/requested.",
            "Iceland": "Yes, all isolates sequenced.",
            "Bulgaria": "No, not sequenced."
        }
    },
    "19.9": {
        "title": "Which of the following pathogens routinely undergo WGS as part of the national surveillance of AMR? : S. aureus (methicillin R) : WGS performed",
        "short_title": "S. aureus (methicillin R) - WGS as part of AMR surveillance? ",
        "type": "SingleChoice",
        "coefficient": 0.077,
        "tags": [
            "National genomic surveillance",
            "S. aureus",
            "Methicillin"
        ],
        "possible_answers": {
            "Yes, all isolates sequenced.": 1,
            "Yes, for specific time periods and/or number of isolates.": 0.8,
            "Yes, when required/requested.": 0.8,
            "No, not sequenced.": 0
        },
        "actual_answers": {
            "Spain": "Yes, for specific time periods and/or number of isolates.",
            "Austria": "Yes, when required/requested.",
            "Lithuania": "No, not sequenced.",
            "Croatia": "Yes, when required/requested.",
            "Netherlands": "Yes, for specific time periods and/or number of isolates.",
            "Ireland": "Yes, when required/requested.",
            "Germany": "Yes, for specific time periods and/or number of isolates.",
            "Poland": "Yes, when required/requested.",
            "Italy": "Yes, when required/requested.",
            "Greece": "Yes, when required/requested.",
            "France": "Yes, all isolates sequenced.",
            "Czechia": "No, not sequenced.",
            "Belgium": "Yes, when required/requested.",
            "Hungary": "Yes, for specific time periods and/or number of isolates.",
            "Finland": "Yes, for specific time periods and/or number of isolates.",
            "Luxembourg": "Yes, when required/requested.",
            "Malta": "Yes, when required/requested.",
            "Portugal": "Yes, when required/requested.",
            "Norway": "Yes, for specific time periods and/or number of isolates.",
            "Slovenia": "Yes, when required/requested.",
            "Estonia": "Yes, when required/requested.",
            "Sweden": "Yes, for specific time periods and/or number of isolates.",
            "Ukraine": "No, not sequenced.",
            "Slovak Republic": "Yes, when required/requested.",
            "Denmark": "Yes, for specific time periods and/or number of isolates.",
            "Latvia": "Yes, for specific time periods and/or number of isolates.",
            "Iceland": "Yes, when required/requested.",
            "Bulgaria": "No, not sequenced."
        }
    },
    "19.10": {
        "title": "Which of the following pathogens routinely undergo WGS as part of the national surveillance of AMR? : E. faecium and/or E. faecalis (vancomycin R) : WGS performed",
        "short_title": "E. faecium and/or E. faecalis (vancomycin R) - WGS as part of AMR surveillance? ",
        "type": "SingleChoice",
        "coefficient": 0.077,
        "tags": [
            "National genomic surveillance",
            "E. faecium/faecalis",
            "Vancomycin"
        ],
        "possible_answers": {
            "Yes, all isolates sequenced.": 1,
            "Yes, for specific time periods and/or number of isolates.": 0.8,
            "Yes, when required/requested.": 0.8,
            "No, not sequenced.": 0
        },
        "actual_answers": {
            "Spain": "Yes, for specific time periods and/or number of isolates.",
            "Austria": "Yes, when required/requested.",
            "Lithuania": "No, not sequenced.",
            "Croatia": "Yes, when required/requested.",
            "Netherlands": "No, not sequenced.",
            "Ireland": "Yes, when required/requested.",
            "Germany": "Yes, when required/requested.",
            "Poland": "Yes, when required/requested.",
            "Italy": "Yes, when required/requested.",
            "Greece": "Yes, when required/requested.",
            "France": "Yes, all isolates sequenced.",
            "Czechia": "No, not sequenced.",
            "Belgium": "Yes, when required/requested.",
            "Hungary": "Yes, for specific time periods and/or number of isolates.",
            "Finland": "Yes, for specific time periods and/or number of isolates.",
            "Luxembourg": "Yes, when required/requested.",
            "Malta": "Yes, when required/requested.",
            "Portugal": "Yes, when required/requested.",
            "Norway": "Yes, all isolates sequenced.",
            "Slovenia": "Yes, when required/requested.",
            "Estonia": "Yes, for specific time periods and/or number of isolates.",
            "Sweden": "Yes, all isolates sequenced.",
            "Ukraine": "No, not sequenced.",
            "Slovak Republic": "Yes, when required/requested.",
            "Denmark": "Yes, for specific time periods and/or number of isolates.",
            "Latvia": "Yes, for specific time periods and/or number of isolates.",
            "Iceland": "Yes, when required/requested.",
            "Bulgaria": "No, not sequenced."
        }
    },
    "19.11": {
        "title": "Which of the following pathogens routinely undergo WGS as part of the national surveillance of AMR? : S. pneumoniae (penicillin and macrolide R) : WGS performed",
        "short_title": "S. pneumoniae (penicillin and macrolide R)  - WGS as part of AMR surveillance? ",
        "type": "SingleChoice",
        "coefficient": 0.077,
        "tags": [
            "National genomic surveillance",
            "S. pneumoniae",
            "Penicillin"
        ],
        "possible_answers": {
            "Yes, all isolates sequenced.": 1,
            "Yes, for specific time periods and/or number of isolates.": 0.8,
            "Yes, when required/requested.": 0.8,
            "No, not sequenced.": 0
        },
        "actual_answers": {
            "Spain": "No, not sequenced.",
            "Austria": "No, not sequenced.",
            "Lithuania": "No, not sequenced.",
            "Croatia": "Yes, when required/requested.",
            "Netherlands": "No, not sequenced.",
            "Ireland": "Yes, all isolates sequenced.",
            "Germany": "Yes, when required/requested.",
            "Poland": "Yes, when required/requested.",
            "Italy": "Yes, when required/requested.",
            "Greece": "Yes, for specific time periods and/or number of isolates.",
            "France": "Yes, when required/requested.",
            "Czechia": "No, not sequenced.",
            "Belgium": "Yes, when required/requested.",
            "Hungary": "No, not sequenced.",
            "Finland": "Yes, for specific time periods and/or number of isolates.",
            "Luxembourg": "Yes, when required/requested.",
            "Malta": "Yes, when required/requested.",
            "Portugal": "Yes, when required/requested.",
            "Norway": "Yes, all isolates sequenced.",
            "Slovenia": "Yes, when required/requested.",
            "Estonia": "No, not sequenced.",
            "Sweden": "No, not sequenced.",
            "Ukraine": "No, not sequenced.",
            "Slovak Republic": "Yes, when required/requested.",
            "Denmark": "Yes, when required/requested.",
            "Latvia": "No, not sequenced.",
            "Iceland": "No, not sequenced.",
            "Bulgaria": "Yes, when required/requested."
        }
    },
    "19.12": {
        "title": "Which of the following pathogens routinely undergo WGS as part of the national surveillance of AMR? : H. influenzae (ampicillin- R) : WGS performed",
        "short_title": "H. influenzae (ampicillin- R) - WGS as part of AMR surveillance?",
        "type": "SingleChoice",
        "coefficient": 0.077,
        "tags": [
            "National genomic surveillance",
            "H. influenzae",
            "Ampicillin"
        ],
        "possible_answers": {
            "Yes, all isolates sequenced.": 1,
            "Yes, for specific time periods and/or number of isolates.": 0.8,
            "Yes, when required/requested.": 0.8,
            "No, not sequenced.": 0
        },
        "actual_answers": {
            "Spain": "Yes, when required/requested.",
            "Austria": "No, not sequenced.",
            "Lithuania": "No, not sequenced.",
            "Croatia": "Yes, when required/requested.",
            "Netherlands": "No, not sequenced.",
            "Ireland": "Yes, all isolates sequenced.",
            "Germany": "Yes, when required/requested.",
            "Poland": "Yes, when required/requested.",
            "Italy": "No, not sequenced.",
            "Greece": "Yes, for specific time periods and/or number of isolates.",
            "France": "Yes, when required/requested.",
            "Czechia": "No, not sequenced.",
            "Belgium": "No, not sequenced.",
            "Hungary": "No, not sequenced.",
            "Finland": "Yes, when required/requested.",
            "Luxembourg": "Yes, when required/requested.",
            "Malta": "Yes, when required/requested.",
            "Portugal": "Yes, when required/requested.",
            "Norway": "Yes, all isolates sequenced.",
            "Slovenia": "Yes, when required/requested.",
            "Estonia": "No, not sequenced.",
            "Sweden": "Yes, for specific time periods and/or number of isolates.",
            "Ukraine": "No, not sequenced.",
            "Slovak Republic": "Yes, when required/requested.",
            "Denmark": "Yes, all isolates sequenced.",
            "Latvia": "Yes, when required/requested.",
            "Iceland": "No, not sequenced.",
            "Bulgaria": "No, not sequenced."
        }
    },
    "19.13": {
        "title": "Which of the following pathogens routinely undergo WGS as part of the national surveillance of AMR? : C. difficile : WGS performed",
        "short_title": "C. difficile - WGS as part of AMR surveillance? ",
        "type": "SingleChoice",
        "coefficient": 0.077,
        "tags": [
            "National genomic surveillance",
            "C. difficile"
        ],
        "possible_answers": {
            "Yes, all isolates sequenced.": 1,
            "Yes, for specific time periods and/or number of isolates.": 0.8,
            "Yes, when required/requested.": 0.8,
            "No, not sequenced.": 0
        },
        "actual_answers": {
            "Spain": "Yes, when required/requested.",
            "Austria": "",
            "Lithuania": "No, not sequenced.",
            "Croatia": "Yes, when required/requested.",
            "Netherlands": "Yes, all isolates sequenced.",
            "Ireland": "Yes, for specific time periods and/or number of isolates.",
            "Germany": "Yes, for specific time periods and/or number of isolates.",
            "Poland": "Yes, when required/requested.",
            "Italy": "No, not sequenced.",
            "Greece": "Yes, for specific time periods and/or number of isolates.",
            "France": "Yes, all isolates sequenced.",
            "Czechia": "Yes, for specific time periods and/or number of isolates.",
            "Belgium": "Yes, when required/requested.",
            "Hungary": "Yes, when required/requested.",
            "Finland": "Yes, when required/requested.",
            "Luxembourg": "Yes, when required/requested.",
            "Malta": "No, not sequenced.",
            "Portugal": "Yes, for specific time periods and/or number of isolates.",
            "Norway": "Yes, when required/requested.",
            "Slovenia": "Yes, for specific time periods and/or number of isolates.",
            "Estonia": "Yes, for specific time periods and/or number of isolates.",
            "Sweden": "Yes, when required/requested.",
            "Ukraine": "No, not sequenced.",
            "Slovak Republic": "Yes, when required/requested.",
            "Denmark": "Yes, all isolates sequenced.",
            "Latvia": "No, not sequenced.",
            "Iceland": "No, not sequenced.",
            "Bulgaria": "Yes, for specific time periods and/or number of isolates."
        }
    },
    "20": {
        "title": "Is there national guidance on how to prioritize AMR isolates for WGS if resources are limited?",
        "short_title": "National guidance on how to prioritize WGS if resources are limited?",
        "type": "SingleChoice",
        "coefficient": 0,
        "tags": [
            "National genomic surveillance"
        ],
        "possible_answers": {
            "Yes.": 1,
            "No.": 1,
            "Do not know.": "null",
            "Other.": 1,
            "WGS not used.": 0
        },
        "actual_answers": {
            "Spain": "Yes.",
            "Austria": "Do not know.",
            "Lithuania": "No.",
            "Croatia": "Other.",
            "Netherlands": "No.",
            "Ireland": "No.",
            "Germany": "Other.",
            "Poland": "No.",
            "Italy": "Other.",
            "Greece": "Other.",
            "France": "Yes.",
            "Czechia": "No.",
            "Belgium": "No.",
            "Hungary": "Yes.",
            "Finland": "Yes.",
            "Luxembourg": "No.",
            "Malta": "Other.",
            "Portugal": "No.",
            "Norway": "No.",
            "Slovenia": "No.",
            "Estonia": "No.",
            "Sweden": "Yes.",
            "Ukraine": "WGS not used.",
            "Slovak Republic": "No.",
            "Denmark": "No.",
            "Latvia": "Yes.",
            "Iceland": "No.",
            "Bulgaria": "No."
        }
    },
    "21": {
        "title": "Are there clinical microbiological laboratories that submit WGS data for surveillance purposes to the national reference/expert laboratory for one or several of the included pathogens? (Tick all that apply)",
        "short_title": "Does clinical microbiological laboratories submit WGS data to NRL?",
        "type": "MultipleChoice",
        "coefficient": 1,
        "tags": [
            "National genomic surveillance"
        ],
        "possible_answers": {
            "Yes, raw read data.": 1,
            "Yes, assembled contigs.": 1,
            "No, some clinical microbiological laboratories perform WGS but data is not submitted.": 0.5,
            "No WGS data submitted from the clinical microbiological laboratories.": 0,
            "Do not know.": "null",
            "Other": 0
        },
        "actual_answers": {
            "Spain": [
                "Yes, raw read data."
            ],
            "Austria": [
                "No, some clinical microbiological laboratories perform WGS but data is not submitted."
            ],
            "Lithuania": [
                "No WGS data submitted from the clinical microbiological laboratories."
            ],
            "Croatia": [
                "No WGS data submitted from the clinical microbiological laboratories."
            ],
            "Netherlands": [
                "Yes, raw read data."
            ],
            "Ireland": [
                "No WGS data submitted from the clinical microbiological laboratories."
            ],
            "Germany": [
                "Yes, raw read data.",
                "Yes, assembled contigs."
            ],
            "Poland": [
                "No WGS data submitted from the clinical microbiological laboratories."
            ],
            "Italy": [
                "Yes, raw read data.",
                "Yes, assembled contigs.",
                "Other"
            ],
            "Greece": [
                "No WGS data submitted from the clinical microbiological laboratories."
            ],
            "France": [
                "No, some clinical microbiological laboratories perform WGS but data is not submitted."
            ],
            "Czechia": [
                "Yes, assembled contigs."
            ],
            "Belgium": [
                "No, some clinical microbiological laboratories perform WGS but data is not submitted."
            ],
            "Hungary": [
                "No, some clinical microbiological laboratories perform WGS but data is not submitted."
            ],
            "Finland": [
                "No, some clinical microbiological laboratories perform WGS but data is not submitted."
            ],
            "Luxembourg": [
                "No WGS data submitted from the clinical microbiological laboratories."
            ],
            "Malta": [
                "No, some clinical microbiological laboratories perform WGS but data is not submitted."
            ],
            "Portugal": [
                "No WGS data submitted from the clinical microbiological laboratories."
            ],
            "Norway": [
                "Yes, raw read data.",
                "No, some clinical microbiological laboratories perform WGS but data is not submitted."
            ],
            "Slovenia": [
                "No WGS data submitted from the clinical microbiological laboratories."
            ],
            "Estonia": [
                "No WGS data submitted from the clinical microbiological laboratories."
            ],
            "Sweden": [
                "No, some clinical microbiological laboratories perform WGS but data is not submitted."
            ],
            "Ukraine": [
                "No WGS data submitted from the clinical microbiological laboratories."
            ],
            "Slovak Republic": [
                "No WGS data submitted from the clinical microbiological laboratories."
            ],
            "Denmark": [
                "Yes, raw read data.",
                "Yes, assembled contigs.",
                "No, some clinical microbiological laboratories perform WGS but data is not submitted."
            ],
            "Latvia": [
                "No, some clinical microbiological laboratories perform WGS but data is not submitted."
            ],
            "Iceland": [
                "No WGS data submitted from the clinical microbiological laboratories."
            ],
            "Bulgaria": [
                "No WGS data submitted from the clinical microbiological laboratories."
            ]
        }
    },
    "22": {
        "title": "You answered \"No, some clinical microbiological laboratories perform WGS but data is not submitted\" in the question above.What are the main reasons that the clinical microbiological laboratories do not submit WGS data? (Select max 4 options)",
        "short_title": "If clinical laboratories sequence, but do not submitt to NRL, what are the reason(s)?",
        "type": "MultipleChoice",
        "coefficient": 0,
        "tags": [
            "National genomic surveillance"
        ],
        "possible_answers": {
            "Lack of infrastructure to submit WGS data.": 1,
            "Lack of capacity to process data at national reference laboratory/ national expert laboratory.": 1,
            "Lack of capacity for clinical microbiology laboratory to submit data.": 1,
            "Different sequencing methodologies between clinical microbiology laboratories and national expert laboratory.": 1,
            "Legal obstacles; sharing of data.": 1,
            "Legal obstacles; storing of data.": 1,
            "Legal, other issues.": 1,
            "Submission of data from clinical microbiology laboratories is voluntary.": 1,
            "Do not know.": "null",
            "Other": 1
        },
        "actual_answers": {
            "Spain": [
                ""
            ],
            "Austria": [
                "Do not know."
            ],
            "Lithuania": [
                ""
            ],
            "Croatia": [
                ""
            ],
            "Netherlands": [
                ""
            ],
            "Ireland": [
                ""
            ],
            "Germany": [
                ""
            ],
            "Poland": [
                ""
            ],
            "Italy": [
                ""
            ],
            "Greece": [
                ""
            ],
            "France": [
                "Submission of data from clinical microbiology laboratories is voluntary."
            ],
            "Czechia": [
                ""
            ],
            "Belgium": [
                "Lack of infrastructure to submit WGS data.",
                "Lack of capacity to process data at national reference laboratory/ national expert laboratory.",
                "Lack of capacity for clinical microbiology laboratory to submit data.",
                "Legal obstacles; sharing of data."
            ],
            "Hungary": [
                "Lack of capacity for clinical microbiology laboratory to submit data.",
                "Submission of data from clinical microbiology laboratories is voluntary."
            ],
            "Finland": [
                "Lack of infrastructure to submit WGS data.",
                "Lack of capacity for clinical microbiology laboratory to submit data.",
                "Submission of data from clinical microbiology laboratories is voluntary.",
                "Other"
            ],
            "Luxembourg": [
                ""
            ],
            "Malta": [
                "Submission of data from clinical microbiology laboratories is voluntary."
            ],
            "Portugal": [
                ""
            ],
            "Norway": [
                "Lack of infrastructure to submit WGS data.",
                "Different sequencing methodologies between clinical microbiology laboratories and national expert laboratory.",
                "Legal obstacles; sharing of data.",
                "Submission of data from clinical microbiology laboratories is voluntary."
            ],
            "Slovenia": [
                ""
            ],
            "Estonia": [
                ""
            ],
            "Sweden": [
                "Other"
            ],
            "Ukraine": [
                ""
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Lack of capacity for clinical microbiology laboratory to submit data.",
                "Legal obstacles; sharing of data.",
                "Submission of data from clinical microbiology laboratories is voluntary."
            ],
            "Latvia": [
                "Different sequencing methodologies between clinical microbiology laboratories and national expert laboratory.",
                "Submission of data from clinical microbiology laboratories is voluntary."
            ],
            "Iceland": [
                ""
            ],
            "Bulgaria": [
                ""
            ]
        }
    },
    "23": {
        "title": "How would you describe the purpose of WGS at the national reference/expert laboratory? (Tick all that apply)",
        "short_title": "Purpose of WGS at the national reference/expert laboratory?",
        "type": "MultipleChoice",
        "coefficient": 1,
        "tags": [
            "National genomic surveillance"
        ],
        "possible_answers": {
            "Identification of the pathogen(s) causing infection/carriage for diagnostic purposes.": 0.5,
            "Outbreak/transmission investigations.": 0.5,
            "Surveillance.": 0.5,
            "Research performed at national reference/expert laboratory.": 0.2,
            "Other.": 0.2,
            "WGS not used.": 0
        },
        "actual_answers": {
            "Spain": [
                "Outbreak/transmission investigations.",
                "Surveillance.",
                "Research performed at national reference/expert laboratory."
            ],
            "Austria": [
                "Outbreak/transmission investigations.",
                "Surveillance.",
                "Research performed at national reference/expert laboratory."
            ],
            "Lithuania": [
                "Outbreak/transmission investigations.",
                "Surveillance."
            ],
            "Croatia": [
                "Outbreak/transmission investigations.",
                "Surveillance.",
                "Research performed at national reference/expert laboratory."
            ],
            "Netherlands": [
                "Outbreak/transmission investigations.",
                "Surveillance.",
                "Research performed at national reference/expert laboratory."
            ],
            "Ireland": [
                "Outbreak/transmission investigations.",
                "Surveillance."
            ],
            "Germany": [
                "Outbreak/transmission investigations.",
                "Surveillance.",
                "Research performed at national reference/expert laboratory."
            ],
            "Poland": [
                "Outbreak/transmission investigations.",
                "Surveillance.",
                "Research performed at national reference/expert laboratory."
            ],
            "Italy": [
                "Identification of the pathogen(s) causing infection/carriage for diagnostic purposes.",
                "Outbreak/transmission investigations.",
                "Surveillance.",
                "Research performed at national reference/expert laboratory."
            ],
            "Greece": [
                "Identification of the pathogen(s) causing infection/carriage for diagnostic purposes.",
                "Outbreak/transmission investigations.",
                "Surveillance.",
                "Research performed at national reference/expert laboratory."
            ],
            "France": [
                "Identification of the pathogen(s) causing infection/carriage for diagnostic purposes.",
                "Outbreak/transmission investigations.",
                "Surveillance.",
                "Research performed at national reference/expert laboratory."
            ],
            "Czechia": [
                "Identification of the pathogen(s) causing infection/carriage for diagnostic purposes.",
                "Outbreak/transmission investigations.",
                "Surveillance.",
                "Research performed at national reference/expert laboratory."
            ],
            "Belgium": [
                "Identification of the pathogen(s) causing infection/carriage for diagnostic purposes.",
                "Outbreak/transmission investigations.",
                "Surveillance.",
                "Research performed at national reference/expert laboratory."
            ],
            "Hungary": [
                "Outbreak/transmission investigations.",
                "Surveillance.",
                "Research performed at national reference/expert laboratory."
            ],
            "Finland": [
                "Outbreak/transmission investigations.",
                "Surveillance."
            ],
            "Luxembourg": [
                "Identification of the pathogen(s) causing infection/carriage for diagnostic purposes.",
                "Outbreak/transmission investigations.",
                "Surveillance."
            ],
            "Malta": [
                "Identification of the pathogen(s) causing infection/carriage for diagnostic purposes.",
                "Outbreak/transmission investigations.",
                "Surveillance."
            ],
            "Portugal": [
                "Outbreak/transmission investigations.",
                "Surveillance.",
                "Research performed at national reference/expert laboratory."
            ],
            "Norway": [
                "Identification of the pathogen(s) causing infection/carriage for diagnostic purposes.",
                "Outbreak/transmission investigations.",
                "Surveillance.",
                "Research performed at national reference/expert laboratory."
            ],
            "Slovenia": [
                "Outbreak/transmission investigations.",
                "Surveillance.",
                "Research performed at national reference/expert laboratory."
            ],
            "Estonia": [
                "Outbreak/transmission investigations.",
                "Surveillance."
            ],
            "Sweden": [
                "Identification of the pathogen(s) causing infection/carriage for diagnostic purposes.",
                "Outbreak/transmission investigations.",
                "Surveillance."
            ],
            "Ukraine": [
                "WGS not used."
            ],
            "Slovak Republic": [
                "Identification of the pathogen(s) causing infection/carriage for diagnostic purposes.",
                "Outbreak/transmission investigations.",
                "Surveillance.",
                "Research performed at national reference/expert laboratory."
            ],
            "Denmark": [
                "Outbreak/transmission investigations.",
                "Surveillance.",
                "Research performed at national reference/expert laboratory."
            ],
            "Latvia": [
                "Identification of the pathogen(s) causing infection/carriage for diagnostic purposes.",
                "Surveillance.",
                "Research performed at national reference/expert laboratory."
            ],
            "Iceland": [
                "Outbreak/transmission investigations.",
                "Surveillance."
            ],
            "Bulgaria": [
                "Identification of the pathogen(s) causing infection/carriage for diagnostic purposes.",
                "Outbreak/transmission investigations.",
                "Surveillance.",
                "Research performed at national reference/expert laboratory."
            ]
        }
    },
    "24": {
        "title": "If WGS is used for outbreak investigations at the national reference/expert laboratory, is the WGS data used in \u2018real-time\u2019?Real-time generally refers to being completed within about 1 week, with the results used to make decisions on how to proceed.",
        "short_title": "Real time (within 1 week) outbreak investigations att NRL?",
        "type": "SingleChoice",
        "coefficient": 1,
        "tags": [
            "National genomic surveillance"
        ],
        "possible_answers": {
            "Yes.": 1,
            "No, WGS not used in real-time.": 0.2,
            "No but under implementation.": 0.5,
            "No, WGS not used for outbreak investigations.": 0,
            "Do not know.": "null",
            "Other.": 0,
            "WGS not used.": 0
        },
        "actual_answers": {
            "Spain": "No, WGS not used in real-time.",
            "Austria": "No, WGS not used in real-time.",
            "Lithuania": "No, WGS not used in real-time.",
            "Croatia": "No but under implementation.",
            "Netherlands": "No, WGS not used in real-time.",
            "Ireland": "Yes.",
            "Germany": "No but under implementation.",
            "Poland": "No, WGS not used in real-time.",
            "Italy": "No but under implementation.",
            "Greece": "No but under implementation.",
            "France": "Yes.",
            "Czechia": "No, WGS not used in real-time.",
            "Belgium": "No, WGS not used in real-time.",
            "Hungary": "Yes.",
            "Finland": "No, WGS not used in real-time.",
            "Luxembourg": "No, WGS not used in real-time.",
            "Malta": "No, WGS not used in real-time.",
            "Portugal": "Yes.",
            "Norway": "Yes.",
            "Slovenia": "No, WGS not used in real-time.",
            "Estonia": "No but under implementation.",
            "Sweden": "Yes.",
            "Ukraine": "WGS not used.",
            "Slovak Republic": "No, WGS not used in real-time.",
            "Denmark": "Yes.",
            "Latvia": "No, WGS not used in real-time.",
            "Iceland": "No but under implementation.",
            "Bulgaria": "No but under implementation."
        }
    },
    "25": {
        "title": "Can the national reference/expert laboratory perform a joint analysis with WGS data from another sector if e.g. an outbreak is identified? Pick the scenario that suits your system the best concerning national outbreaks. Examples could be food production, veterinary medicine, etc.",
        "short_title": "Possibility for joint analysis between NRL and other sector?",
        "type": "SingleChoice",
        "coefficient": 0,
        "tags": [
            "National genomic surveillance"
        ],
        "possible_answers": {
            "Yes, we have a data sharing/analysis pipeline set-up for this analysis.": 1,
            "Yes, it can be done but there is no official data sharing/analysis pipeline.": 0.5,
            "No, legal issues prevent this type of sharing and analysis.": 0,
            "No joint analysis is performed with WGS data.": 0,
            "Do not know.": "null",
            "Other.": 0,
            "WGS not used.": 0
        },
        "actual_answers": {
            "Spain": "Yes, it can be done but there is no official data sharing/analysis pipeline.",
            "Austria": "No joint analysis is performed with WGS data.",
            "Lithuania": "Yes, it can be done but there is no official data sharing/analysis pipeline.",
            "Croatia": "Yes, it can be done but there is no official data sharing/analysis pipeline.",
            "Netherlands": "Yes, it can be done but there is no official data sharing/analysis pipeline.",
            "Ireland": "Yes, we have a data sharing/analysis pipeline set-up for this analysis.",
            "Germany": "Yes, it can be done but there is no official data sharing/analysis pipeline.",
            "Poland": "Yes, it can be done but there is no official data sharing/analysis pipeline.",
            "Italy": "Yes, it can be done but there is no official data sharing/analysis pipeline.",
            "Greece": "Yes, it can be done but there is no official data sharing/analysis pipeline.",
            "France": "Yes, it can be done but there is no official data sharing/analysis pipeline.",
            "Czechia": "Yes, it can be done but there is no official data sharing/analysis pipeline.",
            "Belgium": "Yes, it can be done but there is no official data sharing/analysis pipeline.",
            "Hungary": "Yes, it can be done but there is no official data sharing/analysis pipeline.",
            "Finland": "Yes, we have a data sharing/analysis pipeline set-up for this analysis.",
            "Luxembourg": "Yes, it can be done but there is no official data sharing/analysis pipeline.",
            "Malta": "Other.",
            "Portugal": "Yes, it can be done but there is no official data sharing/analysis pipeline.",
            "Norway": "Yes, it can be done but there is no official data sharing/analysis pipeline.",
            "Slovenia": "Yes, it can be done but there is no official data sharing/analysis pipeline.",
            "Estonia": "Yes, it can be done but there is no official data sharing/analysis pipeline.",
            "Sweden": "Yes, it can be done but there is no official data sharing/analysis pipeline.",
            "Ukraine": "WGS not used.",
            "Slovak Republic": "Yes, it can be done but there is no official data sharing/analysis pipeline.",
            "Denmark": "Yes, we have a data sharing/analysis pipeline set-up for this analysis.",
            "Latvia": "Yes, it can be done but there is no official data sharing/analysis pipeline.",
            "Iceland": "Yes, it can be done but there is no official data sharing/analysis pipeline.",
            "Bulgaria": "Yes, it can be done but there is no official data sharing/analysis pipeline."
        }
    },
    "26": {
        "title": "If applicable, which of the following methods are used for outbreak detection and/or determining relatedness of bacteria at the national reference/expert laboratory? (Tick all that apply)",
        "short_title": "Methods for outbreak detection at NRL?",
        "type": "MultipleChoice",
        "coefficient": 1,
        "tags": [
            "National genomic surveillance"
        ],
        "possible_answers": {
            "Not applicable": "null",
            "Core genome multi-locus sequence typing (cgMLST).": 1,
            "Whole genome multi-locus sequence typing (wgMLST).": 1,
            "Single nucleotide polymorphism (SNP) analysis.": 1,
            "Pulsed-field gel electrophoresis (PFGE).": 0.3,
            "Multilocus variable-number tandem repeat analysis (MLVA).": 0.3,
            "Do not know.": "null",
            "Other, non WGS-based methods.": 0.3
        },
        "actual_answers": {
            "Spain": [
                "Core genome multi-locus sequence typing (cgMLST).",
                "Single nucleotide polymorphism (SNP) analysis."
            ],
            "Austria": [
                "Core genome multi-locus sequence typing (cgMLST).",
                "Single nucleotide polymorphism (SNP) analysis."
            ],
            "Lithuania": [
                "Core genome multi-locus sequence typing (cgMLST)."
            ],
            "Croatia": [
                "Core genome multi-locus sequence typing (cgMLST).",
                "Whole genome multi-locus sequence typing (wgMLST).",
                "Single nucleotide polymorphism (SNP) analysis.",
                "Pulsed-field gel electrophoresis (PFGE)."
            ],
            "Netherlands": [
                "Core genome multi-locus sequence typing (cgMLST).",
                "Whole genome multi-locus sequence typing (wgMLST).",
                "Single nucleotide polymorphism (SNP) analysis.",
                "Multilocus variable-number tandem repeat analysis (MLVA)."
            ],
            "Ireland": [
                "Core genome multi-locus sequence typing (cgMLST).",
                "Whole genome multi-locus sequence typing (wgMLST).",
                "Single nucleotide polymorphism (SNP) analysis."
            ],
            "Germany": [
                "Core genome multi-locus sequence typing (cgMLST).",
                "Whole genome multi-locus sequence typing (wgMLST).",
                "Single nucleotide polymorphism (SNP) analysis."
            ],
            "Poland": [
                "Core genome multi-locus sequence typing (cgMLST).",
                "Whole genome multi-locus sequence typing (wgMLST).",
                "Single nucleotide polymorphism (SNP) analysis.",
                "Pulsed-field gel electrophoresis (PFGE).",
                "Multilocus variable-number tandem repeat analysis (MLVA)."
            ],
            "Italy": [
                "Core genome multi-locus sequence typing (cgMLST).",
                "Single nucleotide polymorphism (SNP) analysis."
            ],
            "Greece": [
                "Core genome multi-locus sequence typing (cgMLST).",
                "Single nucleotide polymorphism (SNP) analysis."
            ],
            "France": [
                "Core genome multi-locus sequence typing (cgMLST).",
                "Whole genome multi-locus sequence typing (wgMLST).",
                "Single nucleotide polymorphism (SNP) analysis.",
                "Multilocus variable-number tandem repeat analysis (MLVA)."
            ],
            "Czechia": [
                "Core genome multi-locus sequence typing (cgMLST).",
                "Whole genome multi-locus sequence typing (wgMLST).",
                "Pulsed-field gel electrophoresis (PFGE).",
                "Other, non WGS-based methods."
            ],
            "Belgium": [
                "Core genome multi-locus sequence typing (cgMLST).",
                "Whole genome multi-locus sequence typing (wgMLST).",
                "Single nucleotide polymorphism (SNP) analysis.",
                "Pulsed-field gel electrophoresis (PFGE).",
                "Multilocus variable-number tandem repeat analysis (MLVA).",
                "Other, non WGS-based methods."
            ],
            "Hungary": [
                "Core genome multi-locus sequence typing (cgMLST).",
                "Whole genome multi-locus sequence typing (wgMLST)."
            ],
            "Finland": [
                "Core genome multi-locus sequence typing (cgMLST).",
                "Other, non WGS-based methods."
            ],
            "Luxembourg": [
                "Core genome multi-locus sequence typing (cgMLST).",
                "Single nucleotide polymorphism (SNP) analysis."
            ],
            "Malta": [
                "Core genome multi-locus sequence typing (cgMLST).",
                "Whole genome multi-locus sequence typing (wgMLST).",
                "Single nucleotide polymorphism (SNP) analysis."
            ],
            "Portugal": [
                "Core genome multi-locus sequence typing (cgMLST).",
                "Whole genome multi-locus sequence typing (wgMLST).",
                "Single nucleotide polymorphism (SNP) analysis."
            ],
            "Norway": [
                "Core genome multi-locus sequence typing (cgMLST).",
                "Single nucleotide polymorphism (SNP) analysis."
            ],
            "Slovenia": [
                "Core genome multi-locus sequence typing (cgMLST).",
                "Whole genome multi-locus sequence typing (wgMLST).",
                "Single nucleotide polymorphism (SNP) analysis."
            ],
            "Estonia": [
                "Core genome multi-locus sequence typing (cgMLST).",
                "Whole genome multi-locus sequence typing (wgMLST).",
                "Single nucleotide polymorphism (SNP) analysis."
            ],
            "Sweden": [
                "Single nucleotide polymorphism (SNP) analysis."
            ],
            "Ukraine": [
                "Not applicable"
            ],
            "Slovak Republic": [
                "Core genome multi-locus sequence typing (cgMLST).",
                "Whole genome multi-locus sequence typing (wgMLST).",
                "Single nucleotide polymorphism (SNP) analysis."
            ],
            "Denmark": [
                "Core genome multi-locus sequence typing (cgMLST).",
                "Whole genome multi-locus sequence typing (wgMLST).",
                "Single nucleotide polymorphism (SNP) analysis."
            ],
            "Latvia": [
                "Not applicable"
            ],
            "Iceland": [
                "Core genome multi-locus sequence typing (cgMLST).",
                "Single nucleotide polymorphism (SNP) analysis."
            ],
            "Bulgaria": [
                "Core genome multi-locus sequence typing (cgMLST).",
                "Single nucleotide polymorphism (SNP) analysis.",
                "Multilocus variable-number tandem repeat analysis (MLVA)."
            ]
        }
    },
    "27": {
        "title": "Which quality control (QC) parameters are used at the national reference/expert laboratory? (Tick all that apply)",
        "short_title": "QC parameters for WGS at NRL?",
        "type": "MultipleChoice",
        "coefficient": 1,
        "tags": [
            "National genomic surveillance"
        ],
        "possible_answers": {
            "Number of reads.": 0.1,
            "Average read length.": 0.33,
            "Depth of Coverage.": 0.33,
            "Number of contigs.": 0.33,
            "N50.": 0.33,
            "Total bp in raw reads.": 0.1,
            "Other.": 0.1,
            "WGS not used.": 0
        },
        "actual_answers": {
            "Spain": [
                "Number of reads.",
                "Average read length.",
                "Depth of Coverage.",
                "N50."
            ],
            "Austria": [
                "Number of reads.",
                "Average read length.",
                "Depth of Coverage.",
                "Number of contigs.",
                "N50.",
                "Total bp in raw reads."
            ],
            "Lithuania": [
                "Average read length.",
                "Depth of Coverage.",
                "Number of contigs.",
                "N50."
            ],
            "Croatia": [
                "Number of reads.",
                "Average read length.",
                "Depth of Coverage.",
                "Number of contigs.",
                "N50.",
                "Total bp in raw reads."
            ],
            "Netherlands": [
                "Number of reads.",
                "Depth of Coverage.",
                "Number of contigs."
            ],
            "Ireland": [
                "Number of reads.",
                "Depth of Coverage.",
                "Number of contigs.",
                "N50.",
                "Other."
            ],
            "Germany": [
                "Number of reads.",
                "Average read length.",
                "Depth of Coverage.",
                "Number of contigs.",
                "N50.",
                "Total bp in raw reads."
            ],
            "Poland": [
                "Number of reads.",
                "Average read length.",
                "Depth of Coverage.",
                "Number of contigs.",
                "N50.",
                "Total bp in raw reads."
            ],
            "Italy": [
                "Number of reads.",
                "Average read length.",
                "Depth of Coverage.",
                "Number of contigs.",
                "N50.",
                "Total bp in raw reads."
            ],
            "Greece": [
                "Number of reads.",
                "Average read length.",
                "Depth of Coverage.",
                "Number of contigs.",
                "N50.",
                "Other."
            ],
            "France": [
                "Number of reads.",
                "Average read length.",
                "Depth of Coverage.",
                "Number of contigs.",
                "N50.",
                "Total bp in raw reads."
            ],
            "Czechia": [
                "Depth of Coverage.",
                "Number of contigs.",
                "N50."
            ],
            "Belgium": [
                "Depth of Coverage.",
                "Number of contigs.",
                "N50."
            ],
            "Hungary": [
                "Depth of Coverage.",
                "Number of contigs.",
                "N50."
            ],
            "Finland": [
                "Number of reads.",
                "Average read length.",
                "Depth of Coverage.",
                "Number of contigs.",
                "N50."
            ],
            "Luxembourg": [
                "Depth of Coverage.",
                "Number of contigs.",
                "N50.",
                "Other."
            ],
            "Malta": [
                "Number of reads.",
                "Average read length.",
                "Depth of Coverage.",
                "Number of contigs.",
                "N50."
            ],
            "Portugal": [
                "Number of reads.",
                "Average read length.",
                "Depth of Coverage.",
                "Number of contigs.",
                "N50.",
                "Total bp in raw reads."
            ],
            "Norway": [
                "Number of reads.",
                "Average read length.",
                "Depth of Coverage.",
                "Number of contigs.",
                "N50.",
                "Other."
            ],
            "Slovenia": [
                "Number of reads.",
                "Depth of Coverage.",
                "Number of contigs.",
                "N50."
            ],
            "Estonia": [
                "Number of reads.",
                "Average read length.",
                "Depth of Coverage.",
                "Number of contigs.",
                "N50."
            ],
            "Sweden": [
                "Depth of Coverage.",
                "Number of contigs.",
                "N50.",
                "Other."
            ],
            "Ukraine": [
                "WGS not used."
            ],
            "Slovak Republic": [
                "Number of reads.",
                "Average read length.",
                "Depth of Coverage.",
                "Number of contigs.",
                "Total bp in raw reads."
            ],
            "Denmark": [
                "Number of reads.",
                "Average read length.",
                "Depth of Coverage.",
                "Number of contigs.",
                "N50.",
                "Total bp in raw reads."
            ],
            "Latvia": [
                "Number of reads."
            ],
            "Iceland": [
                "Other."
            ],
            "Bulgaria": [
                "Number of reads.",
                "Average read length.",
                "Depth of Coverage.",
                "Number of contigs.",
                "N50."
            ]
        }
    },
    "28": {
        "title": "How is the sequencing data assembled and analyzed at the national reference/expert laboratory? (Tick all that apply)",
        "short_title": "How is the sequencing data assembled and analyzed at NRL?",
        "type": "MultipleChoice",
        "coefficient": 0,
        "tags": [
            "National genomic surveillance"
        ],
        "possible_answers": {
            "Inhouse pipeline; open access tools only.": 1,
            "Inhouse pipeline; commercial tools only.": 1,
            "Inhouse pipeline; combination open access and commercial tools.": 1,
            "Outsourced to private company.": 1,
            "Do not know.": 1,
            "Other.": 1,
            "WGS not used.": 1
        },
        "actual_answers": {
            "Spain": [
                "Inhouse pipeline; open access tools only."
            ],
            "Austria": [
                "Inhouse pipeline; combination open access and commercial tools."
            ],
            "Lithuania": [
                "Inhouse pipeline; combination open access and commercial tools."
            ],
            "Croatia": [
                "Inhouse pipeline; open access tools only."
            ],
            "Netherlands": [
                "Inhouse pipeline; open access tools only."
            ],
            "Ireland": [
                "Inhouse pipeline; commercial tools only."
            ],
            "Germany": [
                "Inhouse pipeline; combination open access and commercial tools."
            ],
            "Poland": [
                "Inhouse pipeline; combination open access and commercial tools."
            ],
            "Italy": [
                "Inhouse pipeline; combination open access and commercial tools."
            ],
            "Greece": [
                "Inhouse pipeline; open access tools only."
            ],
            "France": [
                "Inhouse pipeline; open access tools only."
            ],
            "Czechia": [
                "Inhouse pipeline; combination open access and commercial tools."
            ],
            "Belgium": [
                "Inhouse pipeline; combination open access and commercial tools."
            ],
            "Hungary": [
                "Inhouse pipeline; combination open access and commercial tools."
            ],
            "Finland": [
                "Inhouse pipeline; combination open access and commercial tools."
            ],
            "Luxembourg": [
                "Inhouse pipeline; combination open access and commercial tools."
            ],
            "Malta": [
                "Other."
            ],
            "Portugal": [
                "Inhouse pipeline; open access tools only."
            ],
            "Norway": [
                "Inhouse pipeline; combination open access and commercial tools."
            ],
            "Slovenia": [
                "Inhouse pipeline; combination open access and commercial tools."
            ],
            "Estonia": [
                "Inhouse pipeline; combination open access and commercial tools."
            ],
            "Sweden": [
                "Inhouse pipeline; commercial tools only."
            ],
            "Ukraine": [
                "WGS not used."
            ],
            "Slovak Republic": [
                "Inhouse pipeline; open access tools only."
            ],
            "Denmark": [
                "Inhouse pipeline; combination open access and commercial tools."
            ],
            "Latvia": [
                "Inhouse pipeline; open access tools only."
            ],
            "Iceland": [
                "Other."
            ],
            "Bulgaria": [
                "Inhouse pipeline; open access tools only."
            ]
        }
    },
    "29": {
        "title": "If applicable, for which purpose can metagenomics sequencing of primary samples be used at the national reference/expert laboratory? (Tick all that apply)Metagenomics sequencing refers to the analysis of the total microbial genomic from a biological sample.",
        "short_title": "Possibility for metagenomic sequencing/analysis at NRL?",
        "type": "MultipleChoice",
        "coefficient": 0,
        "tags": [
            "National genomic surveillance"
        ],
        "possible_answers": {
            "Not applicable.": "null",
            "Diagnostics for individual patients.": 1,
            "Specific research projects.": 1,
            "Do not know.": "null",
            "Other.": 1,
            "WGS not used.": 0
        },
        "actual_answers": {
            "Spain": [
                "Specific research projects."
            ],
            "Austria": [
                "Not applicable."
            ],
            "Lithuania": [
                "Not applicable."
            ],
            "Croatia": [
                "Specific research projects."
            ],
            "Netherlands": [
                "Not applicable."
            ],
            "Ireland": [
                "Not applicable."
            ],
            "Germany": [
                "Not applicable."
            ],
            "Poland": [
                "Specific research projects."
            ],
            "Italy": [
                "Not applicable."
            ],
            "Greece": [
                "Not applicable."
            ],
            "France": [
                "Specific research projects."
            ],
            "Czechia": [
                "Not applicable."
            ],
            "Belgium": [
                "Diagnostics for individual patients.",
                "Specific research projects."
            ],
            "Hungary": [
                "Not applicable."
            ],
            "Finland": [
                "WGS not used."
            ],
            "Luxembourg": [
                "Not applicable."
            ],
            "Malta": [
                "Diagnostics for individual patients.",
                "Specific research projects."
            ],
            "Portugal": [
                "Specific research projects."
            ],
            "Norway": [
                "Not applicable."
            ],
            "Slovenia": [
                "Specific research projects."
            ],
            "Estonia": [
                "Not applicable."
            ],
            "Sweden": [
                "Specific research projects."
            ],
            "Ukraine": [
                "WGS not used."
            ],
            "Slovak Republic": [
                "Not applicable."
            ],
            "Denmark": [
                "Specific research projects."
            ],
            "Latvia": [
                "Specific research projects."
            ],
            "Iceland": [
                "WGS not used."
            ],
            "Bulgaria": [
                "Specific research projects."
            ]
        }
    },
    "30": {
        "title": "Does the national reference/expert laboratory participate in national and/or international external quality assessment (EQA) programs for WGS for one or several of the included pathogens?",
        "short_title": "Participation of NRL in EQA for WGS?",
        "type": "SingleChoice",
        "coefficient": 1,
        "tags": [
            "National genomic surveillance"
        ],
        "possible_answers": {
            "Yes, annually.": 1,
            "Yes, less often than annually.": 0.5,
            "No.": 0,
            "Do not know.": "null",
            "WGS not used.": 0
        },
        "actual_answers": {
            "Spain": "Yes, less often than annually.",
            "Austria": "Yes, annually.",
            "Lithuania": "Yes, annually.",
            "Croatia": "Yes, less often than annually.",
            "Netherlands": "Yes, less often than annually.",
            "Ireland": "Yes, annually.",
            "Germany": "Yes, less often than annually.",
            "Poland": "Yes, annually.",
            "Italy": "Yes, annually.",
            "Greece": "Yes, annually.",
            "France": "No.",
            "Czechia": "Yes, less often than annually.",
            "Belgium": "Yes, annually.",
            "Hungary": "Yes, annually.",
            "Finland": "Yes, annually.",
            "Luxembourg": "Yes, annually.",
            "Malta": "Yes, annually.",
            "Portugal": "Yes, less often than annually.",
            "Norway": "Yes, annually.",
            "Slovenia": "Yes, annually.",
            "Estonia": "Yes, annually.",
            "Sweden": "Yes, annually.",
            "Ukraine": "WGS not used.",
            "Slovak Republic": "Yes, annually.",
            "Denmark": "Yes, annually.",
            "Latvia": "Yes, annually.",
            "Iceland": "Yes, annually.",
            "Bulgaria": "Yes, annually."
        }
    },
    "31": {
        "title": "Does the national reference/expert laboratory organize national external quality assessment (EQA) programs for WGS for one or several of the included pathogens within the country?",
        "short_title": "NRL organizing EQAs within country?",
        "type": "SingleChoice",
        "coefficient": 0,
        "tags": [
            "National genomic surveillance"
        ],
        "possible_answers": {
            "Yes.": 1,
            "No.": 1,
            "Do not know.": "null",
            "WGS not used.": 0
        },
        "actual_answers": {
            "Spain": "No.",
            "Austria": "No.",
            "Lithuania": "No.",
            "Croatia": "No.",
            "Netherlands": "No.",
            "Ireland": "No.",
            "Germany": "No.",
            "Poland": "No.",
            "Italy": "No.",
            "Greece": "No.",
            "France": "No.",
            "Czechia": "No.",
            "Belgium": "Yes.",
            "Hungary": "No.",
            "Finland": "No.",
            "Luxembourg": "No.",
            "Malta": "No.",
            "Portugal": "No.",
            "Norway": "No.",
            "Slovenia": "No.",
            "Estonia": "No.",
            "Sweden": "No.",
            "Ukraine": "WGS not used.",
            "Slovak Republic": "No.",
            "Denmark": "Yes.",
            "Latvia": "No.",
            "Iceland": "No.",
            "Bulgaria": "No."
        }
    },
    "32": {
        "title": "Where is the WGS raw read data collected or produced by the national reference/expert laboratory stored?",
        "short_title": "Where is the WGS raw read data stored by NRL?",
        "type": "SingleChoice",
        "coefficient": 0,
        "tags": [
            "National genomic surveillance"
        ],
        "possible_answers": {
            "Inhouse storage.": 1,
            "External storage.": 1,
            "Other.": 1,
            "WGS not used.": 0
        },
        "actual_answers": {
            "Spain": "Inhouse storage.",
            "Austria": "Inhouse storage.",
            "Lithuania": "Inhouse storage.",
            "Croatia": "Inhouse storage.",
            "Netherlands": "Inhouse storage.",
            "Ireland": "Inhouse storage.",
            "Germany": "Inhouse storage.",
            "Poland": "Inhouse storage.",
            "Italy": "Inhouse storage.",
            "Greece": "Inhouse storage.",
            "France": "External storage.",
            "Czechia": "Inhouse storage.",
            "Belgium": "Inhouse storage.",
            "Hungary": "Inhouse storage.",
            "Finland": "Inhouse storage.",
            "Luxembourg": "Inhouse storage.",
            "Malta": "Inhouse storage.",
            "Portugal": "Inhouse storage.",
            "Norway": "Inhouse storage.",
            "Slovenia": "Inhouse storage.",
            "Estonia": "Inhouse storage.",
            "Sweden": "Inhouse storage.",
            "Ukraine": "WGS not used.",
            "Slovak Republic": "External storage.",
            "Denmark": "External storage.",
            "Latvia": "Inhouse storage.",
            "Iceland": "Other.",
            "Bulgaria": "Inhouse storage."
        }
    },
    "33": {
        "title": "Is the WGS data produced by the national reference/expert laboratory submitted to public repositories (e.g., NCBI, ENA) on a regular basis (i.e. monthly, annually)?",
        "short_title": "WGS data submitted by NRL to public repositories?",
        "type": "SingleChoice",
        "coefficient": 1,
        "tags": [
            "National genomic surveillance"
        ],
        "possible_answers": {
            "Yes, all data.": 1,
            "Yes, some data.": 0.5,
            "No.": 0,
            "WGS not used.": 0
        },
        "actual_answers": {
            "Spain": "Yes, some data.",
            "Austria": "Yes, some data.",
            "Lithuania": "No.",
            "Croatia": "Yes, some data.",
            "Netherlands": "No.",
            "Ireland": "Yes, some data.",
            "Germany": "Yes, some data.",
            "Poland": "Yes, some data.",
            "Italy": "Yes, some data.",
            "Greece": "Yes, some data.",
            "France": "No.",
            "Czechia": "No.",
            "Belgium": "No.",
            "Hungary": "No.",
            "Finland": "No.",
            "Luxembourg": "Yes, some data.",
            "Malta": "No.",
            "Portugal": "Yes, some data.",
            "Norway": "No.",
            "Slovenia": "Yes, some data.",
            "Estonia": "Yes, some data.",
            "Sweden": "No.",
            "Ukraine": "WGS not used.",
            "Slovak Republic": "Yes, all data.",
            "Denmark": "Yes, some data.",
            "Latvia": "Yes, all data.",
            "Iceland": "No.",
            "Bulgaria": "Yes, some data."
        }
    },
    "34": {
        "title": "What are the main areas in need of development in the implementation and application of WGS at the national reference/expert laboratory? (Select max 4 options)",
        "short_title": "Main areas for development of WGS at NRL?",
        "type": "MultipleChoice",
        "coefficient": 0,
        "tags": [
            "National genomic surveillance"
        ],
        "possible_answers": {
            "Technical infrastructure relating to sequencing instruments.": 1,
            "Technical infrastructure relating to data processing, analysis and visualization.": 1,
            "Technical infrastructure relating to data storage.": 1,
            "Capacity, laboratory knowledge/skills.": 1,
            "Capacity, bioinformatics.": 1,
            "Capacity, use of data for management of patient treatment(s) and/or for public health surveillance.": 1,
            "Funding, infrastructure.": 1,
            "Funding, human resources.": 1,
            "Funding, training for available personnel.": 1,
            "Legal obstacles.": 1,
            "Lack of political decision/willingness.": 1,
            "Other": 1
        },
        "actual_answers": {
            "Spain": [
                "Funding, human resources.",
                "Funding, training for available personnel."
            ],
            "Austria": [
                "Capacity, laboratory knowledge/skills.",
                "Capacity, bioinformatics.",
                "Funding, infrastructure.",
                "Funding, human resources."
            ],
            "Lithuania": [
                "Capacity, use of data for management of patient treatment(s) and/or for public health surveillance.",
                "Funding, human resources.",
                "Funding, training for available personnel.",
                "Legal obstacles."
            ],
            "Croatia": [
                "Technical infrastructure relating to data storage.",
                "Funding, infrastructure."
            ],
            "Netherlands": [
                "Technical infrastructure relating to data processing, analysis and visualization.",
                "Funding, infrastructure.",
                "Other"
            ],
            "Ireland": [
                "Funding, infrastructure.",
                "Funding, human resources.",
                "Other"
            ],
            "Germany": [
                "Capacity, bioinformatics.",
                "Capacity, use of data for management of patient treatment(s) and/or for public health surveillance.",
                "Funding, infrastructure.",
                "Funding, human resources."
            ],
            "Poland": [
                "Capacity, bioinformatics.",
                "Funding, human resources.",
                "Legal obstacles.",
                "Lack of political decision/willingness."
            ],
            "Italy": [
                "Technical infrastructure relating to data storage.",
                "Capacity, bioinformatics.",
                "Funding, infrastructure.",
                "Funding, human resources."
            ],
            "Greece": [
                "Funding, human resources.",
                "Other"
            ],
            "France": [
                "Funding, human resources.",
                "Funding, training for available personnel.",
                "Other"
            ],
            "Czechia": [
                "Capacity, use of data for management of patient treatment(s) and/or for public health surveillance.",
                "Funding, infrastructure.",
                "Funding, human resources.",
                "Lack of political decision/willingness."
            ],
            "Belgium": [
                "Technical infrastructure relating to data storage.",
                "Capacity, use of data for management of patient treatment(s) and/or for public health surveillance.",
                "Funding, infrastructure.",
                "Legal obstacles."
            ],
            "Hungary": [
                "Technical infrastructure relating to data processing, analysis and visualization.",
                "Technical infrastructure relating to data storage.",
                "Capacity, bioinformatics.",
                "Funding, infrastructure."
            ],
            "Finland": [
                "Technical infrastructure relating to data processing, analysis and visualization.",
                "Capacity, bioinformatics.",
                "Funding, infrastructure.",
                "Lack of political decision/willingness."
            ],
            "Luxembourg": [
                "Capacity, use of data for management of patient treatment(s) and/or for public health surveillance.",
                "Legal obstacles.",
                "Lack of political decision/willingness."
            ],
            "Malta": [
                "Capacity, bioinformatics.",
                "Funding, infrastructure.",
                "Funding, human resources.",
                "Funding, training for available personnel."
            ],
            "Portugal": [
                "Technical infrastructure relating to data processing, analysis and visualization.",
                "Capacity, laboratory knowledge/skills.",
                "Capacity, use of data for management of patient treatment(s) and/or for public health surveillance.",
                "Funding, human resources."
            ],
            "Norway": [
                "Capacity, bioinformatics.",
                "Funding, infrastructure.",
                "Funding, human resources.",
                "Legal obstacles."
            ],
            "Slovenia": [
                "Capacity, use of data for management of patient treatment(s) and/or for public health surveillance.",
                "Funding, human resources.",
                "Legal obstacles.",
                "Lack of political decision/willingness."
            ],
            "Estonia": [
                "Technical infrastructure relating to data processing, analysis and visualization.",
                "Capacity, bioinformatics.",
                "Capacity, use of data for management of patient treatment(s) and/or for public health surveillance.",
                "Funding, human resources."
            ],
            "Sweden": [
                "Technical infrastructure relating to data processing, analysis and visualization.",
                "Technical infrastructure relating to data storage.",
                "Funding, human resources."
            ],
            "Ukraine": [
                "Technical infrastructure relating to data processing, analysis and visualization.",
                "Technical infrastructure relating to data storage.",
                "Capacity, use of data for management of patient treatment(s) and/or for public health surveillance.",
                "Funding, training for available personnel."
            ],
            "Slovak Republic": [
                "Technical infrastructure relating to sequencing instruments.",
                "Capacity, laboratory knowledge/skills.",
                "Funding, infrastructure.",
                "Lack of political decision/willingness."
            ],
            "Denmark": [
                "Funding, infrastructure.",
                "Funding, human resources."
            ],
            "Latvia": [
                "Capacity, laboratory knowledge/skills.",
                "Capacity, bioinformatics.",
                "Capacity, use of data for management of patient treatment(s) and/or for public health surveillance.",
                "Funding, human resources."
            ],
            "Iceland": [
                "Funding, human resources.",
                "Funding, training for available personnel.",
                "Lack of political decision/willingness.",
                "Other"
            ],
            "Bulgaria": [
                "Funding, infrastructure.",
                "Funding, human resources.",
                "Lack of political decision/willingness."
            ]
        }
    },
    "35": {
        "title": "You answered other to the question: \"What are the main areas in need of development in the implementation and application of WGS at the national expert laboratory?\"Please specify.",
        "short_title": "",
        "type": "FreeText",
        "coefficient": 0,
        "tags": [
            "National genomic surveillance"
        ],
        "possible_answers": {},
        "actual_answers": {
            "Spain": "",
            "Austria": "",
            "Lithuania": "",
            "Croatia": "",
            "Netherlands": "We are working on AMR surveillance with third generation sequencing (TGS) only, because this is cheaper (then we can sequence more isolates) and then we don't have to combine next-generation sequencing and TGS for plasmid analysis.\r\nFurthermore, we want to be able to detect plasmid outbreaks an we are working on that as well.",
            "Ireland": "The microbiology reference laboratory services are fragmented \u2013 delivered from multiple sites without coordination as a national service \u2013 planning to try to address this is in progress ",
            "Germany": "",
            "Poland": "",
            "Italy": "",
            "Greece": "Capacity, access to WGS data from another sector if e.g. an outbreak is identified",
            "France": "funding for reagents and consumables",
            "Czechia": "",
            "Belgium": "",
            "Hungary": "",
            "Finland": "",
            "Luxembourg": "",
            "Malta": "",
            "Portugal": "",
            "Norway": "",
            "Slovenia": "",
            "Estonia": "",
            "Sweden": "",
            "Ukraine": "",
            "Slovak Republic": "",
            "Denmark": "",
            "Latvia": "",
            "Iceland": "Answer to #34: Funding for cost of consumables for WGS. \r\n\r\nGeneral comment: Please note that WGS of bacteria/AMR is not in routine use yet in the NRL. Selected strains are sent for WGS to laboratories in abroad (mainly carbapenemase-producing organisms).\r\nWGS is currently being implemented in the NRL but validation of the WGS assays / methodology is not complete. WGS has been used \"experimentally\" in the NRL in the case of domestic FWD outbreak investigations. \r\n\r\n",
            "Bulgaria": ""
        }
    },
    "36.1": {
        "title": "Which of the following pathogens are under national surveillance? Mandatory: Means that the pathogen is notifiable according to your country communicable disease legislation or an equivalent legislation. Voluntary: Not mandatory/notifiable but still under national surveillance. Screening: culturing to identify carriage and/or colonization. This can be different sample types but not related to clinical infection. : E. coli (carbapenem R and/or P) : Blood/CSF",
        "short_title": "Which pathogens are under mandatory national surveillance? Carbapenem resistant E. coli - blood.",
        "type": "SingleChoice",
        "coefficient": 0.019,
        "tags": [
            "National surveillance",
            "E. coli",
            "Carbapenem",
            "Blood"
        ],
        "possible_answers": {
            "Yes, mandatory": 1,
            "Yes, voluntary": 1,
            "No": 0
        },
        "actual_answers": {
            "Spain": "Yes, mandatory",
            "Austria": "Yes, voluntary",
            "Lithuania": "Yes, mandatory",
            "Croatia": "Yes, voluntary",
            "Netherlands": "Yes, mandatory",
            "Ireland": "Yes, mandatory",
            "Germany": "Yes, mandatory",
            "Poland": "Yes, mandatory",
            "Italy": "Yes, voluntary",
            "Greece": "Yes, voluntary",
            "France": "Yes, voluntary",
            "Czechia": "Yes, mandatory",
            "Belgium": "Yes, mandatory",
            "Hungary": "Yes, mandatory",
            "Finland": "Yes, mandatory",
            "Luxembourg": "Yes, mandatory",
            "Malta": "Yes, voluntary",
            "Portugal": "Yes, mandatory",
            "Norway": "Yes, mandatory",
            "Slovenia": "Yes, mandatory",
            "Estonia": "Yes, mandatory",
            "Sweden": "Yes, mandatory",
            "Ukraine": "Yes, mandatory",
            "Slovak Republic": "Yes, mandatory",
            "Denmark": "Yes, mandatory",
            "Latvia": "Yes, mandatory",
            "Iceland": "Yes, mandatory",
            "Bulgaria": "Yes, mandatory"
        }
    },
    "36.2": {
        "title": "Which of the following pathogens are under national surveillance? Mandatory: Means that the pathogen is notifiable according to your country communicable disease legislation or an equivalent legislation. Voluntary: Not mandatory/notifiable but still under national surveillance. Screening: culturing to identify carriage and/or colonization. This can be different sample types but not related to clinical infection. : E. coli (carbapenem R and/or P) : Urine",
        "short_title": "Which pathogens are under mandatory national surveillance? Carbapenem resistant E. coli - urine.",
        "type": "SingleChoice",
        "coefficient": 0.019,
        "tags": [
            "National surveillance",
            "E. coli",
            "Carbapenem",
            "Urine"
        ],
        "possible_answers": {
            "Yes, mandatory": 1,
            "Yes, voluntary": 1,
            "No": 0
        },
        "actual_answers": {
            "Spain": "Yes, mandatory",
            "Austria": "Yes, voluntary",
            "Lithuania": "Yes, mandatory",
            "Croatia": "Yes, voluntary",
            "Netherlands": "Yes, mandatory",
            "Ireland": "Yes, mandatory",
            "Germany": "Yes, mandatory",
            "Poland": "Yes, mandatory",
            "Italy": "Yes, voluntary",
            "Greece": "Yes, voluntary",
            "France": "Yes, voluntary",
            "Czechia": "Yes, mandatory",
            "Belgium": "Yes, mandatory",
            "Hungary": "Yes, mandatory",
            "Finland": "Yes, mandatory",
            "Luxembourg": "Yes, voluntary",
            "Malta": "Yes, voluntary",
            "Portugal": "Yes, voluntary",
            "Norway": "Yes, mandatory",
            "Slovenia": "No",
            "Estonia": "Yes, mandatory",
            "Sweden": "Yes, mandatory",
            "Ukraine": "No",
            "Slovak Republic": "Yes, mandatory",
            "Denmark": "Yes, mandatory",
            "Latvia": "Yes, voluntary",
            "Iceland": "Yes, mandatory",
            "Bulgaria": "Yes, voluntary"
        }
    },
    "36.3": {
        "title": "Which of the following pathogens are under national surveillance? Mandatory: Means that the pathogen is notifiable according to your country communicable disease legislation or an equivalent legislation. Voluntary: Not mandatory/notifiable but still under national surveillance. Screening: culturing to identify carriage and/or colonization. This can be different sample types but not related to clinical infection. : E. coli (carbapenem R and/or P) : Lower respiratory tract",
        "short_title": "Which pathogens are under mandatory national surveillance? Carbapenem resistant E. coli - lower respiratory tract.",
        "type": "SingleChoice",
        "coefficient": 0.019,
        "tags": [
            "National surveillance",
            "E. coli",
            "Carbapenem",
            "Respiratory tract"
        ],
        "possible_answers": {
            "Yes, mandatory": 1,
            "Yes, voluntary": 1,
            "No": 0
        },
        "actual_answers": {
            "Spain": "Yes, voluntary",
            "Austria": "Yes, voluntary",
            "Lithuania": "Yes, mandatory",
            "Croatia": "Yes, voluntary",
            "Netherlands": "Yes, mandatory",
            "Ireland": "Yes, mandatory",
            "Germany": "Yes, mandatory",
            "Poland": "Yes, mandatory",
            "Italy": "No",
            "Greece": "Yes, voluntary",
            "France": "Yes, voluntary",
            "Czechia": "Yes, mandatory",
            "Belgium": "No",
            "Hungary": "Yes, mandatory",
            "Finland": "Yes, mandatory",
            "Luxembourg": "Yes, voluntary",
            "Malta": "Yes, voluntary",
            "Portugal": "Yes, voluntary",
            "Norway": "Yes, mandatory",
            "Slovenia": "No",
            "Estonia": "Yes, mandatory",
            "Sweden": "Yes, mandatory",
            "Ukraine": "No",
            "Slovak Republic": "Yes, mandatory",
            "Denmark": "Yes, mandatory",
            "Latvia": "Yes, voluntary",
            "Iceland": "Yes, mandatory",
            "Bulgaria": "Yes, voluntary"
        }
    },
    "36.4": {
        "title": "Which of the following pathogens are under national surveillance? Mandatory: Means that the pathogen is notifiable according to your country communicable disease legislation or an equivalent legislation. Voluntary: Not mandatory/notifiable but still under national surveillance. Screening: culturing to identify carriage and/or colonization. This can be different sample types but not related to clinical infection. : E. coli (carbapenem R and/or P) : Screening",
        "short_title": "Which pathogens are under mandatory national surveillance? Carbapenem resistant E. coli - screening",
        "type": "SingleChoice",
        "coefficient": 0.019,
        "tags": [
            "National surveillance",
            "E. coli",
            "Carbapenem",
            "Screening"
        ],
        "possible_answers": {
            "Yes, mandatory": 1,
            "Yes, voluntary": 1,
            "No": 0
        },
        "actual_answers": {
            "Spain": "Yes, voluntary",
            "Austria": "Yes, voluntary",
            "Lithuania": "No",
            "Croatia": "Yes, voluntary",
            "Netherlands": "Yes, mandatory",
            "Ireland": "Yes, mandatory",
            "Germany": "Yes, mandatory",
            "Poland": "No",
            "Italy": "No",
            "Greece": "Yes, voluntary",
            "France": "No",
            "Czechia": "Yes, mandatory",
            "Belgium": "Yes, mandatory",
            "Hungary": "Yes, mandatory",
            "Finland": "Yes, mandatory",
            "Luxembourg": "Yes, voluntary",
            "Malta": "Yes, voluntary",
            "Portugal": "Yes, voluntary",
            "Norway": "Yes, mandatory",
            "Slovenia": "Yes, mandatory",
            "Estonia": "Yes, mandatory",
            "Sweden": "Yes, mandatory",
            "Ukraine": "No",
            "Slovak Republic": "Yes, mandatory",
            "Denmark": "Yes, voluntary",
            "Latvia": "Yes, voluntary",
            "Iceland": "Yes, mandatory",
            "Bulgaria": "No"
        }
    },
    "36.5": {
        "title": "Which of the following pathogens are under national surveillance? Mandatory: Means that the pathogen is notifiable according to your country communicable disease legislation or an equivalent legislation. Voluntary: Not mandatory/notifiable but still under national surveillance. Screening: culturing to identify carriage and/or colonization. This can be different sample types but not related to clinical infection. : E. coli (colistin R) : Blood/CSF",
        "short_title": "Which pathogens are under mandatory national surveillance? Colistin resistant E. coli - blood.",
        "type": "SingleChoice",
        "coefficient": 0.019,
        "tags": [
            "National surveillance",
            "E. coli",
            "Colistin",
            "Blood"
        ],
        "possible_answers": {
            "Yes, mandatory": 1,
            "Yes, voluntary": 1,
            "No": 0
        },
        "actual_answers": {
            "Spain": "Yes, voluntary",
            "Austria": "Yes, voluntary",
            "Lithuania": "No",
            "Croatia": "Yes, voluntary",
            "Netherlands": "Yes, voluntary",
            "Ireland": "Yes, mandatory",
            "Germany": "No",
            "Poland": "Yes, mandatory",
            "Italy": "Yes, voluntary",
            "Greece": "Yes, voluntary",
            "France": "Yes, voluntary",
            "Czechia": "Yes, voluntary",
            "Belgium": "No",
            "Hungary": "Yes, mandatory",
            "Finland": "No",
            "Luxembourg": "Yes, voluntary",
            "Malta": "Yes, voluntary",
            "Portugal": "Yes, mandatory",
            "Norway": "Yes, mandatory",
            "Slovenia": "Yes, voluntary",
            "Estonia": "Yes, mandatory",
            "Sweden": "Yes, voluntary",
            "Ukraine": "Yes, mandatory",
            "Slovak Republic": "Yes, voluntary",
            "Denmark": "Yes, mandatory",
            "Latvia": "Yes, mandatory",
            "Iceland": "No",
            "Bulgaria": "Yes, mandatory"
        }
    },
    "36.6": {
        "title": "Which of the following pathogens are under national surveillance? Mandatory: Means that the pathogen is notifiable according to your country communicable disease legislation or an equivalent legislation. Voluntary: Not mandatory/notifiable but still under national surveillance. Screening: culturing to identify carriage and/or colonization. This can be different sample types but not related to clinical infection. : E. coli (3GC- R and/or P) : Blood/CSF",
        "short_title": "Which pathogens are under mandatory national surveillance? 3rd-generation cephalosporins resistant E. coli - blood.",
        "type": "SingleChoice",
        "coefficient": 0.019,
        "tags": [
            "National surveillance",
            "E. coli",
            "3rd-generation Cephalosporin",
            "Blood"
        ],
        "possible_answers": {
            "Yes, mandatory": 1,
            "Yes, voluntary": 1,
            "No": 0
        },
        "actual_answers": {
            "Spain": "Yes, voluntary",
            "Austria": "Yes, voluntary",
            "Lithuania": "Yes, mandatory",
            "Croatia": "Yes, voluntary",
            "Netherlands": "Yes, voluntary",
            "Ireland": "Yes, mandatory",
            "Germany": "No",
            "Poland": "Yes, mandatory",
            "Italy": "Yes, voluntary",
            "Greece": "Yes, voluntary",
            "France": "Yes, voluntary",
            "Czechia": "Yes, voluntary",
            "Belgium": "Yes, mandatory",
            "Hungary": "Yes, mandatory",
            "Finland": "Yes, mandatory",
            "Luxembourg": "Yes, mandatory",
            "Malta": "Yes, voluntary",
            "Portugal": "Yes, mandatory",
            "Norway": "Yes, voluntary",
            "Slovenia": "Yes, voluntary",
            "Estonia": "Yes, mandatory",
            "Sweden": "Yes, mandatory",
            "Ukraine": "Yes, mandatory",
            "Slovak Republic": "Yes, voluntary",
            "Denmark": "Yes, voluntary",
            "Latvia": "Yes, mandatory",
            "Iceland": "Yes, mandatory",
            "Bulgaria": "Yes, voluntary"
        }
    },
    "36.7": {
        "title": "Which of the following pathogens are under national surveillance? Mandatory: Means that the pathogen is notifiable according to your country communicable disease legislation or an equivalent legislation. Voluntary: Not mandatory/notifiable but still under national surveillance. Screening: culturing to identify carriage and/or colonization. This can be different sample types but not related to clinical infection. : E. coli (3GC- R and/or P) : Urine",
        "short_title": "Which pathogens are under mandatory national surveillance? 3rd-generation cephalosporins resistant E. coli - urine.",
        "type": "SingleChoice",
        "coefficient": 0.019,
        "tags": [
            "National surveillance",
            "E. coli",
            "3rd-generation Cephalosporin",
            "Urine"
        ],
        "possible_answers": {
            "Yes, mandatory": 1,
            "Yes, voluntary": 1,
            "No": 0
        },
        "actual_answers": {
            "Spain": "Yes, voluntary",
            "Austria": "Yes, voluntary",
            "Lithuania": "No",
            "Croatia": "No",
            "Netherlands": "Yes, voluntary",
            "Ireland": "Yes, voluntary",
            "Germany": "No",
            "Poland": "Yes, mandatory",
            "Italy": "Yes, voluntary",
            "Greece": "Yes, voluntary",
            "France": "Yes, voluntary",
            "Czechia": "Yes, voluntary",
            "Belgium": "Yes, mandatory",
            "Hungary": "Yes, mandatory",
            "Finland": "Yes, mandatory",
            "Luxembourg": "Yes, voluntary",
            "Malta": "Yes, voluntary",
            "Portugal": "No",
            "Norway": "Yes, voluntary",
            "Slovenia": "No",
            "Estonia": "Yes, mandatory",
            "Sweden": "Yes, mandatory",
            "Ukraine": "No",
            "Slovak Republic": "Yes, voluntary",
            "Denmark": "Yes, voluntary",
            "Latvia": "Yes, voluntary",
            "Iceland": "Yes, mandatory",
            "Bulgaria": "Yes, voluntary"
        }
    },
    "36.8": {
        "title": "Which of the following pathogens are under national surveillance? Mandatory: Means that the pathogen is notifiable according to your country communicable disease legislation or an equivalent legislation. Voluntary: Not mandatory/notifiable but still under national surveillance. Screening: culturing to identify carriage and/or colonization. This can be different sample types but not related to clinical infection. : E. coli (3GC- R and/or P) : Lower respiratory tract",
        "short_title": "Which pathogens are under mandatory national surveillance? 3rd-generation cephalosporins resistant E. coli - lower respiratory tract.",
        "type": "SingleChoice",
        "coefficient": 0.019,
        "tags": [
            "National surveillance",
            "E. coli",
            "3rd-generation Cephalosporin",
            "Respiratory tract"
        ],
        "possible_answers": {
            "Yes, mandatory": 1,
            "Yes, voluntary": 1,
            "No": 0
        },
        "actual_answers": {
            "Spain": "Yes, voluntary",
            "Austria": "No",
            "Lithuania": "No",
            "Croatia": "No",
            "Netherlands": "Yes, voluntary",
            "Ireland": "Yes, voluntary",
            "Germany": "No",
            "Poland": "Yes, mandatory",
            "Italy": "No",
            "Greece": "Yes, voluntary",
            "France": "Yes, voluntary",
            "Czechia": "No",
            "Belgium": "Yes, voluntary",
            "Hungary": "Yes, mandatory",
            "Finland": "Yes, mandatory",
            "Luxembourg": "Yes, voluntary",
            "Malta": "Yes, voluntary",
            "Portugal": "No",
            "Norway": "Yes, voluntary",
            "Slovenia": "No",
            "Estonia": "Yes, mandatory",
            "Sweden": "Yes, mandatory",
            "Ukraine": "No",
            "Slovak Republic": "Yes, voluntary",
            "Denmark": "No",
            "Latvia": "No",
            "Iceland": "Yes, mandatory",
            "Bulgaria": "Yes, voluntary"
        }
    },
    "36.9": {
        "title": "Which of the following pathogens are under national surveillance? Mandatory: Means that the pathogen is notifiable according to your country communicable disease legislation or an equivalent legislation. Voluntary: Not mandatory/notifiable but still under national surveillance. Screening: culturing to identify carriage and/or colonization. This can be different sample types but not related to clinical infection. : E. coli (3GC- R and/or P) : Screening",
        "short_title": "Which pathogens are under mandatory national surveillance? 3rd-generation cephalosporins resistant E. coli - screening.",
        "type": "SingleChoice",
        "coefficient": 0.019,
        "tags": [
            "National surveillance",
            "E. coli",
            "3rd-generation Cephalosporin",
            "Screening"
        ],
        "possible_answers": {
            "Yes, mandatory": 1,
            "Yes, voluntary": 1,
            "No": 0
        },
        "actual_answers": {
            "Spain": "Yes, voluntary",
            "Austria": "No",
            "Lithuania": "No",
            "Croatia": "No",
            "Netherlands": "Yes, voluntary",
            "Ireland": "Yes, mandatory",
            "Germany": "No",
            "Poland": "No",
            "Italy": "No",
            "Greece": "Yes, voluntary",
            "France": "No",
            "Czechia": "No",
            "Belgium": "No",
            "Hungary": "Yes, mandatory",
            "Finland": "Yes, mandatory",
            "Luxembourg": "Yes, voluntary",
            "Malta": "Yes, voluntary",
            "Portugal": "No",
            "Norway": "Yes, voluntary",
            "Slovenia": "Yes, mandatory",
            "Estonia": "Yes, mandatory",
            "Sweden": "Yes, mandatory",
            "Ukraine": "No",
            "Slovak Republic": "Yes, voluntary",
            "Denmark": "No",
            "Latvia": "No",
            "Iceland": "Yes, mandatory",
            "Bulgaria": "No"
        }
    },
    "36.10": {
        "title": "Which of the following pathogens are under national surveillance? Mandatory: Means that the pathogen is notifiable according to your country communicable disease legislation or an equivalent legislation. Voluntary: Not mandatory/notifiable but still under national surveillance. Screening: culturing to identify carriage and/or colonization. This can be different sample types but not related to clinical infection. : E. coli (colistin R) : Screening",
        "short_title": "Which pathogens are under mandatory national surveillance? Colistin resistant E. coli - screening.",
        "type": "SingleChoice",
        "coefficient": 0.019,
        "tags": [
            "National surveillance",
            "E. coli",
            "Colistin",
            "Screening"
        ],
        "possible_answers": {
            "Yes, mandatory": 1,
            "Yes, voluntary": 1,
            "No": 0
        },
        "actual_answers": {
            "Spain": "Yes, voluntary",
            "Austria": "No",
            "Lithuania": "No",
            "Croatia": "No",
            "Netherlands": "Yes, voluntary",
            "Ireland": "Yes, mandatory",
            "Germany": "No",
            "Poland": "No",
            "Italy": "No",
            "Greece": "Yes, voluntary",
            "France": "No",
            "Czechia": "Yes, voluntary",
            "Belgium": "No",
            "Hungary": "Yes, mandatory",
            "Finland": "No",
            "Luxembourg": "Yes, voluntary",
            "Malta": "Yes, voluntary",
            "Portugal": "Yes, mandatory",
            "Norway": "Yes, mandatory",
            "Slovenia": "No",
            "Estonia": "Yes, mandatory",
            "Sweden": "Yes, voluntary",
            "Ukraine": "No",
            "Slovak Republic": "Yes, voluntary",
            "Denmark": "Yes, mandatory",
            "Latvia": "Yes, voluntary",
            "Iceland": "No",
            "Bulgaria": "No"
        }
    },
    "36.11": {
        "title": "Which of the following pathogens are under national surveillance? Mandatory: Means that the pathogen is notifiable according to your country communicable disease legislation or an equivalent legislation. Voluntary: Not mandatory/notifiable but still under national surveillance. Screening: culturing to identify carriage and/or colonization. This can be different sample types but not related to clinical infection. : K. pneumoniae (carbapenem R and/or P) : Screening",
        "short_title": "Which pathogens are under mandatory national surveillance? Carbapenem resistant K. pneumoniae - screening.",
        "type": "SingleChoice",
        "coefficient": 0.019,
        "tags": [
            "National surveillance",
            "K. pneumoniae",
            "Carbapenem",
            "Screening"
        ],
        "possible_answers": {
            "Yes, mandatory": 1,
            "Yes, voluntary": 1,
            "No": 0
        },
        "actual_answers": {
            "Spain": "Yes, voluntary",
            "Austria": "Yes, voluntary",
            "Lithuania": "No",
            "Croatia": "Yes, voluntary",
            "Netherlands": "Yes, mandatory",
            "Ireland": "Yes, mandatory",
            "Germany": "Yes, mandatory",
            "Poland": "Yes, mandatory",
            "Italy": "No",
            "Greece": "Yes, voluntary",
            "France": "No",
            "Czechia": "Yes, mandatory",
            "Belgium": "Yes, mandatory",
            "Hungary": "Yes, mandatory",
            "Finland": "Yes, mandatory",
            "Luxembourg": "Yes, voluntary",
            "Malta": "Yes, voluntary",
            "Portugal": "Yes, voluntary",
            "Norway": "Yes, mandatory",
            "Slovenia": "Yes, mandatory",
            "Estonia": "Yes, mandatory",
            "Sweden": "Yes, mandatory",
            "Ukraine": "No",
            "Slovak Republic": "Yes, mandatory",
            "Denmark": "Yes, mandatory",
            "Latvia": "Yes, voluntary",
            "Iceland": "Yes, mandatory",
            "Bulgaria": "No"
        }
    },
    "36.12": {
        "title": "Which of the following pathogens are under national surveillance? Mandatory: Means that the pathogen is notifiable according to your country communicable disease legislation or an equivalent legislation. Voluntary: Not mandatory/notifiable but still under national surveillance. Screening: culturing to identify carriage and/or colonization. This can be different sample types but not related to clinical infection. : K. pneumoniae (3GC- R and/or P) : Screening",
        "short_title": "Which pathogens are under mandatory national surveillance? 3rd-generation cephalosporins resistant K. pneumoniae - screening.",
        "type": "SingleChoice",
        "coefficient": 0.019,
        "tags": [
            "National surveillance",
            "K. pneumoniae",
            "3rd-generation Cephalosporin",
            "Screening"
        ],
        "possible_answers": {
            "Yes, mandatory": 1,
            "Yes, voluntary": 1,
            "No": 0
        },
        "actual_answers": {
            "Spain": "Yes, voluntary",
            "Austria": "Yes, voluntary",
            "Lithuania": "No",
            "Croatia": "No",
            "Netherlands": "Yes, voluntary",
            "Ireland": "Yes, mandatory",
            "Germany": "No",
            "Poland": "No",
            "Italy": "No",
            "Greece": "Yes, voluntary",
            "France": "No",
            "Czechia": "No",
            "Belgium": "Yes, mandatory",
            "Hungary": "Yes, mandatory",
            "Finland": "Yes, mandatory",
            "Luxembourg": "Yes, voluntary",
            "Malta": "Yes, voluntary",
            "Portugal": "No",
            "Norway": "Yes, voluntary",
            "Slovenia": "Yes, mandatory",
            "Estonia": "Yes, mandatory",
            "Sweden": "Yes, mandatory",
            "Ukraine": "No",
            "Slovak Republic": "Yes, voluntary",
            "Denmark": "No",
            "Latvia": "Yes, voluntary",
            "Iceland": "Yes, mandatory",
            "Bulgaria": "No"
        }
    },
    "36.13": {
        "title": "Which of the following pathogens are under national surveillance? Mandatory: Means that the pathogen is notifiable according to your country communicable disease legislation or an equivalent legislation. Voluntary: Not mandatory/notifiable but still under national surveillance. Screening: culturing to identify carriage and/or colonization. This can be different sample types but not related to clinical infection. : K. pneumoniae (colistin R) : Screening",
        "short_title": "Which pathogens are under mandatory national surveillance? Colistin resistant K. pneumoniae - screening.",
        "type": "SingleChoice",
        "coefficient": 0.019,
        "tags": [
            "National surveillance",
            "K. pneumoniae",
            "Colistin",
            "Screening"
        ],
        "possible_answers": {
            "Yes, mandatory": 1,
            "Yes, voluntary": 1,
            "No": 0
        },
        "actual_answers": {
            "Spain": "Yes, voluntary",
            "Austria": "Yes, voluntary",
            "Lithuania": "No",
            "Croatia": "No",
            "Netherlands": "Yes, voluntary",
            "Ireland": "Yes, voluntary",
            "Germany": "No",
            "Poland": "No",
            "Italy": "No",
            "Greece": "Yes, voluntary",
            "France": "No",
            "Czechia": "Yes, voluntary",
            "Belgium": "No",
            "Hungary": "Yes, mandatory",
            "Finland": "No",
            "Luxembourg": "Yes, voluntary",
            "Malta": "Yes, voluntary",
            "Portugal": "Yes, mandatory",
            "Norway": "Yes, mandatory",
            "Slovenia": "No",
            "Estonia": "Yes, mandatory",
            "Sweden": "Yes, voluntary",
            "Ukraine": "No",
            "Slovak Republic": "Yes, voluntary",
            "Denmark": "Yes, mandatory",
            "Latvia": "Yes, voluntary",
            "Iceland": "No",
            "Bulgaria": "No"
        }
    },
    "36.14": {
        "title": "Which of the following pathogens are under national surveillance? Mandatory: Means that the pathogen is notifiable according to your country communicable disease legislation or an equivalent legislation. Voluntary: Not mandatory/notifiable but still under national surveillance. Screening: culturing to identify carriage and/or colonization. This can be different sample types but not related to clinical infection. : C. difficile : Diarrhea/stool sample",
        "short_title": "Which pathogens are under mandatory national surveillance? C. difficile - stool.",
        "type": "SingleChoice",
        "coefficient": 0.019,
        "tags": [
            "National surveillance",
            "C. difficile",
            "Stool"
        ],
        "possible_answers": {
            "Yes, mandatory": 1,
            "Yes, voluntary": 1,
            "No": 0
        },
        "actual_answers": {
            "Spain": "Yes, voluntary",
            "Austria": "",
            "Lithuania": "No",
            "Croatia": "Yes, voluntary",
            "Netherlands": "Yes, voluntary",
            "Ireland": "Yes, mandatory",
            "Germany": "Yes, mandatory",
            "Poland": "Yes, mandatory",
            "Italy": "No",
            "Greece": "Yes, voluntary",
            "France": "No",
            "Czechia": "Yes, voluntary",
            "Belgium": "Yes, voluntary",
            "Hungary": "No",
            "Finland": "Yes, mandatory",
            "Luxembourg": "Yes, voluntary",
            "Malta": "Yes, voluntary",
            "Portugal": "Yes, voluntary",
            "Norway": "Yes, mandatory",
            "Slovenia": "No",
            "Estonia": "Yes, mandatory",
            "Sweden": "Yes, voluntary",
            "Ukraine": "No",
            "Slovak Republic": "Yes, voluntary",
            "Denmark": "Yes, mandatory",
            "Latvia": "No",
            "Iceland": "No",
            "Bulgaria": "No"
        }
    },
    "36.15": {
        "title": "Which of the following pathogens are under national surveillance? Mandatory: Means that the pathogen is notifiable according to your country communicable disease legislation or an equivalent legislation. Voluntary: Not mandatory/notifiable but still under national surveillance. Screening: culturing to identify carriage and/or colonization. This can be different sample types but not related to clinical infection. : H. influenzae (ampicillin- R) : Screening",
        "short_title": "Which pathogens are under mandatory national surveillance? Ampicillin resistant H. influenzae - screening.",
        "type": "SingleChoice",
        "coefficient": 0.019,
        "tags": [
            "National surveillance",
            "H. influenzae",
            "Ampicillin",
            "Screening"
        ],
        "possible_answers": {
            "Yes, mandatory": 1,
            "Yes, voluntary": 1,
            "No": 0
        },
        "actual_answers": {
            "Spain": "No",
            "Austria": "Yes, voluntary",
            "Lithuania": "No",
            "Croatia": "No",
            "Netherlands": "Yes, voluntary",
            "Ireland": "No",
            "Germany": "No",
            "Poland": "No",
            "Italy": "No",
            "Greece": "Yes, voluntary",
            "France": "No",
            "Czechia": "No",
            "Belgium": "No",
            "Hungary": "Yes, mandatory",
            "Finland": "No",
            "Luxembourg": "Yes, voluntary",
            "Malta": "Yes, voluntary",
            "Portugal": "No",
            "Norway": "Yes, voluntary",
            "Slovenia": "No",
            "Estonia": "Yes, mandatory",
            "Sweden": "Yes, voluntary",
            "Ukraine": "No",
            "Slovak Republic": "Yes, voluntary",
            "Denmark": "No",
            "Latvia": "No",
            "Iceland": "No",
            "Bulgaria": "No"
        }
    },
    "36.16": {
        "title": "Which of the following pathogens are under national surveillance? Mandatory: Means that the pathogen is notifiable according to your country communicable disease legislation or an equivalent legislation. Voluntary: Not mandatory/notifiable but still under national surveillance. Screening: culturing to identify carriage and/or colonization. This can be different sample types but not related to clinical infection. : S. pneumoniae (penicillin and macrolide R) : Screening",
        "short_title": "Which pathogens are under mandatory national surveillance? Penicillin resistant S. pneumoniae - screening.",
        "type": "SingleChoice",
        "coefficient": 0.019,
        "tags": [
            "National surveillance",
            "S. pneumoniae",
            "Penicillin",
            "Screening"
        ],
        "possible_answers": {
            "Yes, mandatory": 1,
            "Yes, voluntary": 1,
            "No": 0
        },
        "actual_answers": {
            "Spain": "Yes, voluntary",
            "Austria": "Yes, voluntary",
            "Lithuania": "No",
            "Croatia": "No",
            "Netherlands": "Yes, voluntary",
            "Ireland": "No",
            "Germany": "No",
            "Poland": "No",
            "Italy": "No",
            "Greece": "Yes, voluntary",
            "France": "No",
            "Czechia": "Yes, voluntary",
            "Belgium": "No",
            "Hungary": "Yes, mandatory",
            "Finland": "No",
            "Luxembourg": "Yes, voluntary",
            "Malta": "Yes, voluntary",
            "Portugal": "No",
            "Norway": "Yes, mandatory",
            "Slovenia": "No",
            "Estonia": "Yes, mandatory",
            "Sweden": "Yes, mandatory",
            "Ukraine": "No",
            "Slovak Republic": "Yes, voluntary",
            "Denmark": "No",
            "Latvia": "No",
            "Iceland": "No",
            "Bulgaria": "No"
        }
    },
    "36.17": {
        "title": "Which of the following pathogens are under national surveillance? Mandatory: Means that the pathogen is notifiable according to your country communicable disease legislation or an equivalent legislation. Voluntary: Not mandatory/notifiable but still under national surveillance. Screening: culturing to identify carriage and/or colonization. This can be different sample types but not related to clinical infection. : E. faecium and/or E. faecalis (vancomycin R) : Screening",
        "short_title": "Which pathogens are under mandatory national surveillance? Vancomycin resistant Enterococci - screening.",
        "type": "SingleChoice",
        "coefficient": 0.019,
        "tags": [
            "National surveillance",
            "E. faecium/faecalis",
            "Vancomycin",
            "Screening"
        ],
        "possible_answers": {
            "Yes, mandatory": 1,
            "Yes, voluntary": 1,
            "No": 0
        },
        "actual_answers": {
            "Spain": "Yes, voluntary",
            "Austria": "No",
            "Lithuania": "No",
            "Croatia": "No",
            "Netherlands": "Yes, voluntary",
            "Ireland": "Yes, voluntary",
            "Germany": "No",
            "Poland": "No",
            "Italy": "No",
            "Greece": "Yes, voluntary",
            "France": "No",
            "Czechia": "Yes, voluntary",
            "Belgium": "Yes, voluntary",
            "Hungary": "Yes, mandatory",
            "Finland": "Yes, mandatory",
            "Luxembourg": "Yes, voluntary",
            "Malta": "Yes, voluntary",
            "Portugal": "No",
            "Norway": "Yes, mandatory",
            "Slovenia": "Yes, mandatory",
            "Estonia": "Yes, mandatory",
            "Sweden": "Yes, mandatory",
            "Ukraine": "No",
            "Slovak Republic": "Yes, voluntary",
            "Denmark": "No",
            "Latvia": "No",
            "Iceland": "Yes, mandatory",
            "Bulgaria": "No"
        }
    },
    "36.18": {
        "title": "Which of the following pathogens are under national surveillance? Mandatory: Means that the pathogen is notifiable according to your country communicable disease legislation or an equivalent legislation. Voluntary: Not mandatory/notifiable but still under national surveillance. Screening: culturing to identify carriage and/or colonization. This can be different sample types but not related to clinical infection. : P. aeruginosa (carbapenem R and/or P) : Screening",
        "short_title": "Which pathogens are under mandatory national surveillance? Carbapenem resistant P. aeruginosa - screening.",
        "type": "SingleChoice",
        "coefficient": 0.019,
        "tags": [
            "National surveillance",
            "P. aeruginosa",
            "Carbapenem",
            "Screening"
        ],
        "possible_answers": {
            "Yes, mandatory": 1,
            "Yes, voluntary": 1,
            "No": 0
        },
        "actual_answers": {
            "Spain": "Yes, voluntary",
            "Austria": "Yes, voluntary",
            "Lithuania": "No",
            "Croatia": "No",
            "Netherlands": "Yes, voluntary",
            "Ireland": "Yes, voluntary",
            "Germany": "No",
            "Poland": "No",
            "Italy": "No",
            "Greece": "Yes, voluntary",
            "France": "No",
            "Czechia": "Yes, voluntary",
            "Belgium": "No",
            "Hungary": "Yes, mandatory",
            "Finland": "No",
            "Luxembourg": "Yes, voluntary",
            "Malta": "Yes, voluntary",
            "Portugal": "No",
            "Norway": "Yes, mandatory",
            "Slovenia": "Yes, mandatory",
            "Estonia": "Yes, mandatory",
            "Sweden": "Yes, voluntary",
            "Ukraine": "No",
            "Slovak Republic": "Yes, voluntary",
            "Denmark": "Yes, mandatory",
            "Latvia": "Yes, voluntary",
            "Iceland": "Yes, mandatory",
            "Bulgaria": "No"
        }
    },
    "36.19": {
        "title": "Which of the following pathogens are under national surveillance? Mandatory: Means that the pathogen is notifiable according to your country communicable disease legislation or an equivalent legislation. Voluntary: Not mandatory/notifiable but still under national surveillance. Screening: culturing to identify carriage and/or colonization. This can be different sample types but not related to clinical infection. : A. baumanii (carbapenem R and/or P) : Screening",
        "short_title": "Which pathogens are under mandatory national surveillance? Carbapenem resistant A. baumanii - screening.",
        "type": "SingleChoice",
        "coefficient": 0.019,
        "tags": [
            "National surveillance",
            "A. baumanii",
            "Carbapenem",
            "Screening"
        ],
        "possible_answers": {
            "Yes, mandatory": 1,
            "Yes, voluntary": 1,
            "No": 0
        },
        "actual_answers": {
            "Spain": "Yes, voluntary",
            "Austria": "Yes, voluntary",
            "Lithuania": "No",
            "Croatia": "No",
            "Netherlands": "Yes, voluntary",
            "Ireland": "Yes, mandatory",
            "Germany": "Yes, mandatory",
            "Poland": "No",
            "Italy": "No",
            "Greece": "Yes, voluntary",
            "France": "No",
            "Czechia": "Yes, voluntary",
            "Belgium": "No",
            "Hungary": "Yes, mandatory",
            "Finland": "No",
            "Luxembourg": "Yes, voluntary",
            "Malta": "Yes, voluntary",
            "Portugal": "No",
            "Norway": "Yes, mandatory",
            "Slovenia": "Yes, mandatory",
            "Estonia": "Yes, mandatory",
            "Sweden": "Yes, voluntary",
            "Ukraine": "No",
            "Slovak Republic": "Yes, voluntary",
            "Denmark": "Yes, mandatory",
            "Latvia": "No",
            "Iceland": "Yes, mandatory",
            "Bulgaria": "No"
        }
    },
    "36.20": {
        "title": "Which of the following pathogens are under national surveillance? Mandatory: Means that the pathogen is notifiable according to your country communicable disease legislation or an equivalent legislation. Voluntary: Not mandatory/notifiable but still under national surveillance. Screening: culturing to identify carriage and/or colonization. This can be different sample types but not related to clinical infection. : S. aureus (methicillin R) : Screening",
        "short_title": "Which pathogens are under mandatory national surveillance? Methicillin resistant S. aureus - screening.",
        "type": "SingleChoice",
        "coefficient": 0.019,
        "tags": [
            "National surveillance",
            "S. aureus",
            "Methicillin",
            "Screening"
        ],
        "possible_answers": {
            "Yes, mandatory": 1,
            "Yes, voluntary": 1,
            "No": 0
        },
        "actual_answers": {
            "Spain": "Yes, voluntary",
            "Austria": "Yes, voluntary",
            "Lithuania": "No",
            "Croatia": "No",
            "Netherlands": "Yes, voluntary",
            "Ireland": "Yes, mandatory",
            "Germany": "No",
            "Poland": "No",
            "Italy": "No",
            "Greece": "Yes, voluntary",
            "France": "No",
            "Czechia": "No",
            "Belgium": "Yes, mandatory",
            "Hungary": "Yes, mandatory",
            "Finland": "Yes, mandatory",
            "Luxembourg": "Yes, voluntary",
            "Malta": "Yes, voluntary",
            "Portugal": "No",
            "Norway": "Yes, mandatory",
            "Slovenia": "Yes, mandatory",
            "Estonia": "Yes, mandatory",
            "Sweden": "Yes, mandatory",
            "Ukraine": "No",
            "Slovak Republic": "Yes, voluntary",
            "Denmark": "Yes, mandatory",
            "Latvia": "No",
            "Iceland": "Yes, mandatory",
            "Bulgaria": "No"
        }
    },
    "36.21": {
        "title": "Which of the following pathogens are under national surveillance? Mandatory: Means that the pathogen is notifiable according to your country communicable disease legislation or an equivalent legislation. Voluntary: Not mandatory/notifiable but still under national surveillance. Screening: culturing to identify carriage and/or colonization. This can be different sample types but not related to clinical infection. : E. coli (colistin R) : Urine",
        "short_title": "Which pathogens are under mandatory national surveillance? Colistin resistant E. coli - urine.",
        "type": "SingleChoice",
        "coefficient": 0.019,
        "tags": [
            "National surveillance",
            "E. coli",
            "Colistin",
            "Urine"
        ],
        "possible_answers": {
            "Yes, mandatory": 1,
            "Yes, voluntary": 1,
            "No": 0
        },
        "actual_answers": {
            "Spain": "Yes, voluntary",
            "Austria": "Yes, voluntary",
            "Lithuania": "No",
            "Croatia": "No",
            "Netherlands": "Yes, voluntary",
            "Ireland": "Yes, mandatory",
            "Germany": "No",
            "Poland": "Yes, mandatory",
            "Italy": "Yes, voluntary",
            "Greece": "Yes, voluntary",
            "France": "Yes, voluntary",
            "Czechia": "Yes, voluntary",
            "Belgium": "No",
            "Hungary": "Yes, mandatory",
            "Finland": "No",
            "Luxembourg": "Yes, voluntary",
            "Malta": "Yes, voluntary",
            "Portugal": "Yes, mandatory",
            "Norway": "Yes, mandatory",
            "Slovenia": "No",
            "Estonia": "Yes, mandatory",
            "Sweden": "Yes, voluntary",
            "Ukraine": "No",
            "Slovak Republic": "Yes, voluntary",
            "Denmark": "Yes, mandatory",
            "Latvia": "Yes, voluntary",
            "Iceland": "No",
            "Bulgaria": "Yes, voluntary"
        }
    },
    "36.22": {
        "title": "Which of the following pathogens are under national surveillance? Mandatory: Means that the pathogen is notifiable according to your country communicable disease legislation or an equivalent legislation. Voluntary: Not mandatory/notifiable but still under national surveillance. Screening: culturing to identify carriage and/or colonization. This can be different sample types but not related to clinical infection. : E. coli (colistin R) : Lower respiratory tract",
        "short_title": "Which pathogens are under mandatory national surveillance? Colistin resistant E. coli - lower respiratory tract.",
        "type": "SingleChoice",
        "coefficient": 0.019,
        "tags": [
            "National surveillance",
            "E. coli",
            "Colistin",
            "Respiratory tract"
        ],
        "possible_answers": {
            "Yes, mandatory": 1,
            "Yes, voluntary": 1,
            "No": 0
        },
        "actual_answers": {
            "Spain": "Yes, voluntary",
            "Austria": "No",
            "Lithuania": "No",
            "Croatia": "No",
            "Netherlands": "Yes, voluntary",
            "Ireland": "Yes, mandatory",
            "Germany": "No",
            "Poland": "Yes, mandatory",
            "Italy": "No",
            "Greece": "Yes, voluntary",
            "France": "Yes, voluntary",
            "Czechia": "Yes, voluntary",
            "Belgium": "No",
            "Hungary": "Yes, mandatory",
            "Finland": "No",
            "Luxembourg": "Yes, voluntary",
            "Malta": "Yes, voluntary",
            "Portugal": "Yes, mandatory",
            "Norway": "Yes, mandatory",
            "Slovenia": "No",
            "Estonia": "Yes, mandatory",
            "Sweden": "Yes, voluntary",
            "Ukraine": "No",
            "Slovak Republic": "Yes, voluntary",
            "Denmark": "Yes, mandatory",
            "Latvia": "Yes, voluntary",
            "Iceland": "No",
            "Bulgaria": "Yes, voluntary"
        }
    },
    "36.23": {
        "title": "Which of the following pathogens are under national surveillance? Mandatory: Means that the pathogen is notifiable according to your country communicable disease legislation or an equivalent legislation. Voluntary: Not mandatory/notifiable but still under national surveillance. Screening: culturing to identify carriage and/or colonization. This can be different sample types but not related to clinical infection. : K. pneumoniae (carbapenem R and/or P) : Lower respiratory tract",
        "short_title": "Which pathogens are under mandatory national surveillance? Carbapenem resistant K. pneumoniae - lower respiratory tract.",
        "type": "SingleChoice",
        "coefficient": 0.019,
        "tags": [
            "National surveillance",
            "K. pneumoniae",
            "Carbapenem",
            "Respiratory tract"
        ],
        "possible_answers": {
            "Yes, mandatory": 1,
            "Yes, voluntary": 1,
            "No": 0
        },
        "actual_answers": {
            "Spain": "Yes, voluntary",
            "Austria": "Yes, voluntary",
            "Lithuania": "Yes, mandatory",
            "Croatia": "Yes, voluntary",
            "Netherlands": "Yes, mandatory",
            "Ireland": "Yes, voluntary",
            "Germany": "Yes, mandatory",
            "Poland": "Yes, mandatory",
            "Italy": "No",
            "Greece": "Yes, voluntary",
            "France": "Yes, voluntary",
            "Czechia": "Yes, mandatory",
            "Belgium": "Yes, mandatory",
            "Hungary": "Yes, mandatory",
            "Finland": "Yes, mandatory",
            "Luxembourg": "Yes, voluntary",
            "Malta": "Yes, voluntary",
            "Portugal": "Yes, voluntary",
            "Norway": "Yes, mandatory",
            "Slovenia": "No",
            "Estonia": "Yes, mandatory",
            "Sweden": "Yes, mandatory",
            "Ukraine": "No",
            "Slovak Republic": "Yes, mandatory",
            "Denmark": "Yes, mandatory",
            "Latvia": "Yes, voluntary",
            "Iceland": "Yes, mandatory",
            "Bulgaria": "Yes, voluntary"
        }
    },
    "36.24": {
        "title": "Which of the following pathogens are under national surveillance? Mandatory: Means that the pathogen is notifiable according to your country communicable disease legislation or an equivalent legislation. Voluntary: Not mandatory/notifiable but still under national surveillance. Screening: culturing to identify carriage and/or colonization. This can be different sample types but not related to clinical infection. : K. pneumoniae (carbapenem R and/or P) : Urine",
        "short_title": "Which pathogens are under mandatory national surveillance? Carbapenem resistant K. pneumoniae - urine.",
        "type": "SingleChoice",
        "coefficient": 0.019,
        "tags": [
            "National surveillance",
            "K. pneumoniae",
            "Carbapenem",
            "Urine"
        ],
        "possible_answers": {
            "Yes, mandatory": 1,
            "Yes, voluntary": 1,
            "No": 0
        },
        "actual_answers": {
            "Spain": "Yes, mandatory",
            "Austria": "Yes, voluntary",
            "Lithuania": "Yes, mandatory",
            "Croatia": "Yes, voluntary",
            "Netherlands": "Yes, mandatory",
            "Ireland": "Yes, voluntary",
            "Germany": "Yes, mandatory",
            "Poland": "Yes, mandatory",
            "Italy": "Yes, voluntary",
            "Greece": "Yes, voluntary",
            "France": "Yes, voluntary",
            "Czechia": "Yes, mandatory",
            "Belgium": "Yes, mandatory",
            "Hungary": "Yes, mandatory",
            "Finland": "Yes, mandatory",
            "Luxembourg": "Yes, voluntary",
            "Malta": "Yes, voluntary",
            "Portugal": "Yes, voluntary",
            "Norway": "Yes, mandatory",
            "Slovenia": "No",
            "Estonia": "Yes, mandatory",
            "Sweden": "Yes, mandatory",
            "Ukraine": "No",
            "Slovak Republic": "Yes, mandatory",
            "Denmark": "Yes, mandatory",
            "Latvia": "Yes, voluntary",
            "Iceland": "Yes, mandatory",
            "Bulgaria": "Yes, voluntary"
        }
    },
    "36.25": {
        "title": "Which of the following pathogens are under national surveillance? Mandatory: Means that the pathogen is notifiable according to your country communicable disease legislation or an equivalent legislation. Voluntary: Not mandatory/notifiable but still under national surveillance. Screening: culturing to identify carriage and/or colonization. This can be different sample types but not related to clinical infection. : K. pneumoniae (carbapenem R and/or P) : Blood/CSF",
        "short_title": "Which pathogens are under mandatory national surveillance? Carbapenem resistant K. pneumoniae - blood.",
        "type": "SingleChoice",
        "coefficient": 0.019,
        "tags": [
            "National surveillance",
            "K. pneumoniae",
            "Carbapenem",
            "Blood"
        ],
        "possible_answers": {
            "Yes, mandatory": 1,
            "Yes, voluntary": 1,
            "No": 0
        },
        "actual_answers": {
            "Spain": "Yes, mandatory",
            "Austria": "Yes, voluntary",
            "Lithuania": "Yes, mandatory",
            "Croatia": "Yes, voluntary",
            "Netherlands": "Yes, mandatory",
            "Ireland": "Yes, mandatory",
            "Germany": "Yes, mandatory",
            "Poland": "Yes, mandatory",
            "Italy": "Yes, voluntary",
            "Greece": "Yes, mandatory",
            "France": "Yes, voluntary",
            "Czechia": "Yes, mandatory",
            "Belgium": "Yes, mandatory",
            "Hungary": "Yes, mandatory",
            "Finland": "Yes, mandatory",
            "Luxembourg": "Yes, mandatory",
            "Malta": "Yes, voluntary",
            "Portugal": "Yes, mandatory",
            "Norway": "Yes, mandatory",
            "Slovenia": "Yes, mandatory",
            "Estonia": "Yes, mandatory",
            "Sweden": "Yes, mandatory",
            "Ukraine": "Yes, mandatory",
            "Slovak Republic": "Yes, mandatory",
            "Denmark": "Yes, mandatory",
            "Latvia": "Yes, mandatory",
            "Iceland": "Yes, mandatory",
            "Bulgaria": "Yes, mandatory"
        }
    },
    "36.26": {
        "title": "Which of the following pathogens are under national surveillance? Mandatory: Means that the pathogen is notifiable according to your country communicable disease legislation or an equivalent legislation. Voluntary: Not mandatory/notifiable but still under national surveillance. Screening: culturing to identify carriage and/or colonization. This can be different sample types but not related to clinical infection. : K. pneumoniae (3GC- R and/or P) : Blood/CSF",
        "short_title": "Which pathogens are under mandatory national surveillance? 3rd-generation cephalosporins resistant K. pneumoniae - blood.",
        "type": "SingleChoice",
        "coefficient": 0.019,
        "tags": [
            "National surveillance",
            "K. pneumoniae",
            "3rd-generation Cephalosporin",
            "Blood"
        ],
        "possible_answers": {
            "Yes, mandatory": 1,
            "Yes, voluntary": 1,
            "No": 0
        },
        "actual_answers": {
            "Spain": "Yes, voluntary",
            "Austria": "Yes, voluntary",
            "Lithuania": "Yes, mandatory",
            "Croatia": "Yes, voluntary",
            "Netherlands": "Yes, voluntary",
            "Ireland": "Yes, mandatory",
            "Germany": "No",
            "Poland": "Yes, mandatory",
            "Italy": "Yes, voluntary",
            "Greece": "Yes, mandatory",
            "France": "Yes, voluntary",
            "Czechia": "Yes, voluntary",
            "Belgium": "Yes, mandatory",
            "Hungary": "Yes, mandatory",
            "Finland": "Yes, mandatory",
            "Luxembourg": "Yes, mandatory",
            "Malta": "Yes, voluntary",
            "Portugal": "Yes, mandatory",
            "Norway": "Yes, voluntary",
            "Slovenia": "Yes, voluntary",
            "Estonia": "Yes, mandatory",
            "Sweden": "Yes, mandatory",
            "Ukraine": "Yes, mandatory",
            "Slovak Republic": "Yes, voluntary",
            "Denmark": "No",
            "Latvia": "Yes, mandatory",
            "Iceland": "Yes, mandatory",
            "Bulgaria": "Yes, voluntary"
        }
    },
    "36.27": {
        "title": "Which of the following pathogens are under national surveillance? Mandatory: Means that the pathogen is notifiable according to your country communicable disease legislation or an equivalent legislation. Voluntary: Not mandatory/notifiable but still under national surveillance. Screening: culturing to identify carriage and/or colonization. This can be different sample types but not related to clinical infection. : K. pneumoniae (3GC- R and/or P) : Urine",
        "short_title": "Which pathogens are under mandatory national surveillance? 3rd-generation cephalosporins resistant K. pneumoniae - urine.",
        "type": "SingleChoice",
        "coefficient": 0.019,
        "tags": [
            "National surveillance",
            "K. pneumoniae",
            "3rd-generation Cephalosporin",
            "Urine"
        ],
        "possible_answers": {
            "Yes, mandatory": 1,
            "Yes, voluntary": 1,
            "No": 0
        },
        "actual_answers": {
            "Spain": "Yes, voluntary",
            "Austria": "Yes, voluntary",
            "Lithuania": "No",
            "Croatia": "No",
            "Netherlands": "Yes, voluntary",
            "Ireland": "Yes, voluntary",
            "Germany": "No",
            "Poland": "Yes, mandatory",
            "Italy": "Yes, voluntary",
            "Greece": "Yes, voluntary",
            "France": "Yes, voluntary",
            "Czechia": "No",
            "Belgium": "Yes, mandatory",
            "Hungary": "Yes, mandatory",
            "Finland": "Yes, mandatory",
            "Luxembourg": "Yes, voluntary",
            "Malta": "Yes, voluntary",
            "Portugal": "No",
            "Norway": "Yes, voluntary",
            "Slovenia": "No",
            "Estonia": "Yes, mandatory",
            "Sweden": "Yes, mandatory",
            "Ukraine": "No",
            "Slovak Republic": "Yes, voluntary",
            "Denmark": "No",
            "Latvia": "Yes, voluntary",
            "Iceland": "Yes, mandatory",
            "Bulgaria": "Yes, voluntary"
        }
    },
    "36.28": {
        "title": "Which of the following pathogens are under national surveillance? Mandatory: Means that the pathogen is notifiable according to your country communicable disease legislation or an equivalent legislation. Voluntary: Not mandatory/notifiable but still under national surveillance. Screening: culturing to identify carriage and/or colonization. This can be different sample types but not related to clinical infection. : K. pneumoniae (3GC- R and/or P) : Lower respiratory tract",
        "short_title": "Which pathogens are under mandatory national surveillance? 3rd-generation cephalosporins resistant K. pneumoniae - lower respiratory tract.",
        "type": "SingleChoice",
        "coefficient": 0.019,
        "tags": [
            "National surveillance",
            "K. pneumoniae",
            "3rd-generation Cephalosporin",
            "Respiratory tract"
        ],
        "possible_answers": {
            "Yes, mandatory": 1,
            "Yes, voluntary": 1,
            "No": 0
        },
        "actual_answers": {
            "Spain": "Yes, voluntary",
            "Austria": "Yes, voluntary",
            "Lithuania": "No",
            "Croatia": "No",
            "Netherlands": "Yes, voluntary",
            "Ireland": "Yes, voluntary",
            "Germany": "No",
            "Poland": "Yes, mandatory",
            "Italy": "No",
            "Greece": "Yes, voluntary",
            "France": "Yes, voluntary",
            "Czechia": "No",
            "Belgium": "Yes, mandatory",
            "Hungary": "Yes, mandatory",
            "Finland": "Yes, mandatory",
            "Luxembourg": "Yes, voluntary",
            "Malta": "Yes, voluntary",
            "Portugal": "No",
            "Norway": "Yes, voluntary",
            "Slovenia": "No",
            "Estonia": "Yes, mandatory",
            "Sweden": "Yes, mandatory",
            "Ukraine": "No",
            "Slovak Republic": "Yes, voluntary",
            "Denmark": "No",
            "Latvia": "Yes, voluntary",
            "Iceland": "Yes, mandatory",
            "Bulgaria": "Yes, voluntary"
        }
    },
    "36.29": {
        "title": "Which of the following pathogens are under national surveillance? Mandatory: Means that the pathogen is notifiable according to your country communicable disease legislation or an equivalent legislation. Voluntary: Not mandatory/notifiable but still under national surveillance. Screening: culturing to identify carriage and/or colonization. This can be different sample types but not related to clinical infection. : K. pneumoniae (colistin R) : Lower respiratory tract",
        "short_title": "Which pathogens are under mandatory national surveillance? Colistin resistant K. pneumoniae - colistin.",
        "type": "SingleChoice",
        "coefficient": 0.019,
        "tags": [
            "National surveillance",
            "K. pneumoniae",
            "Colistin",
            "Respiratory tract"
        ],
        "possible_answers": {
            "Yes, mandatory": 1,
            "Yes, voluntary": 1,
            "No": 0
        },
        "actual_answers": {
            "Spain": "Yes, voluntary",
            "Austria": "Yes, voluntary",
            "Lithuania": "No",
            "Croatia": "No",
            "Netherlands": "Yes, voluntary",
            "Ireland": "Yes, voluntary",
            "Germany": "No",
            "Poland": "Yes, mandatory",
            "Italy": "No",
            "Greece": "Yes, voluntary",
            "France": "Yes, voluntary",
            "Czechia": "Yes, voluntary",
            "Belgium": "No",
            "Hungary": "Yes, mandatory",
            "Finland": "No",
            "Luxembourg": "Yes, voluntary",
            "Malta": "Yes, voluntary",
            "Portugal": "Yes, mandatory",
            "Norway": "Yes, mandatory",
            "Slovenia": "No",
            "Estonia": "Yes, mandatory",
            "Sweden": "Yes, voluntary",
            "Ukraine": "No",
            "Slovak Republic": "Yes, voluntary",
            "Denmark": "Yes, mandatory",
            "Latvia": "Yes, voluntary",
            "Iceland": "No",
            "Bulgaria": "Yes, voluntary"
        }
    },
    "36.30": {
        "title": "Which of the following pathogens are under national surveillance? Mandatory: Means that the pathogen is notifiable according to your country communicable disease legislation or an equivalent legislation. Voluntary: Not mandatory/notifiable but still under national surveillance. Screening: culturing to identify carriage and/or colonization. This can be different sample types but not related to clinical infection. : K. pneumoniae (colistin R) : Urine",
        "short_title": "Which pathogens are under mandatory national surveillance? Colistin resistant K. pneumoniae - urine.",
        "type": "SingleChoice",
        "coefficient": 0.019,
        "tags": [
            "National surveillance",
            "K. pneumoniae",
            "Colistin",
            "Urine"
        ],
        "possible_answers": {
            "Yes, mandatory": 1,
            "Yes, voluntary": 1,
            "No": 0
        },
        "actual_answers": {
            "Spain": "Yes, voluntary",
            "Austria": "Yes, voluntary",
            "Lithuania": "No",
            "Croatia": "No",
            "Netherlands": "Yes, voluntary",
            "Ireland": "Yes, voluntary",
            "Germany": "No",
            "Poland": "Yes, mandatory",
            "Italy": "Yes, voluntary",
            "Greece": "Yes, voluntary",
            "France": "Yes, voluntary",
            "Czechia": "Yes, voluntary",
            "Belgium": "No",
            "Hungary": "Yes, mandatory",
            "Finland": "No",
            "Luxembourg": "Yes, voluntary",
            "Malta": "Yes, voluntary",
            "Portugal": "Yes, mandatory",
            "Norway": "Yes, mandatory",
            "Slovenia": "No",
            "Estonia": "Yes, mandatory",
            "Sweden": "Yes, voluntary",
            "Ukraine": "No",
            "Slovak Republic": "Yes, voluntary",
            "Denmark": "Yes, mandatory",
            "Latvia": "Yes, voluntary",
            "Iceland": "No",
            "Bulgaria": "Yes, voluntary"
        }
    },
    "36.31": {
        "title": "Which of the following pathogens are under national surveillance? Mandatory: Means that the pathogen is notifiable according to your country communicable disease legislation or an equivalent legislation. Voluntary: Not mandatory/notifiable but still under national surveillance. Screening: culturing to identify carriage and/or colonization. This can be different sample types but not related to clinical infection. : K. pneumoniae (colistin R) : Blood/CSF",
        "short_title": "Which pathogens are under mandatory national surveillance? Colistin resistant K. pneumoniae - blood.",
        "type": "SingleChoice",
        "coefficient": 0.019,
        "tags": [
            "National surveillance",
            "K. pneumoniae",
            "Colistin",
            "Blood"
        ],
        "possible_answers": {
            "Yes, mandatory": 1,
            "Yes, voluntary": 1,
            "No": 0
        },
        "actual_answers": {
            "Spain": "Yes, voluntary",
            "Austria": "Yes, voluntary",
            "Lithuania": "No",
            "Croatia": "Yes, voluntary",
            "Netherlands": "Yes, voluntary",
            "Ireland": "Yes, mandatory",
            "Germany": "No",
            "Poland": "Yes, mandatory",
            "Italy": "Yes, voluntary",
            "Greece": "Yes, voluntary",
            "France": "Yes, voluntary",
            "Czechia": "Yes, voluntary",
            "Belgium": "No",
            "Hungary": "Yes, mandatory",
            "Finland": "No",
            "Luxembourg": "Yes, voluntary",
            "Malta": "Yes, voluntary",
            "Portugal": "Yes, mandatory",
            "Norway": "Yes, mandatory",
            "Slovenia": "Yes, voluntary",
            "Estonia": "Yes, mandatory",
            "Sweden": "Yes, voluntary",
            "Ukraine": "Yes, mandatory",
            "Slovak Republic": "Yes, voluntary",
            "Denmark": "Yes, mandatory",
            "Latvia": "Yes, mandatory",
            "Iceland": "No",
            "Bulgaria": "Yes, mandatory"
        }
    },
    "36.32": {
        "title": "Which of the following pathogens are under national surveillance? Mandatory: Means that the pathogen is notifiable according to your country communicable disease legislation or an equivalent legislation. Voluntary: Not mandatory/notifiable but still under national surveillance. Screening: culturing to identify carriage and/or colonization. This can be different sample types but not related to clinical infection. : P. aeruginosa (carbapenem R and/or P) : Blood/CSF",
        "short_title": "Which pathogens are under mandatory national surveillance? Carbapenem resistant P. aeruginosa - blood.",
        "type": "SingleChoice",
        "coefficient": 0.019,
        "tags": [
            "National surveillance",
            "P. aeruginosa",
            "Carbapenem",
            "Blood"
        ],
        "possible_answers": {
            "Yes, mandatory": 1,
            "Yes, voluntary": 1,
            "No": 0
        },
        "actual_answers": {
            "Spain": "Yes, mandatory",
            "Austria": "Yes, voluntary",
            "Lithuania": "Yes, mandatory",
            "Croatia": "Yes, voluntary",
            "Netherlands": "Yes, voluntary",
            "Ireland": "Yes, mandatory",
            "Germany": "No",
            "Poland": "Yes, mandatory",
            "Italy": "Yes, voluntary",
            "Greece": "Yes, mandatory",
            "France": "Yes, voluntary",
            "Czechia": "Yes, voluntary",
            "Belgium": "No",
            "Hungary": "Yes, mandatory",
            "Finland": "Yes, mandatory",
            "Luxembourg": "Yes, mandatory",
            "Malta": "Yes, voluntary",
            "Portugal": "Yes, mandatory",
            "Norway": "Yes, mandatory",
            "Slovenia": "Yes, voluntary",
            "Estonia": "Yes, mandatory",
            "Sweden": "Yes, voluntary",
            "Ukraine": "Yes, mandatory",
            "Slovak Republic": "Yes, voluntary",
            "Denmark": "Yes, mandatory",
            "Latvia": "No",
            "Iceland": "Yes, mandatory",
            "Bulgaria": "Yes, mandatory"
        }
    },
    "36.33": {
        "title": "Which of the following pathogens are under national surveillance? Mandatory: Means that the pathogen is notifiable according to your country communicable disease legislation or an equivalent legislation. Voluntary: Not mandatory/notifiable but still under national surveillance. Screening: culturing to identify carriage and/or colonization. This can be different sample types but not related to clinical infection. : P. aeruginosa (carbapenem R and/or P) : Urine",
        "short_title": "Which pathogens are under mandatory national surveillance? Carbapenem resistant P. aeruginosa - urine.",
        "type": "SingleChoice",
        "coefficient": 0.019,
        "tags": [
            "National surveillance",
            "P. aeruginosa",
            "Carbapenem",
            "Urine"
        ],
        "possible_answers": {
            "Yes, mandatory": 1,
            "Yes, voluntary": 1,
            "No": 0
        },
        "actual_answers": {
            "Spain": "Yes, mandatory",
            "Austria": "Yes, voluntary",
            "Lithuania": "No",
            "Croatia": "No",
            "Netherlands": "Yes, voluntary",
            "Ireland": "Yes, voluntary",
            "Germany": "No",
            "Poland": "Yes, mandatory",
            "Italy": "No",
            "Greece": "Yes, voluntary",
            "France": "Yes, voluntary",
            "Czechia": "Yes, voluntary",
            "Belgium": "No",
            "Hungary": "Yes, mandatory",
            "Finland": "No",
            "Luxembourg": "Yes, voluntary",
            "Malta": "Yes, voluntary",
            "Portugal": "No",
            "Norway": "Yes, mandatory",
            "Slovenia": "No",
            "Estonia": "Yes, mandatory",
            "Sweden": "Yes, voluntary",
            "Ukraine": "No",
            "Slovak Republic": "Yes, voluntary",
            "Denmark": "Yes, mandatory",
            "Latvia": "No",
            "Iceland": "Yes, mandatory",
            "Bulgaria": "Yes, voluntary"
        }
    },
    "36.34": {
        "title": "Which of the following pathogens are under national surveillance? Mandatory: Means that the pathogen is notifiable according to your country communicable disease legislation or an equivalent legislation. Voluntary: Not mandatory/notifiable but still under national surveillance. Screening: culturing to identify carriage and/or colonization. This can be different sample types but not related to clinical infection. : P. aeruginosa (carbapenem R and/or P) : Wound/Tissue swab",
        "short_title": "Which pathogens are under mandatory national surveillance? Carbapenem resistant P. aeruginosa - soft tissue.",
        "type": "SingleChoice",
        "coefficient": 0.019,
        "tags": [
            "National surveillance",
            "P. aeruginosa",
            "Carbapenem",
            "Soft tissue"
        ],
        "possible_answers": {
            "Yes, mandatory": 1,
            "Yes, voluntary": 1,
            "No": 0
        },
        "actual_answers": {
            "Spain": "Yes, mandatory",
            "Austria": "No",
            "Lithuania": "No",
            "Croatia": "No",
            "Netherlands": "Yes, voluntary",
            "Ireland": "Yes, voluntary",
            "Germany": "No",
            "Poland": "Yes, mandatory",
            "Italy": "No",
            "Greece": "Yes, voluntary",
            "France": "Yes, voluntary",
            "Czechia": "Yes, voluntary",
            "Belgium": "No",
            "Hungary": "Yes, mandatory",
            "Finland": "No",
            "Luxembourg": "Yes, voluntary",
            "Malta": "Yes, voluntary",
            "Portugal": "No",
            "Norway": "Yes, mandatory",
            "Slovenia": "No",
            "Estonia": "Yes, mandatory",
            "Sweden": "Yes, voluntary",
            "Ukraine": "Yes, mandatory",
            "Slovak Republic": "Yes, voluntary",
            "Denmark": "Yes, mandatory",
            "Latvia": "No",
            "Iceland": "Yes, mandatory",
            "Bulgaria": "Yes, voluntary"
        }
    },
    "36.35": {
        "title": "Which of the following pathogens are under national surveillance? Mandatory: Means that the pathogen is notifiable according to your country communicable disease legislation or an equivalent legislation. Voluntary: Not mandatory/notifiable but still under national surveillance. Screening: culturing to identify carriage and/or colonization. This can be different sample types but not related to clinical infection. : P. aeruginosa (carbapenem R and/or P) : Lower respiratory tract",
        "short_title": "Which pathogens are under mandatory national surveillance? Carbapenem resistant P. aeruginosa - lower respiratory tract.",
        "type": "SingleChoice",
        "coefficient": 0.019,
        "tags": [
            "National surveillance",
            "P. aeruginosa",
            "Carbapenem",
            "Respiratory tract"
        ],
        "possible_answers": {
            "Yes, mandatory": 1,
            "Yes, voluntary": 1,
            "No": 0
        },
        "actual_answers": {
            "Spain": "Yes, voluntary",
            "Austria": "Yes, voluntary",
            "Lithuania": "No",
            "Croatia": "No",
            "Netherlands": "Yes, voluntary",
            "Ireland": "Yes, voluntary",
            "Germany": "No",
            "Poland": "Yes, mandatory",
            "Italy": "No",
            "Greece": "Yes, voluntary",
            "France": "Yes, voluntary",
            "Czechia": "Yes, voluntary",
            "Belgium": "No",
            "Hungary": "Yes, mandatory",
            "Finland": "No",
            "Luxembourg": "Yes, voluntary",
            "Malta": "Yes, voluntary",
            "Portugal": "No",
            "Norway": "Yes, mandatory",
            "Slovenia": "No",
            "Estonia": "Yes, mandatory",
            "Sweden": "Yes, voluntary",
            "Ukraine": "No",
            "Slovak Republic": "Yes, voluntary",
            "Denmark": "Yes, mandatory",
            "Latvia": "No",
            "Iceland": "Yes, mandatory",
            "Bulgaria": "Yes, voluntary"
        }
    },
    "36.36": {
        "title": "Which of the following pathogens are under national surveillance? Mandatory: Means that the pathogen is notifiable according to your country communicable disease legislation or an equivalent legislation. Voluntary: Not mandatory/notifiable but still under national surveillance. Screening: culturing to identify carriage and/or colonization. This can be different sample types but not related to clinical infection. : A. baumanii (carbapenem R and/or P) : Lower respiratory tract",
        "short_title": "Which pathogens are under mandatory national surveillance? Carbapenem resistant A. baumanii - lower respiratory tract.",
        "type": "SingleChoice",
        "coefficient": 0.019,
        "tags": [
            "National surveillance",
            "A. baumanii",
            "Carbapenem",
            "Respiratory tract"
        ],
        "possible_answers": {
            "Yes, mandatory": 1,
            "Yes, voluntary": 1,
            "No": 0
        },
        "actual_answers": {
            "Spain": "Yes, voluntary",
            "Austria": "Yes, voluntary",
            "Lithuania": "No",
            "Croatia": "No",
            "Netherlands": "Yes, voluntary",
            "Ireland": "Yes, voluntary",
            "Germany": "Yes, mandatory",
            "Poland": "Yes, mandatory",
            "Italy": "No",
            "Greece": "Yes, voluntary",
            "France": "Yes, voluntary",
            "Czechia": "Yes, voluntary",
            "Belgium": "Yes, mandatory",
            "Hungary": "Yes, mandatory",
            "Finland": "No",
            "Luxembourg": "Yes, voluntary",
            "Malta": "Yes, voluntary",
            "Portugal": "No",
            "Norway": "Yes, mandatory",
            "Slovenia": "No",
            "Estonia": "Yes, mandatory",
            "Sweden": "Yes, voluntary",
            "Ukraine": "No",
            "Slovak Republic": "Yes, voluntary",
            "Denmark": "Yes, mandatory",
            "Latvia": "No",
            "Iceland": "Yes, mandatory",
            "Bulgaria": "Yes, voluntary"
        }
    },
    "36.37": {
        "title": "Which of the following pathogens are under national surveillance? Mandatory: Means that the pathogen is notifiable according to your country communicable disease legislation or an equivalent legislation. Voluntary: Not mandatory/notifiable but still under national surveillance. Screening: culturing to identify carriage and/or colonization. This can be different sample types but not related to clinical infection. : A. baumanii (carbapenem R and/or P) : Blood/CSF",
        "short_title": "Which pathogens are under mandatory national surveillance? Carbapenem resistant A. baumanii - blood.",
        "type": "SingleChoice",
        "coefficient": 0.019,
        "tags": [
            "National surveillance",
            "A. baumanii",
            "Carbapenem",
            "Blood"
        ],
        "possible_answers": {
            "Yes, mandatory": 1,
            "Yes, voluntary": 1,
            "No": 0
        },
        "actual_answers": {
            "Spain": "Yes, voluntary",
            "Austria": "Yes, voluntary",
            "Lithuania": "Yes, mandatory",
            "Croatia": "Yes, voluntary",
            "Netherlands": "Yes, voluntary",
            "Ireland": "Yes, mandatory",
            "Germany": "Yes, mandatory",
            "Poland": "Yes, mandatory",
            "Italy": "Yes, voluntary",
            "Greece": "Yes, mandatory",
            "France": "Yes, voluntary",
            "Czechia": "Yes, voluntary",
            "Belgium": "Yes, mandatory",
            "Hungary": "Yes, mandatory",
            "Finland": "Yes, mandatory",
            "Luxembourg": "Yes, mandatory",
            "Malta": "Yes, voluntary",
            "Portugal": "Yes, mandatory",
            "Norway": "Yes, mandatory",
            "Slovenia": "Yes, voluntary",
            "Estonia": "Yes, mandatory",
            "Sweden": "Yes, voluntary",
            "Ukraine": "Yes, mandatory",
            "Slovak Republic": "Yes, voluntary",
            "Denmark": "Yes, mandatory",
            "Latvia": "Yes, mandatory",
            "Iceland": "Yes, mandatory",
            "Bulgaria": "Yes, mandatory"
        }
    },
    "36.38": {
        "title": "Which of the following pathogens are under national surveillance? Mandatory: Means that the pathogen is notifiable according to your country communicable disease legislation or an equivalent legislation. Voluntary: Not mandatory/notifiable but still under national surveillance. Screening: culturing to identify carriage and/or colonization. This can be different sample types but not related to clinical infection. : A. baumanii (carbapenem R and/or P) : Urine",
        "short_title": "Which pathogens are under mandatory national surveillance? Carbapenem resistant A. baumanii - urine.",
        "type": "SingleChoice",
        "coefficient": 0.019,
        "tags": [
            "National surveillance",
            "A. baumanii",
            "Carbapenem",
            "Urine"
        ],
        "possible_answers": {
            "Yes, mandatory": 1,
            "Yes, voluntary": 1,
            "No": 0
        },
        "actual_answers": {
            "Spain": "Yes, voluntary",
            "Austria": "Yes, voluntary",
            "Lithuania": "No",
            "Croatia": "No",
            "Netherlands": "Yes, voluntary",
            "Ireland": "Yes, voluntary",
            "Germany": "Yes, mandatory",
            "Poland": "Yes, mandatory",
            "Italy": "No",
            "Greece": "Yes, voluntary",
            "France": "Yes, voluntary",
            "Czechia": "Yes, voluntary",
            "Belgium": "Yes, mandatory",
            "Hungary": "Yes, mandatory",
            "Finland": "No",
            "Luxembourg": "Yes, voluntary",
            "Malta": "Yes, voluntary",
            "Portugal": "No",
            "Norway": "Yes, mandatory",
            "Slovenia": "No",
            "Estonia": "Yes, mandatory",
            "Sweden": "Yes, voluntary",
            "Ukraine": "No",
            "Slovak Republic": "Yes, voluntary",
            "Denmark": "Yes, mandatory",
            "Latvia": "No",
            "Iceland": "Yes, mandatory",
            "Bulgaria": "Yes, voluntary"
        }
    },
    "36.39": {
        "title": "Which of the following pathogens are under national surveillance? Mandatory: Means that the pathogen is notifiable according to your country communicable disease legislation or an equivalent legislation. Voluntary: Not mandatory/notifiable but still under national surveillance. Screening: culturing to identify carriage and/or colonization. This can be different sample types but not related to clinical infection. : A. baumanii (carbapenem R and/or P) : Wound/Tissue swab",
        "short_title": "Which pathogens are under mandatory national surveillance? Carbapenem resistant A. baumanii - soft tissue.",
        "type": "SingleChoice",
        "coefficient": 0.019,
        "tags": [
            "National surveillance",
            "A. baumanii",
            "Carbapenem",
            "Soft tissue"
        ],
        "possible_answers": {
            "Yes, mandatory": 1,
            "Yes, voluntary": 1,
            "No": 0
        },
        "actual_answers": {
            "Spain": "Yes, voluntary",
            "Austria": "Yes, voluntary",
            "Lithuania": "No",
            "Croatia": "No",
            "Netherlands": "Yes, voluntary",
            "Ireland": "Yes, voluntary",
            "Germany": "Yes, mandatory",
            "Poland": "Yes, mandatory",
            "Italy": "No",
            "Greece": "Yes, voluntary",
            "France": "Yes, voluntary",
            "Czechia": "Yes, voluntary",
            "Belgium": "Yes, mandatory",
            "Hungary": "Yes, mandatory",
            "Finland": "No",
            "Luxembourg": "Yes, voluntary",
            "Malta": "Yes, voluntary",
            "Portugal": "No",
            "Norway": "Yes, mandatory",
            "Slovenia": "No",
            "Estonia": "Yes, mandatory",
            "Sweden": "Yes, voluntary",
            "Ukraine": "Yes, mandatory",
            "Slovak Republic": "Yes, voluntary",
            "Denmark": "Yes, mandatory",
            "Latvia": "No",
            "Iceland": "Yes, mandatory",
            "Bulgaria": "Yes, voluntary"
        }
    },
    "36.40": {
        "title": "Which of the following pathogens are under national surveillance? Mandatory: Means that the pathogen is notifiable according to your country communicable disease legislation or an equivalent legislation. Voluntary: Not mandatory/notifiable but still under national surveillance. Screening: culturing to identify carriage and/or colonization. This can be different sample types but not related to clinical infection. : S. aureus (methicillin R) : Lower respiratory tract",
        "short_title": "Which pathogens are under mandatory national surveillance? Methicillin resistant S. aureus - lower respiratory tract.",
        "type": "SingleChoice",
        "coefficient": 0.019,
        "tags": [
            "National surveillance",
            "S. aureus",
            "Methicillin",
            "Respiratory tract"
        ],
        "possible_answers": {
            "Yes, mandatory": 1,
            "Yes, voluntary": 1,
            "No": 0
        },
        "actual_answers": {
            "Spain": "Yes, voluntary",
            "Austria": "Yes, voluntary",
            "Lithuania": "No",
            "Croatia": "No",
            "Netherlands": "Yes, voluntary",
            "Ireland": "Yes, mandatory",
            "Germany": "No",
            "Poland": "Yes, mandatory",
            "Italy": "No",
            "Greece": "Yes, voluntary",
            "France": "Yes, voluntary",
            "Czechia": "No",
            "Belgium": "Yes, mandatory",
            "Hungary": "Yes, mandatory",
            "Finland": "Yes, mandatory",
            "Luxembourg": "Yes, voluntary",
            "Malta": "Yes, voluntary",
            "Portugal": "No",
            "Norway": "Yes, mandatory",
            "Slovenia": "No",
            "Estonia": "Yes, mandatory",
            "Sweden": "Yes, mandatory",
            "Ukraine": "No",
            "Slovak Republic": "Yes, voluntary",
            "Denmark": "Yes, mandatory",
            "Latvia": "No",
            "Iceland": "Yes, mandatory",
            "Bulgaria": "Yes, voluntary"
        }
    },
    "36.41": {
        "title": "Which of the following pathogens are under national surveillance? Mandatory: Means that the pathogen is notifiable according to your country communicable disease legislation or an equivalent legislation. Voluntary: Not mandatory/notifiable but still under national surveillance. Screening: culturing to identify carriage and/or colonization. This can be different sample types but not related to clinical infection. : S. aureus (methicillin R) : Upper respiratory tract",
        "short_title": "Which pathogens are under mandatory national surveillance? Methicillin resistant S. aureus - upper respiratory tract.",
        "type": "SingleChoice",
        "coefficient": 0.019,
        "tags": [
            "National surveillance",
            "S. aureus",
            "Methicillin",
            "Respiratory tract"
        ],
        "possible_answers": {
            "Yes, mandatory": 1,
            "Yes, voluntary": 1,
            "No": 0
        },
        "actual_answers": {
            "Spain": "Yes, mandatory",
            "Austria": "Yes, voluntary",
            "Lithuania": "No",
            "Croatia": "No",
            "Netherlands": "Yes, voluntary",
            "Ireland": "Yes, mandatory",
            "Germany": "No",
            "Poland": "Yes, mandatory",
            "Italy": "No",
            "Greece": "Yes, voluntary",
            "France": "Yes, voluntary",
            "Czechia": "No",
            "Belgium": "Yes, mandatory",
            "Hungary": "Yes, mandatory",
            "Finland": "Yes, mandatory",
            "Luxembourg": "Yes, voluntary",
            "Malta": "Yes, voluntary",
            "Portugal": "No",
            "Norway": "Yes, mandatory",
            "Slovenia": "No",
            "Estonia": "Yes, mandatory",
            "Sweden": "Yes, mandatory",
            "Ukraine": "No",
            "Slovak Republic": "Yes, voluntary",
            "Denmark": "Yes, mandatory",
            "Latvia": "No",
            "Iceland": "Yes, mandatory",
            "Bulgaria": "Yes, voluntary"
        }
    },
    "36.42": {
        "title": "Which of the following pathogens are under national surveillance? Mandatory: Means that the pathogen is notifiable according to your country communicable disease legislation or an equivalent legislation. Voluntary: Not mandatory/notifiable but still under national surveillance. Screening: culturing to identify carriage and/or colonization. This can be different sample types but not related to clinical infection. : S. pneumoniae (penicillin and macrolide R) : Lower respiratory tract",
        "short_title": "Which pathogens are under mandatory national surveillance? Penicillin resistant S. pneumoniae - lower respiratory tract.",
        "type": "SingleChoice",
        "coefficient": 0.019,
        "tags": [
            "National surveillance",
            "S. pneumoniae",
            "Penicillin",
            "Respiratory tract"
        ],
        "possible_answers": {
            "Yes, mandatory": 1,
            "Yes, voluntary": 1,
            "No": 0
        },
        "actual_answers": {
            "Spain": "Yes, voluntary",
            "Austria": "Yes, voluntary",
            "Lithuania": "No",
            "Croatia": "No",
            "Netherlands": "Yes, voluntary",
            "Ireland": "Yes, voluntary",
            "Germany": "No",
            "Poland": "Yes, mandatory",
            "Italy": "No",
            "Greece": "Yes, voluntary",
            "France": "Yes, voluntary",
            "Czechia": "Yes, voluntary",
            "Belgium": "Yes, voluntary",
            "Hungary": "Yes, mandatory",
            "Finland": "No",
            "Luxembourg": "Yes, voluntary",
            "Malta": "Yes, voluntary",
            "Portugal": "Yes, voluntary",
            "Norway": "Yes, mandatory",
            "Slovenia": "No",
            "Estonia": "Yes, mandatory",
            "Sweden": "Yes, mandatory",
            "Ukraine": "No",
            "Slovak Republic": "Yes, voluntary",
            "Denmark": "No",
            "Latvia": "No",
            "Iceland": "Yes, voluntary",
            "Bulgaria": "Yes, voluntary"
        }
    },
    "36.43": {
        "title": "Which of the following pathogens are under national surveillance? Mandatory: Means that the pathogen is notifiable according to your country communicable disease legislation or an equivalent legislation. Voluntary: Not mandatory/notifiable but still under national surveillance. Screening: culturing to identify carriage and/or colonization. This can be different sample types but not related to clinical infection. : H. influenzae (ampicillin- R) : Lower respiratory tract",
        "short_title": "Which pathogens are under mandatory national surveillance? Ampicillin resistant H. influenzae - lower respiratory tract.",
        "type": "SingleChoice",
        "coefficient": 0.019,
        "tags": [
            "National surveillance",
            "H. influenzae",
            "Ampicillin",
            "Respiratory tract"
        ],
        "possible_answers": {
            "Yes, mandatory": 1,
            "Yes, voluntary": 1,
            "No": 0
        },
        "actual_answers": {
            "Spain": "No",
            "Austria": "Yes, voluntary",
            "Lithuania": "No",
            "Croatia": "No",
            "Netherlands": "Yes, voluntary",
            "Ireland": "No",
            "Germany": "No",
            "Poland": "Yes, voluntary",
            "Italy": "No",
            "Greece": "Yes, voluntary",
            "France": "Yes, voluntary",
            "Czechia": "Yes, voluntary",
            "Belgium": "Yes, voluntary",
            "Hungary": "Yes, mandatory",
            "Finland": "No",
            "Luxembourg": "Yes, voluntary",
            "Malta": "Yes, voluntary",
            "Portugal": "Yes, voluntary",
            "Norway": "Yes, voluntary",
            "Slovenia": "No",
            "Estonia": "Yes, mandatory",
            "Sweden": "Yes, voluntary",
            "Ukraine": "No",
            "Slovak Republic": "Yes, voluntary",
            "Denmark": "No",
            "Latvia": "No",
            "Iceland": "Yes, voluntary",
            "Bulgaria": "No"
        }
    },
    "36.44": {
        "title": "Which of the following pathogens are under national surveillance? Mandatory: Means that the pathogen is notifiable according to your country communicable disease legislation or an equivalent legislation. Voluntary: Not mandatory/notifiable but still under national surveillance. Screening: culturing to identify carriage and/or colonization. This can be different sample types but not related to clinical infection. : S. pneumoniae (penicillin and macrolide R) : Upper respiratory tract",
        "short_title": "Which pathogens are under mandatory national surveillance? Penicillin resistant S. pneumoniae - upper respiratory tract.",
        "type": "SingleChoice",
        "coefficient": 0.019,
        "tags": [
            "National surveillance",
            "S. pneumoniae",
            "Penicillin",
            "Respiratory tract"
        ],
        "possible_answers": {
            "Yes, mandatory": 1,
            "Yes, voluntary": 1,
            "No": 0
        },
        "actual_answers": {
            "Spain": "Yes, voluntary",
            "Austria": "Yes, voluntary",
            "Lithuania": "No",
            "Croatia": "No",
            "Netherlands": "Yes, voluntary",
            "Ireland": "Yes, voluntary",
            "Germany": "No",
            "Poland": "Yes, mandatory",
            "Italy": "No",
            "Greece": "Yes, voluntary",
            "France": "No",
            "Czechia": "Yes, voluntary",
            "Belgium": "Yes, voluntary",
            "Hungary": "Yes, mandatory",
            "Finland": "No",
            "Luxembourg": "Yes, voluntary",
            "Malta": "Yes, voluntary",
            "Portugal": "Yes, voluntary",
            "Norway": "Yes, mandatory",
            "Slovenia": "No",
            "Estonia": "Yes, mandatory",
            "Sweden": "Yes, mandatory",
            "Ukraine": "No",
            "Slovak Republic": "Yes, voluntary",
            "Denmark": "No",
            "Latvia": "No",
            "Iceland": "Yes, voluntary",
            "Bulgaria": "Yes, voluntary"
        }
    },
    "36.45": {
        "title": "Which of the following pathogens are under national surveillance? Mandatory: Means that the pathogen is notifiable according to your country communicable disease legislation or an equivalent legislation. Voluntary: Not mandatory/notifiable but still under national surveillance. Screening: culturing to identify carriage and/or colonization. This can be different sample types but not related to clinical infection. : H. influenzae (ampicillin- R) : Upper respiratory tract",
        "short_title": "Which pathogens are under mandatory national surveillance? Ampicillin resistant H. influenzae - upper respiratory tract.",
        "type": "SingleChoice",
        "coefficient": 0.019,
        "tags": [
            "National surveillance",
            "H. influenzae",
            "Ampicillin",
            "Respiratory tract"
        ],
        "possible_answers": {
            "Yes, mandatory": 1,
            "Yes, voluntary": 1,
            "No": 0
        },
        "actual_answers": {
            "Spain": "No",
            "Austria": "Yes, voluntary",
            "Lithuania": "No",
            "Croatia": "No",
            "Netherlands": "Yes, voluntary",
            "Ireland": "No",
            "Germany": "No",
            "Poland": "Yes, voluntary",
            "Italy": "No",
            "Greece": "Yes, voluntary",
            "France": "No",
            "Czechia": "Yes, voluntary",
            "Belgium": "Yes, voluntary",
            "Hungary": "Yes, mandatory",
            "Finland": "No",
            "Luxembourg": "Yes, voluntary",
            "Malta": "Yes, voluntary",
            "Portugal": "Yes, voluntary",
            "Norway": "Yes, voluntary",
            "Slovenia": "No",
            "Estonia": "Yes, mandatory",
            "Sweden": "Yes, voluntary",
            "Ukraine": "No",
            "Slovak Republic": "Yes, voluntary",
            "Denmark": "No",
            "Latvia": "No",
            "Iceland": "Yes, voluntary",
            "Bulgaria": "No"
        }
    },
    "36.46": {
        "title": "Which of the following pathogens are under national surveillance? Mandatory: Means that the pathogen is notifiable according to your country communicable disease legislation or an equivalent legislation. Voluntary: Not mandatory/notifiable but still under national surveillance. Screening: culturing to identify carriage and/or colonization. This can be different sample types but not related to clinical infection. : S. aureus (methicillin R) : Wound/Tissue swab",
        "short_title": "Which pathogens are under mandatory national surveillance? Methicillin resistant S. aureus - soft tissue.",
        "type": "SingleChoice",
        "coefficient": 0.019,
        "tags": [
            "National surveillance",
            "S. aureus",
            "Methicillin",
            "Soft tissue"
        ],
        "possible_answers": {
            "Yes, mandatory": 1,
            "Yes, voluntary": 1,
            "No": 0
        },
        "actual_answers": {
            "Spain": "Yes, mandatory",
            "Austria": "Yes, voluntary",
            "Lithuania": "No",
            "Croatia": "No",
            "Netherlands": "Yes, voluntary",
            "Ireland": "Yes, mandatory",
            "Germany": "No",
            "Poland": "Yes, mandatory",
            "Italy": "No",
            "Greece": "Yes, voluntary",
            "France": "Yes, voluntary",
            "Czechia": "No",
            "Belgium": "Yes, mandatory",
            "Hungary": "Yes, mandatory",
            "Finland": "Yes, mandatory",
            "Luxembourg": "Yes, voluntary",
            "Malta": "Yes, voluntary",
            "Portugal": "No",
            "Norway": "Yes, mandatory",
            "Slovenia": "No",
            "Estonia": "Yes, mandatory",
            "Sweden": "Yes, mandatory",
            "Ukraine": "Yes, mandatory",
            "Slovak Republic": "Yes, voluntary",
            "Denmark": "Yes, mandatory",
            "Latvia": "No",
            "Iceland": "Yes, mandatory",
            "Bulgaria": "Yes, voluntary"
        }
    },
    "36.47": {
        "title": "Which of the following pathogens are under national surveillance? Mandatory: Means that the pathogen is notifiable according to your country communicable disease legislation or an equivalent legislation. Voluntary: Not mandatory/notifiable but still under national surveillance. Screening: culturing to identify carriage and/or colonization. This can be different sample types but not related to clinical infection. : S. aureus (methicillin R) : Urine",
        "short_title": "Which pathogens are under mandatory national surveillance? Methicillin resistant S. aureus - Urine.",
        "type": "SingleChoice",
        "coefficient": 0.019,
        "tags": [
            "National surveillance",
            "S. aureus",
            "Methicillin",
            "Urine"
        ],
        "possible_answers": {
            "Yes, mandatory": 1,
            "Yes, voluntary": 1,
            "No": 0
        },
        "actual_answers": {
            "Spain": "Yes, mandatory",
            "Austria": "Yes, voluntary",
            "Lithuania": "No",
            "Croatia": "No",
            "Netherlands": "Yes, voluntary",
            "Ireland": "Yes, mandatory",
            "Germany": "No",
            "Poland": "No",
            "Italy": "No",
            "Greece": "Yes, voluntary",
            "France": "Yes, voluntary",
            "Czechia": "No",
            "Belgium": "Yes, mandatory",
            "Hungary": "Yes, mandatory",
            "Finland": "Yes, mandatory",
            "Luxembourg": "Yes, voluntary",
            "Malta": "Yes, voluntary",
            "Portugal": "No",
            "Norway": "Yes, mandatory",
            "Slovenia": "No",
            "Estonia": "No",
            "Sweden": "Yes, mandatory",
            "Ukraine": "No",
            "Slovak Republic": "Yes, voluntary",
            "Denmark": "Yes, mandatory",
            "Latvia": "No",
            "Iceland": "Yes, mandatory",
            "Bulgaria": "Yes, voluntary"
        }
    },
    "36.48": {
        "title": "Which of the following pathogens are under national surveillance? Mandatory: Means that the pathogen is notifiable according to your country communicable disease legislation or an equivalent legislation. Voluntary: Not mandatory/notifiable but still under national surveillance. Screening: culturing to identify carriage and/or colonization. This can be different sample types but not related to clinical infection. : S. aureus (methicillin R) : Blood/CSF",
        "short_title": "Which pathogens are under mandatory national surveillance? Methicillin resistant S. aureus - blood.",
        "type": "SingleChoice",
        "coefficient": 0.019,
        "tags": [
            "National surveillance",
            "S. aureus",
            "Methicillin",
            "Blood"
        ],
        "possible_answers": {
            "Yes, mandatory": 1,
            "Yes, voluntary": 1,
            "No": 0
        },
        "actual_answers": {
            "Spain": "Yes, mandatory",
            "Austria": "Yes, voluntary",
            "Lithuania": "Yes, mandatory",
            "Croatia": "Yes, voluntary",
            "Netherlands": "Yes, voluntary",
            "Ireland": "Yes, mandatory",
            "Germany": "Yes, mandatory",
            "Poland": "Yes, mandatory",
            "Italy": "Yes, voluntary",
            "Greece": "Yes, mandatory",
            "France": "Yes, voluntary",
            "Czechia": "Yes, voluntary",
            "Belgium": "Yes, mandatory",
            "Hungary": "Yes, mandatory",
            "Finland": "Yes, mandatory",
            "Luxembourg": "Yes, mandatory",
            "Malta": "Yes, voluntary",
            "Portugal": "Yes, mandatory",
            "Norway": "Yes, mandatory",
            "Slovenia": "Yes, voluntary",
            "Estonia": "Yes, mandatory",
            "Sweden": "Yes, mandatory",
            "Ukraine": "Yes, mandatory",
            "Slovak Republic": "Yes, voluntary",
            "Denmark": "Yes, mandatory",
            "Latvia": "Yes, mandatory",
            "Iceland": "Yes, mandatory",
            "Bulgaria": "Yes, mandatory"
        }
    },
    "36.49": {
        "title": "Which of the following pathogens are under national surveillance? Mandatory: Means that the pathogen is notifiable according to your country communicable disease legislation or an equivalent legislation. Voluntary: Not mandatory/notifiable but still under national surveillance. Screening: culturing to identify carriage and/or colonization. This can be different sample types but not related to clinical infection. : E. faecium and/or E. faecalis (vancomycin R) : Blood/CSF",
        "short_title": "Which pathogens are under mandatory national surveillance? Vancomycin resistant Enterococci - blood.",
        "type": "SingleChoice",
        "coefficient": 0.019,
        "tags": [
            "National surveillance",
            "E. faecium/faecalis",
            "Vancomycin",
            "Blood"
        ],
        "possible_answers": {
            "Yes, mandatory": 1,
            "Yes, voluntary": 1,
            "No": 0
        },
        "actual_answers": {
            "Spain": "Yes, voluntary",
            "Austria": "Yes, voluntary",
            "Lithuania": "Yes, mandatory",
            "Croatia": "Yes, voluntary",
            "Netherlands": "Yes, voluntary",
            "Ireland": "Yes, mandatory",
            "Germany": "No",
            "Poland": "Yes, mandatory",
            "Italy": "Yes, voluntary",
            "Greece": "Yes, mandatory",
            "France": "Yes, voluntary",
            "Czechia": "Yes, voluntary",
            "Belgium": "Yes, voluntary",
            "Hungary": "Yes, mandatory",
            "Finland": "Yes, mandatory",
            "Luxembourg": "Yes, mandatory",
            "Malta": "Yes, voluntary",
            "Portugal": "Yes, mandatory",
            "Norway": "Yes, mandatory",
            "Slovenia": "Yes, voluntary",
            "Estonia": "Yes, mandatory",
            "Sweden": "Yes, mandatory",
            "Ukraine": "Yes, mandatory",
            "Slovak Republic": "Yes, voluntary",
            "Denmark": "Yes, voluntary",
            "Latvia": "Yes, mandatory",
            "Iceland": "Yes, mandatory",
            "Bulgaria": "Yes, mandatory"
        }
    },
    "36.50": {
        "title": "Which of the following pathogens are under national surveillance? Mandatory: Means that the pathogen is notifiable according to your country communicable disease legislation or an equivalent legislation. Voluntary: Not mandatory/notifiable but still under national surveillance. Screening: culturing to identify carriage and/or colonization. This can be different sample types but not related to clinical infection. : E. faecium and/or E. faecalis (vancomycin R) : Urine",
        "short_title": "Which pathogens are under mandatory national surveillance? Vancomycin resistant Enterococci - urine.",
        "type": "SingleChoice",
        "coefficient": 0.019,
        "tags": [
            "National surveillance",
            "E. faecium/faecalis",
            "Vancomycin",
            "Urine"
        ],
        "possible_answers": {
            "Yes, mandatory": 1,
            "Yes, voluntary": 1,
            "No": 0
        },
        "actual_answers": {
            "Spain": "Yes, voluntary",
            "Austria": "No",
            "Lithuania": "Yes, mandatory",
            "Croatia": "No",
            "Netherlands": "Yes, voluntary",
            "Ireland": "Yes, voluntary",
            "Germany": "No",
            "Poland": "Yes, mandatory",
            "Italy": "No",
            "Greece": "Yes, voluntary",
            "France": "Yes, voluntary",
            "Czechia": "Yes, voluntary",
            "Belgium": "Yes, voluntary",
            "Hungary": "Yes, mandatory",
            "Finland": "Yes, mandatory",
            "Luxembourg": "Yes, voluntary",
            "Malta": "Yes, voluntary",
            "Portugal": "No",
            "Norway": "Yes, mandatory",
            "Slovenia": "No",
            "Estonia": "Yes, mandatory",
            "Sweden": "Yes, mandatory",
            "Ukraine": "No",
            "Slovak Republic": "Yes, voluntary",
            "Denmark": "No",
            "Latvia": "No",
            "Iceland": "Yes, mandatory",
            "Bulgaria": "Yes, voluntary"
        }
    },
    "36.51": {
        "title": "Which of the following pathogens are under national surveillance? Mandatory: Means that the pathogen is notifiable according to your country communicable disease legislation or an equivalent legislation. Voluntary: Not mandatory/notifiable but still under national surveillance. Screening: culturing to identify carriage and/or colonization. This can be different sample types but not related to clinical infection. : S. pneumoniae (penicillin and macrolide R) : Blood/CSF",
        "short_title": "Which pathogens are under mandatory national surveillance? Penicillin resistant S. pneumoniae - blood.",
        "type": "SingleChoice",
        "coefficient": 0.019,
        "tags": [
            "National surveillance",
            "S. pneumoniae",
            "Penicillin",
            "Blood"
        ],
        "possible_answers": {
            "Yes, mandatory": 1,
            "Yes, voluntary": 1,
            "No": 0
        },
        "actual_answers": {
            "Spain": "Yes, voluntary",
            "Austria": "Yes, voluntary",
            "Lithuania": "Yes, mandatory",
            "Croatia": "Yes, voluntary",
            "Netherlands": "Yes, voluntary",
            "Ireland": "Yes, mandatory",
            "Germany": "No",
            "Poland": "Yes, mandatory",
            "Italy": "Yes, voluntary",
            "Greece": "Yes, voluntary",
            "France": "Yes, voluntary",
            "Czechia": "Yes, mandatory",
            "Belgium": "Yes, voluntary",
            "Hungary": "Yes, mandatory",
            "Finland": "Yes, mandatory",
            "Luxembourg": "Yes, mandatory",
            "Malta": "Yes, voluntary",
            "Portugal": "Yes, voluntary",
            "Norway": "Yes, mandatory",
            "Slovenia": "Yes, mandatory",
            "Estonia": "Yes, mandatory",
            "Sweden": "Yes, mandatory",
            "Ukraine": "Yes, mandatory",
            "Slovak Republic": "Yes, voluntary",
            "Denmark": "Yes, mandatory",
            "Latvia": "Yes, mandatory",
            "Iceland": "Yes, voluntary",
            "Bulgaria": "Yes, voluntary"
        }
    },
    "36.52": {
        "title": "Which of the following pathogens are under national surveillance? Mandatory: Means that the pathogen is notifiable according to your country communicable disease legislation or an equivalent legislation. Voluntary: Not mandatory/notifiable but still under national surveillance. Screening: culturing to identify carriage and/or colonization. This can be different sample types but not related to clinical infection. : S. pneumoniae (penicillin and macrolide R) : Urine",
        "short_title": "Which pathogens are under mandatory national surveillance? Penicillin resistant S. pneumoniae - urine.",
        "type": "SingleChoice",
        "coefficient": 0.019,
        "tags": [
            "National surveillance",
            "S. pneumoniae",
            "Penicillin",
            "Urine"
        ],
        "possible_answers": {
            "Yes, mandatory": 1,
            "Yes, voluntary": 1,
            "No": 0
        },
        "actual_answers": {
            "Spain": "Yes, voluntary",
            "Austria": "Yes, voluntary",
            "Lithuania": "No",
            "Croatia": "No",
            "Netherlands": "Yes, voluntary",
            "Ireland": "Yes, voluntary",
            "Germany": "No",
            "Poland": "No",
            "Italy": "No",
            "Greece": "Yes, voluntary",
            "France": "No",
            "Czechia": "Yes, voluntary",
            "Belgium": "No",
            "Hungary": "Yes, mandatory",
            "Finland": "No",
            "Luxembourg": "Yes, voluntary",
            "Malta": "Yes, voluntary",
            "Portugal": "No",
            "Norway": "Yes, mandatory",
            "Slovenia": "No",
            "Estonia": "Yes, mandatory",
            "Sweden": "Yes, mandatory",
            "Ukraine": "No",
            "Slovak Republic": "Yes, voluntary",
            "Denmark": "No",
            "Latvia": "No",
            "Iceland": "Yes, voluntary",
            "Bulgaria": "Yes, voluntary"
        }
    },
    "36.53": {
        "title": "Which of the following pathogens are under national surveillance? Mandatory: Means that the pathogen is notifiable according to your country communicable disease legislation or an equivalent legislation. Voluntary: Not mandatory/notifiable but still under national surveillance. Screening: culturing to identify carriage and/or colonization. This can be different sample types but not related to clinical infection. : H. influenzae (ampicillin- R) : Blood/CSF",
        "short_title": "Which pathogens are under mandatory national surveillance? Ampicillin resistant H. influenzae - blood.",
        "type": "SingleChoice",
        "coefficient": 0.019,
        "tags": [
            "National surveillance",
            "H. influenzae",
            "Ampicillin",
            "Blood"
        ],
        "possible_answers": {
            "Yes, mandatory": 1,
            "Yes, voluntary": 1,
            "No": 0
        },
        "actual_answers": {
            "Spain": "Yes, voluntary",
            "Austria": "No",
            "Lithuania": "Yes, mandatory",
            "Croatia": "No",
            "Netherlands": "Yes, voluntary",
            "Ireland": "Yes, mandatory",
            "Germany": "No",
            "Poland": "Yes, voluntary",
            "Italy": "No",
            "Greece": "Yes, voluntary",
            "France": "No",
            "Czechia": "Yes, mandatory",
            "Belgium": "Yes, voluntary",
            "Hungary": "Yes, mandatory",
            "Finland": "Yes, mandatory",
            "Luxembourg": "Yes, voluntary",
            "Malta": "Yes, voluntary",
            "Portugal": "Yes, voluntary",
            "Norway": "Yes, voluntary",
            "Slovenia": "Yes, mandatory",
            "Estonia": "Yes, mandatory",
            "Sweden": "Yes, mandatory",
            "Ukraine": "Yes, mandatory",
            "Slovak Republic": "Yes, voluntary",
            "Denmark": "Yes, mandatory",
            "Latvia": "No",
            "Iceland": "Yes, voluntary",
            "Bulgaria": "Yes, voluntary"
        }
    },
    "36.54": {
        "title": "Which of the following pathogens are under national surveillance? Mandatory: Means that the pathogen is notifiable according to your country communicable disease legislation or an equivalent legislation. Voluntary: Not mandatory/notifiable but still under national surveillance. Screening: culturing to identify carriage and/or colonization. This can be different sample types but not related to clinical infection. : H. influenzae (ampicillin- R) : Urine",
        "short_title": "Which pathogens are under mandatory national surveillance? Ampicillin resistant H. influenzae - urine.",
        "type": "SingleChoice",
        "coefficient": 0.019,
        "tags": [
            "National surveillance",
            "H. influenzae",
            "Ampicillin",
            "Urine"
        ],
        "possible_answers": {
            "Yes, mandatory": 1,
            "Yes, voluntary": 1,
            "No": 0
        },
        "actual_answers": {
            "Spain": "No",
            "Austria": "Yes, voluntary",
            "Lithuania": "No",
            "Croatia": "No",
            "Netherlands": "Yes, voluntary",
            "Ireland": "No",
            "Germany": "No",
            "Poland": "No",
            "Italy": "No",
            "Greece": "Yes, voluntary",
            "France": "No",
            "Czechia": "No",
            "Belgium": "Yes, voluntary",
            "Hungary": "Yes, mandatory",
            "Finland": "No",
            "Luxembourg": "Yes, voluntary",
            "Malta": "Yes, voluntary",
            "Portugal": "No",
            "Norway": "Yes, voluntary",
            "Slovenia": "No",
            "Estonia": "Yes, mandatory",
            "Sweden": "Yes, voluntary",
            "Ukraine": "No",
            "Slovak Republic": "Yes, voluntary",
            "Denmark": "No",
            "Latvia": "No",
            "Iceland": "Yes, voluntary",
            "Bulgaria": "No"
        }
    },
    "37.1": {
        "title": "Which laboratories submit data for AST and genotypic confirmation for the following pathogens to your national AMR surveillance system(s)?AST data can be in any format (zones, MIC, SIR, aggregated). Genotypic confirmation refers to the identification of a resistance gene; e.g., NDM-1.CML: Clinical Microbiological Laboratory NRL: National Reference or Expert LaboratoryPlease select NRL if it is the only provider of AST and/or genotypic data. : E. coli (carbapenem R and/or P) : AST data",
        "short_title": "AST data available on national level. Carbapenem resistant E. coli.",
        "type": "SingleChoice",
        "coefficient": 0.038,
        "tags": [
            "National surveillance",
            "E. coli",
            "Carbapenem"
        ],
        "possible_answers": {
            "All CMLs": 1,
            "A subset of CMLs": 0.5,
            "NRL": 1,
            "Other": 0,
            "Do not know": "null",
            "Not submitted": 0
        },
        "actual_answers": {
            "Spain": "All CMLs",
            "Austria": "A subset of CMLs",
            "Lithuania": "All CMLs",
            "Croatia": "A subset of CMLs",
            "Netherlands": "All CMLs",
            "Ireland": "All CMLs",
            "Germany": "A subset of CMLs",
            "Poland": "All CMLs",
            "Italy": "A subset of CMLs",
            "Greece": "A subset of CMLs",
            "France": "A subset of CMLs",
            "Czechia": "NRL",
            "Belgium": "A subset of CMLs",
            "Hungary": "A subset of CMLs",
            "Finland": "All CMLs",
            "Luxembourg": "All CMLs",
            "Malta": "A subset of CMLs",
            "Portugal": "NRL",
            "Norway": "All CMLs",
            "Slovenia": "All CMLs",
            "Estonia": "All CMLs",
            "Sweden": "All CMLs",
            "Ukraine": "A subset of CMLs",
            "Slovak Republic": "A subset of CMLs",
            "Denmark": "All CMLs",
            "Latvia": "A subset of CMLs",
            "Iceland": "NRL",
            "Bulgaria": "A subset of CMLs"
        }
    },
    "37.2": {
        "title": "Which laboratories submit data for AST and genotypic confirmation for the following pathogens to your national AMR surveillance system(s)?AST data can be in any format (zones, MIC, SIR, aggregated). Genotypic confirmation refers to the identification of a resistance gene; e.g., NDM-1.CML: Clinical Microbiological Laboratory NRL: National Reference or Expert LaboratoryPlease select NRL if it is the only provider of AST and/or genotypic data. : E. coli (carbapenem R and/or P) : Genotypic confirmation data",
        "short_title": "Genotypic confirmation data available on national level? Carbapenem resistant E. coli.",
        "type": "SingleChoice",
        "coefficient": 0.038,
        "tags": [
            "National surveillance",
            "E. coli",
            "Carbapenem"
        ],
        "possible_answers": {
            "All CMLs": 1,
            "A subset of CMLs": 0.5,
            "NRL": 1,
            "Other": 0,
            "Do not know": "null",
            "Not submitted": 0
        },
        "actual_answers": {
            "Spain": "Other",
            "Austria": "A subset of CMLs",
            "Lithuania": "NRL",
            "Croatia": "A subset of CMLs",
            "Netherlands": "All CMLs",
            "Ireland": "Do not know",
            "Germany": "Not submitted",
            "Poland": "NRL",
            "Italy": "A subset of CMLs",
            "Greece": "A subset of CMLs",
            "France": "Not submitted",
            "Czechia": "NRL",
            "Belgium": "A subset of CMLs",
            "Hungary": "NRL",
            "Finland": "All CMLs",
            "Luxembourg": "NRL",
            "Malta": "Not submitted",
            "Portugal": "NRL",
            "Norway": "All CMLs",
            "Slovenia": "Other",
            "Estonia": "All CMLs",
            "Sweden": "All CMLs",
            "Ukraine": "Not submitted",
            "Slovak Republic": "NRL",
            "Denmark": "NRL",
            "Latvia": "NRL",
            "Iceland": "NRL",
            "Bulgaria": "Not submitted"
        }
    },
    "37.3": {
        "title": "Which laboratories submit data for AST and genotypic confirmation for the following pathogens to your national AMR surveillance system(s)?AST data can be in any format (zones, MIC, SIR, aggregated). Genotypic confirmation refers to the identification of a resistance gene; e.g., NDM-1.CML: Clinical Microbiological Laboratory NRL: National Reference or Expert LaboratoryPlease select NRL if it is the only provider of AST and/or genotypic data. : E. coli (3GC- R and/or P) : Genotypic confirmation data",
        "short_title": "Genotypic confirmation data available on national level? 3rd-generation cephalosporins resistant E. coli.",
        "type": "SingleChoice",
        "coefficient": 0.038,
        "tags": [
            "National surveillance",
            "E. coli",
            "3rd-generation Cephalosporin"
        ],
        "possible_answers": {
            "All CMLs": 1,
            "A subset of CMLs": 0.5,
            "NRL": 1,
            "Other": 0,
            "Do not know": "null",
            "Not submitted": 0
        },
        "actual_answers": {
            "Spain": "Other",
            "Austria": "Not submitted",
            "Lithuania": "Not submitted",
            "Croatia": "Not submitted",
            "Netherlands": "A subset of CMLs",
            "Ireland": "Do not know",
            "Germany": "Not submitted",
            "Poland": "Not submitted",
            "Italy": "Other",
            "Greece": "A subset of CMLs",
            "France": "Not submitted",
            "Czechia": "Not submitted",
            "Belgium": "A subset of CMLs",
            "Hungary": "Not submitted",
            "Finland": "Not submitted",
            "Luxembourg": "NRL",
            "Malta": "Not submitted",
            "Portugal": "NRL",
            "Norway": "All CMLs",
            "Slovenia": "Other",
            "Estonia": "All CMLs",
            "Sweden": "All CMLs",
            "Ukraine": "Not submitted",
            "Slovak Republic": "NRL",
            "Denmark": "NRL",
            "Latvia": "NRL",
            "Iceland": "Not submitted",
            "Bulgaria": "Not submitted"
        }
    },
    "37.4": {
        "title": "Which laboratories submit data for AST and genotypic confirmation for the following pathogens to your national AMR surveillance system(s)?AST data can be in any format (zones, MIC, SIR, aggregated). Genotypic confirmation refers to the identification of a resistance gene; e.g., NDM-1.CML: Clinical Microbiological Laboratory NRL: National Reference or Expert LaboratoryPlease select NRL if it is the only provider of AST and/or genotypic data. : E. coli (colistin R) : Genotypic confirmation data",
        "short_title": "Genotypic confirmation data available on national level? Colistin resistant E. coli.",
        "type": "SingleChoice",
        "coefficient": 0.038,
        "tags": [
            "National surveillance",
            "E. coli",
            "Colistin"
        ],
        "possible_answers": {
            "All CMLs": 1,
            "A subset of CMLs": 0.5,
            "NRL": 1,
            "Other": 0,
            "Do not know": "null",
            "Not submitted": 0
        },
        "actual_answers": {
            "Spain": "Other",
            "Austria": "A subset of CMLs",
            "Lithuania": "Not submitted",
            "Croatia": "A subset of CMLs",
            "Netherlands": "A subset of CMLs",
            "Ireland": "Do not know",
            "Germany": "Not submitted",
            "Poland": "Not submitted",
            "Italy": "Other",
            "Greece": "A subset of CMLs",
            "France": "Not submitted",
            "Czechia": "NRL",
            "Belgium": "A subset of CMLs",
            "Hungary": "Not submitted",
            "Finland": "Not submitted",
            "Luxembourg": "NRL",
            "Malta": "Not submitted",
            "Portugal": "NRL",
            "Norway": "All CMLs",
            "Slovenia": "Other",
            "Estonia": "NRL",
            "Sweden": "A subset of CMLs",
            "Ukraine": "Not submitted",
            "Slovak Republic": "NRL",
            "Denmark": "NRL",
            "Latvia": "NRL",
            "Iceland": "Not submitted",
            "Bulgaria": "Not submitted"
        }
    },
    "37.5": {
        "title": "Which laboratories submit data for AST and genotypic confirmation for the following pathogens to your national AMR surveillance system(s)?AST data can be in any format (zones, MIC, SIR, aggregated). Genotypic confirmation refers to the identification of a resistance gene; e.g., NDM-1.CML: Clinical Microbiological Laboratory NRL: National Reference or Expert LaboratoryPlease select NRL if it is the only provider of AST and/or genotypic data. : E. coli (3GC- R and/or P) : AST data",
        "short_title": "AST data available on national level. 3rd-generation cephalosporins resistant E. coli.",
        "type": "SingleChoice",
        "coefficient": 0.038,
        "tags": [
            "National surveillance",
            "E. coli",
            "3rd-generation Cephalosporin"
        ],
        "possible_answers": {
            "All CMLs": 1,
            "A subset of CMLs": 0.5,
            "NRL": 1,
            "Other": 0,
            "Do not know": "null",
            "Not submitted": 0
        },
        "actual_answers": {
            "Spain": "All CMLs",
            "Austria": "A subset of CMLs",
            "Lithuania": "All CMLs",
            "Croatia": "Not submitted",
            "Netherlands": "A subset of CMLs",
            "Ireland": "All CMLs",
            "Germany": "A subset of CMLs",
            "Poland": "All CMLs",
            "Italy": "A subset of CMLs",
            "Greece": "A subset of CMLs",
            "France": "A subset of CMLs",
            "Czechia": "A subset of CMLs",
            "Belgium": "A subset of CMLs",
            "Hungary": "A subset of CMLs",
            "Finland": "All CMLs",
            "Luxembourg": "All CMLs",
            "Malta": "A subset of CMLs",
            "Portugal": "NRL",
            "Norway": "All CMLs",
            "Slovenia": "All CMLs",
            "Estonia": "All CMLs",
            "Sweden": "All CMLs",
            "Ukraine": "A subset of CMLs",
            "Slovak Republic": "A subset of CMLs",
            "Denmark": "All CMLs",
            "Latvia": "A subset of CMLs",
            "Iceland": "NRL",
            "Bulgaria": "A subset of CMLs"
        }
    },
    "37.6": {
        "title": "Which laboratories submit data for AST and genotypic confirmation for the following pathogens to your national AMR surveillance system(s)?AST data can be in any format (zones, MIC, SIR, aggregated). Genotypic confirmation refers to the identification of a resistance gene; e.g., NDM-1.CML: Clinical Microbiological Laboratory NRL: National Reference or Expert LaboratoryPlease select NRL if it is the only provider of AST and/or genotypic data. : E. coli (colistin R) : AST data",
        "short_title": "AST data available on national level. Colistin resistant E. coli.",
        "type": "SingleChoice",
        "coefficient": 0.038,
        "tags": [
            "National surveillance",
            "E. coli",
            "Colistin"
        ],
        "possible_answers": {
            "All CMLs": 1,
            "A subset of CMLs": 0.5,
            "NRL": 1,
            "Other": 0,
            "Do not know": "null",
            "Not submitted": 0
        },
        "actual_answers": {
            "Spain": "All CMLs",
            "Austria": "A subset of CMLs",
            "Lithuania": "All CMLs",
            "Croatia": "A subset of CMLs",
            "Netherlands": "A subset of CMLs",
            "Ireland": "All CMLs",
            "Germany": "A subset of CMLs",
            "Poland": "All CMLs",
            "Italy": "A subset of CMLs",
            "Greece": "A subset of CMLs",
            "France": "A subset of CMLs",
            "Czechia": "NRL",
            "Belgium": "A subset of CMLs",
            "Hungary": "A subset of CMLs",
            "Finland": "Not submitted",
            "Luxembourg": "All CMLs",
            "Malta": "A subset of CMLs",
            "Portugal": "NRL",
            "Norway": "All CMLs",
            "Slovenia": "A subset of CMLs",
            "Estonia": "All CMLs",
            "Sweden": "A subset of CMLs",
            "Ukraine": "A subset of CMLs",
            "Slovak Republic": "A subset of CMLs",
            "Denmark": "NRL",
            "Latvia": "A subset of CMLs",
            "Iceland": "Not submitted",
            "Bulgaria": "A subset of CMLs"
        }
    },
    "37.7": {
        "title": "Which laboratories submit data for AST and genotypic confirmation for the following pathogens to your national AMR surveillance system(s)?AST data can be in any format (zones, MIC, SIR, aggregated). Genotypic confirmation refers to the identification of a resistance gene; e.g., NDM-1.CML: Clinical Microbiological Laboratory NRL: National Reference or Expert LaboratoryPlease select NRL if it is the only provider of AST and/or genotypic data. : K. pneumoniae (carbapenem R and/or P) : AST data",
        "short_title": "AST data available on national level. Carbapenem resistant K. pneumoniae.",
        "type": "SingleChoice",
        "coefficient": 0.038,
        "tags": [
            "National surveillance",
            "K. pneumoniae",
            "Carbapenem"
        ],
        "possible_answers": {
            "All CMLs": 1,
            "A subset of CMLs": 0.5,
            "NRL": 1,
            "Other": 0,
            "Do not know": "null",
            "Not submitted": 0
        },
        "actual_answers": {
            "Spain": "All CMLs",
            "Austria": "A subset of CMLs",
            "Lithuania": "All CMLs",
            "Croatia": "A subset of CMLs",
            "Netherlands": "All CMLs",
            "Ireland": "All CMLs",
            "Germany": "A subset of CMLs",
            "Poland": "All CMLs",
            "Italy": "A subset of CMLs",
            "Greece": "A subset of CMLs",
            "France": "A subset of CMLs",
            "Czechia": "NRL",
            "Belgium": "A subset of CMLs",
            "Hungary": "A subset of CMLs",
            "Finland": "All CMLs",
            "Luxembourg": "All CMLs",
            "Malta": "A subset of CMLs",
            "Portugal": "NRL",
            "Norway": "All CMLs",
            "Slovenia": "All CMLs",
            "Estonia": "All CMLs",
            "Sweden": "All CMLs",
            "Ukraine": "A subset of CMLs",
            "Slovak Republic": "A subset of CMLs",
            "Denmark": "All CMLs",
            "Latvia": "A subset of CMLs",
            "Iceland": "NRL",
            "Bulgaria": "A subset of CMLs"
        }
    },
    "37.8": {
        "title": "Which laboratories submit data for AST and genotypic confirmation for the following pathogens to your national AMR surveillance system(s)?AST data can be in any format (zones, MIC, SIR, aggregated). Genotypic confirmation refers to the identification of a resistance gene; e.g., NDM-1.CML: Clinical Microbiological Laboratory NRL: National Reference or Expert LaboratoryPlease select NRL if it is the only provider of AST and/or genotypic data. : K. pneumoniae (3GC- R and/or P) : AST data",
        "short_title": "AST data available on national level. 3rd-generation cephalosporins resistant K. pneumoniae.",
        "type": "SingleChoice",
        "coefficient": 0.038,
        "tags": [
            "National surveillance",
            "K. pneumoniae",
            "3rd-generation Cephalosporin"
        ],
        "possible_answers": {
            "All CMLs": 1,
            "A subset of CMLs": 0.5,
            "NRL": 1,
            "Other": 0,
            "Do not know": "null",
            "Not submitted": 0
        },
        "actual_answers": {
            "Spain": "All CMLs",
            "Austria": "A subset of CMLs",
            "Lithuania": "All CMLs",
            "Croatia": "Not submitted",
            "Netherlands": "A subset of CMLs",
            "Ireland": "All CMLs",
            "Germany": "A subset of CMLs",
            "Poland": "All CMLs",
            "Italy": "A subset of CMLs",
            "Greece": "A subset of CMLs",
            "France": "A subset of CMLs",
            "Czechia": "A subset of CMLs",
            "Belgium": "A subset of CMLs",
            "Hungary": "A subset of CMLs",
            "Finland": "All CMLs",
            "Luxembourg": "All CMLs",
            "Malta": "A subset of CMLs",
            "Portugal": "NRL",
            "Norway": "All CMLs",
            "Slovenia": "All CMLs",
            "Estonia": "All CMLs",
            "Sweden": "All CMLs",
            "Ukraine": "A subset of CMLs",
            "Slovak Republic": "A subset of CMLs",
            "Denmark": "All CMLs",
            "Latvia": "A subset of CMLs",
            "Iceland": "NRL",
            "Bulgaria": "A subset of CMLs"
        }
    },
    "37.9": {
        "title": "Which laboratories submit data for AST and genotypic confirmation for the following pathogens to your national AMR surveillance system(s)?AST data can be in any format (zones, MIC, SIR, aggregated). Genotypic confirmation refers to the identification of a resistance gene; e.g., NDM-1.CML: Clinical Microbiological Laboratory NRL: National Reference or Expert LaboratoryPlease select NRL if it is the only provider of AST and/or genotypic data. : K. pneumoniae (colistin R) : AST data",
        "short_title": "AST data available on national level. Colistin resistant K. pneumoniae.",
        "type": "SingleChoice",
        "coefficient": 0.038,
        "tags": [
            "National surveillance",
            "K. pneumoniae",
            "Colistin"
        ],
        "possible_answers": {
            "All CMLs": 1,
            "A subset of CMLs": 0.5,
            "NRL": 1,
            "Other": 0,
            "Do not know": "null",
            "Not submitted": 0
        },
        "actual_answers": {
            "Spain": "A subset of CMLs",
            "Austria": "A subset of CMLs",
            "Lithuania": "All CMLs",
            "Croatia": "A subset of CMLs",
            "Netherlands": "A subset of CMLs",
            "Ireland": "All CMLs",
            "Germany": "A subset of CMLs",
            "Poland": "All CMLs",
            "Italy": "A subset of CMLs",
            "Greece": "A subset of CMLs",
            "France": "A subset of CMLs",
            "Czechia": "NRL",
            "Belgium": "Not submitted",
            "Hungary": "A subset of CMLs",
            "Finland": "Not submitted",
            "Luxembourg": "All CMLs",
            "Malta": "A subset of CMLs",
            "Portugal": "NRL",
            "Norway": "All CMLs",
            "Slovenia": "A subset of CMLs",
            "Estonia": "All CMLs",
            "Sweden": "A subset of CMLs",
            "Ukraine": "A subset of CMLs",
            "Slovak Republic": "A subset of CMLs",
            "Denmark": "NRL",
            "Latvia": "A subset of CMLs",
            "Iceland": "Not submitted",
            "Bulgaria": "A subset of CMLs"
        }
    },
    "37.10": {
        "title": "Which laboratories submit data for AST and genotypic confirmation for the following pathogens to your national AMR surveillance system(s)?AST data can be in any format (zones, MIC, SIR, aggregated). Genotypic confirmation refers to the identification of a resistance gene; e.g., NDM-1.CML: Clinical Microbiological Laboratory NRL: National Reference or Expert LaboratoryPlease select NRL if it is the only provider of AST and/or genotypic data. : P. aeruginosa (carbapenem R and/or P) : AST data",
        "short_title": "AST data available on national level. Carbapenem resistant P. aeruginosa.",
        "type": "SingleChoice",
        "coefficient": 0.038,
        "tags": [
            "National surveillance",
            "P. aeruginosa",
            "Carbapenem"
        ],
        "possible_answers": {
            "All CMLs": 1,
            "A subset of CMLs": 0.5,
            "NRL": 1,
            "Other": 0,
            "Do not know": "null",
            "Not submitted": 0
        },
        "actual_answers": {
            "Spain": "All CMLs",
            "Austria": "A subset of CMLs",
            "Lithuania": "All CMLs",
            "Croatia": "Not submitted",
            "Netherlands": "A subset of CMLs",
            "Ireland": "All CMLs",
            "Germany": "A subset of CMLs",
            "Poland": "All CMLs",
            "Italy": "A subset of CMLs",
            "Greece": "A subset of CMLs",
            "France": "A subset of CMLs",
            "Czechia": "NRL",
            "Belgium": "A subset of CMLs",
            "Hungary": "A subset of CMLs",
            "Finland": "Not submitted",
            "Luxembourg": "All CMLs",
            "Malta": "A subset of CMLs",
            "Portugal": "NRL",
            "Norway": "All CMLs",
            "Slovenia": "All CMLs",
            "Estonia": "All CMLs",
            "Sweden": "All CMLs",
            "Ukraine": "A subset of CMLs",
            "Slovak Republic": "A subset of CMLs",
            "Denmark": "All CMLs",
            "Latvia": "A subset of CMLs",
            "Iceland": "NRL",
            "Bulgaria": "A subset of CMLs"
        }
    },
    "37.11": {
        "title": "Which laboratories submit data for AST and genotypic confirmation for the following pathogens to your national AMR surveillance system(s)?AST data can be in any format (zones, MIC, SIR, aggregated). Genotypic confirmation refers to the identification of a resistance gene; e.g., NDM-1.CML: Clinical Microbiological Laboratory NRL: National Reference or Expert LaboratoryPlease select NRL if it is the only provider of AST and/or genotypic data. : A. baumanii (carbapenem R and/or P) : AST data",
        "short_title": "AST data available on national level. Carbapenem resistant A. baumanii.",
        "type": "SingleChoice",
        "coefficient": 0.038,
        "tags": [
            "National surveillance",
            "A. baumanii",
            "Carbapenem"
        ],
        "possible_answers": {
            "All CMLs": 1,
            "A subset of CMLs": 0.5,
            "NRL": 1,
            "Other": 0,
            "Do not know": "null",
            "Not submitted": 0
        },
        "actual_answers": {
            "Spain": "All CMLs",
            "Austria": "A subset of CMLs",
            "Lithuania": "All CMLs",
            "Croatia": "Not submitted",
            "Netherlands": "A subset of CMLs",
            "Ireland": "All CMLs",
            "Germany": "A subset of CMLs",
            "Poland": "All CMLs",
            "Italy": "A subset of CMLs",
            "Greece": "A subset of CMLs",
            "France": "A subset of CMLs",
            "Czechia": "NRL",
            "Belgium": "A subset of CMLs",
            "Hungary": "A subset of CMLs",
            "Finland": "Not submitted",
            "Luxembourg": "All CMLs",
            "Malta": "A subset of CMLs",
            "Portugal": "NRL",
            "Norway": "All CMLs",
            "Slovenia": "All CMLs",
            "Estonia": "All CMLs",
            "Sweden": "All CMLs",
            "Ukraine": "A subset of CMLs",
            "Slovak Republic": "A subset of CMLs",
            "Denmark": "All CMLs",
            "Latvia": "A subset of CMLs",
            "Iceland": "NRL",
            "Bulgaria": "A subset of CMLs"
        }
    },
    "37.12": {
        "title": "Which laboratories submit data for AST and genotypic confirmation for the following pathogens to your national AMR surveillance system(s)?AST data can be in any format (zones, MIC, SIR, aggregated). Genotypic confirmation refers to the identification of a resistance gene; e.g., NDM-1.CML: Clinical Microbiological Laboratory NRL: National Reference or Expert LaboratoryPlease select NRL if it is the only provider of AST and/or genotypic data. : S. aureus (methicillin R) : AST data",
        "short_title": "AST data available on national level. Methicillin resistant S. aureus.",
        "type": "SingleChoice",
        "coefficient": 0.038,
        "tags": [
            "National surveillance",
            "S. aureus",
            "Methicillin"
        ],
        "possible_answers": {
            "All CMLs": 1,
            "A subset of CMLs": 0.5,
            "NRL": 1,
            "Other": 0,
            "Do not know": "null",
            "Not submitted": 0
        },
        "actual_answers": {
            "Spain": "All CMLs",
            "Austria": "A subset of CMLs",
            "Lithuania": "All CMLs",
            "Croatia": "Not submitted",
            "Netherlands": "A subset of CMLs",
            "Ireland": "All CMLs",
            "Germany": "A subset of CMLs",
            "Poland": "All CMLs",
            "Italy": "A subset of CMLs",
            "Greece": "A subset of CMLs",
            "France": "A subset of CMLs",
            "Czechia": "NRL",
            "Belgium": "A subset of CMLs",
            "Hungary": "A subset of CMLs",
            "Finland": "All CMLs",
            "Luxembourg": "All CMLs",
            "Malta": "A subset of CMLs",
            "Portugal": "NRL",
            "Norway": "All CMLs",
            "Slovenia": "All CMLs",
            "Estonia": "All CMLs",
            "Sweden": "All CMLs",
            "Ukraine": "A subset of CMLs",
            "Slovak Republic": "A subset of CMLs",
            "Denmark": "All CMLs",
            "Latvia": "All CMLs",
            "Iceland": "NRL",
            "Bulgaria": "A subset of CMLs"
        }
    },
    "37.13": {
        "title": "Which laboratories submit data for AST and genotypic confirmation for the following pathogens to your national AMR surveillance system(s)?AST data can be in any format (zones, MIC, SIR, aggregated). Genotypic confirmation refers to the identification of a resistance gene; e.g., NDM-1.CML: Clinical Microbiological Laboratory NRL: National Reference or Expert LaboratoryPlease select NRL if it is the only provider of AST and/or genotypic data. : E. faecium and/or E. faecalis (vancomycin R) : AST data",
        "short_title": "AST data available on national level. Vancomycin resistant Enterococci.",
        "type": "SingleChoice",
        "coefficient": 0.038,
        "tags": [
            "National surveillance",
            "E. faecium/faecalis",
            "Vancomycin"
        ],
        "possible_answers": {
            "All CMLs": 1,
            "A subset of CMLs": 0.5,
            "NRL": 1,
            "Other": 0,
            "Do not know": "null",
            "Not submitted": 0
        },
        "actual_answers": {
            "Spain": "All CMLs",
            "Austria": "A subset of CMLs",
            "Lithuania": "All CMLs",
            "Croatia": "Not submitted",
            "Netherlands": "A subset of CMLs",
            "Ireland": "All CMLs",
            "Germany": "A subset of CMLs",
            "Poland": "All CMLs",
            "Italy": "A subset of CMLs",
            "Greece": "A subset of CMLs",
            "France": "A subset of CMLs",
            "Czechia": "NRL",
            "Belgium": "A subset of CMLs",
            "Hungary": "A subset of CMLs",
            "Finland": "All CMLs",
            "Luxembourg": "All CMLs",
            "Malta": "A subset of CMLs",
            "Portugal": "NRL",
            "Norway": "All CMLs",
            "Slovenia": "All CMLs",
            "Estonia": "All CMLs",
            "Sweden": "All CMLs",
            "Ukraine": "A subset of CMLs",
            "Slovak Republic": "A subset of CMLs",
            "Denmark": "All CMLs",
            "Latvia": "All CMLs",
            "Iceland": "NRL",
            "Bulgaria": "A subset of CMLs"
        }
    },
    "37.14": {
        "title": "Which laboratories submit data for AST and genotypic confirmation for the following pathogens to your national AMR surveillance system(s)?AST data can be in any format (zones, MIC, SIR, aggregated). Genotypic confirmation refers to the identification of a resistance gene; e.g., NDM-1.CML: Clinical Microbiological Laboratory NRL: National Reference or Expert LaboratoryPlease select NRL if it is the only provider of AST and/or genotypic data. : S. pneumoniae (penicillin and macrolide R) : AST data",
        "short_title": "AST data available on national level. Penicillin resistant S. pneumoniae.",
        "type": "SingleChoice",
        "coefficient": 0.038,
        "tags": [
            "National surveillance",
            "S. pneumoniae",
            "Penicillin"
        ],
        "possible_answers": {
            "All CMLs": 1,
            "A subset of CMLs": 0.5,
            "NRL": 1,
            "Other": 0,
            "Do not know": "null",
            "Not submitted": 0
        },
        "actual_answers": {
            "Spain": "Not submitted",
            "Austria": "A subset of CMLs",
            "Lithuania": "All CMLs",
            "Croatia": "Not submitted",
            "Netherlands": "A subset of CMLs",
            "Ireland": "All CMLs",
            "Germany": "A subset of CMLs",
            "Poland": "All CMLs",
            "Italy": "A subset of CMLs",
            "Greece": "A subset of CMLs",
            "France": "A subset of CMLs",
            "Czechia": "NRL",
            "Belgium": "NRL",
            "Hungary": "A subset of CMLs",
            "Finland": "Not submitted",
            "Luxembourg": "All CMLs",
            "Malta": "A subset of CMLs",
            "Portugal": "NRL",
            "Norway": "All CMLs",
            "Slovenia": "All CMLs",
            "Estonia": "All CMLs",
            "Sweden": "All CMLs",
            "Ukraine": "A subset of CMLs",
            "Slovak Republic": "A subset of CMLs",
            "Denmark": "All CMLs",
            "Latvia": "All CMLs",
            "Iceland": "NRL",
            "Bulgaria": "Not submitted"
        }
    },
    "37.15": {
        "title": "Which laboratories submit data for AST and genotypic confirmation for the following pathogens to your national AMR surveillance system(s)?AST data can be in any format (zones, MIC, SIR, aggregated). Genotypic confirmation refers to the identification of a resistance gene; e.g., NDM-1.CML: Clinical Microbiological Laboratory NRL: National Reference or Expert LaboratoryPlease select NRL if it is the only provider of AST and/or genotypic data. : H. influenzae (ampicillin- R) : AST data",
        "short_title": "AST data available on national level. Ampicillin resistant H. influenzae.",
        "type": "SingleChoice",
        "coefficient": 0.038,
        "tags": [
            "National surveillance",
            "H. influenzae",
            "Ampicillin"
        ],
        "possible_answers": {
            "All CMLs": 1,
            "A subset of CMLs": 0.5,
            "NRL": 1,
            "Other": 0,
            "Do not know": "null",
            "Not submitted": 0
        },
        "actual_answers": {
            "Spain": "All CMLs",
            "Austria": "A subset of CMLs",
            "Lithuania": "All CMLs",
            "Croatia": "Not submitted",
            "Netherlands": "A subset of CMLs",
            "Ireland": "Not submitted",
            "Germany": "A subset of CMLs",
            "Poland": "A subset of CMLs",
            "Italy": "Not submitted",
            "Greece": "Not submitted",
            "France": "A subset of CMLs",
            "Czechia": "A subset of CMLs",
            "Belgium": "NRL",
            "Hungary": "A subset of CMLs",
            "Finland": "Not submitted",
            "Luxembourg": "All CMLs",
            "Malta": "A subset of CMLs",
            "Portugal": "NRL",
            "Norway": "All CMLs",
            "Slovenia": "All CMLs",
            "Estonia": "All CMLs",
            "Sweden": "All CMLs",
            "Ukraine": "Not submitted",
            "Slovak Republic": "A subset of CMLs",
            "Denmark": "All CMLs",
            "Latvia": "All CMLs",
            "Iceland": "NRL",
            "Bulgaria": "Not submitted"
        }
    },
    "37.16": {
        "title": "Which laboratories submit data for AST and genotypic confirmation for the following pathogens to your national AMR surveillance system(s)?AST data can be in any format (zones, MIC, SIR, aggregated). Genotypic confirmation refers to the identification of a resistance gene; e.g., NDM-1.CML: Clinical Microbiological Laboratory NRL: National Reference or Expert LaboratoryPlease select NRL if it is the only provider of AST and/or genotypic data. : C. difficile : AST data",
        "short_title": "AST data available on national level. C. difficile.",
        "type": "SingleChoice",
        "coefficient": 0.038,
        "tags": [
            "National surveillance",
            "C. difficile"
        ],
        "possible_answers": {
            "All CMLs": 1,
            "A subset of CMLs": 0.5,
            "NRL": 1,
            "Other": 0,
            "Do not know": "null",
            "Not submitted": 0
        },
        "actual_answers": {
            "Spain": "Not submitted",
            "Austria": "Do not know",
            "Lithuania": "NRL",
            "Croatia": "Not submitted",
            "Netherlands": "A subset of CMLs",
            "Ireland": "All CMLs",
            "Germany": "A subset of CMLs",
            "Poland": "A subset of CMLs",
            "Italy": "Not submitted",
            "Greece": "Not submitted",
            "France": "A subset of CMLs",
            "Czechia": "A subset of CMLs",
            "Belgium": "NRL",
            "Hungary": "Not submitted",
            "Finland": "Do not know",
            "Luxembourg": "All CMLs",
            "Malta": "A subset of CMLs",
            "Portugal": "NRL",
            "Norway": "All CMLs",
            "Slovenia": "A subset of CMLs",
            "Estonia": "All CMLs",
            "Sweden": "A subset of CMLs",
            "Ukraine": "Not submitted",
            "Slovak Republic": "Do not know",
            "Denmark": "All CMLs",
            "Latvia": "A subset of CMLs",
            "Iceland": "Not submitted",
            "Bulgaria": "Not submitted"
        }
    },
    "37.17": {
        "title": "Which laboratories submit data for AST and genotypic confirmation for the following pathogens to your national AMR surveillance system(s)?AST data can be in any format (zones, MIC, SIR, aggregated). Genotypic confirmation refers to the identification of a resistance gene; e.g., NDM-1.CML: Clinical Microbiological Laboratory NRL: National Reference or Expert LaboratoryPlease select NRL if it is the only provider of AST and/or genotypic data. : K. pneumoniae (carbapenem R and/or P) : Genotypic confirmation data",
        "short_title": "Genotypic confirmation data available on national level? Carbapenem resistant K. pneumoniae.",
        "type": "SingleChoice",
        "coefficient": 0.038,
        "tags": [
            "National surveillance",
            "K. pneumoniae",
            "Carbapenem"
        ],
        "possible_answers": {
            "All CMLs": 1,
            "A subset of CMLs": 0.5,
            "NRL": 1,
            "Other": 0,
            "Do not know": "null",
            "Not submitted": 0
        },
        "actual_answers": {
            "Spain": "Other",
            "Austria": "A subset of CMLs",
            "Lithuania": "NRL",
            "Croatia": "A subset of CMLs",
            "Netherlands": "All CMLs",
            "Ireland": "Do not know",
            "Germany": "Not submitted",
            "Poland": "NRL",
            "Italy": "A subset of CMLs",
            "Greece": "A subset of CMLs",
            "France": "Not submitted",
            "Czechia": "NRL",
            "Belgium": "A subset of CMLs",
            "Hungary": "NRL",
            "Finland": "All CMLs",
            "Luxembourg": "NRL",
            "Malta": "Not submitted",
            "Portugal": "NRL",
            "Norway": "All CMLs",
            "Slovenia": "Other",
            "Estonia": "All CMLs",
            "Sweden": "All CMLs",
            "Ukraine": "Not submitted",
            "Slovak Republic": "NRL",
            "Denmark": "NRL",
            "Latvia": "NRL",
            "Iceland": "NRL",
            "Bulgaria": "Not submitted"
        }
    },
    "37.18": {
        "title": "Which laboratories submit data for AST and genotypic confirmation for the following pathogens to your national AMR surveillance system(s)?AST data can be in any format (zones, MIC, SIR, aggregated). Genotypic confirmation refers to the identification of a resistance gene; e.g., NDM-1.CML: Clinical Microbiological Laboratory NRL: National Reference or Expert LaboratoryPlease select NRL if it is the only provider of AST and/or genotypic data. : K. pneumoniae (3GC- R and/or P) : Genotypic confirmation data",
        "short_title": "Genotypic confirmation data available on national level? 3rd-generation cephalosporins resistant K. pneumoniae.",
        "type": "SingleChoice",
        "coefficient": 0.038,
        "tags": [
            "National surveillance",
            "K. pneumoniae",
            "3rd-generation Cephalosporin"
        ],
        "possible_answers": {
            "All CMLs": 1,
            "A subset of CMLs": 0.5,
            "NRL": 1,
            "Other": 0,
            "Do not know": "null",
            "Not submitted": 0
        },
        "actual_answers": {
            "Spain": "Other",
            "Austria": "Not submitted",
            "Lithuania": "Not submitted",
            "Croatia": "Not submitted",
            "Netherlands": "A subset of CMLs",
            "Ireland": "All CMLs",
            "Germany": "Not submitted",
            "Poland": "Not submitted",
            "Italy": "Other",
            "Greece": "A subset of CMLs",
            "France": "Not submitted",
            "Czechia": "Not submitted",
            "Belgium": "A subset of CMLs",
            "Hungary": "Not submitted",
            "Finland": "Not submitted",
            "Luxembourg": "NRL",
            "Malta": "Not submitted",
            "Portugal": "NRL",
            "Norway": "All CMLs",
            "Slovenia": "Other",
            "Estonia": "All CMLs",
            "Sweden": "All CMLs",
            "Ukraine": "Not submitted",
            "Slovak Republic": "NRL",
            "Denmark": "Not submitted",
            "Latvia": "NRL",
            "Iceland": "Not submitted",
            "Bulgaria": "Not submitted"
        }
    },
    "37.19": {
        "title": "Which laboratories submit data for AST and genotypic confirmation for the following pathogens to your national AMR surveillance system(s)?AST data can be in any format (zones, MIC, SIR, aggregated). Genotypic confirmation refers to the identification of a resistance gene; e.g., NDM-1.CML: Clinical Microbiological Laboratory NRL: National Reference or Expert LaboratoryPlease select NRL if it is the only provider of AST and/or genotypic data. : K. pneumoniae (colistin R) : Genotypic confirmation data",
        "short_title": "Genotypic confirmation data available on national level? Colistin resistant K. pneumoniae.",
        "type": "SingleChoice",
        "coefficient": 0.038,
        "tags": [
            "National surveillance",
            "K. pneumoniae",
            "Colistin"
        ],
        "possible_answers": {
            "All CMLs": 1,
            "A subset of CMLs": 0.5,
            "NRL": 1,
            "Other": 0,
            "Do not know": "null",
            "Not submitted": 0
        },
        "actual_answers": {
            "Spain": "Other",
            "Austria": "A subset of CMLs",
            "Lithuania": "Not submitted",
            "Croatia": "A subset of CMLs",
            "Netherlands": "A subset of CMLs",
            "Ireland": "Do not know",
            "Germany": "Not submitted",
            "Poland": "Not submitted",
            "Italy": "Other",
            "Greece": "A subset of CMLs",
            "France": "Not submitted",
            "Czechia": "NRL",
            "Belgium": "Not submitted",
            "Hungary": "Not submitted",
            "Finland": "Not submitted",
            "Luxembourg": "NRL",
            "Malta": "Not submitted",
            "Portugal": "NRL",
            "Norway": "All CMLs",
            "Slovenia": "Other",
            "Estonia": "NRL",
            "Sweden": "A subset of CMLs",
            "Ukraine": "Not submitted",
            "Slovak Republic": "NRL",
            "Denmark": "NRL",
            "Latvia": "NRL",
            "Iceland": "Not submitted",
            "Bulgaria": "Not submitted"
        }
    },
    "37.20": {
        "title": "Which laboratories submit data for AST and genotypic confirmation for the following pathogens to your national AMR surveillance system(s)?AST data can be in any format (zones, MIC, SIR, aggregated). Genotypic confirmation refers to the identification of a resistance gene; e.g., NDM-1.CML: Clinical Microbiological Laboratory NRL: National Reference or Expert LaboratoryPlease select NRL if it is the only provider of AST and/or genotypic data. : P. aeruginosa (carbapenem R and/or P) : Genotypic confirmation data",
        "short_title": "Genotypic confirmation data available on national level? Carbapenem resistant P. aeruginosa.",
        "type": "SingleChoice",
        "coefficient": 0.038,
        "tags": [
            "National surveillance",
            "P. aeruginosa",
            "Carbapenem"
        ],
        "possible_answers": {
            "All CMLs": 1,
            "A subset of CMLs": 0.5,
            "NRL": 1,
            "Other": 0,
            "Do not know": "null",
            "Not submitted": 0
        },
        "actual_answers": {
            "Spain": "Other",
            "Austria": "A subset of CMLs",
            "Lithuania": "NRL",
            "Croatia": "Not submitted",
            "Netherlands": "A subset of CMLs",
            "Ireland": "Do not know",
            "Germany": "Not submitted",
            "Poland": "Not submitted",
            "Italy": "Other",
            "Greece": "A subset of CMLs",
            "France": "Not submitted",
            "Czechia": "NRL",
            "Belgium": "A subset of CMLs",
            "Hungary": "NRL",
            "Finland": "Not submitted",
            "Luxembourg": "NRL",
            "Malta": "Not submitted",
            "Portugal": "NRL",
            "Norway": "All CMLs",
            "Slovenia": "Other",
            "Estonia": "All CMLs",
            "Sweden": "All CMLs",
            "Ukraine": "Not submitted",
            "Slovak Republic": "NRL",
            "Denmark": "NRL",
            "Latvia": "NRL",
            "Iceland": "NRL",
            "Bulgaria": "Not submitted"
        }
    },
    "37.21": {
        "title": "Which laboratories submit data for AST and genotypic confirmation for the following pathogens to your national AMR surveillance system(s)?AST data can be in any format (zones, MIC, SIR, aggregated). Genotypic confirmation refers to the identification of a resistance gene; e.g., NDM-1.CML: Clinical Microbiological Laboratory NRL: National Reference or Expert LaboratoryPlease select NRL if it is the only provider of AST and/or genotypic data. : A. baumanii (carbapenem R and/or P) : Genotypic confirmation data",
        "short_title": "Genotypic confirmation data available on national level? Carbapenem resistant A. baumanii.",
        "type": "SingleChoice",
        "coefficient": 0.038,
        "tags": [
            "National surveillance",
            "A. baumanii",
            "Carbapenem"
        ],
        "possible_answers": {
            "All CMLs": 1,
            "A subset of CMLs": 0.5,
            "NRL": 1,
            "Other": 0,
            "Do not know": "null",
            "Not submitted": 0
        },
        "actual_answers": {
            "Spain": "Other",
            "Austria": "A subset of CMLs",
            "Lithuania": "NRL",
            "Croatia": "Not submitted",
            "Netherlands": "A subset of CMLs",
            "Ireland": "Do not know",
            "Germany": "Not submitted",
            "Poland": "Not submitted",
            "Italy": "Other",
            "Greece": "A subset of CMLs",
            "France": "Not submitted",
            "Czechia": "NRL",
            "Belgium": "A subset of CMLs",
            "Hungary": "NRL",
            "Finland": "Not submitted",
            "Luxembourg": "NRL",
            "Malta": "Not submitted",
            "Portugal": "NRL",
            "Norway": "All CMLs",
            "Slovenia": "Other",
            "Estonia": "All CMLs",
            "Sweden": "A subset of CMLs",
            "Ukraine": "Not submitted",
            "Slovak Republic": "NRL",
            "Denmark": "NRL",
            "Latvia": "NRL",
            "Iceland": "NRL",
            "Bulgaria": "Not submitted"
        }
    },
    "37.22": {
        "title": "Which laboratories submit data for AST and genotypic confirmation for the following pathogens to your national AMR surveillance system(s)?AST data can be in any format (zones, MIC, SIR, aggregated). Genotypic confirmation refers to the identification of a resistance gene; e.g., NDM-1.CML: Clinical Microbiological Laboratory NRL: National Reference or Expert LaboratoryPlease select NRL if it is the only provider of AST and/or genotypic data. : S. aureus (methicillin R) : Genotypic confirmation data",
        "short_title": "Genotypic confirmation data available on national level? Methicillin resistant S. aureus.",
        "type": "SingleChoice",
        "coefficient": 0.038,
        "tags": [
            "National surveillance",
            "S. aureus",
            "Methicillin"
        ],
        "possible_answers": {
            "All CMLs": 1,
            "A subset of CMLs": 0.5,
            "NRL": 1,
            "Other": 0,
            "Do not know": "null",
            "Not submitted": 0
        },
        "actual_answers": {
            "Spain": "Other",
            "Austria": "A subset of CMLs",
            "Lithuania": "NRL",
            "Croatia": "Not submitted",
            "Netherlands": "A subset of CMLs",
            "Ireland": "Do not know",
            "Germany": "Not submitted",
            "Poland": "Not submitted",
            "Italy": "Other",
            "Greece": "A subset of CMLs",
            "France": "Not submitted",
            "Czechia": "NRL",
            "Belgium": "A subset of CMLs",
            "Hungary": "NRL",
            "Finland": "All CMLs",
            "Luxembourg": "NRL",
            "Malta": "Not submitted",
            "Portugal": "NRL",
            "Norway": "All CMLs",
            "Slovenia": "Other",
            "Estonia": "All CMLs",
            "Sweden": "All CMLs",
            "Ukraine": "Not submitted",
            "Slovak Republic": "NRL",
            "Denmark": "NRL",
            "Latvia": "NRL",
            "Iceland": "Not submitted",
            "Bulgaria": "Not submitted"
        }
    },
    "37.23": {
        "title": "Which laboratories submit data for AST and genotypic confirmation for the following pathogens to your national AMR surveillance system(s)?AST data can be in any format (zones, MIC, SIR, aggregated). Genotypic confirmation refers to the identification of a resistance gene; e.g., NDM-1.CML: Clinical Microbiological Laboratory NRL: National Reference or Expert LaboratoryPlease select NRL if it is the only provider of AST and/or genotypic data. : E. faecium and/or E. faecalis (vancomycin R) : Genotypic confirmation data",
        "short_title": "Genotypic confirmation data available on national level? Vancomycin resistant Enterococci.",
        "type": "SingleChoice",
        "coefficient": 0.038,
        "tags": [
            "National surveillance",
            "E. faecium/faecalis",
            "Vancomycin"
        ],
        "possible_answers": {
            "All CMLs": 1,
            "A subset of CMLs": 0.5,
            "NRL": 1,
            "Other": 0,
            "Do not know": "null",
            "Not submitted": 0
        },
        "actual_answers": {
            "Spain": "Other",
            "Austria": "Not submitted",
            "Lithuania": "NRL",
            "Croatia": "Not submitted",
            "Netherlands": "A subset of CMLs",
            "Ireland": "Do not know",
            "Germany": "Not submitted",
            "Poland": "Not submitted",
            "Italy": "Other",
            "Greece": "A subset of CMLs",
            "France": "Not submitted",
            "Czechia": "NRL",
            "Belgium": "A subset of CMLs",
            "Hungary": "NRL",
            "Finland": "All CMLs",
            "Luxembourg": "NRL",
            "Malta": "Not submitted",
            "Portugal": "NRL",
            "Norway": "All CMLs",
            "Slovenia": "Other",
            "Estonia": "All CMLs",
            "Sweden": "All CMLs",
            "Ukraine": "Not submitted",
            "Slovak Republic": "NRL",
            "Denmark": "NRL",
            "Latvia": "NRL",
            "Iceland": "NRL",
            "Bulgaria": "Not submitted"
        }
    },
    "37.24": {
        "title": "Which laboratories submit data for AST and genotypic confirmation for the following pathogens to your national AMR surveillance system(s)?AST data can be in any format (zones, MIC, SIR, aggregated). Genotypic confirmation refers to the identification of a resistance gene; e.g., NDM-1.CML: Clinical Microbiological Laboratory NRL: National Reference or Expert LaboratoryPlease select NRL if it is the only provider of AST and/or genotypic data. : S. pneumoniae (penicillin and macrolide R) : Genotypic confirmation data",
        "short_title": "Genotypic confirmation data available on national level? Penicillin resistant S. pneumoniae.",
        "type": "SingleChoice",
        "coefficient": 0.038,
        "tags": [
            "National surveillance",
            "S. pneumoniae",
            "Penicillin"
        ],
        "possible_answers": {
            "All CMLs": 1,
            "A subset of CMLs": 0.5,
            "NRL": 1,
            "Other": 0,
            "Do not know": "null",
            "Not submitted": 0
        },
        "actual_answers": {
            "Spain": "Not submitted",
            "Austria": "Do not know",
            "Lithuania": "Not submitted",
            "Croatia": "Not submitted",
            "Netherlands": "A subset of CMLs",
            "Ireland": "Do not know",
            "Germany": "Not submitted",
            "Poland": "NRL",
            "Italy": "Other",
            "Greece": "A subset of CMLs",
            "France": "Not submitted",
            "Czechia": "Not submitted",
            "Belgium": "NRL",
            "Hungary": "Not submitted",
            "Finland": "Not submitted",
            "Luxembourg": "NRL",
            "Malta": "Not submitted",
            "Portugal": "NRL",
            "Norway": "All CMLs",
            "Slovenia": "Other",
            "Estonia": "All CMLs",
            "Sweden": "NRL",
            "Ukraine": "Not submitted",
            "Slovak Republic": "NRL",
            "Denmark": "NRL",
            "Latvia": "NRL",
            "Iceland": "Not submitted",
            "Bulgaria": "Not submitted"
        }
    },
    "37.25": {
        "title": "Which laboratories submit data for AST and genotypic confirmation for the following pathogens to your national AMR surveillance system(s)?AST data can be in any format (zones, MIC, SIR, aggregated). Genotypic confirmation refers to the identification of a resistance gene; e.g., NDM-1.CML: Clinical Microbiological Laboratory NRL: National Reference or Expert LaboratoryPlease select NRL if it is the only provider of AST and/or genotypic data. : H. influenzae (ampicillin- R) : Genotypic confirmation data",
        "short_title": "Genotypic confirmation data available on national level? Ampicillin resistant H. influenzae.",
        "type": "SingleChoice",
        "coefficient": 0.038,
        "tags": [
            "National surveillance",
            "H. influenzae",
            "Ampicillin"
        ],
        "possible_answers": {
            "All CMLs": 1,
            "A subset of CMLs": 0.5,
            "NRL": 1,
            "Other": 0,
            "Do not know": "null",
            "Not submitted": 0
        },
        "actual_answers": {
            "Spain": "Other",
            "Austria": "Do not know",
            "Lithuania": "Not submitted",
            "Croatia": "Not submitted",
            "Netherlands": "A subset of CMLs",
            "Ireland": "Do not know",
            "Germany": "Not submitted",
            "Poland": "NRL",
            "Italy": "Not submitted",
            "Greece": "Not submitted",
            "France": "Do not know",
            "Czechia": "NRL",
            "Belgium": "NRL",
            "Hungary": "Not submitted",
            "Finland": "Not submitted",
            "Luxembourg": "NRL",
            "Malta": "Not submitted",
            "Portugal": "NRL",
            "Norway": "All CMLs",
            "Slovenia": "Other",
            "Estonia": "All CMLs",
            "Sweden": "NRL",
            "Ukraine": "Not submitted",
            "Slovak Republic": "NRL",
            "Denmark": "NRL",
            "Latvia": "NRL",
            "Iceland": "Not submitted",
            "Bulgaria": "Not submitted"
        }
    },
    "37.26": {
        "title": "Which laboratories submit data for AST and genotypic confirmation for the following pathogens to your national AMR surveillance system(s)?AST data can be in any format (zones, MIC, SIR, aggregated). Genotypic confirmation refers to the identification of a resistance gene; e.g., NDM-1.CML: Clinical Microbiological Laboratory NRL: National Reference or Expert LaboratoryPlease select NRL if it is the only provider of AST and/or genotypic data. : C. difficile : Genotypic confirmation data",
        "short_title": "Genotypic confirmation data available on national level? C. difficile.",
        "type": "SingleChoice",
        "coefficient": 0.038,
        "tags": [
            "National surveillance",
            "C. difficile"
        ],
        "possible_answers": {
            "All CMLs": 1,
            "A subset of CMLs": 0.5,
            "NRL": 1,
            "Other": 0,
            "Do not know": "null",
            "Not submitted": 0
        },
        "actual_answers": {
            "Spain": "Not submitted",
            "Austria": "Do not know",
            "Lithuania": "Not submitted",
            "Croatia": "Not submitted",
            "Netherlands": "A subset of CMLs",
            "Ireland": "NRL",
            "Germany": "Not submitted",
            "Poland": "Not submitted",
            "Italy": "Not submitted",
            "Greece": "Not submitted",
            "France": "Not submitted",
            "Czechia": "Not submitted",
            "Belgium": "NRL",
            "Hungary": "Not submitted",
            "Finland": "Do not know",
            "Luxembourg": "NRL",
            "Malta": "Not submitted",
            "Portugal": "NRL",
            "Norway": "All CMLs",
            "Slovenia": "Other",
            "Estonia": "All CMLs",
            "Sweden": "NRL",
            "Ukraine": "Not submitted",
            "Slovak Republic": "NRL",
            "Denmark": "NRL",
            "Latvia": "NRL",
            "Iceland": "Not submitted",
            "Bulgaria": "Not submitted"
        }
    },
    "38.1": {
        "title": "Is AST data for the following pathogen part of your national surveillance, and how would you estimate the population coverage and the geographical representativeness of the submitteddata?  Applies to AST data for all tested isolates (susceptible, intermediate and resistant). Can be in any format (zones, MIC, SIR, aggregated).Estimation range of population coverage:The percentage of the population that is roughly covered by the clinical microbiology laboratories that submit data. Estimation of geographical representativeness: A rough estimation of the quantity of geographical regions that are covered by the clinical microbiology laboratories that submit data. Similar estimations are included in the annual report to EARS-Net. If you are unsure about the estimations, please consult the EARS-Net focal point in your country. : Blood/CSF E. coli : If data is submitted: Estimated range of population coverage",
        "short_title": "Population coverage for AST data part of national surveillance. E. coli - blood.",
        "type": "SingleChoice",
        "coefficient": 0.033,
        "tags": [
            "National surveillance",
            "E. coli",
            "Blood"
        ],
        "possible_answers": {
            "76-100%": 1,
            "51-75%": 0.75,
            "26-50%": 0.5,
            "1-25%": 0.25,
            "Do not know": "null",
            "Not part of national surveillance": "null"
        },
        "actual_answers": {
            "Spain": "26-50%",
            "Austria": "76-100%",
            "Lithuania": "76-100%",
            "Croatia": "76-100%",
            "Netherlands": "76-100%",
            "Ireland": "76-100%",
            "Germany": "26-50%",
            "Poland": "1-25%",
            "Italy": "51-75%",
            "Greece": "51-75%",
            "France": "76-100%",
            "Czechia": "76-100%",
            "Belgium": "76-100%",
            "Hungary": "76-100%",
            "Finland": "76-100%",
            "Luxembourg": "76-100%",
            "Malta": "76-100%",
            "Portugal": "76-100%",
            "Norway": "76-100%",
            "Slovenia": "76-100%",
            "Estonia": "76-100%",
            "Sweden": "76-100%",
            "Ukraine": "Do not know",
            "Slovak Republic": "51-75%",
            "Denmark": "76-100%",
            "Latvia": "76-100%",
            "Iceland": "76-100%",
            "Bulgaria": "51-75%"
        }
    },
    "38.2": {
        "title": "Is AST data for the following pathogen part of your national surveillance, and how would you estimate the population coverage and the geographical representativeness of the submitteddata?  Applies to AST data for all tested isolates (susceptible, intermediate and resistant). Can be in any format (zones, MIC, SIR, aggregated).Estimation range of population coverage:The percentage of the population that is roughly covered by the clinical microbiology laboratories that submit data. Estimation of geographical representativeness: A rough estimation of the quantity of geographical regions that are covered by the clinical microbiology laboratories that submit data. Similar estimations are included in the annual report to EARS-Net. If you are unsure about the estimations, please consult the EARS-Net focal point in your country. : Blood/CSF K. pneumoniae : If data is submitted: Estimated range of population coverage",
        "short_title": "Population coverage for AST data part of national surveillance. K. pneumoniae - blood.",
        "type": "SingleChoice",
        "coefficient": 0.033,
        "tags": [
            "National surveillance",
            "K. pneumoniae",
            "Blood"
        ],
        "possible_answers": {
            "76-100%": 1,
            "51-75%": 0.75,
            "26-50%": 0.5,
            "1-25%": 0.25,
            "Do not know": "null",
            "Not part of national surveillance": "null"
        },
        "actual_answers": {
            "Spain": "26-50%",
            "Austria": "76-100%",
            "Lithuania": "76-100%",
            "Croatia": "76-100%",
            "Netherlands": "76-100%",
            "Ireland": "76-100%",
            "Germany": "26-50%",
            "Poland": "1-25%",
            "Italy": "51-75%",
            "Greece": "76-100%",
            "France": "76-100%",
            "Czechia": "76-100%",
            "Belgium": "76-100%",
            "Hungary": "76-100%",
            "Finland": "76-100%",
            "Luxembourg": "76-100%",
            "Malta": "76-100%",
            "Portugal": "76-100%",
            "Norway": "76-100%",
            "Slovenia": "76-100%",
            "Estonia": "76-100%",
            "Sweden": "76-100%",
            "Ukraine": "Do not know",
            "Slovak Republic": "51-75%",
            "Denmark": "76-100%",
            "Latvia": "76-100%",
            "Iceland": "76-100%",
            "Bulgaria": "51-75%"
        }
    },
    "38.3": {
        "title": "Is AST data for the following pathogen part of your national surveillance, and how would you estimate the population coverage and the geographical representativeness of the submitteddata?  Applies to AST data for all tested isolates (susceptible, intermediate and resistant). Can be in any format (zones, MIC, SIR, aggregated).Estimation range of population coverage:The percentage of the population that is roughly covered by the clinical microbiology laboratories that submit data. Estimation of geographical representativeness: A rough estimation of the quantity of geographical regions that are covered by the clinical microbiology laboratories that submit data. Similar estimations are included in the annual report to EARS-Net. If you are unsure about the estimations, please consult the EARS-Net focal point in your country. : Blood/CSFP. aeruginosa : If data is submitted: Estimated range of population coverage",
        "short_title": "Population coverage for AST data part of national surveillance. P. aeruginosa - blood.",
        "type": "SingleChoice",
        "coefficient": 0.033,
        "tags": [
            "National surveillance",
            "P. aeruginosa",
            "Blood"
        ],
        "possible_answers": {
            "76-100%": 1,
            "51-75%": 0.75,
            "26-50%": 0.5,
            "1-25%": 0.25,
            "Do not know": "null",
            "Not part of national surveillance": "null"
        },
        "actual_answers": {
            "Spain": "26-50%",
            "Austria": "76-100%",
            "Lithuania": "76-100%",
            "Croatia": "76-100%",
            "Netherlands": "76-100%",
            "Ireland": "76-100%",
            "Germany": "26-50%",
            "Poland": "1-25%",
            "Italy": "51-75%",
            "Greece": "76-100%",
            "France": "76-100%",
            "Czechia": "76-100%",
            "Belgium": "76-100%",
            "Hungary": "76-100%",
            "Finland": "76-100%",
            "Luxembourg": "76-100%",
            "Malta": "76-100%",
            "Portugal": "76-100%",
            "Norway": "76-100%",
            "Slovenia": "76-100%",
            "Estonia": "76-100%",
            "Sweden": "76-100%",
            "Ukraine": "Do not know",
            "Slovak Republic": "51-75%",
            "Denmark": "76-100%",
            "Latvia": "76-100%",
            "Iceland": "76-100%",
            "Bulgaria": "51-75%"
        }
    },
    "38.4": {
        "title": "Is AST data for the following pathogen part of your national surveillance, and how would you estimate the population coverage and the geographical representativeness of the submitteddata?  Applies to AST data for all tested isolates (susceptible, intermediate and resistant). Can be in any format (zones, MIC, SIR, aggregated).Estimation range of population coverage:The percentage of the population that is roughly covered by the clinical microbiology laboratories that submit data. Estimation of geographical representativeness: A rough estimation of the quantity of geographical regions that are covered by the clinical microbiology laboratories that submit data. Similar estimations are included in the annual report to EARS-Net. If you are unsure about the estimations, please consult the EARS-Net focal point in your country. : Blood/CSFA. baumanii : If data is submitted: Estimated range of population coverage",
        "short_title": "Population coverage for AST data part of national surveillance. A. baumanii - blood.",
        "type": "SingleChoice",
        "coefficient": 0.033,
        "tags": [
            "National surveillance",
            "A. baumanii",
            "Blood"
        ],
        "possible_answers": {
            "76-100%": 1,
            "51-75%": 0.75,
            "26-50%": 0.5,
            "1-25%": 0.25,
            "Do not know": "null",
            "Not part of national surveillance": "null"
        },
        "actual_answers": {
            "Spain": "26-50%",
            "Austria": "76-100%",
            "Lithuania": "76-100%",
            "Croatia": "76-100%",
            "Netherlands": "76-100%",
            "Ireland": "76-100%",
            "Germany": "26-50%",
            "Poland": "1-25%",
            "Italy": "51-75%",
            "Greece": "76-100%",
            "France": "76-100%",
            "Czechia": "76-100%",
            "Belgium": "76-100%",
            "Hungary": "76-100%",
            "Finland": "76-100%",
            "Luxembourg": "76-100%",
            "Malta": "76-100%",
            "Portugal": "76-100%",
            "Norway": "76-100%",
            "Slovenia": "76-100%",
            "Estonia": "76-100%",
            "Sweden": "76-100%",
            "Ukraine": "Do not know",
            "Slovak Republic": "51-75%",
            "Denmark": "76-100%",
            "Latvia": "76-100%",
            "Iceland": "76-100%",
            "Bulgaria": "51-75%"
        }
    },
    "38.5": {
        "title": "Is AST data for the following pathogen part of your national surveillance, and how would you estimate the population coverage and the geographical representativeness of the submitteddata?  Applies to AST data for all tested isolates (susceptible, intermediate and resistant). Can be in any format (zones, MIC, SIR, aggregated).Estimation range of population coverage:The percentage of the population that is roughly covered by the clinical microbiology laboratories that submit data. Estimation of geographical representativeness: A rough estimation of the quantity of geographical regions that are covered by the clinical microbiology laboratories that submit data. Similar estimations are included in the annual report to EARS-Net. If you are unsure about the estimations, please consult the EARS-Net focal point in your country. : Blood/CSFS. aureus : If data is submitted: Estimated range of population coverage",
        "short_title": "Population coverage for AST data part of national surveillance. S. aureus - blood.",
        "type": "SingleChoice",
        "coefficient": 0.033,
        "tags": [
            "National surveillance",
            "S. aureus",
            "Blood"
        ],
        "possible_answers": {
            "76-100%": 1,
            "51-75%": 0.75,
            "26-50%": 0.5,
            "1-25%": 0.25,
            "Do not know": "null",
            "Not part of national surveillance": "null"
        },
        "actual_answers": {
            "Spain": "26-50%",
            "Austria": "76-100%",
            "Lithuania": "76-100%",
            "Croatia": "76-100%",
            "Netherlands": "76-100%",
            "Ireland": "76-100%",
            "Germany": "26-50%",
            "Poland": "1-25%",
            "Italy": "51-75%",
            "Greece": "76-100%",
            "France": "76-100%",
            "Czechia": "76-100%",
            "Belgium": "76-100%",
            "Hungary": "76-100%",
            "Finland": "76-100%",
            "Luxembourg": "76-100%",
            "Malta": "76-100%",
            "Portugal": "76-100%",
            "Norway": "76-100%",
            "Slovenia": "76-100%",
            "Estonia": "76-100%",
            "Sweden": "76-100%",
            "Ukraine": "Do not know",
            "Slovak Republic": "51-75%",
            "Denmark": "76-100%",
            "Latvia": "76-100%",
            "Iceland": "76-100%",
            "Bulgaria": "51-75%"
        }
    },
    "38.6": {
        "title": "Is AST data for the following pathogen part of your national surveillance, and how would you estimate the population coverage and the geographical representativeness of the submitteddata?  Applies to AST data for all tested isolates (susceptible, intermediate and resistant). Can be in any format (zones, MIC, SIR, aggregated).Estimation range of population coverage:The percentage of the population that is roughly covered by the clinical microbiology laboratories that submit data. Estimation of geographical representativeness: A rough estimation of the quantity of geographical regions that are covered by the clinical microbiology laboratories that submit data. Similar estimations are included in the annual report to EARS-Net. If you are unsure about the estimations, please consult the EARS-Net focal point in your country. : Blood/CSFE. faecium and/or E. faecalis : If data is submitted: Estimated range of population coverage",
        "short_title": "Population coverage for AST data part of national surveillance. VRE - blood.",
        "type": "SingleChoice",
        "coefficient": 0.033,
        "tags": [
            "National surveillance",
            "E. faecium/faecalis",
            "Blood"
        ],
        "possible_answers": {
            "76-100%": 1,
            "51-75%": 0.75,
            "26-50%": 0.5,
            "1-25%": 0.25,
            "Do not know": "null",
            "Not part of national surveillance": "null"
        },
        "actual_answers": {
            "Spain": "26-50%",
            "Austria": "76-100%",
            "Lithuania": "76-100%",
            "Croatia": "76-100%",
            "Netherlands": "76-100%",
            "Ireland": "76-100%",
            "Germany": "26-50%",
            "Poland": "1-25%",
            "Italy": "51-75%",
            "Greece": "76-100%",
            "France": "76-100%",
            "Czechia": "76-100%",
            "Belgium": "76-100%",
            "Hungary": "76-100%",
            "Finland": "76-100%",
            "Luxembourg": "76-100%",
            "Malta": "76-100%",
            "Portugal": "76-100%",
            "Norway": "76-100%",
            "Slovenia": "76-100%",
            "Estonia": "76-100%",
            "Sweden": "76-100%",
            "Ukraine": "Do not know",
            "Slovak Republic": "51-75%",
            "Denmark": "76-100%",
            "Latvia": "76-100%",
            "Iceland": "76-100%",
            "Bulgaria": "51-75%"
        }
    },
    "38.7": {
        "title": "Is AST data for the following pathogen part of your national surveillance, and how would you estimate the population coverage and the geographical representativeness of the submitteddata?  Applies to AST data for all tested isolates (susceptible, intermediate and resistant). Can be in any format (zones, MIC, SIR, aggregated).Estimation range of population coverage:The percentage of the population that is roughly covered by the clinical microbiology laboratories that submit data. Estimation of geographical representativeness: A rough estimation of the quantity of geographical regions that are covered by the clinical microbiology laboratories that submit data. Similar estimations are included in the annual report to EARS-Net. If you are unsure about the estimations, please consult the EARS-Net focal point in your country. : Blood/CSFS. pneumoniae : If data is submitted: Estimated range of population coverage",
        "short_title": "Population coverage for AST data part of national surveillance. S. pneumoniae - blood.",
        "type": "SingleChoice",
        "coefficient": 0.033,
        "tags": [
            "National surveillance",
            "S. pneumoniae",
            "Blood"
        ],
        "possible_answers": {
            "76-100%": 1,
            "51-75%": 0.75,
            "26-50%": 0.5,
            "1-25%": 0.25,
            "Do not know": "null",
            "Not part of national surveillance": "null"
        },
        "actual_answers": {
            "Spain": "26-50%",
            "Austria": "76-100%",
            "Lithuania": "76-100%",
            "Croatia": "76-100%",
            "Netherlands": "76-100%",
            "Ireland": "76-100%",
            "Germany": "26-50%",
            "Poland": "1-25%",
            "Italy": "51-75%",
            "Greece": "51-75%",
            "France": "Do not know",
            "Czechia": "76-100%",
            "Belgium": "Do not know",
            "Hungary": "76-100%",
            "Finland": "76-100%",
            "Luxembourg": "76-100%",
            "Malta": "76-100%",
            "Portugal": "76-100%",
            "Norway": "76-100%",
            "Slovenia": "76-100%",
            "Estonia": "76-100%",
            "Sweden": "76-100%",
            "Ukraine": "Do not know",
            "Slovak Republic": "51-75%",
            "Denmark": "76-100%",
            "Latvia": "76-100%",
            "Iceland": "76-100%",
            "Bulgaria": "51-75%"
        }
    },
    "38.8": {
        "title": "Is AST data for the following pathogen part of your national surveillance, and how would you estimate the population coverage and the geographical representativeness of the submitteddata?  Applies to AST data for all tested isolates (susceptible, intermediate and resistant). Can be in any format (zones, MIC, SIR, aggregated).Estimation range of population coverage:The percentage of the population that is roughly covered by the clinical microbiology laboratories that submit data. Estimation of geographical representativeness: A rough estimation of the quantity of geographical regions that are covered by the clinical microbiology laboratories that submit data. Similar estimations are included in the annual report to EARS-Net. If you are unsure about the estimations, please consult the EARS-Net focal point in your country. : Blood/CSFH. influenzae : If data is submitted: Estimated range of population coverage",
        "short_title": "Population coverage for AST data part of national surveillance. H. influenzae - blood.",
        "type": "SingleChoice",
        "coefficient": 0.033,
        "tags": [
            "National surveillance",
            "H. influenzae",
            "Blood"
        ],
        "possible_answers": {
            "76-100%": 1,
            "51-75%": 0.75,
            "26-50%": 0.5,
            "1-25%": 0.25,
            "Do not know": "null",
            "Not part of national surveillance": "null"
        },
        "actual_answers": {
            "Spain": "51-75%",
            "Austria": "Do not know",
            "Lithuania": "76-100%",
            "Croatia": "1-25%",
            "Netherlands": "76-100%",
            "Ireland": "Not part of national surveillance",
            "Germany": "26-50%",
            "Poland": "51-75%",
            "Italy": "Not part of national surveillance",
            "Greece": "Not part of national surveillance",
            "France": "Not part of national surveillance",
            "Czechia": "76-100%",
            "Belgium": "Do not know",
            "Hungary": "76-100%",
            "Finland": "76-100%",
            "Luxembourg": "76-100%",
            "Malta": "76-100%",
            "Portugal": "Do not know",
            "Norway": "76-100%",
            "Slovenia": "76-100%",
            "Estonia": "76-100%",
            "Sweden": "76-100%",
            "Ukraine": "Not part of national surveillance",
            "Slovak Republic": "51-75%",
            "Denmark": "76-100%",
            "Latvia": "76-100%",
            "Iceland": "76-100%",
            "Bulgaria": "26-50%"
        }
    },
    "38.9": {
        "title": "Is AST data for the following pathogen part of your national surveillance, and how would you estimate the population coverage and the geographical representativeness of the submitteddata?  Applies to AST data for all tested isolates (susceptible, intermediate and resistant). Can be in any format (zones, MIC, SIR, aggregated).Estimation range of population coverage:The percentage of the population that is roughly covered by the clinical microbiology laboratories that submit data. Estimation of geographical representativeness: A rough estimation of the quantity of geographical regions that are covered by the clinical microbiology laboratories that submit data. Similar estimations are included in the annual report to EARS-Net. If you are unsure about the estimations, please consult the EARS-Net focal point in your country. : Urine E. coli : If data is submitted: Estimated range of population coverage",
        "short_title": "Population coverage for AST data part of national surveillance. E. coli - urine.",
        "type": "SingleChoice",
        "coefficient": 0.033,
        "tags": [
            "National surveillance",
            "E. coli",
            "Urine"
        ],
        "possible_answers": {
            "76-100%": 1,
            "51-75%": 0.75,
            "26-50%": 0.5,
            "1-25%": 0.25,
            "Do not know": "null",
            "Not part of national surveillance": "null"
        },
        "actual_answers": {
            "Spain": "1-25%",
            "Austria": "26-50%",
            "Lithuania": "1-25%",
            "Croatia": "Not part of national surveillance",
            "Netherlands": "76-100%",
            "Ireland": "Not part of national surveillance",
            "Germany": "26-50%",
            "Poland": "Not part of national surveillance",
            "Italy": "51-75%",
            "Greece": "51-75%",
            "France": "51-75%",
            "Czechia": "26-50%",
            "Belgium": "76-100%",
            "Hungary": "76-100%",
            "Finland": "76-100%",
            "Luxembourg": "Do not know",
            "Malta": "76-100%",
            "Portugal": "Not part of national surveillance",
            "Norway": "76-100%",
            "Slovenia": "Not part of national surveillance",
            "Estonia": "76-100%",
            "Sweden": "76-100%",
            "Ukraine": "Not part of national surveillance",
            "Slovak Republic": "51-75%",
            "Denmark": "76-100%",
            "Latvia": "26-50%",
            "Iceland": "Do not know",
            "Bulgaria": "51-75%"
        }
    },
    "38.10": {
        "title": "Is AST data for the following pathogen part of your national surveillance, and how would you estimate the population coverage and the geographical representativeness of the submitteddata?  Applies to AST data for all tested isolates (susceptible, intermediate and resistant). Can be in any format (zones, MIC, SIR, aggregated).Estimation range of population coverage:The percentage of the population that is roughly covered by the clinical microbiology laboratories that submit data. Estimation of geographical representativeness: A rough estimation of the quantity of geographical regions that are covered by the clinical microbiology laboratories that submit data. Similar estimations are included in the annual report to EARS-Net. If you are unsure about the estimations, please consult the EARS-Net focal point in your country. : Urine K. pneumoniae : If data is submitted: Estimated range of population coverage",
        "short_title": "Population coverage for AST data part of national surveillance. K. pneumoniae - urine.",
        "type": "SingleChoice",
        "coefficient": 0.033,
        "tags": [
            "National surveillance",
            "K. pneumoniae",
            "Urine"
        ],
        "possible_answers": {
            "76-100%": 1,
            "51-75%": 0.75,
            "26-50%": 0.5,
            "1-25%": 0.25,
            "Do not know": "null",
            "Not part of national surveillance": "null"
        },
        "actual_answers": {
            "Spain": "1-25%",
            "Austria": "26-50%",
            "Lithuania": "1-25%",
            "Croatia": "Not part of national surveillance",
            "Netherlands": "76-100%",
            "Ireland": "Not part of national surveillance",
            "Germany": "26-50%",
            "Poland": "Not part of national surveillance",
            "Italy": "51-75%",
            "Greece": "51-75%",
            "France": "51-75%",
            "Czechia": "Not part of national surveillance",
            "Belgium": "76-100%",
            "Hungary": "76-100%",
            "Finland": "76-100%",
            "Luxembourg": "Do not know",
            "Malta": "76-100%",
            "Portugal": "Not part of national surveillance",
            "Norway": "76-100%",
            "Slovenia": "Not part of national surveillance",
            "Estonia": "76-100%",
            "Sweden": "76-100%",
            "Ukraine": "Not part of national surveillance",
            "Slovak Republic": "51-75%",
            "Denmark": "76-100%",
            "Latvia": "26-50%",
            "Iceland": "Do not know",
            "Bulgaria": "51-75%"
        }
    },
    "38.11": {
        "title": "Is AST data for the following pathogen part of your national surveillance, and how would you estimate the population coverage and the geographical representativeness of the submitteddata?  Applies to AST data for all tested isolates (susceptible, intermediate and resistant). Can be in any format (zones, MIC, SIR, aggregated).Estimation range of population coverage:The percentage of the population that is roughly covered by the clinical microbiology laboratories that submit data. Estimation of geographical representativeness: A rough estimation of the quantity of geographical regions that are covered by the clinical microbiology laboratories that submit data. Similar estimations are included in the annual report to EARS-Net. If you are unsure about the estimations, please consult the EARS-Net focal point in your country. : UrineP. aeruginosa : If data is submitted: Estimated range of population coverage",
        "short_title": "Population coverage for AST data part of national surveillance. P. aeruginosa - urine.",
        "type": "SingleChoice",
        "coefficient": 0.033,
        "tags": [
            "National surveillance",
            "P. aeruginosa",
            "Urine"
        ],
        "possible_answers": {
            "76-100%": 1,
            "51-75%": 0.75,
            "26-50%": 0.5,
            "1-25%": 0.25,
            "Do not know": "null",
            "Not part of national surveillance": "null"
        },
        "actual_answers": {
            "Spain": "1-25%",
            "Austria": "26-50%",
            "Lithuania": "Not part of national surveillance",
            "Croatia": "Not part of national surveillance",
            "Netherlands": "76-100%",
            "Ireland": "Not part of national surveillance",
            "Germany": "26-50%",
            "Poland": "Not part of national surveillance",
            "Italy": "Not part of national surveillance",
            "Greece": "51-75%",
            "France": "51-75%",
            "Czechia": "Not part of national surveillance",
            "Belgium": "76-100%",
            "Hungary": "76-100%",
            "Finland": "76-100%",
            "Luxembourg": "Do not know",
            "Malta": "76-100%",
            "Portugal": "Not part of national surveillance",
            "Norway": "26-50%",
            "Slovenia": "Not part of national surveillance",
            "Estonia": "76-100%",
            "Sweden": "76-100%",
            "Ukraine": "Not part of national surveillance",
            "Slovak Republic": "51-75%",
            "Denmark": "76-100%",
            "Latvia": "Not part of national surveillance",
            "Iceland": "Do not know",
            "Bulgaria": "51-75%"
        }
    },
    "38.12": {
        "title": "Is AST data for the following pathogen part of your national surveillance, and how would you estimate the population coverage and the geographical representativeness of the submitteddata?  Applies to AST data for all tested isolates (susceptible, intermediate and resistant). Can be in any format (zones, MIC, SIR, aggregated).Estimation range of population coverage:The percentage of the population that is roughly covered by the clinical microbiology laboratories that submit data. Estimation of geographical representativeness: A rough estimation of the quantity of geographical regions that are covered by the clinical microbiology laboratories that submit data. Similar estimations are included in the annual report to EARS-Net. If you are unsure about the estimations, please consult the EARS-Net focal point in your country. : Urine A. baumanii : If data is submitted: Estimated range of population coverage",
        "short_title": "Population coverage for AST data part of national surveillance. A. baumanii - urine.",
        "type": "SingleChoice",
        "coefficient": 0.033,
        "tags": [
            "National surveillance",
            "A. baumanii",
            "Urine"
        ],
        "possible_answers": {
            "76-100%": 1,
            "51-75%": 0.75,
            "26-50%": 0.5,
            "1-25%": 0.25,
            "Do not know": "null",
            "Not part of national surveillance": "null"
        },
        "actual_answers": {
            "Spain": "1-25%",
            "Austria": "51-75%",
            "Lithuania": "Not part of national surveillance",
            "Croatia": "Not part of national surveillance",
            "Netherlands": "76-100%",
            "Ireland": "Not part of national surveillance",
            "Germany": "26-50%",
            "Poland": "Not part of national surveillance",
            "Italy": "Not part of national surveillance",
            "Greece": "51-75%",
            "France": "51-75%",
            "Czechia": "Not part of national surveillance",
            "Belgium": "76-100%",
            "Hungary": "76-100%",
            "Finland": "76-100%",
            "Luxembourg": "Do not know",
            "Malta": "76-100%",
            "Portugal": "Not part of national surveillance",
            "Norway": "26-50%",
            "Slovenia": "Not part of national surveillance",
            "Estonia": "76-100%",
            "Sweden": "76-100%",
            "Ukraine": "Not part of national surveillance",
            "Slovak Republic": "51-75%",
            "Denmark": "Not part of national surveillance",
            "Latvia": "Not part of national surveillance",
            "Iceland": "Do not know",
            "Bulgaria": "51-75%"
        }
    },
    "38.13": {
        "title": "Is AST data for the following pathogen part of your national surveillance, and how would you estimate the population coverage and the geographical representativeness of the submitteddata?  Applies to AST data for all tested isolates (susceptible, intermediate and resistant). Can be in any format (zones, MIC, SIR, aggregated).Estimation range of population coverage:The percentage of the population that is roughly covered by the clinical microbiology laboratories that submit data. Estimation of geographical representativeness: A rough estimation of the quantity of geographical regions that are covered by the clinical microbiology laboratories that submit data. Similar estimations are included in the annual report to EARS-Net. If you are unsure about the estimations, please consult the EARS-Net focal point in your country. : UrineS. aureus : If data is submitted: Estimated range of population coverage",
        "short_title": "Population coverage for AST data part of national surveillance. S. aureus - urine.",
        "type": "SingleChoice",
        "coefficient": 0.033,
        "tags": [
            "National surveillance",
            "S. aureus",
            "Urine"
        ],
        "possible_answers": {
            "76-100%": 1,
            "51-75%": 0.75,
            "26-50%": 0.5,
            "1-25%": 0.25,
            "Do not know": "null",
            "Not part of national surveillance": "null"
        },
        "actual_answers": {
            "Spain": "1-25%",
            "Austria": "26-50%",
            "Lithuania": "Not part of national surveillance",
            "Croatia": "Not part of national surveillance",
            "Netherlands": "76-100%",
            "Ireland": "Not part of national surveillance",
            "Germany": "26-50%",
            "Poland": "Not part of national surveillance",
            "Italy": "Not part of national surveillance",
            "Greece": "51-75%",
            "France": "51-75%",
            "Czechia": "Not part of national surveillance",
            "Belgium": "76-100%",
            "Hungary": "76-100%",
            "Finland": "Do not know",
            "Luxembourg": "Do not know",
            "Malta": "76-100%",
            "Portugal": "Not part of national surveillance",
            "Norway": "Not part of national surveillance",
            "Slovenia": "Not part of national surveillance",
            "Estonia": "76-100%",
            "Sweden": "76-100%",
            "Ukraine": "Not part of national surveillance",
            "Slovak Republic": "51-75%",
            "Denmark": "Not part of national surveillance",
            "Latvia": "Not part of national surveillance",
            "Iceland": "Do not know",
            "Bulgaria": "51-75%"
        }
    },
    "38.14": {
        "title": "Is AST data for the following pathogen part of your national surveillance, and how would you estimate the population coverage and the geographical representativeness of the submitteddata?  Applies to AST data for all tested isolates (susceptible, intermediate and resistant). Can be in any format (zones, MIC, SIR, aggregated).Estimation range of population coverage:The percentage of the population that is roughly covered by the clinical microbiology laboratories that submit data. Estimation of geographical representativeness: A rough estimation of the quantity of geographical regions that are covered by the clinical microbiology laboratories that submit data. Similar estimations are included in the annual report to EARS-Net. If you are unsure about the estimations, please consult the EARS-Net focal point in your country. : UrineE. faecium and/or E. faecalis : If data is submitted: Estimated range of population coverage",
        "short_title": "Population coverage for AST data part of national surveillance. VRE - urine.",
        "type": "SingleChoice",
        "coefficient": 0.033,
        "tags": [
            "National surveillance",
            "E. faecium/faecalis",
            "Urine"
        ],
        "possible_answers": {
            "76-100%": 1,
            "51-75%": 0.75,
            "26-50%": 0.5,
            "1-25%": 0.25,
            "Do not know": "null",
            "Not part of national surveillance": "null"
        },
        "actual_answers": {
            "Spain": "1-25%",
            "Austria": "26-50%",
            "Lithuania": "Not part of national surveillance",
            "Croatia": "Not part of national surveillance",
            "Netherlands": "76-100%",
            "Ireland": "Not part of national surveillance",
            "Germany": "26-50%",
            "Poland": "Not part of national surveillance",
            "Italy": "Not part of national surveillance",
            "Greece": "51-75%",
            "France": "51-75%",
            "Czechia": "Not part of national surveillance",
            "Belgium": "76-100%",
            "Hungary": "76-100%",
            "Finland": "76-100%",
            "Luxembourg": "Do not know",
            "Malta": "76-100%",
            "Portugal": "Not part of national surveillance",
            "Norway": "26-50%",
            "Slovenia": "Not part of national surveillance",
            "Estonia": "76-100%",
            "Sweden": "76-100%",
            "Ukraine": "Not part of national surveillance",
            "Slovak Republic": "51-75%",
            "Denmark": "76-100%",
            "Latvia": "Not part of national surveillance",
            "Iceland": "Do not know",
            "Bulgaria": "51-75%"
        }
    },
    "38.15": {
        "title": "Is AST data for the following pathogen part of your national surveillance, and how would you estimate the population coverage and the geographical representativeness of the submitteddata?  Applies to AST data for all tested isolates (susceptible, intermediate and resistant). Can be in any format (zones, MIC, SIR, aggregated).Estimation range of population coverage:The percentage of the population that is roughly covered by the clinical microbiology laboratories that submit data. Estimation of geographical representativeness: A rough estimation of the quantity of geographical regions that are covered by the clinical microbiology laboratories that submit data. Similar estimations are included in the annual report to EARS-Net. If you are unsure about the estimations, please consult the EARS-Net focal point in your country. : UrineS. pneumoniae : If data is submitted: Estimated range of population coverage",
        "short_title": "Population coverage for AST data part of national surveillance. S. pneumoniae - urine.",
        "type": "SingleChoice",
        "coefficient": 0.033,
        "tags": [
            "National surveillance",
            "S. pneumoniae",
            "Urine"
        ],
        "possible_answers": {
            "76-100%": 1,
            "51-75%": 0.75,
            "26-50%": 0.5,
            "1-25%": 0.25,
            "Do not know": "null",
            "Not part of national surveillance": "null"
        },
        "actual_answers": {
            "Spain": "Not part of national surveillance",
            "Austria": "Do not know",
            "Lithuania": "Not part of national surveillance",
            "Croatia": "Not part of national surveillance",
            "Netherlands": "76-100%",
            "Ireland": "Not part of national surveillance",
            "Germany": "26-50%",
            "Poland": "Not part of national surveillance",
            "Italy": "Not part of national surveillance",
            "Greece": "51-75%",
            "France": "Not part of national surveillance",
            "Czechia": "Not part of national surveillance",
            "Belgium": "Not part of national surveillance",
            "Hungary": "76-100%",
            "Finland": "Not part of national surveillance",
            "Luxembourg": "Do not know",
            "Malta": "76-100%",
            "Portugal": "Not part of national surveillance",
            "Norway": "Not part of national surveillance",
            "Slovenia": "Not part of national surveillance",
            "Estonia": "76-100%",
            "Sweden": "76-100%",
            "Ukraine": "Not part of national surveillance",
            "Slovak Republic": "51-75%",
            "Denmark": "Not part of national surveillance",
            "Latvia": "Not part of national surveillance",
            "Iceland": "Do not know",
            "Bulgaria": "Not part of national surveillance"
        }
    },
    "38.16": {
        "title": "Is AST data for the following pathogen part of your national surveillance, and how would you estimate the population coverage and the geographical representativeness of the submitteddata?  Applies to AST data for all tested isolates (susceptible, intermediate and resistant). Can be in any format (zones, MIC, SIR, aggregated).Estimation range of population coverage:The percentage of the population that is roughly covered by the clinical microbiology laboratories that submit data. Estimation of geographical representativeness: A rough estimation of the quantity of geographical regions that are covered by the clinical microbiology laboratories that submit data. Similar estimations are included in the annual report to EARS-Net. If you are unsure about the estimations, please consult the EARS-Net focal point in your country. : UrineH. influenzae : If data is submitted: Estimated range of population coverage",
        "short_title": "Population coverage for AST data part of national surveillance. H. influenzae - urine.",
        "type": "SingleChoice",
        "coefficient": 0.033,
        "tags": [
            "National surveillance",
            "H. influenzae",
            "Urine"
        ],
        "possible_answers": {
            "76-100%": 1,
            "51-75%": 0.75,
            "26-50%": 0.5,
            "1-25%": 0.25,
            "Do not know": "null",
            "Not part of national surveillance": "null"
        },
        "actual_answers": {
            "Spain": "Not part of national surveillance",
            "Austria": "Do not know",
            "Lithuania": "Not part of national surveillance",
            "Croatia": "Not part of national surveillance",
            "Netherlands": "76-100%",
            "Ireland": "Not part of national surveillance",
            "Germany": "26-50%",
            "Poland": "Not part of national surveillance",
            "Italy": "Not part of national surveillance",
            "Greece": "Not part of national surveillance",
            "France": "Not part of national surveillance",
            "Czechia": "Not part of national surveillance",
            "Belgium": "Do not know",
            "Hungary": "76-100%",
            "Finland": "Not part of national surveillance",
            "Luxembourg": "Do not know",
            "Malta": "76-100%",
            "Portugal": "Do not know",
            "Norway": "Not part of national surveillance",
            "Slovenia": "Not part of national surveillance",
            "Estonia": "76-100%",
            "Sweden": "76-100%",
            "Ukraine": "Not part of national surveillance",
            "Slovak Republic": "51-75%",
            "Denmark": "Not part of national surveillance",
            "Latvia": "Not part of national surveillance",
            "Iceland": "Do not know",
            "Bulgaria": "Not part of national surveillance"
        }
    },
    "38.17": {
        "title": "Is AST data for the following pathogen part of your national surveillance, and how would you estimate the population coverage and the geographical representativeness of the submitteddata?  Applies to AST data for all tested isolates (susceptible, intermediate and resistant). Can be in any format (zones, MIC, SIR, aggregated).Estimation range of population coverage:The percentage of the population that is roughly covered by the clinical microbiology laboratories that submit data. Estimation of geographical representativeness: A rough estimation of the quantity of geographical regions that are covered by the clinical microbiology laboratories that submit data. Similar estimations are included in the annual report to EARS-Net. If you are unsure about the estimations, please consult the EARS-Net focal point in your country. : Wound/tissue swabP. aeruginosa : If data is submitted: Estimated range of population coverage",
        "short_title": "Population coverage for AST data part of national surveillance. P. aeruginosa - soft tissue.",
        "type": "SingleChoice",
        "coefficient": 0.033,
        "tags": [
            "National surveillance",
            "P. aeruginosa",
            "Soft tissue"
        ],
        "possible_answers": {
            "76-100%": 1,
            "51-75%": 0.75,
            "26-50%": 0.5,
            "1-25%": 0.25,
            "Do not know": "null",
            "Not part of national surveillance": "null"
        },
        "actual_answers": {
            "Spain": "1-25%",
            "Austria": "26-50%",
            "Lithuania": "Not part of national surveillance",
            "Croatia": "Not part of national surveillance",
            "Netherlands": "76-100%",
            "Ireland": "Not part of national surveillance",
            "Germany": "26-50%",
            "Poland": "Not part of national surveillance",
            "Italy": "Not part of national surveillance",
            "Greece": "51-75%",
            "France": "51-75%",
            "Czechia": "Not part of national surveillance",
            "Belgium": "76-100%",
            "Hungary": "76-100%",
            "Finland": "76-100%",
            "Luxembourg": "Do not know",
            "Malta": "76-100%",
            "Portugal": "Not part of national surveillance",
            "Norway": "Not part of national surveillance",
            "Slovenia": "Not part of national surveillance",
            "Estonia": "76-100%",
            "Sweden": "76-100%",
            "Ukraine": "Do not know",
            "Slovak Republic": "51-75%",
            "Denmark": "Not part of national surveillance",
            "Latvia": "1-25%",
            "Iceland": "Do not know",
            "Bulgaria": "51-75%"
        }
    },
    "38.18": {
        "title": "Is AST data for the following pathogen part of your national surveillance, and how would you estimate the population coverage and the geographical representativeness of the submitteddata?  Applies to AST data for all tested isolates (susceptible, intermediate and resistant). Can be in any format (zones, MIC, SIR, aggregated).Estimation range of population coverage:The percentage of the population that is roughly covered by the clinical microbiology laboratories that submit data. Estimation of geographical representativeness: A rough estimation of the quantity of geographical regions that are covered by the clinical microbiology laboratories that submit data. Similar estimations are included in the annual report to EARS-Net. If you are unsure about the estimations, please consult the EARS-Net focal point in your country. : Wound/tissue swab A. baumanii : If data is submitted: Estimated range of population coverage",
        "short_title": "Population coverage for AST data part of national surveillance. A. baumanii - soft tissue.",
        "type": "SingleChoice",
        "coefficient": 0.033,
        "tags": [
            "National surveillance",
            "A. baumanii",
            "Soft tissue"
        ],
        "possible_answers": {
            "76-100%": 1,
            "51-75%": 0.75,
            "26-50%": 0.5,
            "1-25%": 0.25,
            "Do not know": "null",
            "Not part of national surveillance": "null"
        },
        "actual_answers": {
            "Spain": "1-25%",
            "Austria": "51-75%",
            "Lithuania": "Not part of national surveillance",
            "Croatia": "Not part of national surveillance",
            "Netherlands": "76-100%",
            "Ireland": "Not part of national surveillance",
            "Germany": "26-50%",
            "Poland": "Not part of national surveillance",
            "Italy": "Not part of national surveillance",
            "Greece": "51-75%",
            "France": "51-75%",
            "Czechia": "Not part of national surveillance",
            "Belgium": "76-100%",
            "Hungary": "76-100%",
            "Finland": "76-100%",
            "Luxembourg": "Do not know",
            "Malta": "76-100%",
            "Portugal": "Not part of national surveillance",
            "Norway": "Not part of national surveillance",
            "Slovenia": "Not part of national surveillance",
            "Estonia": "76-100%",
            "Sweden": "76-100%",
            "Ukraine": "Do not know",
            "Slovak Republic": "51-75%",
            "Denmark": "76-100%",
            "Latvia": "1-25%",
            "Iceland": "Do not know",
            "Bulgaria": "51-75%"
        }
    },
    "38.19": {
        "title": "Is AST data for the following pathogen part of your national surveillance, and how would you estimate the population coverage and the geographical representativeness of the submitteddata?  Applies to AST data for all tested isolates (susceptible, intermediate and resistant). Can be in any format (zones, MIC, SIR, aggregated).Estimation range of population coverage:The percentage of the population that is roughly covered by the clinical microbiology laboratories that submit data. Estimation of geographical representativeness: A rough estimation of the quantity of geographical regions that are covered by the clinical microbiology laboratories that submit data. Similar estimations are included in the annual report to EARS-Net. If you are unsure about the estimations, please consult the EARS-Net focal point in your country. : Wound/tissue swab S. aureus : If data is submitted: Estimated range of population coverage",
        "short_title": "Population coverage for AST data part of national surveillance. S. aureus - soft tissue.",
        "type": "SingleChoice",
        "coefficient": 0.033,
        "tags": [
            "National surveillance",
            "S. aureus",
            "Soft tissue"
        ],
        "possible_answers": {
            "76-100%": 1,
            "51-75%": 0.75,
            "26-50%": 0.5,
            "1-25%": 0.25,
            "Do not know": "null",
            "Not part of national surveillance": "null"
        },
        "actual_answers": {
            "Spain": "1-25%",
            "Austria": "26-50%",
            "Lithuania": "Not part of national surveillance",
            "Croatia": "Not part of national surveillance",
            "Netherlands": "76-100%",
            "Ireland": "Not part of national surveillance",
            "Germany": "26-50%",
            "Poland": "Not part of national surveillance",
            "Italy": "Not part of national surveillance",
            "Greece": "51-75%",
            "France": "51-75%",
            "Czechia": "Not part of national surveillance",
            "Belgium": "76-100%",
            "Hungary": "76-100%",
            "Finland": "76-100%",
            "Luxembourg": "Do not know",
            "Malta": "76-100%",
            "Portugal": "Not part of national surveillance",
            "Norway": "76-100%",
            "Slovenia": "Not part of national surveillance",
            "Estonia": "76-100%",
            "Sweden": "76-100%",
            "Ukraine": "Do not know",
            "Slovak Republic": "51-75%",
            "Denmark": "Not part of national surveillance",
            "Latvia": "1-25%",
            "Iceland": "Do not know",
            "Bulgaria": "51-75%"
        }
    },
    "38.20": {
        "title": "Is AST data for the following pathogen part of your national surveillance, and how would you estimate the population coverage and the geographical representativeness of the submitteddata?  Applies to AST data for all tested isolates (susceptible, intermediate and resistant). Can be in any format (zones, MIC, SIR, aggregated).Estimation range of population coverage:The percentage of the population that is roughly covered by the clinical microbiology laboratories that submit data. Estimation of geographical representativeness: A rough estimation of the quantity of geographical regions that are covered by the clinical microbiology laboratories that submit data. Similar estimations are included in the annual report to EARS-Net. If you are unsure about the estimations, please consult the EARS-Net focal point in your country. : Upper respiratory tractS. aureus : If data is submitted: Estimated range of population coverage",
        "short_title": "Population coverage for AST data part of national surveillance. S. aureus - upper respiratory tract.",
        "type": "SingleChoice",
        "coefficient": 0.033,
        "tags": [
            "National surveillance",
            "S. aureus",
            "Respiratory tract"
        ],
        "possible_answers": {
            "76-100%": 1,
            "51-75%": 0.75,
            "26-50%": 0.5,
            "1-25%": 0.25,
            "Do not know": "null",
            "Not part of national surveillance": "null"
        },
        "actual_answers": {
            "Spain": "1-25%",
            "Austria": "26-50%",
            "Lithuania": "Not part of national surveillance",
            "Croatia": "Not part of national surveillance",
            "Netherlands": "76-100%",
            "Ireland": "Not part of national surveillance",
            "Germany": "26-50%",
            "Poland": "Not part of national surveillance",
            "Italy": "Not part of national surveillance",
            "Greece": "51-75%",
            "France": "51-75%",
            "Czechia": "Not part of national surveillance",
            "Belgium": "76-100%",
            "Hungary": "76-100%",
            "Finland": "76-100%",
            "Luxembourg": "Do not know",
            "Malta": "76-100%",
            "Portugal": "Not part of national surveillance",
            "Norway": "Not part of national surveillance",
            "Slovenia": "Not part of national surveillance",
            "Estonia": "76-100%",
            "Sweden": "76-100%",
            "Ukraine": "Not part of national surveillance",
            "Slovak Republic": "51-75%",
            "Denmark": "Not part of national surveillance",
            "Latvia": "Not part of national surveillance",
            "Iceland": "Do not know",
            "Bulgaria": "51-75%"
        }
    },
    "38.21": {
        "title": "Is AST data for the following pathogen part of your national surveillance, and how would you estimate the population coverage and the geographical representativeness of the submitteddata?  Applies to AST data for all tested isolates (susceptible, intermediate and resistant). Can be in any format (zones, MIC, SIR, aggregated).Estimation range of population coverage:The percentage of the population that is roughly covered by the clinical microbiology laboratories that submit data. Estimation of geographical representativeness: A rough estimation of the quantity of geographical regions that are covered by the clinical microbiology laboratories that submit data. Similar estimations are included in the annual report to EARS-Net. If you are unsure about the estimations, please consult the EARS-Net focal point in your country. : Upper respiratory tractS. pneumoniae : If data is submitted: Estimated range of population coverage",
        "short_title": "Population coverage for AST data part of national surveillance. S. pneumoniae - upper respiratory tract.",
        "type": "SingleChoice",
        "coefficient": 0.033,
        "tags": [
            "National surveillance",
            "S. pneumoniae",
            "Respiratory tract"
        ],
        "possible_answers": {
            "76-100%": 1,
            "51-75%": 0.75,
            "26-50%": 0.5,
            "1-25%": 0.25,
            "Do not know": "null",
            "Not part of national surveillance": "null"
        },
        "actual_answers": {
            "Spain": "76-100%",
            "Austria": "26-50%",
            "Lithuania": "Not part of national surveillance",
            "Croatia": "Not part of national surveillance",
            "Netherlands": "76-100%",
            "Ireland": "Not part of national surveillance",
            "Germany": "26-50%",
            "Poland": "Not part of national surveillance",
            "Italy": "Not part of national surveillance",
            "Greece": "51-75%",
            "France": "Not part of national surveillance",
            "Czechia": "26-50%",
            "Belgium": "Not part of national surveillance",
            "Hungary": "76-100%",
            "Finland": "76-100%",
            "Luxembourg": "Do not know",
            "Malta": "76-100%",
            "Portugal": "Not part of national surveillance",
            "Norway": "26-50%",
            "Slovenia": "Not part of national surveillance",
            "Estonia": "76-100%",
            "Sweden": "76-100%",
            "Ukraine": "Not part of national surveillance",
            "Slovak Republic": "51-75%",
            "Denmark": "76-100%",
            "Latvia": "Not part of national surveillance",
            "Iceland": "Do not know",
            "Bulgaria": "26-50%"
        }
    },
    "38.22": {
        "title": "Is AST data for the following pathogen part of your national surveillance, and how would you estimate the population coverage and the geographical representativeness of the submitteddata?  Applies to AST data for all tested isolates (susceptible, intermediate and resistant). Can be in any format (zones, MIC, SIR, aggregated).Estimation range of population coverage:The percentage of the population that is roughly covered by the clinical microbiology laboratories that submit data. Estimation of geographical representativeness: A rough estimation of the quantity of geographical regions that are covered by the clinical microbiology laboratories that submit data. Similar estimations are included in the annual report to EARS-Net. If you are unsure about the estimations, please consult the EARS-Net focal point in your country. : Upper respiratory tractH. influenzae : If data is submitted: Estimated range of population coverage",
        "short_title": "Population coverage for AST data part of national surveillance. H. influenzae - upper respiratory tract.",
        "type": "SingleChoice",
        "coefficient": 0.033,
        "tags": [
            "National surveillance",
            "H. influenzae",
            "Respiratory tract"
        ],
        "possible_answers": {
            "76-100%": 1,
            "51-75%": 0.75,
            "26-50%": 0.5,
            "1-25%": 0.25,
            "Do not know": "null",
            "Not part of national surveillance": "null"
        },
        "actual_answers": {
            "Spain": "Not part of national surveillance",
            "Austria": "26-50%",
            "Lithuania": "Not part of national surveillance",
            "Croatia": "Not part of national surveillance",
            "Netherlands": "76-100%",
            "Ireland": "Not part of national surveillance",
            "Germany": "26-50%",
            "Poland": "Not part of national surveillance",
            "Italy": "Not part of national surveillance",
            "Greece": "51-75%",
            "France": "Not part of national surveillance",
            "Czechia": "26-50%",
            "Belgium": "Do not know",
            "Hungary": "76-100%",
            "Finland": "76-100%",
            "Luxembourg": "Do not know",
            "Malta": "76-100%",
            "Portugal": "Not part of national surveillance",
            "Norway": "26-50%",
            "Slovenia": "Not part of national surveillance",
            "Estonia": "76-100%",
            "Sweden": "76-100%",
            "Ukraine": "Not part of national surveillance",
            "Slovak Republic": "51-75%",
            "Denmark": "Not part of national surveillance",
            "Latvia": "Not part of national surveillance",
            "Iceland": "Do not know",
            "Bulgaria": "26-50%"
        }
    },
    "38.23": {
        "title": "Is AST data for the following pathogen part of your national surveillance, and how would you estimate the population coverage and the geographical representativeness of the submitteddata?  Applies to AST data for all tested isolates (susceptible, intermediate and resistant). Can be in any format (zones, MIC, SIR, aggregated).Estimation range of population coverage:The percentage of the population that is roughly covered by the clinical microbiology laboratories that submit data. Estimation of geographical representativeness: A rough estimation of the quantity of geographical regions that are covered by the clinical microbiology laboratories that submit data. Similar estimations are included in the annual report to EARS-Net. If you are unsure about the estimations, please consult the EARS-Net focal point in your country. : Lower respiratory tract E. coli : If data is submitted: Estimated range of population coverage",
        "short_title": "Population coverage for AST data part of national surveillance. E. coli - lower respiratory tract.",
        "type": "SingleChoice",
        "coefficient": 0.033,
        "tags": [
            "National surveillance",
            "E. coli",
            "Respiratory tract"
        ],
        "possible_answers": {
            "76-100%": 1,
            "51-75%": 0.75,
            "26-50%": 0.5,
            "1-25%": 0.25,
            "Do not know": "null",
            "Not part of national surveillance": "null"
        },
        "actual_answers": {
            "Spain": "1-25%",
            "Austria": "51-75%",
            "Lithuania": "Not part of national surveillance",
            "Croatia": "Not part of national surveillance",
            "Netherlands": "76-100%",
            "Ireland": "Not part of national surveillance",
            "Germany": "26-50%",
            "Poland": "Not part of national surveillance",
            "Italy": "Not part of national surveillance",
            "Greece": "51-75%",
            "France": "51-75%",
            "Czechia": "Not part of national surveillance",
            "Belgium": "76-100%",
            "Hungary": "76-100%",
            "Finland": "Do not know",
            "Luxembourg": "Do not know",
            "Malta": "76-100%",
            "Portugal": "Not part of national surveillance",
            "Norway": "Not part of national surveillance",
            "Slovenia": "Not part of national surveillance",
            "Estonia": "76-100%",
            "Sweden": "76-100%",
            "Ukraine": "Not part of national surveillance",
            "Slovak Republic": "51-75%",
            "Denmark": "Not part of national surveillance",
            "Latvia": "Not part of national surveillance",
            "Iceland": "Do not know",
            "Bulgaria": "51-75%"
        }
    },
    "38.24": {
        "title": "Is AST data for the following pathogen part of your national surveillance, and how would you estimate the population coverage and the geographical representativeness of the submitteddata?  Applies to AST data for all tested isolates (susceptible, intermediate and resistant). Can be in any format (zones, MIC, SIR, aggregated).Estimation range of population coverage:The percentage of the population that is roughly covered by the clinical microbiology laboratories that submit data. Estimation of geographical representativeness: A rough estimation of the quantity of geographical regions that are covered by the clinical microbiology laboratories that submit data. Similar estimations are included in the annual report to EARS-Net. If you are unsure about the estimations, please consult the EARS-Net focal point in your country. : Lower respiratory tract K. pneumoniae : If data is submitted: Estimated range of population coverage",
        "short_title": "Population coverage for AST data part of national surveillance. K. pneumoniae - lower respiratory tract.",
        "type": "SingleChoice",
        "coefficient": 0.033,
        "tags": [
            "National surveillance",
            "K. pneumoniae",
            "Respiratory tract"
        ],
        "possible_answers": {
            "76-100%": 1,
            "51-75%": 0.75,
            "26-50%": 0.5,
            "1-25%": 0.25,
            "Do not know": "null",
            "Not part of national surveillance": "null"
        },
        "actual_answers": {
            "Spain": "1-25%",
            "Austria": "51-75%",
            "Lithuania": "Not part of national surveillance",
            "Croatia": "Not part of national surveillance",
            "Netherlands": "76-100%",
            "Ireland": "Not part of national surveillance",
            "Germany": "26-50%",
            "Poland": "Not part of national surveillance",
            "Italy": "Not part of national surveillance",
            "Greece": "51-75%",
            "France": "51-75%",
            "Czechia": "Not part of national surveillance",
            "Belgium": "76-100%",
            "Hungary": "76-100%",
            "Finland": "76-100%",
            "Luxembourg": "Do not know",
            "Malta": "76-100%",
            "Portugal": "Not part of national surveillance",
            "Norway": "Not part of national surveillance",
            "Slovenia": "Not part of national surveillance",
            "Estonia": "76-100%",
            "Sweden": "76-100%",
            "Ukraine": "Not part of national surveillance",
            "Slovak Republic": "51-75%",
            "Denmark": "Not part of national surveillance",
            "Latvia": "1-25%",
            "Iceland": "Do not know",
            "Bulgaria": "51-75%"
        }
    },
    "38.25": {
        "title": "Is AST data for the following pathogen part of your national surveillance, and how would you estimate the population coverage and the geographical representativeness of the submitteddata?  Applies to AST data for all tested isolates (susceptible, intermediate and resistant). Can be in any format (zones, MIC, SIR, aggregated).Estimation range of population coverage:The percentage of the population that is roughly covered by the clinical microbiology laboratories that submit data. Estimation of geographical representativeness: A rough estimation of the quantity of geographical regions that are covered by the clinical microbiology laboratories that submit data. Similar estimations are included in the annual report to EARS-Net. If you are unsure about the estimations, please consult the EARS-Net focal point in your country. : Lower respiratory tractP. aeruginosa : If data is submitted: Estimated range of population coverage",
        "short_title": "Population coverage for AST data part of national surveillance. P. aeruginosa - lower respiratory tract.",
        "type": "SingleChoice",
        "coefficient": 0.033,
        "tags": [
            "National surveillance",
            "P. aeruginosa",
            "Respiratory tract"
        ],
        "possible_answers": {
            "76-100%": 1,
            "51-75%": 0.75,
            "26-50%": 0.5,
            "1-25%": 0.25,
            "Do not know": "null",
            "Not part of national surveillance": "null"
        },
        "actual_answers": {
            "Spain": "1-25%",
            "Austria": "26-50%",
            "Lithuania": "Not part of national surveillance",
            "Croatia": "Not part of national surveillance",
            "Netherlands": "76-100%",
            "Ireland": "Not part of national surveillance",
            "Germany": "26-50%",
            "Poland": "Not part of national surveillance",
            "Italy": "Not part of national surveillance",
            "Greece": "51-75%",
            "France": "51-75%",
            "Czechia": "Not part of national surveillance",
            "Belgium": "76-100%",
            "Hungary": "76-100%",
            "Finland": "76-100%",
            "Luxembourg": "Do not know",
            "Malta": "76-100%",
            "Portugal": "Not part of national surveillance",
            "Norway": "Not part of national surveillance",
            "Slovenia": "Not part of national surveillance",
            "Estonia": "76-100%",
            "Sweden": "76-100%",
            "Ukraine": "Not part of national surveillance",
            "Slovak Republic": "51-75%",
            "Denmark": "Not part of national surveillance",
            "Latvia": "1-25%",
            "Iceland": "Do not know",
            "Bulgaria": "51-75%"
        }
    },
    "38.26": {
        "title": "Is AST data for the following pathogen part of your national surveillance, and how would you estimate the population coverage and the geographical representativeness of the submitteddata?  Applies to AST data for all tested isolates (susceptible, intermediate and resistant). Can be in any format (zones, MIC, SIR, aggregated).Estimation range of population coverage:The percentage of the population that is roughly covered by the clinical microbiology laboratories that submit data. Estimation of geographical representativeness: A rough estimation of the quantity of geographical regions that are covered by the clinical microbiology laboratories that submit data. Similar estimations are included in the annual report to EARS-Net. If you are unsure about the estimations, please consult the EARS-Net focal point in your country. : Lower respiratory tract A. baumanii : If data is submitted: Estimated range of population coverage",
        "short_title": "Population coverage for AST data part of national surveillance. A. baumanii - lower respiratory tract.",
        "type": "SingleChoice",
        "coefficient": 0.033,
        "tags": [
            "National surveillance",
            "A. baumanii",
            "Respiratory tract"
        ],
        "possible_answers": {
            "76-100%": 1,
            "51-75%": 0.75,
            "26-50%": 0.5,
            "1-25%": 0.25,
            "Do not know": "null",
            "Not part of national surveillance": "null"
        },
        "actual_answers": {
            "Spain": "1-25%",
            "Austria": "51-75%",
            "Lithuania": "Not part of national surveillance",
            "Croatia": "Not part of national surveillance",
            "Netherlands": "76-100%",
            "Ireland": "Not part of national surveillance",
            "Germany": "26-50%",
            "Poland": "Not part of national surveillance",
            "Italy": "Not part of national surveillance",
            "Greece": "51-75%",
            "France": "51-75%",
            "Czechia": "Not part of national surveillance",
            "Belgium": "76-100%",
            "Hungary": "76-100%",
            "Finland": "76-100%",
            "Luxembourg": "Do not know",
            "Malta": "76-100%",
            "Portugal": "Not part of national surveillance",
            "Norway": "Not part of national surveillance",
            "Slovenia": "Not part of national surveillance",
            "Estonia": "76-100%",
            "Sweden": "76-100%",
            "Ukraine": "Not part of national surveillance",
            "Slovak Republic": "51-75%",
            "Denmark": "Not part of national surveillance",
            "Latvia": "1-25%",
            "Iceland": "Do not know",
            "Bulgaria": "51-75%"
        }
    },
    "38.27": {
        "title": "Is AST data for the following pathogen part of your national surveillance, and how would you estimate the population coverage and the geographical representativeness of the submitteddata?  Applies to AST data for all tested isolates (susceptible, intermediate and resistant). Can be in any format (zones, MIC, SIR, aggregated).Estimation range of population coverage:The percentage of the population that is roughly covered by the clinical microbiology laboratories that submit data. Estimation of geographical representativeness: A rough estimation of the quantity of geographical regions that are covered by the clinical microbiology laboratories that submit data. Similar estimations are included in the annual report to EARS-Net. If you are unsure about the estimations, please consult the EARS-Net focal point in your country. : Lower respiratory tractS. aureus : If data is submitted: Estimated range of population coverage",
        "short_title": "Population coverage for AST data part of national surveillance. S. aureus - lower respiratory tract.",
        "type": "SingleChoice",
        "coefficient": 0.033,
        "tags": [
            "National surveillance",
            "S. aureus",
            "Respiratory tract"
        ],
        "possible_answers": {
            "76-100%": 1,
            "51-75%": 0.75,
            "26-50%": 0.5,
            "1-25%": 0.25,
            "Do not know": "null",
            "Not part of national surveillance": "null"
        },
        "actual_answers": {
            "Spain": "1-25%",
            "Austria": "26-50%",
            "Lithuania": "Not part of national surveillance",
            "Croatia": "Not part of national surveillance",
            "Netherlands": "76-100%",
            "Ireland": "Not part of national surveillance",
            "Germany": "26-50%",
            "Poland": "Not part of national surveillance",
            "Italy": "Not part of national surveillance",
            "Greece": "51-75%",
            "France": "51-75%",
            "Czechia": "Not part of national surveillance",
            "Belgium": "76-100%",
            "Hungary": "76-100%",
            "Finland": "76-100%",
            "Luxembourg": "Do not know",
            "Malta": "76-100%",
            "Portugal": "Not part of national surveillance",
            "Norway": "Not part of national surveillance",
            "Slovenia": "Not part of national surveillance",
            "Estonia": "76-100%",
            "Sweden": "76-100%",
            "Ukraine": "Not part of national surveillance",
            "Slovak Republic": "51-75%",
            "Denmark": "Not part of national surveillance",
            "Latvia": "Not part of national surveillance",
            "Iceland": "Do not know",
            "Bulgaria": "51-75%"
        }
    },
    "38.28": {
        "title": "Is AST data for the following pathogen part of your national surveillance, and how would you estimate the population coverage and the geographical representativeness of the submitteddata?  Applies to AST data for all tested isolates (susceptible, intermediate and resistant). Can be in any format (zones, MIC, SIR, aggregated).Estimation range of population coverage:The percentage of the population that is roughly covered by the clinical microbiology laboratories that submit data. Estimation of geographical representativeness: A rough estimation of the quantity of geographical regions that are covered by the clinical microbiology laboratories that submit data. Similar estimations are included in the annual report to EARS-Net. If you are unsure about the estimations, please consult the EARS-Net focal point in your country. : Lower respiratory tractS. pneumoniae : If data is submitted: Estimated range of population coverage",
        "short_title": "Population coverage for AST data part of national surveillance. S. pneumoniae - lower respiratory tract.",
        "type": "SingleChoice",
        "coefficient": 0.033,
        "tags": [
            "National surveillance",
            "S. pneumoniae",
            "Respiratory tract"
        ],
        "possible_answers": {
            "76-100%": 1,
            "51-75%": 0.75,
            "26-50%": 0.5,
            "1-25%": 0.25,
            "Do not know": "null",
            "Not part of national surveillance": "null"
        },
        "actual_answers": {
            "Spain": "76-100%",
            "Austria": "26-50%",
            "Lithuania": "Not part of national surveillance",
            "Croatia": "Not part of national surveillance",
            "Netherlands": "76-100%",
            "Ireland": "Not part of national surveillance",
            "Germany": "26-50%",
            "Poland": "Not part of national surveillance",
            "Italy": "Not part of national surveillance",
            "Greece": "51-75%",
            "France": "Not part of national surveillance",
            "Czechia": "26-50%",
            "Belgium": "Not part of national surveillance",
            "Hungary": "76-100%",
            "Finland": "76-100%",
            "Luxembourg": "Do not know",
            "Malta": "76-100%",
            "Portugal": "Not part of national surveillance",
            "Norway": "26-50%",
            "Slovenia": "Not part of national surveillance",
            "Estonia": "76-100%",
            "Sweden": "76-100%",
            "Ukraine": "Not part of national surveillance",
            "Slovak Republic": "51-75%",
            "Denmark": "76-100%",
            "Latvia": "Not part of national surveillance",
            "Iceland": "Do not know",
            "Bulgaria": "51-75%"
        }
    },
    "38.29": {
        "title": "Is AST data for the following pathogen part of your national surveillance, and how would you estimate the population coverage and the geographical representativeness of the submitteddata?  Applies to AST data for all tested isolates (susceptible, intermediate and resistant). Can be in any format (zones, MIC, SIR, aggregated).Estimation range of population coverage:The percentage of the population that is roughly covered by the clinical microbiology laboratories that submit data. Estimation of geographical representativeness: A rough estimation of the quantity of geographical regions that are covered by the clinical microbiology laboratories that submit data. Similar estimations are included in the annual report to EARS-Net. If you are unsure about the estimations, please consult the EARS-Net focal point in your country. : Lower respiratory tractH. influenzae : If data is submitted: Estimated range of population coverage",
        "short_title": "Population coverage for AST data part of national surveillance. H. influenzae - lower respiratory tract.",
        "type": "SingleChoice",
        "coefficient": 0.033,
        "tags": [
            "National surveillance",
            "H. influenzae",
            "Respiratory tract"
        ],
        "possible_answers": {
            "76-100%": 1,
            "51-75%": 0.75,
            "26-50%": 0.5,
            "1-25%": 0.25,
            "Do not know": "null",
            "Not part of national surveillance": "null"
        },
        "actual_answers": {
            "Spain": "Not part of national surveillance",
            "Austria": "26-50%",
            "Lithuania": "Not part of national surveillance",
            "Croatia": "Not part of national surveillance",
            "Netherlands": "76-100%",
            "Ireland": "Not part of national surveillance",
            "Germany": "26-50%",
            "Poland": "Not part of national surveillance",
            "Italy": "Not part of national surveillance",
            "Greece": "Not part of national surveillance",
            "France": "Not part of national surveillance",
            "Czechia": "26-50%",
            "Belgium": "Do not know",
            "Hungary": "76-100%",
            "Finland": "76-100%",
            "Luxembourg": "Do not know",
            "Malta": "76-100%",
            "Portugal": "Do not know",
            "Norway": "26-50%",
            "Slovenia": "Not part of national surveillance",
            "Estonia": "76-100%",
            "Sweden": "76-100%",
            "Ukraine": "Not part of national surveillance",
            "Slovak Republic": "51-75%",
            "Denmark": "76-100%",
            "Latvia": "Not part of national surveillance",
            "Iceland": "Do not know",
            "Bulgaria": "51-75%"
        }
    },
    "38.30": {
        "title": "Is AST data for the following pathogen part of your national surveillance, and how would you estimate the population coverage and the geographical representativeness of the submitteddata?  Applies to AST data for all tested isolates (susceptible, intermediate and resistant). Can be in any format (zones, MIC, SIR, aggregated).Estimation range of population coverage:The percentage of the population that is roughly covered by the clinical microbiology laboratories that submit data. Estimation of geographical representativeness: A rough estimation of the quantity of geographical regions that are covered by the clinical microbiology laboratories that submit data. Similar estimations are included in the annual report to EARS-Net. If you are unsure about the estimations, please consult the EARS-Net focal point in your country. : Diarrhea C. difficile : If data is submitted: Estimated range of population coverage",
        "short_title": "Population coverage for AST data part of national surveillance. C. difficile - stool.",
        "type": "SingleChoice",
        "coefficient": 0.033,
        "tags": [
            "National surveillance",
            "C. difficile",
            "Stool"
        ],
        "possible_answers": {
            "76-100%": 1,
            "51-75%": 0.75,
            "26-50%": 0.5,
            "1-25%": 0.25,
            "Do not know": "null",
            "Not part of national surveillance": "null"
        },
        "actual_answers": {
            "Spain": "Not part of national surveillance",
            "Austria": "Do not know",
            "Lithuania": "Not part of national surveillance",
            "Croatia": "Do not know",
            "Netherlands": "76-100%",
            "Ireland": "76-100%",
            "Germany": "26-50%",
            "Poland": "Not part of national surveillance",
            "Italy": "Not part of national surveillance",
            "Greece": "Not part of national surveillance",
            "France": "Not part of national surveillance",
            "Czechia": "Do not know",
            "Belgium": "76-100%",
            "Hungary": "Not part of national surveillance",
            "Finland": "Do not know",
            "Luxembourg": "Do not know",
            "Malta": "76-100%",
            "Portugal": "51-75%",
            "Norway": "76-100%",
            "Slovenia": "Not part of national surveillance",
            "Estonia": "76-100%",
            "Sweden": "76-100%",
            "Ukraine": "Not part of national surveillance",
            "Slovak Republic": "1-25%",
            "Denmark": "76-100%",
            "Latvia": "1-25%",
            "Iceland": "Do not know",
            "Bulgaria": "1-25%"
        }
    },
    "38.31": {
        "title": "Is AST data for the following pathogen part of your national surveillance, and how would you estimate the population coverage and the geographical representativeness of the submitteddata?  Applies to AST data for all tested isolates (susceptible, intermediate and resistant). Can be in any format (zones, MIC, SIR, aggregated).Estimation range of population coverage:The percentage of the population that is roughly covered by the clinical microbiology laboratories that submit data. Estimation of geographical representativeness: A rough estimation of the quantity of geographical regions that are covered by the clinical microbiology laboratories that submit data. Similar estimations are included in the annual report to EARS-Net. If you are unsure about the estimations, please consult the EARS-Net focal point in your country. : Blood/CSF E. coli : If data is submitted:Estimated geographical representativeness",
        "short_title": "Geographical representativeness for AST data part of national surveillance. E. coli - blood.",
        "type": "SingleChoice",
        "coefficient": 0.033,
        "tags": [
            "National surveillance",
            "E. coli",
            "Blood"
        ],
        "possible_answers": {
            "HIGH: all main geographical regions of the country are covered.": 1,
            "MEDIUM: most geographical regions of the country are covered.": 0.5,
            "LOW: a few geographical areas of the country are covered.": 0,
            "Do not know": "null"
        },
        "actual_answers": {
            "Spain": "MEDIUM: most geographical regions of the country are covered.",
            "Austria": "HIGH: all main geographical regions of the country are covered.",
            "Lithuania": "HIGH: all main geographical regions of the country are covered.",
            "Croatia": "HIGH: all main geographical regions of the country are covered.",
            "Netherlands": "HIGH: all main geographical regions of the country are covered.",
            "Ireland": "HIGH: all main geographical regions of the country are covered.",
            "Germany": "HIGH: all main geographical regions of the country are covered.",
            "Poland": "HIGH: all main geographical regions of the country are covered.",
            "Italy": "HIGH: all main geographical regions of the country are covered.",
            "Greece": "HIGH: all main geographical regions of the country are covered.",
            "France": "HIGH: all main geographical regions of the country are covered.",
            "Czechia": "HIGH: all main geographical regions of the country are covered.",
            "Belgium": "HIGH: all main geographical regions of the country are covered.",
            "Hungary": "HIGH: all main geographical regions of the country are covered.",
            "Finland": "MEDIUM: most geographical regions of the country are covered.",
            "Luxembourg": "HIGH: all main geographical regions of the country are covered.",
            "Malta": "HIGH: all main geographical regions of the country are covered.",
            "Portugal": "HIGH: all main geographical regions of the country are covered.",
            "Norway": "HIGH: all main geographical regions of the country are covered.",
            "Slovenia": "HIGH: all main geographical regions of the country are covered.",
            "Estonia": "HIGH: all main geographical regions of the country are covered.",
            "Sweden": "HIGH: all main geographical regions of the country are covered.",
            "Ukraine": "HIGH: all main geographical regions of the country are covered.",
            "Slovak Republic": "HIGH: all main geographical regions of the country are covered.",
            "Denmark": "HIGH: all main geographical regions of the country are covered.",
            "Latvia": "HIGH: all main geographical regions of the country are covered.",
            "Iceland": "HIGH: all main geographical regions of the country are covered.",
            "Bulgaria": "HIGH: all main geographical regions of the country are covered."
        }
    },
    "38.32": {
        "title": "Is AST data for the following pathogen part of your national surveillance, and how would you estimate the population coverage and the geographical representativeness of the submitteddata?  Applies to AST data for all tested isolates (susceptible, intermediate and resistant). Can be in any format (zones, MIC, SIR, aggregated).Estimation range of population coverage:The percentage of the population that is roughly covered by the clinical microbiology laboratories that submit data. Estimation of geographical representativeness: A rough estimation of the quantity of geographical regions that are covered by the clinical microbiology laboratories that submit data. Similar estimations are included in the annual report to EARS-Net. If you are unsure about the estimations, please consult the EARS-Net focal point in your country. : Wound/tissue swab A. baumanii : If data is submitted:Estimated geographical representativeness",
        "short_title": "Geographical representativeness for AST data part of national surveillance. A. baumanii - soft tissue.",
        "type": "SingleChoice",
        "coefficient": 0.033,
        "tags": [
            "National surveillance",
            "A. baumanii",
            "soft tisse"
        ],
        "possible_answers": {
            "HIGH: all main geographical regions of the country are covered.": 1,
            "MEDIUM: most geographical regions of the country are covered.": 0.5,
            "LOW: a few geographical areas of the country are covered.": 0,
            "Do not know": "null"
        },
        "actual_answers": {
            "Spain": "LOW: a few geographical areas of the country are covered.",
            "Austria": "HIGH: all main geographical regions of the country are covered.",
            "Lithuania": "Do not know",
            "Croatia": "Do not know",
            "Netherlands": "HIGH: all main geographical regions of the country are covered.",
            "Ireland": "Do not know",
            "Germany": "HIGH: all main geographical regions of the country are covered.",
            "Poland": "Do not know",
            "Italy": "Do not know",
            "Greece": "HIGH: all main geographical regions of the country are covered.",
            "France": "HIGH: all main geographical regions of the country are covered.",
            "Czechia": "Do not know",
            "Belgium": "HIGH: all main geographical regions of the country are covered.",
            "Hungary": "HIGH: all main geographical regions of the country are covered.",
            "Finland": "MEDIUM: most geographical regions of the country are covered.",
            "Luxembourg": "Do not know",
            "Malta": "HIGH: all main geographical regions of the country are covered.",
            "Portugal": "Do not know",
            "Norway": "HIGH: all main geographical regions of the country are covered.",
            "Slovenia": "Do not know",
            "Estonia": "HIGH: all main geographical regions of the country are covered.",
            "Sweden": "HIGH: all main geographical regions of the country are covered.",
            "Ukraine": "HIGH: all main geographical regions of the country are covered.",
            "Slovak Republic": "HIGH: all main geographical regions of the country are covered.",
            "Denmark": "HIGH: all main geographical regions of the country are covered.",
            "Latvia": "LOW: a few geographical areas of the country are covered.",
            "Iceland": "Do not know",
            "Bulgaria": "HIGH: all main geographical regions of the country are covered."
        }
    },
    "38.33": {
        "title": "Is AST data for the following pathogen part of your national surveillance, and how would you estimate the population coverage and the geographical representativeness of the submitteddata?  Applies to AST data for all tested isolates (susceptible, intermediate and resistant). Can be in any format (zones, MIC, SIR, aggregated).Estimation range of population coverage:The percentage of the population that is roughly covered by the clinical microbiology laboratories that submit data. Estimation of geographical representativeness: A rough estimation of the quantity of geographical regions that are covered by the clinical microbiology laboratories that submit data. Similar estimations are included in the annual report to EARS-Net. If you are unsure about the estimations, please consult the EARS-Net focal point in your country. : Blood/CSF K. pneumoniae : If data is submitted:Estimated geographical representativeness",
        "short_title": "Geographical representativeness for AST data part of national surveillance. K. pneumoniae - blood.",
        "type": "SingleChoice",
        "coefficient": 0.033,
        "tags": [
            "National surveillance",
            "K. pneumoniae",
            "Blood"
        ],
        "possible_answers": {
            "HIGH: all main geographical regions of the country are covered.": 1,
            "MEDIUM: most geographical regions of the country are covered.": 0.5,
            "LOW: a few geographical areas of the country are covered.": 0,
            "Do not know": "null"
        },
        "actual_answers": {
            "Spain": "MEDIUM: most geographical regions of the country are covered.",
            "Austria": "HIGH: all main geographical regions of the country are covered.",
            "Lithuania": "HIGH: all main geographical regions of the country are covered.",
            "Croatia": "HIGH: all main geographical regions of the country are covered.",
            "Netherlands": "HIGH: all main geographical regions of the country are covered.",
            "Ireland": "HIGH: all main geographical regions of the country are covered.",
            "Germany": "HIGH: all main geographical regions of the country are covered.",
            "Poland": "HIGH: all main geographical regions of the country are covered.",
            "Italy": "HIGH: all main geographical regions of the country are covered.",
            "Greece": "HIGH: all main geographical regions of the country are covered.",
            "France": "HIGH: all main geographical regions of the country are covered.",
            "Czechia": "HIGH: all main geographical regions of the country are covered.",
            "Belgium": "HIGH: all main geographical regions of the country are covered.",
            "Hungary": "HIGH: all main geographical regions of the country are covered.",
            "Finland": "MEDIUM: most geographical regions of the country are covered.",
            "Luxembourg": "HIGH: all main geographical regions of the country are covered.",
            "Malta": "HIGH: all main geographical regions of the country are covered.",
            "Portugal": "HIGH: all main geographical regions of the country are covered.",
            "Norway": "HIGH: all main geographical regions of the country are covered.",
            "Slovenia": "HIGH: all main geographical regions of the country are covered.",
            "Estonia": "HIGH: all main geographical regions of the country are covered.",
            "Sweden": "HIGH: all main geographical regions of the country are covered.",
            "Ukraine": "HIGH: all main geographical regions of the country are covered.",
            "Slovak Republic": "HIGH: all main geographical regions of the country are covered.",
            "Denmark": "HIGH: all main geographical regions of the country are covered.",
            "Latvia": "HIGH: all main geographical regions of the country are covered.",
            "Iceland": "HIGH: all main geographical regions of the country are covered.",
            "Bulgaria": "HIGH: all main geographical regions of the country are covered."
        }
    },
    "38.34": {
        "title": "Is AST data for the following pathogen part of your national surveillance, and how would you estimate the population coverage and the geographical representativeness of the submitteddata?  Applies to AST data for all tested isolates (susceptible, intermediate and resistant). Can be in any format (zones, MIC, SIR, aggregated).Estimation range of population coverage:The percentage of the population that is roughly covered by the clinical microbiology laboratories that submit data. Estimation of geographical representativeness: A rough estimation of the quantity of geographical regions that are covered by the clinical microbiology laboratories that submit data. Similar estimations are included in the annual report to EARS-Net. If you are unsure about the estimations, please consult the EARS-Net focal point in your country. : Blood/CSFP. aeruginosa : If data is submitted:Estimated geographical representativeness",
        "short_title": "Geographical representativeness for AST data part of national surveillance. P. aeruginosa - blood.",
        "type": "SingleChoice",
        "coefficient": 0.033,
        "tags": [
            "National surveillance",
            "P. aeruginosa",
            "Blood"
        ],
        "possible_answers": {
            "HIGH: all main geographical regions of the country are covered.": 1,
            "MEDIUM: most geographical regions of the country are covered.": 0.5,
            "LOW: a few geographical areas of the country are covered.": 0,
            "Do not know": "null"
        },
        "actual_answers": {
            "Spain": "MEDIUM: most geographical regions of the country are covered.",
            "Austria": "HIGH: all main geographical regions of the country are covered.",
            "Lithuania": "HIGH: all main geographical regions of the country are covered.",
            "Croatia": "HIGH: all main geographical regions of the country are covered.",
            "Netherlands": "HIGH: all main geographical regions of the country are covered.",
            "Ireland": "HIGH: all main geographical regions of the country are covered.",
            "Germany": "HIGH: all main geographical regions of the country are covered.",
            "Poland": "HIGH: all main geographical regions of the country are covered.",
            "Italy": "HIGH: all main geographical regions of the country are covered.",
            "Greece": "HIGH: all main geographical regions of the country are covered.",
            "France": "HIGH: all main geographical regions of the country are covered.",
            "Czechia": "HIGH: all main geographical regions of the country are covered.",
            "Belgium": "HIGH: all main geographical regions of the country are covered.",
            "Hungary": "HIGH: all main geographical regions of the country are covered.",
            "Finland": "MEDIUM: most geographical regions of the country are covered.",
            "Luxembourg": "HIGH: all main geographical regions of the country are covered.",
            "Malta": "HIGH: all main geographical regions of the country are covered.",
            "Portugal": "HIGH: all main geographical regions of the country are covered.",
            "Norway": "HIGH: all main geographical regions of the country are covered.",
            "Slovenia": "HIGH: all main geographical regions of the country are covered.",
            "Estonia": "HIGH: all main geographical regions of the country are covered.",
            "Sweden": "HIGH: all main geographical regions of the country are covered.",
            "Ukraine": "HIGH: all main geographical regions of the country are covered.",
            "Slovak Republic": "HIGH: all main geographical regions of the country are covered.",
            "Denmark": "HIGH: all main geographical regions of the country are covered.",
            "Latvia": "HIGH: all main geographical regions of the country are covered.",
            "Iceland": "HIGH: all main geographical regions of the country are covered.",
            "Bulgaria": "HIGH: all main geographical regions of the country are covered."
        }
    },
    "38.35": {
        "title": "Is AST data for the following pathogen part of your national surveillance, and how would you estimate the population coverage and the geographical representativeness of the submitteddata?  Applies to AST data for all tested isolates (susceptible, intermediate and resistant). Can be in any format (zones, MIC, SIR, aggregated).Estimation range of population coverage:The percentage of the population that is roughly covered by the clinical microbiology laboratories that submit data. Estimation of geographical representativeness: A rough estimation of the quantity of geographical regions that are covered by the clinical microbiology laboratories that submit data. Similar estimations are included in the annual report to EARS-Net. If you are unsure about the estimations, please consult the EARS-Net focal point in your country. : Blood/CSFA. baumanii : If data is submitted:Estimated geographical representativeness",
        "short_title": "Geographical representativeness for AST data part of national surveillance. A. baumanii - blood.",
        "type": "SingleChoice",
        "coefficient": 0.033,
        "tags": [
            "National surveillance",
            "A. baumanii",
            "Blood"
        ],
        "possible_answers": {
            "HIGH: all main geographical regions of the country are covered.": 1,
            "MEDIUM: most geographical regions of the country are covered.": 0.5,
            "LOW: a few geographical areas of the country are covered.": 0,
            "Do not know": "null"
        },
        "actual_answers": {
            "Spain": "MEDIUM: most geographical regions of the country are covered.",
            "Austria": "HIGH: all main geographical regions of the country are covered.",
            "Lithuania": "HIGH: all main geographical regions of the country are covered.",
            "Croatia": "HIGH: all main geographical regions of the country are covered.",
            "Netherlands": "HIGH: all main geographical regions of the country are covered.",
            "Ireland": "HIGH: all main geographical regions of the country are covered.",
            "Germany": "HIGH: all main geographical regions of the country are covered.",
            "Poland": "HIGH: all main geographical regions of the country are covered.",
            "Italy": "HIGH: all main geographical regions of the country are covered.",
            "Greece": "HIGH: all main geographical regions of the country are covered.",
            "France": "HIGH: all main geographical regions of the country are covered.",
            "Czechia": "HIGH: all main geographical regions of the country are covered.",
            "Belgium": "HIGH: all main geographical regions of the country are covered.",
            "Hungary": "HIGH: all main geographical regions of the country are covered.",
            "Finland": "MEDIUM: most geographical regions of the country are covered.",
            "Luxembourg": "HIGH: all main geographical regions of the country are covered.",
            "Malta": "HIGH: all main geographical regions of the country are covered.",
            "Portugal": "HIGH: all main geographical regions of the country are covered.",
            "Norway": "HIGH: all main geographical regions of the country are covered.",
            "Slovenia": "HIGH: all main geographical regions of the country are covered.",
            "Estonia": "HIGH: all main geographical regions of the country are covered.",
            "Sweden": "HIGH: all main geographical regions of the country are covered.",
            "Ukraine": "HIGH: all main geographical regions of the country are covered.",
            "Slovak Republic": "HIGH: all main geographical regions of the country are covered.",
            "Denmark": "HIGH: all main geographical regions of the country are covered.",
            "Latvia": "HIGH: all main geographical regions of the country are covered.",
            "Iceland": "HIGH: all main geographical regions of the country are covered.",
            "Bulgaria": "HIGH: all main geographical regions of the country are covered."
        }
    },
    "38.36": {
        "title": "Is AST data for the following pathogen part of your national surveillance, and how would you estimate the population coverage and the geographical representativeness of the submitteddata?  Applies to AST data for all tested isolates (susceptible, intermediate and resistant). Can be in any format (zones, MIC, SIR, aggregated).Estimation range of population coverage:The percentage of the population that is roughly covered by the clinical microbiology laboratories that submit data. Estimation of geographical representativeness: A rough estimation of the quantity of geographical regions that are covered by the clinical microbiology laboratories that submit data. Similar estimations are included in the annual report to EARS-Net. If you are unsure about the estimations, please consult the EARS-Net focal point in your country. : Blood/CSFS. aureus : If data is submitted:Estimated geographical representativeness",
        "short_title": "Geographical representativeness for AST data part of national surveillance. S. aureus - blood.",
        "type": "SingleChoice",
        "coefficient": 0.033,
        "tags": [
            "National surveillance",
            "S. aureus",
            "Blood"
        ],
        "possible_answers": {
            "HIGH: all main geographical regions of the country are covered.": 1,
            "MEDIUM: most geographical regions of the country are covered.": 0.5,
            "LOW: a few geographical areas of the country are covered.": 0,
            "Do not know": "null"
        },
        "actual_answers": {
            "Spain": "MEDIUM: most geographical regions of the country are covered.",
            "Austria": "HIGH: all main geographical regions of the country are covered.",
            "Lithuania": "HIGH: all main geographical regions of the country are covered.",
            "Croatia": "HIGH: all main geographical regions of the country are covered.",
            "Netherlands": "HIGH: all main geographical regions of the country are covered.",
            "Ireland": "HIGH: all main geographical regions of the country are covered.",
            "Germany": "HIGH: all main geographical regions of the country are covered.",
            "Poland": "HIGH: all main geographical regions of the country are covered.",
            "Italy": "HIGH: all main geographical regions of the country are covered.",
            "Greece": "HIGH: all main geographical regions of the country are covered.",
            "France": "HIGH: all main geographical regions of the country are covered.",
            "Czechia": "HIGH: all main geographical regions of the country are covered.",
            "Belgium": "HIGH: all main geographical regions of the country are covered.",
            "Hungary": "HIGH: all main geographical regions of the country are covered.",
            "Finland": "MEDIUM: most geographical regions of the country are covered.",
            "Luxembourg": "HIGH: all main geographical regions of the country are covered.",
            "Malta": "HIGH: all main geographical regions of the country are covered.",
            "Portugal": "HIGH: all main geographical regions of the country are covered.",
            "Norway": "HIGH: all main geographical regions of the country are covered.",
            "Slovenia": "HIGH: all main geographical regions of the country are covered.",
            "Estonia": "HIGH: all main geographical regions of the country are covered.",
            "Sweden": "HIGH: all main geographical regions of the country are covered.",
            "Ukraine": "HIGH: all main geographical regions of the country are covered.",
            "Slovak Republic": "HIGH: all main geographical regions of the country are covered.",
            "Denmark": "HIGH: all main geographical regions of the country are covered.",
            "Latvia": "HIGH: all main geographical regions of the country are covered.",
            "Iceland": "HIGH: all main geographical regions of the country are covered.",
            "Bulgaria": "HIGH: all main geographical regions of the country are covered."
        }
    },
    "38.37": {
        "title": "Is AST data for the following pathogen part of your national surveillance, and how would you estimate the population coverage and the geographical representativeness of the submitteddata?  Applies to AST data for all tested isolates (susceptible, intermediate and resistant). Can be in any format (zones, MIC, SIR, aggregated).Estimation range of population coverage:The percentage of the population that is roughly covered by the clinical microbiology laboratories that submit data. Estimation of geographical representativeness: A rough estimation of the quantity of geographical regions that are covered by the clinical microbiology laboratories that submit data. Similar estimations are included in the annual report to EARS-Net. If you are unsure about the estimations, please consult the EARS-Net focal point in your country. : Blood/CSFE. faecium and/or E. faecalis : If data is submitted:Estimated geographical representativeness",
        "short_title": "Geographical representativeness for AST data part of national surveillance. VRE - blood.",
        "type": "SingleChoice",
        "coefficient": 0.033,
        "tags": [
            "National surveillance",
            "E. faecium/faecalis",
            "Blood"
        ],
        "possible_answers": {
            "HIGH: all main geographical regions of the country are covered.": 1,
            "MEDIUM: most geographical regions of the country are covered.": 0.5,
            "LOW: a few geographical areas of the country are covered.": 0,
            "Do not know": "null"
        },
        "actual_answers": {
            "Spain": "MEDIUM: most geographical regions of the country are covered.",
            "Austria": "HIGH: all main geographical regions of the country are covered.",
            "Lithuania": "HIGH: all main geographical regions of the country are covered.",
            "Croatia": "HIGH: all main geographical regions of the country are covered.",
            "Netherlands": "HIGH: all main geographical regions of the country are covered.",
            "Ireland": "HIGH: all main geographical regions of the country are covered.",
            "Germany": "HIGH: all main geographical regions of the country are covered.",
            "Poland": "HIGH: all main geographical regions of the country are covered.",
            "Italy": "HIGH: all main geographical regions of the country are covered.",
            "Greece": "HIGH: all main geographical regions of the country are covered.",
            "France": "HIGH: all main geographical regions of the country are covered.",
            "Czechia": "HIGH: all main geographical regions of the country are covered.",
            "Belgium": "HIGH: all main geographical regions of the country are covered.",
            "Hungary": "HIGH: all main geographical regions of the country are covered.",
            "Finland": "MEDIUM: most geographical regions of the country are covered.",
            "Luxembourg": "HIGH: all main geographical regions of the country are covered.",
            "Malta": "HIGH: all main geographical regions of the country are covered.",
            "Portugal": "HIGH: all main geographical regions of the country are covered.",
            "Norway": "HIGH: all main geographical regions of the country are covered.",
            "Slovenia": "HIGH: all main geographical regions of the country are covered.",
            "Estonia": "HIGH: all main geographical regions of the country are covered.",
            "Sweden": "HIGH: all main geographical regions of the country are covered.",
            "Ukraine": "HIGH: all main geographical regions of the country are covered.",
            "Slovak Republic": "HIGH: all main geographical regions of the country are covered.",
            "Denmark": "HIGH: all main geographical regions of the country are covered.",
            "Latvia": "HIGH: all main geographical regions of the country are covered.",
            "Iceland": "HIGH: all main geographical regions of the country are covered.",
            "Bulgaria": "HIGH: all main geographical regions of the country are covered."
        }
    },
    "38.38": {
        "title": "Is AST data for the following pathogen part of your national surveillance, and how would you estimate the population coverage and the geographical representativeness of the submitteddata?  Applies to AST data for all tested isolates (susceptible, intermediate and resistant). Can be in any format (zones, MIC, SIR, aggregated).Estimation range of population coverage:The percentage of the population that is roughly covered by the clinical microbiology laboratories that submit data. Estimation of geographical representativeness: A rough estimation of the quantity of geographical regions that are covered by the clinical microbiology laboratories that submit data. Similar estimations are included in the annual report to EARS-Net. If you are unsure about the estimations, please consult the EARS-Net focal point in your country. : Blood/CSFS. pneumoniae : If data is submitted:Estimated geographical representativeness",
        "short_title": "Geographical representativeness for AST data part of national surveillance. S. pneumoniae - blood.",
        "type": "SingleChoice",
        "coefficient": 0.033,
        "tags": [
            "National surveillance",
            "S. pneumoniae",
            "Blood"
        ],
        "possible_answers": {
            "HIGH: all main geographical regions of the country are covered.": 1,
            "MEDIUM: most geographical regions of the country are covered.": 0.5,
            "LOW: a few geographical areas of the country are covered.": 0,
            "Do not know": "null"
        },
        "actual_answers": {
            "Spain": "MEDIUM: most geographical regions of the country are covered.",
            "Austria": "HIGH: all main geographical regions of the country are covered.",
            "Lithuania": "HIGH: all main geographical regions of the country are covered.",
            "Croatia": "HIGH: all main geographical regions of the country are covered.",
            "Netherlands": "HIGH: all main geographical regions of the country are covered.",
            "Ireland": "HIGH: all main geographical regions of the country are covered.",
            "Germany": "HIGH: all main geographical regions of the country are covered.",
            "Poland": "HIGH: all main geographical regions of the country are covered.",
            "Italy": "HIGH: all main geographical regions of the country are covered.",
            "Greece": "HIGH: all main geographical regions of the country are covered.",
            "France": "HIGH: all main geographical regions of the country are covered.",
            "Czechia": "HIGH: all main geographical regions of the country are covered.",
            "Belgium": "HIGH: all main geographical regions of the country are covered.",
            "Hungary": "HIGH: all main geographical regions of the country are covered.",
            "Finland": "MEDIUM: most geographical regions of the country are covered.",
            "Luxembourg": "HIGH: all main geographical regions of the country are covered.",
            "Malta": "HIGH: all main geographical regions of the country are covered.",
            "Portugal": "HIGH: all main geographical regions of the country are covered.",
            "Norway": "HIGH: all main geographical regions of the country are covered.",
            "Slovenia": "HIGH: all main geographical regions of the country are covered.",
            "Estonia": "HIGH: all main geographical regions of the country are covered.",
            "Sweden": "HIGH: all main geographical regions of the country are covered.",
            "Ukraine": "HIGH: all main geographical regions of the country are covered.",
            "Slovak Republic": "HIGH: all main geographical regions of the country are covered.",
            "Denmark": "HIGH: all main geographical regions of the country are covered.",
            "Latvia": "HIGH: all main geographical regions of the country are covered.",
            "Iceland": "HIGH: all main geographical regions of the country are covered.",
            "Bulgaria": "HIGH: all main geographical regions of the country are covered."
        }
    },
    "38.39": {
        "title": "Is AST data for the following pathogen part of your national surveillance, and how would you estimate the population coverage and the geographical representativeness of the submitteddata?  Applies to AST data for all tested isolates (susceptible, intermediate and resistant). Can be in any format (zones, MIC, SIR, aggregated).Estimation range of population coverage:The percentage of the population that is roughly covered by the clinical microbiology laboratories that submit data. Estimation of geographical representativeness: A rough estimation of the quantity of geographical regions that are covered by the clinical microbiology laboratories that submit data. Similar estimations are included in the annual report to EARS-Net. If you are unsure about the estimations, please consult the EARS-Net focal point in your country. : Blood/CSFH. influenzae : If data is submitted:Estimated geographical representativeness",
        "short_title": "Geographical representativeness for AST data part of national surveillance. H. influenzae - blood.",
        "type": "SingleChoice",
        "coefficient": 0.033,
        "tags": [
            "National surveillance",
            "H. influenzae",
            "Blood"
        ],
        "possible_answers": {
            "HIGH: all main geographical regions of the country are covered.": 1,
            "MEDIUM: most geographical regions of the country are covered.": 0.5,
            "LOW: a few geographical areas of the country are covered.": 0,
            "Do not know": "null"
        },
        "actual_answers": {
            "Spain": "MEDIUM: most geographical regions of the country are covered.",
            "Austria": "HIGH: all main geographical regions of the country are covered.",
            "Lithuania": "HIGH: all main geographical regions of the country are covered.",
            "Croatia": "LOW: a few geographical areas of the country are covered.",
            "Netherlands": "HIGH: all main geographical regions of the country are covered.",
            "Ireland": "Do not know",
            "Germany": "HIGH: all main geographical regions of the country are covered.",
            "Poland": "HIGH: all main geographical regions of the country are covered.",
            "Italy": "Do not know",
            "Greece": "Do not know",
            "France": "HIGH: all main geographical regions of the country are covered.",
            "Czechia": "HIGH: all main geographical regions of the country are covered.",
            "Belgium": "HIGH: all main geographical regions of the country are covered.",
            "Hungary": "HIGH: all main geographical regions of the country are covered.",
            "Finland": "MEDIUM: most geographical regions of the country are covered.",
            "Luxembourg": "HIGH: all main geographical regions of the country are covered.",
            "Malta": "HIGH: all main geographical regions of the country are covered.",
            "Portugal": "Do not know",
            "Norway": "HIGH: all main geographical regions of the country are covered.",
            "Slovenia": "HIGH: all main geographical regions of the country are covered.",
            "Estonia": "HIGH: all main geographical regions of the country are covered.",
            "Sweden": "HIGH: all main geographical regions of the country are covered.",
            "Ukraine": "Do not know",
            "Slovak Republic": "HIGH: all main geographical regions of the country are covered.",
            "Denmark": "HIGH: all main geographical regions of the country are covered.",
            "Latvia": "HIGH: all main geographical regions of the country are covered.",
            "Iceland": "HIGH: all main geographical regions of the country are covered.",
            "Bulgaria": "MEDIUM: most geographical regions of the country are covered."
        }
    },
    "38.40": {
        "title": "Is AST data for the following pathogen part of your national surveillance, and how would you estimate the population coverage and the geographical representativeness of the submitteddata?  Applies to AST data for all tested isolates (susceptible, intermediate and resistant). Can be in any format (zones, MIC, SIR, aggregated).Estimation range of population coverage:The percentage of the population that is roughly covered by the clinical microbiology laboratories that submit data. Estimation of geographical representativeness: A rough estimation of the quantity of geographical regions that are covered by the clinical microbiology laboratories that submit data. Similar estimations are included in the annual report to EARS-Net. If you are unsure about the estimations, please consult the EARS-Net focal point in your country. : Urine E. coli : If data is submitted:Estimated geographical representativeness",
        "short_title": "Geographical representativeness for AST data part of national surveillance. E. coli - urine.",
        "type": "SingleChoice",
        "coefficient": 0.033,
        "tags": [
            "National surveillance",
            "E. coli",
            "Urine"
        ],
        "possible_answers": {
            "HIGH: all main geographical regions of the country are covered.": 1,
            "MEDIUM: most geographical regions of the country are covered.": 0.5,
            "LOW: a few geographical areas of the country are covered.": 0,
            "Do not know": "null"
        },
        "actual_answers": {
            "Spain": "LOW: a few geographical areas of the country are covered.",
            "Austria": "HIGH: all main geographical regions of the country are covered.",
            "Lithuania": "LOW: a few geographical areas of the country are covered.",
            "Croatia": "Do not know",
            "Netherlands": "HIGH: all main geographical regions of the country are covered.",
            "Ireland": "Do not know",
            "Germany": "HIGH: all main geographical regions of the country are covered.",
            "Poland": "Do not know",
            "Italy": "HIGH: all main geographical regions of the country are covered.",
            "Greece": "HIGH: all main geographical regions of the country are covered.",
            "France": "HIGH: all main geographical regions of the country are covered.",
            "Czechia": "MEDIUM: most geographical regions of the country are covered.",
            "Belgium": "HIGH: all main geographical regions of the country are covered.",
            "Hungary": "HIGH: all main geographical regions of the country are covered.",
            "Finland": "MEDIUM: most geographical regions of the country are covered.",
            "Luxembourg": "Do not know",
            "Malta": "HIGH: all main geographical regions of the country are covered.",
            "Portugal": "Do not know",
            "Norway": "HIGH: all main geographical regions of the country are covered.",
            "Slovenia": "Do not know",
            "Estonia": "HIGH: all main geographical regions of the country are covered.",
            "Sweden": "HIGH: all main geographical regions of the country are covered.",
            "Ukraine": "Do not know",
            "Slovak Republic": "HIGH: all main geographical regions of the country are covered.",
            "Denmark": "HIGH: all main geographical regions of the country are covered.",
            "Latvia": "MEDIUM: most geographical regions of the country are covered.",
            "Iceland": "Do not know",
            "Bulgaria": "HIGH: all main geographical regions of the country are covered."
        }
    },
    "38.41": {
        "title": "Is AST data for the following pathogen part of your national surveillance, and how would you estimate the population coverage and the geographical representativeness of the submitteddata?  Applies to AST data for all tested isolates (susceptible, intermediate and resistant). Can be in any format (zones, MIC, SIR, aggregated).Estimation range of population coverage:The percentage of the population that is roughly covered by the clinical microbiology laboratories that submit data. Estimation of geographical representativeness: A rough estimation of the quantity of geographical regions that are covered by the clinical microbiology laboratories that submit data. Similar estimations are included in the annual report to EARS-Net. If you are unsure about the estimations, please consult the EARS-Net focal point in your country. : Urine K. pneumoniae : If data is submitted:Estimated geographical representativeness",
        "short_title": "Geographical representativeness for AST data part of national surveillance. K. pneumoniae - urine.",
        "type": "SingleChoice",
        "coefficient": 0.033,
        "tags": [
            "National surveillance",
            "K. pneumoniae",
            "Urine"
        ],
        "possible_answers": {
            "HIGH: all main geographical regions of the country are covered.": 1,
            "MEDIUM: most geographical regions of the country are covered.": 0.5,
            "LOW: a few geographical areas of the country are covered.": 0,
            "Do not know": "null"
        },
        "actual_answers": {
            "Spain": "LOW: a few geographical areas of the country are covered.",
            "Austria": "HIGH: all main geographical regions of the country are covered.",
            "Lithuania": "LOW: a few geographical areas of the country are covered.",
            "Croatia": "Do not know",
            "Netherlands": "HIGH: all main geographical regions of the country are covered.",
            "Ireland": "Do not know",
            "Germany": "HIGH: all main geographical regions of the country are covered.",
            "Poland": "Do not know",
            "Italy": "HIGH: all main geographical regions of the country are covered.",
            "Greece": "HIGH: all main geographical regions of the country are covered.",
            "France": "HIGH: all main geographical regions of the country are covered.",
            "Czechia": "Do not know",
            "Belgium": "HIGH: all main geographical regions of the country are covered.",
            "Hungary": "HIGH: all main geographical regions of the country are covered.",
            "Finland": "MEDIUM: most geographical regions of the country are covered.",
            "Luxembourg": "Do not know",
            "Malta": "HIGH: all main geographical regions of the country are covered.",
            "Portugal": "Do not know",
            "Norway": "HIGH: all main geographical regions of the country are covered.",
            "Slovenia": "Do not know",
            "Estonia": "HIGH: all main geographical regions of the country are covered.",
            "Sweden": "HIGH: all main geographical regions of the country are covered.",
            "Ukraine": "Do not know",
            "Slovak Republic": "HIGH: all main geographical regions of the country are covered.",
            "Denmark": "HIGH: all main geographical regions of the country are covered.",
            "Latvia": "MEDIUM: most geographical regions of the country are covered.",
            "Iceland": "Do not know",
            "Bulgaria": "HIGH: all main geographical regions of the country are covered."
        }
    },
    "38.42": {
        "title": "Is AST data for the following pathogen part of your national surveillance, and how would you estimate the population coverage and the geographical representativeness of the submitteddata?  Applies to AST data for all tested isolates (susceptible, intermediate and resistant). Can be in any format (zones, MIC, SIR, aggregated).Estimation range of population coverage:The percentage of the population that is roughly covered by the clinical microbiology laboratories that submit data. Estimation of geographical representativeness: A rough estimation of the quantity of geographical regions that are covered by the clinical microbiology laboratories that submit data. Similar estimations are included in the annual report to EARS-Net. If you are unsure about the estimations, please consult the EARS-Net focal point in your country. : UrineP. aeruginosa : If data is submitted:Estimated geographical representativeness",
        "short_title": "Geographical representativeness for AST data part of national surveillance. P. aeruginosa - urine.",
        "type": "SingleChoice",
        "coefficient": 0.033,
        "tags": [
            "National surveillance",
            "P. aeruginosa",
            "Urine"
        ],
        "possible_answers": {
            "HIGH: all main geographical regions of the country are covered.": 1,
            "MEDIUM: most geographical regions of the country are covered.": 0.5,
            "LOW: a few geographical areas of the country are covered.": 0,
            "Do not know": "null"
        },
        "actual_answers": {
            "Spain": "LOW: a few geographical areas of the country are covered.",
            "Austria": "HIGH: all main geographical regions of the country are covered.",
            "Lithuania": "Do not know",
            "Croatia": "Do not know",
            "Netherlands": "HIGH: all main geographical regions of the country are covered.",
            "Ireland": "Do not know",
            "Germany": "HIGH: all main geographical regions of the country are covered.",
            "Poland": "Do not know",
            "Italy": "Do not know",
            "Greece": "HIGH: all main geographical regions of the country are covered.",
            "France": "HIGH: all main geographical regions of the country are covered.",
            "Czechia": "Do not know",
            "Belgium": "HIGH: all main geographical regions of the country are covered.",
            "Hungary": "HIGH: all main geographical regions of the country are covered.",
            "Finland": "MEDIUM: most geographical regions of the country are covered.",
            "Luxembourg": "Do not know",
            "Malta": "HIGH: all main geographical regions of the country are covered.",
            "Portugal": "Do not know",
            "Norway": "HIGH: all main geographical regions of the country are covered.",
            "Slovenia": "Do not know",
            "Estonia": "HIGH: all main geographical regions of the country are covered.",
            "Sweden": "HIGH: all main geographical regions of the country are covered.",
            "Ukraine": "Do not know",
            "Slovak Republic": "HIGH: all main geographical regions of the country are covered.",
            "Denmark": "HIGH: all main geographical regions of the country are covered.",
            "Latvia": "LOW: a few geographical areas of the country are covered.",
            "Iceland": "Do not know",
            "Bulgaria": "HIGH: all main geographical regions of the country are covered."
        }
    },
    "38.43": {
        "title": "Is AST data for the following pathogen part of your national surveillance, and how would you estimate the population coverage and the geographical representativeness of the submitteddata?  Applies to AST data for all tested isolates (susceptible, intermediate and resistant). Can be in any format (zones, MIC, SIR, aggregated).Estimation range of population coverage:The percentage of the population that is roughly covered by the clinical microbiology laboratories that submit data. Estimation of geographical representativeness: A rough estimation of the quantity of geographical regions that are covered by the clinical microbiology laboratories that submit data. Similar estimations are included in the annual report to EARS-Net. If you are unsure about the estimations, please consult the EARS-Net focal point in your country. : Urine A. baumanii : If data is submitted:Estimated geographical representativeness",
        "short_title": "Geographical representativeness for AST data part of national surveillance. A. baumanii - urine.",
        "type": "SingleChoice",
        "coefficient": 0.033,
        "tags": [
            "National surveillance",
            "A. baumanii",
            "Urine"
        ],
        "possible_answers": {
            "HIGH: all main geographical regions of the country are covered.": 1,
            "MEDIUM: most geographical regions of the country are covered.": 0.5,
            "LOW: a few geographical areas of the country are covered.": 0,
            "Do not know": "null"
        },
        "actual_answers": {
            "Spain": "LOW: a few geographical areas of the country are covered.",
            "Austria": "HIGH: all main geographical regions of the country are covered.",
            "Lithuania": "Do not know",
            "Croatia": "Do not know",
            "Netherlands": "HIGH: all main geographical regions of the country are covered.",
            "Ireland": "Do not know",
            "Germany": "HIGH: all main geographical regions of the country are covered.",
            "Poland": "Do not know",
            "Italy": "Do not know",
            "Greece": "HIGH: all main geographical regions of the country are covered.",
            "France": "HIGH: all main geographical regions of the country are covered.",
            "Czechia": "Do not know",
            "Belgium": "HIGH: all main geographical regions of the country are covered.",
            "Hungary": "HIGH: all main geographical regions of the country are covered.",
            "Finland": "MEDIUM: most geographical regions of the country are covered.",
            "Luxembourg": "Do not know",
            "Malta": "HIGH: all main geographical regions of the country are covered.",
            "Portugal": "Do not know",
            "Norway": "HIGH: all main geographical regions of the country are covered.",
            "Slovenia": "Do not know",
            "Estonia": "HIGH: all main geographical regions of the country are covered.",
            "Sweden": "HIGH: all main geographical regions of the country are covered.",
            "Ukraine": "Do not know",
            "Slovak Republic": "HIGH: all main geographical regions of the country are covered.",
            "Denmark": "HIGH: all main geographical regions of the country are covered.",
            "Latvia": "LOW: a few geographical areas of the country are covered.",
            "Iceland": "Do not know",
            "Bulgaria": "HIGH: all main geographical regions of the country are covered."
        }
    },
    "38.44": {
        "title": "Is AST data for the following pathogen part of your national surveillance, and how would you estimate the population coverage and the geographical representativeness of the submitteddata?  Applies to AST data for all tested isolates (susceptible, intermediate and resistant). Can be in any format (zones, MIC, SIR, aggregated).Estimation range of population coverage:The percentage of the population that is roughly covered by the clinical microbiology laboratories that submit data. Estimation of geographical representativeness: A rough estimation of the quantity of geographical regions that are covered by the clinical microbiology laboratories that submit data. Similar estimations are included in the annual report to EARS-Net. If you are unsure about the estimations, please consult the EARS-Net focal point in your country. : UrineS. aureus : If data is submitted:Estimated geographical representativeness",
        "short_title": "Geographical representativeness for AST data part of national surveillance. S. aureus - urine.",
        "type": "SingleChoice",
        "coefficient": 0.033,
        "tags": [
            "National surveillance",
            "S. aureus",
            "Urine"
        ],
        "possible_answers": {
            "HIGH: all main geographical regions of the country are covered.": 1,
            "MEDIUM: most geographical regions of the country are covered.": 0.5,
            "LOW: a few geographical areas of the country are covered.": 0,
            "Do not know": "null"
        },
        "actual_answers": {
            "Spain": "LOW: a few geographical areas of the country are covered.",
            "Austria": "HIGH: all main geographical regions of the country are covered.",
            "Lithuania": "Do not know",
            "Croatia": "Do not know",
            "Netherlands": "HIGH: all main geographical regions of the country are covered.",
            "Ireland": "Do not know",
            "Germany": "HIGH: all main geographical regions of the country are covered.",
            "Poland": "Do not know",
            "Italy": "Do not know",
            "Greece": "HIGH: all main geographical regions of the country are covered.",
            "France": "HIGH: all main geographical regions of the country are covered.",
            "Czechia": "Do not know",
            "Belgium": "HIGH: all main geographical regions of the country are covered.",
            "Hungary": "HIGH: all main geographical regions of the country are covered.",
            "Finland": "Do not know",
            "Luxembourg": "Do not know",
            "Malta": "HIGH: all main geographical regions of the country are covered.",
            "Portugal": "Do not know",
            "Norway": "HIGH: all main geographical regions of the country are covered.",
            "Slovenia": "Do not know",
            "Estonia": "HIGH: all main geographical regions of the country are covered.",
            "Sweden": "HIGH: all main geographical regions of the country are covered.",
            "Ukraine": "Do not know",
            "Slovak Republic": "HIGH: all main geographical regions of the country are covered.",
            "Denmark": "HIGH: all main geographical regions of the country are covered.",
            "Latvia": "LOW: a few geographical areas of the country are covered.",
            "Iceland": "Do not know",
            "Bulgaria": "HIGH: all main geographical regions of the country are covered."
        }
    },
    "38.45": {
        "title": "Is AST data for the following pathogen part of your national surveillance, and how would you estimate the population coverage and the geographical representativeness of the submitteddata?  Applies to AST data for all tested isolates (susceptible, intermediate and resistant). Can be in any format (zones, MIC, SIR, aggregated).Estimation range of population coverage:The percentage of the population that is roughly covered by the clinical microbiology laboratories that submit data. Estimation of geographical representativeness: A rough estimation of the quantity of geographical regions that are covered by the clinical microbiology laboratories that submit data. Similar estimations are included in the annual report to EARS-Net. If you are unsure about the estimations, please consult the EARS-Net focal point in your country. : UrineE. faecium and/or E. faecalis : If data is submitted:Estimated geographical representativeness",
        "short_title": "Geographical representativeness for AST data part of national surveillance. VRE - urine.",
        "type": "SingleChoice",
        "coefficient": 0.033,
        "tags": [
            "National surveillance",
            "E. faecium/faecalis",
            "Urine"
        ],
        "possible_answers": {
            "HIGH: all main geographical regions of the country are covered.": 1,
            "MEDIUM: most geographical regions of the country are covered.": 0.5,
            "LOW: a few geographical areas of the country are covered.": 0,
            "Do not know": "null"
        },
        "actual_answers": {
            "Spain": "LOW: a few geographical areas of the country are covered.",
            "Austria": "HIGH: all main geographical regions of the country are covered.",
            "Lithuania": "Do not know",
            "Croatia": "Do not know",
            "Netherlands": "HIGH: all main geographical regions of the country are covered.",
            "Ireland": "Do not know",
            "Germany": "HIGH: all main geographical regions of the country are covered.",
            "Poland": "Do not know",
            "Italy": "Do not know",
            "Greece": "HIGH: all main geographical regions of the country are covered.",
            "France": "HIGH: all main geographical regions of the country are covered.",
            "Czechia": "Do not know",
            "Belgium": "HIGH: all main geographical regions of the country are covered.",
            "Hungary": "HIGH: all main geographical regions of the country are covered.",
            "Finland": "MEDIUM: most geographical regions of the country are covered.",
            "Luxembourg": "Do not know",
            "Malta": "HIGH: all main geographical regions of the country are covered.",
            "Portugal": "Do not know",
            "Norway": "HIGH: all main geographical regions of the country are covered.",
            "Slovenia": "Do not know",
            "Estonia": "HIGH: all main geographical regions of the country are covered.",
            "Sweden": "HIGH: all main geographical regions of the country are covered.",
            "Ukraine": "Do not know",
            "Slovak Republic": "HIGH: all main geographical regions of the country are covered.",
            "Denmark": "HIGH: all main geographical regions of the country are covered.",
            "Latvia": "LOW: a few geographical areas of the country are covered.",
            "Iceland": "Do not know",
            "Bulgaria": "HIGH: all main geographical regions of the country are covered."
        }
    },
    "38.46": {
        "title": "Is AST data for the following pathogen part of your national surveillance, and how would you estimate the population coverage and the geographical representativeness of the submitteddata?  Applies to AST data for all tested isolates (susceptible, intermediate and resistant). Can be in any format (zones, MIC, SIR, aggregated).Estimation range of population coverage:The percentage of the population that is roughly covered by the clinical microbiology laboratories that submit data. Estimation of geographical representativeness: A rough estimation of the quantity of geographical regions that are covered by the clinical microbiology laboratories that submit data. Similar estimations are included in the annual report to EARS-Net. If you are unsure about the estimations, please consult the EARS-Net focal point in your country. : UrineS. pneumoniae : If data is submitted:Estimated geographical representativeness",
        "short_title": "Geographical representativeness for AST data part of national surveillance. S. pneumoniae - urine.",
        "type": "SingleChoice",
        "coefficient": 0.033,
        "tags": [
            "National surveillance",
            "S. pneumoniae",
            "Urine"
        ],
        "possible_answers": {
            "HIGH: all main geographical regions of the country are covered.": 1,
            "MEDIUM: most geographical regions of the country are covered.": 0.5,
            "LOW: a few geographical areas of the country are covered.": 0,
            "Do not know": "null"
        },
        "actual_answers": {
            "Spain": "Do not know",
            "Austria": "Do not know",
            "Lithuania": "Do not know",
            "Croatia": "Do not know",
            "Netherlands": "HIGH: all main geographical regions of the country are covered.",
            "Ireland": "Do not know",
            "Germany": "HIGH: all main geographical regions of the country are covered.",
            "Poland": "Do not know",
            "Italy": "Do not know",
            "Greece": "HIGH: all main geographical regions of the country are covered.",
            "France": "Do not know",
            "Czechia": "Do not know",
            "Belgium": "HIGH: all main geographical regions of the country are covered.",
            "Hungary": "HIGH: all main geographical regions of the country are covered.",
            "Finland": "Do not know",
            "Luxembourg": "Do not know",
            "Malta": "HIGH: all main geographical regions of the country are covered.",
            "Portugal": "Do not know",
            "Norway": "HIGH: all main geographical regions of the country are covered.",
            "Slovenia": "Do not know",
            "Estonia": "HIGH: all main geographical regions of the country are covered.",
            "Sweden": "HIGH: all main geographical regions of the country are covered.",
            "Ukraine": "Do not know",
            "Slovak Republic": "HIGH: all main geographical regions of the country are covered.",
            "Denmark": "HIGH: all main geographical regions of the country are covered.",
            "Latvia": "LOW: a few geographical areas of the country are covered.",
            "Iceland": "Do not know",
            "Bulgaria": "Do not know"
        }
    },
    "38.47": {
        "title": "Is AST data for the following pathogen part of your national surveillance, and how would you estimate the population coverage and the geographical representativeness of the submitteddata?  Applies to AST data for all tested isolates (susceptible, intermediate and resistant). Can be in any format (zones, MIC, SIR, aggregated).Estimation range of population coverage:The percentage of the population that is roughly covered by the clinical microbiology laboratories that submit data. Estimation of geographical representativeness: A rough estimation of the quantity of geographical regions that are covered by the clinical microbiology laboratories that submit data. Similar estimations are included in the annual report to EARS-Net. If you are unsure about the estimations, please consult the EARS-Net focal point in your country. : UrineH. influenzae : If data is submitted:Estimated geographical representativeness",
        "short_title": "Geographical representativeness for AST data part of national surveillance. H. influenzae - urine.",
        "type": "SingleChoice",
        "coefficient": 0.033,
        "tags": [
            "National surveillance",
            "H. influenzae",
            "Urine"
        ],
        "possible_answers": {
            "HIGH: all main geographical regions of the country are covered.": 1,
            "MEDIUM: most geographical regions of the country are covered.": 0.5,
            "LOW: a few geographical areas of the country are covered.": 0,
            "Do not know": "null"
        },
        "actual_answers": {
            "Spain": "Do not know",
            "Austria": "Do not know",
            "Lithuania": "Do not know",
            "Croatia": "Do not know",
            "Netherlands": "HIGH: all main geographical regions of the country are covered.",
            "Ireland": "Do not know",
            "Germany": "HIGH: all main geographical regions of the country are covered.",
            "Poland": "Do not know",
            "Italy": "Do not know",
            "Greece": "Do not know",
            "France": "Do not know",
            "Czechia": "Do not know",
            "Belgium": "HIGH: all main geographical regions of the country are covered.",
            "Hungary": "HIGH: all main geographical regions of the country are covered.",
            "Finland": "Do not know",
            "Luxembourg": "Do not know",
            "Malta": "HIGH: all main geographical regions of the country are covered.",
            "Portugal": "Do not know",
            "Norway": "HIGH: all main geographical regions of the country are covered.",
            "Slovenia": "Do not know",
            "Estonia": "HIGH: all main geographical regions of the country are covered.",
            "Sweden": "HIGH: all main geographical regions of the country are covered.",
            "Ukraine": "Do not know",
            "Slovak Republic": "HIGH: all main geographical regions of the country are covered.",
            "Denmark": "HIGH: all main geographical regions of the country are covered.",
            "Latvia": "Do not know",
            "Iceland": "Do not know",
            "Bulgaria": "Do not know"
        }
    },
    "38.48": {
        "title": "Is AST data for the following pathogen part of your national surveillance, and how would you estimate the population coverage and the geographical representativeness of the submitteddata?  Applies to AST data for all tested isolates (susceptible, intermediate and resistant). Can be in any format (zones, MIC, SIR, aggregated).Estimation range of population coverage:The percentage of the population that is roughly covered by the clinical microbiology laboratories that submit data. Estimation of geographical representativeness: A rough estimation of the quantity of geographical regions that are covered by the clinical microbiology laboratories that submit data. Similar estimations are included in the annual report to EARS-Net. If you are unsure about the estimations, please consult the EARS-Net focal point in your country. : Wound/tissue swabP. aeruginosa : If data is submitted:Estimated geographical representativeness",
        "short_title": "Geographical representativeness for AST data part of national surveillance. P. aeruginosa - soft tissue.",
        "type": "SingleChoice",
        "coefficient": 0.033,
        "tags": [
            "National surveillance",
            "P. aeruginosa",
            "Soft tissue"
        ],
        "possible_answers": {
            "HIGH: all main geographical regions of the country are covered.": 1,
            "MEDIUM: most geographical regions of the country are covered.": 0.5,
            "LOW: a few geographical areas of the country are covered.": 0,
            "Do not know": "null"
        },
        "actual_answers": {
            "Spain": "LOW: a few geographical areas of the country are covered.",
            "Austria": "HIGH: all main geographical regions of the country are covered.",
            "Lithuania": "Do not know",
            "Croatia": "Do not know",
            "Netherlands": "HIGH: all main geographical regions of the country are covered.",
            "Ireland": "Do not know",
            "Germany": "HIGH: all main geographical regions of the country are covered.",
            "Poland": "Do not know",
            "Italy": "Do not know",
            "Greece": "HIGH: all main geographical regions of the country are covered.",
            "France": "HIGH: all main geographical regions of the country are covered.",
            "Czechia": "Do not know",
            "Belgium": "HIGH: all main geographical regions of the country are covered.",
            "Hungary": "HIGH: all main geographical regions of the country are covered.",
            "Finland": "MEDIUM: most geographical regions of the country are covered.",
            "Luxembourg": "Do not know",
            "Malta": "HIGH: all main geographical regions of the country are covered.",
            "Portugal": "Do not know",
            "Norway": "HIGH: all main geographical regions of the country are covered.",
            "Slovenia": "Do not know",
            "Estonia": "HIGH: all main geographical regions of the country are covered.",
            "Sweden": "HIGH: all main geographical regions of the country are covered.",
            "Ukraine": "HIGH: all main geographical regions of the country are covered.",
            "Slovak Republic": "HIGH: all main geographical regions of the country are covered.",
            "Denmark": "HIGH: all main geographical regions of the country are covered.",
            "Latvia": "Do not know",
            "Iceland": "Do not know",
            "Bulgaria": "HIGH: all main geographical regions of the country are covered."
        }
    },
    "38.49": {
        "title": "Is AST data for the following pathogen part of your national surveillance, and how would you estimate the population coverage and the geographical representativeness of the submitteddata?  Applies to AST data for all tested isolates (susceptible, intermediate and resistant). Can be in any format (zones, MIC, SIR, aggregated).Estimation range of population coverage:The percentage of the population that is roughly covered by the clinical microbiology laboratories that submit data. Estimation of geographical representativeness: A rough estimation of the quantity of geographical regions that are covered by the clinical microbiology laboratories that submit data. Similar estimations are included in the annual report to EARS-Net. If you are unsure about the estimations, please consult the EARS-Net focal point in your country. : Wound/tissue swab S. aureus : If data is submitted:Estimated geographical representativeness",
        "short_title": "Geographical representativeness for AST data part of national surveillance. S. aureus - soft tissue.",
        "type": "SingleChoice",
        "coefficient": 0.033,
        "tags": [
            "National surveillance",
            "S. aureus",
            "Soft tissue"
        ],
        "possible_answers": {
            "HIGH: all main geographical regions of the country are covered.": 1,
            "MEDIUM: most geographical regions of the country are covered.": 0.5,
            "LOW: a few geographical areas of the country are covered.": 0,
            "Do not know": "null"
        },
        "actual_answers": {
            "Spain": "LOW: a few geographical areas of the country are covered.",
            "Austria": "HIGH: all main geographical regions of the country are covered.",
            "Lithuania": "Do not know",
            "Croatia": "Do not know",
            "Netherlands": "HIGH: all main geographical regions of the country are covered.",
            "Ireland": "Do not know",
            "Germany": "HIGH: all main geographical regions of the country are covered.",
            "Poland": "Do not know",
            "Italy": "Do not know",
            "Greece": "HIGH: all main geographical regions of the country are covered.",
            "France": "HIGH: all main geographical regions of the country are covered.",
            "Czechia": "Do not know",
            "Belgium": "HIGH: all main geographical regions of the country are covered.",
            "Hungary": "HIGH: all main geographical regions of the country are covered.",
            "Finland": "MEDIUM: most geographical regions of the country are covered.",
            "Luxembourg": "Do not know",
            "Malta": "HIGH: all main geographical regions of the country are covered.",
            "Portugal": "Do not know",
            "Norway": "HIGH: all main geographical regions of the country are covered.",
            "Slovenia": "Do not know",
            "Estonia": "HIGH: all main geographical regions of the country are covered.",
            "Sweden": "HIGH: all main geographical regions of the country are covered.",
            "Ukraine": "HIGH: all main geographical regions of the country are covered.",
            "Slovak Republic": "HIGH: all main geographical regions of the country are covered.",
            "Denmark": "HIGH: all main geographical regions of the country are covered.",
            "Latvia": "LOW: a few geographical areas of the country are covered.",
            "Iceland": "Do not know",
            "Bulgaria": "HIGH: all main geographical regions of the country are covered."
        }
    },
    "38.50": {
        "title": "Is AST data for the following pathogen part of your national surveillance, and how would you estimate the population coverage and the geographical representativeness of the submitteddata?  Applies to AST data for all tested isolates (susceptible, intermediate and resistant). Can be in any format (zones, MIC, SIR, aggregated).Estimation range of population coverage:The percentage of the population that is roughly covered by the clinical microbiology laboratories that submit data. Estimation of geographical representativeness: A rough estimation of the quantity of geographical regions that are covered by the clinical microbiology laboratories that submit data. Similar estimations are included in the annual report to EARS-Net. If you are unsure about the estimations, please consult the EARS-Net focal point in your country. : Upper respiratory tractS. aureus : If data is submitted:Estimated geographical representativeness",
        "short_title": "Geographical representativeness for AST data part of national surveillance. S. aureus - upper respiratory tract.",
        "type": "SingleChoice",
        "coefficient": 0.033,
        "tags": [
            "National surveillance",
            "S. aureus",
            "Respiratory tract"
        ],
        "possible_answers": {
            "HIGH: all main geographical regions of the country are covered.": 1,
            "MEDIUM: most geographical regions of the country are covered.": 0.5,
            "LOW: a few geographical areas of the country are covered.": 0,
            "Do not know": "null"
        },
        "actual_answers": {
            "Spain": "LOW: a few geographical areas of the country are covered.",
            "Austria": "HIGH: all main geographical regions of the country are covered.",
            "Lithuania": "Do not know",
            "Croatia": "Do not know",
            "Netherlands": "HIGH: all main geographical regions of the country are covered.",
            "Ireland": "Do not know",
            "Germany": "HIGH: all main geographical regions of the country are covered.",
            "Poland": "Do not know",
            "Italy": "Do not know",
            "Greece": "HIGH: all main geographical regions of the country are covered.",
            "France": "HIGH: all main geographical regions of the country are covered.",
            "Czechia": "Do not know",
            "Belgium": "HIGH: all main geographical regions of the country are covered.",
            "Hungary": "HIGH: all main geographical regions of the country are covered.",
            "Finland": "MEDIUM: most geographical regions of the country are covered.",
            "Luxembourg": "Do not know",
            "Malta": "HIGH: all main geographical regions of the country are covered.",
            "Portugal": "Do not know",
            "Norway": "HIGH: all main geographical regions of the country are covered.",
            "Slovenia": "Do not know",
            "Estonia": "HIGH: all main geographical regions of the country are covered.",
            "Sweden": "HIGH: all main geographical regions of the country are covered.",
            "Ukraine": "Do not know",
            "Slovak Republic": "HIGH: all main geographical regions of the country are covered.",
            "Denmark": "HIGH: all main geographical regions of the country are covered.",
            "Latvia": "Do not know",
            "Iceland": "Do not know",
            "Bulgaria": "HIGH: all main geographical regions of the country are covered."
        }
    },
    "38.51": {
        "title": "Is AST data for the following pathogen part of your national surveillance, and how would you estimate the population coverage and the geographical representativeness of the submitteddata?  Applies to AST data for all tested isolates (susceptible, intermediate and resistant). Can be in any format (zones, MIC, SIR, aggregated).Estimation range of population coverage:The percentage of the population that is roughly covered by the clinical microbiology laboratories that submit data. Estimation of geographical representativeness: A rough estimation of the quantity of geographical regions that are covered by the clinical microbiology laboratories that submit data. Similar estimations are included in the annual report to EARS-Net. If you are unsure about the estimations, please consult the EARS-Net focal point in your country. : Upper respiratory tractS. pneumoniae : If data is submitted:Estimated geographical representativeness",
        "short_title": "Geographical representativeness for AST data part of national surveillance. S. pneumoniae - upper respiratory tract.",
        "type": "SingleChoice",
        "coefficient": 0.033,
        "tags": [
            "National surveillance",
            "S. pneumoniae",
            "Respiratory tract"
        ],
        "possible_answers": {
            "HIGH: all main geographical regions of the country are covered.": 1,
            "MEDIUM: most geographical regions of the country are covered.": 0.5,
            "LOW: a few geographical areas of the country are covered.": 0,
            "Do not know": "null"
        },
        "actual_answers": {
            "Spain": "HIGH: all main geographical regions of the country are covered.",
            "Austria": "HIGH: all main geographical regions of the country are covered.",
            "Lithuania": "Do not know",
            "Croatia": "Do not know",
            "Netherlands": "HIGH: all main geographical regions of the country are covered.",
            "Ireland": "Do not know",
            "Germany": "HIGH: all main geographical regions of the country are covered.",
            "Poland": "Do not know",
            "Italy": "Do not know",
            "Greece": "HIGH: all main geographical regions of the country are covered.",
            "France": "Do not know",
            "Czechia": "MEDIUM: most geographical regions of the country are covered.",
            "Belgium": "HIGH: all main geographical regions of the country are covered.",
            "Hungary": "HIGH: all main geographical regions of the country are covered.",
            "Finland": "MEDIUM: most geographical regions of the country are covered.",
            "Luxembourg": "Do not know",
            "Malta": "HIGH: all main geographical regions of the country are covered.",
            "Portugal": "Do not know",
            "Norway": "HIGH: all main geographical regions of the country are covered.",
            "Slovenia": "Do not know",
            "Estonia": "HIGH: all main geographical regions of the country are covered.",
            "Sweden": "HIGH: all main geographical regions of the country are covered.",
            "Ukraine": "Do not know",
            "Slovak Republic": "HIGH: all main geographical regions of the country are covered.",
            "Denmark": "HIGH: all main geographical regions of the country are covered.",
            "Latvia": "Do not know",
            "Iceland": "Do not know",
            "Bulgaria": "MEDIUM: most geographical regions of the country are covered."
        }
    },
    "38.52": {
        "title": "Is AST data for the following pathogen part of your national surveillance, and how would you estimate the population coverage and the geographical representativeness of the submitteddata?  Applies to AST data for all tested isolates (susceptible, intermediate and resistant). Can be in any format (zones, MIC, SIR, aggregated).Estimation range of population coverage:The percentage of the population that is roughly covered by the clinical microbiology laboratories that submit data. Estimation of geographical representativeness: A rough estimation of the quantity of geographical regions that are covered by the clinical microbiology laboratories that submit data. Similar estimations are included in the annual report to EARS-Net. If you are unsure about the estimations, please consult the EARS-Net focal point in your country. : Upper respiratory tractH. influenzae : If data is submitted:Estimated geographical representativeness",
        "short_title": "Geographical representativeness for AST data part of national surveillance. H. influenzae - upper respiratory tract.",
        "type": "SingleChoice",
        "coefficient": 0.033,
        "tags": [
            "National surveillance",
            "H. influenzae",
            "Respiratory tract"
        ],
        "possible_answers": {
            "HIGH: all main geographical regions of the country are covered.": 1,
            "MEDIUM: most geographical regions of the country are covered.": 0.5,
            "LOW: a few geographical areas of the country are covered.": 0,
            "Do not know": "null"
        },
        "actual_answers": {
            "Spain": "Do not know",
            "Austria": "HIGH: all main geographical regions of the country are covered.",
            "Lithuania": "Do not know",
            "Croatia": "Do not know",
            "Netherlands": "HIGH: all main geographical regions of the country are covered.",
            "Ireland": "Do not know",
            "Germany": "HIGH: all main geographical regions of the country are covered.",
            "Poland": "Do not know",
            "Italy": "Do not know",
            "Greece": "HIGH: all main geographical regions of the country are covered.",
            "France": "Do not know",
            "Czechia": "MEDIUM: most geographical regions of the country are covered.",
            "Belgium": "HIGH: all main geographical regions of the country are covered.",
            "Hungary": "HIGH: all main geographical regions of the country are covered.",
            "Finland": "MEDIUM: most geographical regions of the country are covered.",
            "Luxembourg": "Do not know",
            "Malta": "HIGH: all main geographical regions of the country are covered.",
            "Portugal": "Do not know",
            "Norway": "HIGH: all main geographical regions of the country are covered.",
            "Slovenia": "Do not know",
            "Estonia": "HIGH: all main geographical regions of the country are covered.",
            "Sweden": "HIGH: all main geographical regions of the country are covered.",
            "Ukraine": "Do not know",
            "Slovak Republic": "HIGH: all main geographical regions of the country are covered.",
            "Denmark": "HIGH: all main geographical regions of the country are covered.",
            "Latvia": "Do not know",
            "Iceland": "Do not know",
            "Bulgaria": "MEDIUM: most geographical regions of the country are covered."
        }
    },
    "38.53": {
        "title": "Is AST data for the following pathogen part of your national surveillance, and how would you estimate the population coverage and the geographical representativeness of the submitteddata?  Applies to AST data for all tested isolates (susceptible, intermediate and resistant). Can be in any format (zones, MIC, SIR, aggregated).Estimation range of population coverage:The percentage of the population that is roughly covered by the clinical microbiology laboratories that submit data. Estimation of geographical representativeness: A rough estimation of the quantity of geographical regions that are covered by the clinical microbiology laboratories that submit data. Similar estimations are included in the annual report to EARS-Net. If you are unsure about the estimations, please consult the EARS-Net focal point in your country. : Lower respiratory tract E. coli : If data is submitted:Estimated geographical representativeness",
        "short_title": "Geographical representativeness for AST data part of national surveillance. E. coli - lower respiratory tract.",
        "type": "SingleChoice",
        "coefficient": 0.033,
        "tags": [
            "National surveillance",
            "E. coli",
            "Respiratory tract"
        ],
        "possible_answers": {
            "HIGH: all main geographical regions of the country are covered.": 1,
            "MEDIUM: most geographical regions of the country are covered.": 0.5,
            "LOW: a few geographical areas of the country are covered.": 0,
            "Do not know": "null"
        },
        "actual_answers": {
            "Spain": "LOW: a few geographical areas of the country are covered.",
            "Austria": "HIGH: all main geographical regions of the country are covered.",
            "Lithuania": "Do not know",
            "Croatia": "Do not know",
            "Netherlands": "HIGH: all main geographical regions of the country are covered.",
            "Ireland": "Do not know",
            "Germany": "HIGH: all main geographical regions of the country are covered.",
            "Poland": "Do not know",
            "Italy": "Do not know",
            "Greece": "HIGH: all main geographical regions of the country are covered.",
            "France": "HIGH: all main geographical regions of the country are covered.",
            "Czechia": "Do not know",
            "Belgium": "HIGH: all main geographical regions of the country are covered.",
            "Hungary": "HIGH: all main geographical regions of the country are covered.",
            "Finland": "Do not know",
            "Luxembourg": "Do not know",
            "Malta": "HIGH: all main geographical regions of the country are covered.",
            "Portugal": "Do not know",
            "Norway": "HIGH: all main geographical regions of the country are covered.",
            "Slovenia": "Do not know",
            "Estonia": "HIGH: all main geographical regions of the country are covered.",
            "Sweden": "HIGH: all main geographical regions of the country are covered.",
            "Ukraine": "Do not know",
            "Slovak Republic": "HIGH: all main geographical regions of the country are covered.",
            "Denmark": "HIGH: all main geographical regions of the country are covered.",
            "Latvia": "Do not know",
            "Iceland": "Do not know",
            "Bulgaria": "HIGH: all main geographical regions of the country are covered."
        }
    },
    "38.54": {
        "title": "Is AST data for the following pathogen part of your national surveillance, and how would you estimate the population coverage and the geographical representativeness of the submitteddata?  Applies to AST data for all tested isolates (susceptible, intermediate and resistant). Can be in any format (zones, MIC, SIR, aggregated).Estimation range of population coverage:The percentage of the population that is roughly covered by the clinical microbiology laboratories that submit data. Estimation of geographical representativeness: A rough estimation of the quantity of geographical regions that are covered by the clinical microbiology laboratories that submit data. Similar estimations are included in the annual report to EARS-Net. If you are unsure about the estimations, please consult the EARS-Net focal point in your country. : Lower respiratory tract K. pneumoniae : If data is submitted:Estimated geographical representativeness",
        "short_title": "Geographical representativeness for AST data part of national surveillance. K. pneumoniae - lower respiratory tract.",
        "type": "SingleChoice",
        "coefficient": 0.033,
        "tags": [
            "National surveillance",
            "K. pneumoniae",
            "Respiratory tract"
        ],
        "possible_answers": {
            "HIGH: all main geographical regions of the country are covered.": 1,
            "MEDIUM: most geographical regions of the country are covered.": 0.5,
            "LOW: a few geographical areas of the country are covered.": 0,
            "Do not know": "null"
        },
        "actual_answers": {
            "Spain": "LOW: a few geographical areas of the country are covered.",
            "Austria": "HIGH: all main geographical regions of the country are covered.",
            "Lithuania": "Do not know",
            "Croatia": "Do not know",
            "Netherlands": "HIGH: all main geographical regions of the country are covered.",
            "Ireland": "Do not know",
            "Germany": "HIGH: all main geographical regions of the country are covered.",
            "Poland": "Do not know",
            "Italy": "Do not know",
            "Greece": "HIGH: all main geographical regions of the country are covered.",
            "France": "HIGH: all main geographical regions of the country are covered.",
            "Czechia": "Do not know",
            "Belgium": "HIGH: all main geographical regions of the country are covered.",
            "Hungary": "HIGH: all main geographical regions of the country are covered.",
            "Finland": "MEDIUM: most geographical regions of the country are covered.",
            "Luxembourg": "Do not know",
            "Malta": "HIGH: all main geographical regions of the country are covered.",
            "Portugal": "Do not know",
            "Norway": "HIGH: all main geographical regions of the country are covered.",
            "Slovenia": "Do not know",
            "Estonia": "HIGH: all main geographical regions of the country are covered.",
            "Sweden": "HIGH: all main geographical regions of the country are covered.",
            "Ukraine": "Do not know",
            "Slovak Republic": "HIGH: all main geographical regions of the country are covered.",
            "Denmark": "HIGH: all main geographical regions of the country are covered.",
            "Latvia": "LOW: a few geographical areas of the country are covered.",
            "Iceland": "Do not know",
            "Bulgaria": "HIGH: all main geographical regions of the country are covered."
        }
    },
    "38.55": {
        "title": "Is AST data for the following pathogen part of your national surveillance, and how would you estimate the population coverage and the geographical representativeness of the submitteddata?  Applies to AST data for all tested isolates (susceptible, intermediate and resistant). Can be in any format (zones, MIC, SIR, aggregated).Estimation range of population coverage:The percentage of the population that is roughly covered by the clinical microbiology laboratories that submit data. Estimation of geographical representativeness: A rough estimation of the quantity of geographical regions that are covered by the clinical microbiology laboratories that submit data. Similar estimations are included in the annual report to EARS-Net. If you are unsure about the estimations, please consult the EARS-Net focal point in your country. : Lower respiratory tractP. aeruginosa : If data is submitted:Estimated geographical representativeness",
        "short_title": "Geographical representativeness for AST data part of national surveillance. P. aeruginosa - lower respiratory tract.",
        "type": "SingleChoice",
        "coefficient": 0.033,
        "tags": [
            "National surveillance",
            "P. aeruginosa",
            "Respiratory tract"
        ],
        "possible_answers": {
            "HIGH: all main geographical regions of the country are covered.": 1,
            "MEDIUM: most geographical regions of the country are covered.": 0.5,
            "LOW: a few geographical areas of the country are covered.": 0,
            "Do not know": "null"
        },
        "actual_answers": {
            "Spain": "LOW: a few geographical areas of the country are covered.",
            "Austria": "HIGH: all main geographical regions of the country are covered.",
            "Lithuania": "Do not know",
            "Croatia": "Do not know",
            "Netherlands": "HIGH: all main geographical regions of the country are covered.",
            "Ireland": "Do not know",
            "Germany": "HIGH: all main geographical regions of the country are covered.",
            "Poland": "Do not know",
            "Italy": "Do not know",
            "Greece": "HIGH: all main geographical regions of the country are covered.",
            "France": "HIGH: all main geographical regions of the country are covered.",
            "Czechia": "Do not know",
            "Belgium": "HIGH: all main geographical regions of the country are covered.",
            "Hungary": "HIGH: all main geographical regions of the country are covered.",
            "Finland": "MEDIUM: most geographical regions of the country are covered.",
            "Luxembourg": "Do not know",
            "Malta": "HIGH: all main geographical regions of the country are covered.",
            "Portugal": "Do not know",
            "Norway": "HIGH: all main geographical regions of the country are covered.",
            "Slovenia": "Do not know",
            "Estonia": "HIGH: all main geographical regions of the country are covered.",
            "Sweden": "HIGH: all main geographical regions of the country are covered.",
            "Ukraine": "Do not know",
            "Slovak Republic": "HIGH: all main geographical regions of the country are covered.",
            "Denmark": "HIGH: all main geographical regions of the country are covered.",
            "Latvia": "LOW: a few geographical areas of the country are covered.",
            "Iceland": "Do not know",
            "Bulgaria": "HIGH: all main geographical regions of the country are covered."
        }
    },
    "38.56": {
        "title": "Is AST data for the following pathogen part of your national surveillance, and how would you estimate the population coverage and the geographical representativeness of the submitteddata?  Applies to AST data for all tested isolates (susceptible, intermediate and resistant). Can be in any format (zones, MIC, SIR, aggregated).Estimation range of population coverage:The percentage of the population that is roughly covered by the clinical microbiology laboratories that submit data. Estimation of geographical representativeness: A rough estimation of the quantity of geographical regions that are covered by the clinical microbiology laboratories that submit data. Similar estimations are included in the annual report to EARS-Net. If you are unsure about the estimations, please consult the EARS-Net focal point in your country. : Lower respiratory tract A. baumanii : If data is submitted:Estimated geographical representativeness",
        "short_title": "Geographical representativeness for AST data part of national surveillance. A. baumanii - lower respiratory tract.",
        "type": "SingleChoice",
        "coefficient": 0.033,
        "tags": [
            "National surveillance",
            "A. baumanii",
            "Respiratory tract"
        ],
        "possible_answers": {
            "HIGH: all main geographical regions of the country are covered.": 1,
            "MEDIUM: most geographical regions of the country are covered.": 0.5,
            "LOW: a few geographical areas of the country are covered.": 0,
            "Do not know": "null"
        },
        "actual_answers": {
            "Spain": "LOW: a few geographical areas of the country are covered.",
            "Austria": "HIGH: all main geographical regions of the country are covered.",
            "Lithuania": "Do not know",
            "Croatia": "Do not know",
            "Netherlands": "HIGH: all main geographical regions of the country are covered.",
            "Ireland": "Do not know",
            "Germany": "HIGH: all main geographical regions of the country are covered.",
            "Poland": "Do not know",
            "Italy": "Do not know",
            "Greece": "HIGH: all main geographical regions of the country are covered.",
            "France": "HIGH: all main geographical regions of the country are covered.",
            "Czechia": "Do not know",
            "Belgium": "HIGH: all main geographical regions of the country are covered.",
            "Hungary": "HIGH: all main geographical regions of the country are covered.",
            "Finland": "MEDIUM: most geographical regions of the country are covered.",
            "Luxembourg": "Do not know",
            "Malta": "HIGH: all main geographical regions of the country are covered.",
            "Portugal": "Do not know",
            "Norway": "HIGH: all main geographical regions of the country are covered.",
            "Slovenia": "Do not know",
            "Estonia": "HIGH: all main geographical regions of the country are covered.",
            "Sweden": "HIGH: all main geographical regions of the country are covered.",
            "Ukraine": "Do not know",
            "Slovak Republic": "HIGH: all main geographical regions of the country are covered.",
            "Denmark": "HIGH: all main geographical regions of the country are covered.",
            "Latvia": "LOW: a few geographical areas of the country are covered.",
            "Iceland": "Do not know",
            "Bulgaria": "HIGH: all main geographical regions of the country are covered."
        }
    },
    "38.57": {
        "title": "Is AST data for the following pathogen part of your national surveillance, and how would you estimate the population coverage and the geographical representativeness of the submitteddata?  Applies to AST data for all tested isolates (susceptible, intermediate and resistant). Can be in any format (zones, MIC, SIR, aggregated).Estimation range of population coverage:The percentage of the population that is roughly covered by the clinical microbiology laboratories that submit data. Estimation of geographical representativeness: A rough estimation of the quantity of geographical regions that are covered by the clinical microbiology laboratories that submit data. Similar estimations are included in the annual report to EARS-Net. If you are unsure about the estimations, please consult the EARS-Net focal point in your country. : Lower respiratory tractS. aureus : If data is submitted:Estimated geographical representativeness",
        "short_title": "Geographical representativeness for AST data part of national surveillance. S. aureus - lower respiratory tract.",
        "type": "SingleChoice",
        "coefficient": 0.033,
        "tags": [
            "National surveillance",
            "S. aureus",
            "Respiratory tract"
        ],
        "possible_answers": {
            "HIGH: all main geographical regions of the country are covered.": 1,
            "MEDIUM: most geographical regions of the country are covered.": 0.5,
            "LOW: a few geographical areas of the country are covered.": 0,
            "Do not know": "null"
        },
        "actual_answers": {
            "Spain": "LOW: a few geographical areas of the country are covered.",
            "Austria": "HIGH: all main geographical regions of the country are covered.",
            "Lithuania": "Do not know",
            "Croatia": "Do not know",
            "Netherlands": "HIGH: all main geographical regions of the country are covered.",
            "Ireland": "Do not know",
            "Germany": "HIGH: all main geographical regions of the country are covered.",
            "Poland": "Do not know",
            "Italy": "Do not know",
            "Greece": "HIGH: all main geographical regions of the country are covered.",
            "France": "HIGH: all main geographical regions of the country are covered.",
            "Czechia": "Do not know",
            "Belgium": "HIGH: all main geographical regions of the country are covered.",
            "Hungary": "HIGH: all main geographical regions of the country are covered.",
            "Finland": "MEDIUM: most geographical regions of the country are covered.",
            "Luxembourg": "Do not know",
            "Malta": "HIGH: all main geographical regions of the country are covered.",
            "Portugal": "Do not know",
            "Norway": "HIGH: all main geographical regions of the country are covered.",
            "Slovenia": "Do not know",
            "Estonia": "HIGH: all main geographical regions of the country are covered.",
            "Sweden": "HIGH: all main geographical regions of the country are covered.",
            "Ukraine": "Do not know",
            "Slovak Republic": "HIGH: all main geographical regions of the country are covered.",
            "Denmark": "HIGH: all main geographical regions of the country are covered.",
            "Latvia": "Do not know",
            "Iceland": "Do not know",
            "Bulgaria": "HIGH: all main geographical regions of the country are covered."
        }
    },
    "38.58": {
        "title": "Is AST data for the following pathogen part of your national surveillance, and how would you estimate the population coverage and the geographical representativeness of the submitteddata?  Applies to AST data for all tested isolates (susceptible, intermediate and resistant). Can be in any format (zones, MIC, SIR, aggregated).Estimation range of population coverage:The percentage of the population that is roughly covered by the clinical microbiology laboratories that submit data. Estimation of geographical representativeness: A rough estimation of the quantity of geographical regions that are covered by the clinical microbiology laboratories that submit data. Similar estimations are included in the annual report to EARS-Net. If you are unsure about the estimations, please consult the EARS-Net focal point in your country. : Lower respiratory tractS. pneumoniae : If data is submitted:Estimated geographical representativeness",
        "short_title": "Geographical representativeness for AST data part of national surveillance. S. pneumoniae - lower respiratory tract.",
        "type": "SingleChoice",
        "coefficient": 0.033,
        "tags": [
            "National surveillance",
            "S. pneumoniae",
            "Respiratory tract"
        ],
        "possible_answers": {
            "HIGH: all main geographical regions of the country are covered.": 1,
            "MEDIUM: most geographical regions of the country are covered.": 0.5,
            "LOW: a few geographical areas of the country are covered.": 0,
            "Do not know": "null"
        },
        "actual_answers": {
            "Spain": "HIGH: all main geographical regions of the country are covered.",
            "Austria": "HIGH: all main geographical regions of the country are covered.",
            "Lithuania": "Do not know",
            "Croatia": "Do not know",
            "Netherlands": "HIGH: all main geographical regions of the country are covered.",
            "Ireland": "Do not know",
            "Germany": "HIGH: all main geographical regions of the country are covered.",
            "Poland": "Do not know",
            "Italy": "Do not know",
            "Greece": "HIGH: all main geographical regions of the country are covered.",
            "France": "Do not know",
            "Czechia": "MEDIUM: most geographical regions of the country are covered.",
            "Belgium": "HIGH: all main geographical regions of the country are covered.",
            "Hungary": "HIGH: all main geographical regions of the country are covered.",
            "Finland": "MEDIUM: most geographical regions of the country are covered.",
            "Luxembourg": "Do not know",
            "Malta": "HIGH: all main geographical regions of the country are covered.",
            "Portugal": "Do not know",
            "Norway": "HIGH: all main geographical regions of the country are covered.",
            "Slovenia": "Do not know",
            "Estonia": "HIGH: all main geographical regions of the country are covered.",
            "Sweden": "HIGH: all main geographical regions of the country are covered.",
            "Ukraine": "Do not know",
            "Slovak Republic": "HIGH: all main geographical regions of the country are covered.",
            "Denmark": "HIGH: all main geographical regions of the country are covered.",
            "Latvia": "Do not know",
            "Iceland": "Do not know",
            "Bulgaria": "HIGH: all main geographical regions of the country are covered."
        }
    },
    "38.59": {
        "title": "Is AST data for the following pathogen part of your national surveillance, and how would you estimate the population coverage and the geographical representativeness of the submitteddata?  Applies to AST data for all tested isolates (susceptible, intermediate and resistant). Can be in any format (zones, MIC, SIR, aggregated).Estimation range of population coverage:The percentage of the population that is roughly covered by the clinical microbiology laboratories that submit data. Estimation of geographical representativeness: A rough estimation of the quantity of geographical regions that are covered by the clinical microbiology laboratories that submit data. Similar estimations are included in the annual report to EARS-Net. If you are unsure about the estimations, please consult the EARS-Net focal point in your country. : Lower respiratory tractH. influenzae : If data is submitted:Estimated geographical representativeness",
        "short_title": "Geographical representativeness for AST data part of national surveillance. H. influenzae - lower respiratory tract.",
        "type": "SingleChoice",
        "coefficient": 0.033,
        "tags": [
            "National surveillance",
            "H. influenzae",
            "Respiratory tract"
        ],
        "possible_answers": {
            "HIGH: all main geographical regions of the country are covered.": 1,
            "MEDIUM: most geographical regions of the country are covered.": 0.5,
            "LOW: a few geographical areas of the country are covered.": 0,
            "Do not know": "null"
        },
        "actual_answers": {
            "Spain": "Do not know",
            "Austria": "HIGH: all main geographical regions of the country are covered.",
            "Lithuania": "Do not know",
            "Croatia": "Do not know",
            "Netherlands": "HIGH: all main geographical regions of the country are covered.",
            "Ireland": "Do not know",
            "Germany": "HIGH: all main geographical regions of the country are covered.",
            "Poland": "Do not know",
            "Italy": "Do not know",
            "Greece": "Do not know",
            "France": "Do not know",
            "Czechia": "MEDIUM: most geographical regions of the country are covered.",
            "Belgium": "HIGH: all main geographical regions of the country are covered.",
            "Hungary": "HIGH: all main geographical regions of the country are covered.",
            "Finland": "MEDIUM: most geographical regions of the country are covered.",
            "Luxembourg": "Do not know",
            "Malta": "HIGH: all main geographical regions of the country are covered.",
            "Portugal": "Do not know",
            "Norway": "HIGH: all main geographical regions of the country are covered.",
            "Slovenia": "Do not know",
            "Estonia": "HIGH: all main geographical regions of the country are covered.",
            "Sweden": "HIGH: all main geographical regions of the country are covered.",
            "Ukraine": "Do not know",
            "Slovak Republic": "HIGH: all main geographical regions of the country are covered.",
            "Denmark": "HIGH: all main geographical regions of the country are covered.",
            "Latvia": "Do not know",
            "Iceland": "Do not know",
            "Bulgaria": "HIGH: all main geographical regions of the country are covered."
        }
    },
    "38.60": {
        "title": "Is AST data for the following pathogen part of your national surveillance, and how would you estimate the population coverage and the geographical representativeness of the submitteddata?  Applies to AST data for all tested isolates (susceptible, intermediate and resistant). Can be in any format (zones, MIC, SIR, aggregated).Estimation range of population coverage:The percentage of the population that is roughly covered by the clinical microbiology laboratories that submit data. Estimation of geographical representativeness: A rough estimation of the quantity of geographical regions that are covered by the clinical microbiology laboratories that submit data. Similar estimations are included in the annual report to EARS-Net. If you are unsure about the estimations, please consult the EARS-Net focal point in your country. : Diarrhea C. difficile : If data is submitted:Estimated geographical representativeness",
        "short_title": "Geographical representativeness for AST data part of national surveillance. C. difficile - stool.",
        "type": "SingleChoice",
        "coefficient": 0.033,
        "tags": [
            "National surveillance",
            "C. difficile",
            "Stool"
        ],
        "possible_answers": {
            "HIGH: all main geographical regions of the country are covered.": 1,
            "MEDIUM: most geographical regions of the country are covered.": 0.5,
            "LOW: a few geographical areas of the country are covered.": 0,
            "Do not know": "null"
        },
        "actual_answers": {
            "Spain": "Do not know",
            "Austria": "Do not know",
            "Lithuania": "Do not know",
            "Croatia": "Do not know",
            "Netherlands": "HIGH: all main geographical regions of the country are covered.",
            "Ireland": "HIGH: all main geographical regions of the country are covered.",
            "Germany": "HIGH: all main geographical regions of the country are covered.",
            "Poland": "Do not know",
            "Italy": "Do not know",
            "Greece": "Do not know",
            "France": "Do not know",
            "Czechia": "HIGH: all main geographical regions of the country are covered.",
            "Belgium": "HIGH: all main geographical regions of the country are covered.",
            "Hungary": "Do not know",
            "Finland": "Do not know",
            "Luxembourg": "Do not know",
            "Malta": "HIGH: all main geographical regions of the country are covered.",
            "Portugal": "HIGH: all main geographical regions of the country are covered.",
            "Norway": "HIGH: all main geographical regions of the country are covered.",
            "Slovenia": "Do not know",
            "Estonia": "HIGH: all main geographical regions of the country are covered.",
            "Sweden": "HIGH: all main geographical regions of the country are covered.",
            "Ukraine": "Do not know",
            "Slovak Republic": "LOW: a few geographical areas of the country are covered.",
            "Denmark": "HIGH: all main geographical regions of the country are covered.",
            "Latvia": "LOW: a few geographical areas of the country are covered.",
            "Iceland": "Do not know",
            "Bulgaria": "LOW: a few geographical areas of the country are covered."
        }
    },
    "39.1": {
        "title": "How would you estimate the comparability of the microbiological culture results from the different sites that submits data to your national AMR surveillance system(s)?Examples of differences that influence comparability in this context include: different reasons for requesting a test, different numbers of tests per patient and/or the different types of included test (e.g. urine dipstick and rapid tests). : Urine : Comparability",
        "short_title": "Comparability of culture results from sites that are part of national surveillance? Urine.",
        "type": "SingleChoice",
        "coefficient": 0.167,
        "tags": [
            "National surveillance",
            "Urine"
        ],
        "possible_answers": {
            "High: Comparable methods are used": 1,
            "Medium: Different methods are used but the culture results are still considered comparable": 0.7,
            "Low: Large differences in methods makes the culture results hard to compare": 0.3,
            "Do not know": "null",
            "No data submitted": "null"
        },
        "actual_answers": {
            "Spain": "Medium: Different methods are used but the culture results are still considered comparable",
            "Austria": "High: Comparable methods are used",
            "Lithuania": "High: Comparable methods are used",
            "Croatia": "No data submitted",
            "Netherlands": "High: Comparable methods are used",
            "Ireland": "No data submitted",
            "Germany": "Medium: Different methods are used but the culture results are still considered comparable",
            "Poland": "No data submitted",
            "Italy": "High: Comparable methods are used",
            "Greece": "Medium: Different methods are used but the culture results are still considered comparable",
            "France": "High: Comparable methods are used",
            "Czechia": "Medium: Different methods are used but the culture results are still considered comparable",
            "Belgium": "High: Comparable methods are used",
            "Hungary": "Medium: Different methods are used but the culture results are still considered comparable",
            "Finland": "Medium: Different methods are used but the culture results are still considered comparable",
            "Luxembourg": "High: Comparable methods are used",
            "Malta": "High: Comparable methods are used",
            "Portugal": "High: Comparable methods are used",
            "Norway": "High: Comparable methods are used",
            "Slovenia": "No data submitted",
            "Estonia": "High: Comparable methods are used",
            "Sweden": "High: Comparable methods are used",
            "Ukraine": "No data submitted",
            "Slovak Republic": "Medium: Different methods are used but the culture results are still considered comparable",
            "Denmark": "High: Comparable methods are used",
            "Latvia": "Medium: Different methods are used but the culture results are still considered comparable",
            "Iceland": "Do not know",
            "Bulgaria": "Medium: Different methods are used but the culture results are still considered comparable"
        }
    },
    "39.2": {
        "title": "How would you estimate the comparability of the microbiological culture results from the different sites that submits data to your national AMR surveillance system(s)?Examples of differences that influence comparability in this context include: different reasons for requesting a test, different numbers of tests per patient and/or the different types of included test (e.g. urine dipstick and rapid tests). : Wound/tissue : Comparability",
        "short_title": "Comparability of culture results from sites that are part of national surveillance? Soft tissue.",
        "type": "SingleChoice",
        "coefficient": 0.167,
        "tags": [
            "National surveillance",
            "Soft tissue"
        ],
        "possible_answers": {
            "High: Comparable methods are used": 1,
            "Medium: Different methods are used but the culture results are still considered comparable": 0.7,
            "Low: Large differences in methods makes the culture results hard to compare": 0.3,
            "Do not know": "null",
            "No data submitted": "null"
        },
        "actual_answers": {
            "Spain": "Medium: Different methods are used but the culture results are still considered comparable",
            "Austria": "High: Comparable methods are used",
            "Lithuania": "High: Comparable methods are used",
            "Croatia": "No data submitted",
            "Netherlands": "High: Comparable methods are used",
            "Ireland": "No data submitted",
            "Germany": "Medium: Different methods are used but the culture results are still considered comparable",
            "Poland": "No data submitted",
            "Italy": "No data submitted",
            "Greece": "Medium: Different methods are used but the culture results are still considered comparable",
            "France": "High: Comparable methods are used",
            "Czechia": "Low: Large differences in methods makes the culture results hard to compare",
            "Belgium": "High: Comparable methods are used",
            "Hungary": "High: Comparable methods are used",
            "Finland": "Medium: Different methods are used but the culture results are still considered comparable",
            "Luxembourg": "High: Comparable methods are used",
            "Malta": "High: Comparable methods are used",
            "Portugal": "High: Comparable methods are used",
            "Norway": "High: Comparable methods are used",
            "Slovenia": "No data submitted",
            "Estonia": "High: Comparable methods are used",
            "Sweden": "High: Comparable methods are used",
            "Ukraine": "Medium: Different methods are used but the culture results are still considered comparable",
            "Slovak Republic": "Medium: Different methods are used but the culture results are still considered comparable",
            "Denmark": "Medium: Different methods are used but the culture results are still considered comparable",
            "Latvia": "Medium: Different methods are used but the culture results are still considered comparable",
            "Iceland": "Do not know",
            "Bulgaria": "Medium: Different methods are used but the culture results are still considered comparable"
        }
    },
    "39.3": {
        "title": "How would you estimate the comparability of the microbiological culture results from the different sites that submits data to your national AMR surveillance system(s)?Examples of differences that influence comparability in this context include: different reasons for requesting a test, different numbers of tests per patient and/or the different types of included test (e.g. urine dipstick and rapid tests). : Upper respiratory tract : Comparability",
        "short_title": "Comparability of culture results from sites that are part of national surveillance? Respiratory tract (upper).",
        "type": "SingleChoice",
        "coefficient": 0.167,
        "tags": [
            "National surveillance",
            "Respiratory tract"
        ],
        "possible_answers": {
            "High: Comparable methods are used": 1,
            "Medium: Different methods are used but the culture results are still considered comparable": 0.7,
            "Low: Large differences in methods makes the culture results hard to compare": 0.3,
            "Do not know": "null",
            "No data submitted": "null"
        },
        "actual_answers": {
            "Spain": "Medium: Different methods are used but the culture results are still considered comparable",
            "Austria": "High: Comparable methods are used",
            "Lithuania": "High: Comparable methods are used",
            "Croatia": "No data submitted",
            "Netherlands": "High: Comparable methods are used",
            "Ireland": "No data submitted",
            "Germany": "Medium: Different methods are used but the culture results are still considered comparable",
            "Poland": "No data submitted",
            "Italy": "No data submitted",
            "Greece": "Medium: Different methods are used but the culture results are still considered comparable",
            "France": "High: Comparable methods are used",
            "Czechia": "Low: Large differences in methods makes the culture results hard to compare",
            "Belgium": "High: Comparable methods are used",
            "Hungary": "High: Comparable methods are used",
            "Finland": "Medium: Different methods are used but the culture results are still considered comparable",
            "Luxembourg": "High: Comparable methods are used",
            "Malta": "High: Comparable methods are used",
            "Portugal": "High: Comparable methods are used",
            "Norway": "High: Comparable methods are used",
            "Slovenia": "No data submitted",
            "Estonia": "High: Comparable methods are used",
            "Sweden": "High: Comparable methods are used",
            "Ukraine": "No data submitted",
            "Slovak Republic": "Medium: Different methods are used but the culture results are still considered comparable",
            "Denmark": "Medium: Different methods are used but the culture results are still considered comparable",
            "Latvia": "Medium: Different methods are used but the culture results are still considered comparable",
            "Iceland": "Do not know",
            "Bulgaria": "Medium: Different methods are used but the culture results are still considered comparable"
        }
    },
    "39.4": {
        "title": "How would you estimate the comparability of the microbiological culture results from the different sites that submits data to your national AMR surveillance system(s)?Examples of differences that influence comparability in this context include: different reasons for requesting a test, different numbers of tests per patient and/or the different types of included test (e.g. urine dipstick and rapid tests). : Lower respiratory tract : Comparability",
        "short_title": "Comparability of culture results from sites that are part of national surveillance? Respiratory tract (lower).",
        "type": "SingleChoice",
        "coefficient": 0.167,
        "tags": [
            "National surveillance",
            "Respiratory tract"
        ],
        "possible_answers": {
            "High: Comparable methods are used": 1,
            "Medium: Different methods are used but the culture results are still considered comparable": 0.7,
            "Low: Large differences in methods makes the culture results hard to compare": 0.3,
            "Do not know": "null",
            "No data submitted": "null"
        },
        "actual_answers": {
            "Spain": "Medium: Different methods are used but the culture results are still considered comparable",
            "Austria": "High: Comparable methods are used",
            "Lithuania": "High: Comparable methods are used",
            "Croatia": "No data submitted",
            "Netherlands": "High: Comparable methods are used",
            "Ireland": "No data submitted",
            "Germany": "Medium: Different methods are used but the culture results are still considered comparable",
            "Poland": "No data submitted",
            "Italy": "No data submitted",
            "Greece": "Medium: Different methods are used but the culture results are still considered comparable",
            "France": "High: Comparable methods are used",
            "Czechia": "Low: Large differences in methods makes the culture results hard to compare",
            "Belgium": "High: Comparable methods are used",
            "Hungary": "High: Comparable methods are used",
            "Finland": "Medium: Different methods are used but the culture results are still considered comparable",
            "Luxembourg": "High: Comparable methods are used",
            "Malta": "High: Comparable methods are used",
            "Portugal": "High: Comparable methods are used",
            "Norway": "High: Comparable methods are used",
            "Slovenia": "No data submitted",
            "Estonia": "High: Comparable methods are used",
            "Sweden": "High: Comparable methods are used",
            "Ukraine": "No data submitted",
            "Slovak Republic": "Medium: Different methods are used but the culture results are still considered comparable",
            "Denmark": "High: Comparable methods are used",
            "Latvia": "Medium: Different methods are used but the culture results are still considered comparable",
            "Iceland": "Do not know",
            "Bulgaria": "Medium: Different methods are used but the culture results are still considered comparable"
        }
    },
    "39.5": {
        "title": "How would you estimate the comparability of the microbiological culture results from the different sites that submits data to your national AMR surveillance system(s)?Examples of differences that influence comparability in this context include: different reasons for requesting a test, different numbers of tests per patient and/or the different types of included test (e.g. urine dipstick and rapid tests). : Diarrhea/stool sample : Comparability",
        "short_title": "Comparability of culture results from sites that are part of national surveillance? Stool.",
        "type": "SingleChoice",
        "coefficient": 0.167,
        "tags": [
            "National surveillance",
            "Stool"
        ],
        "possible_answers": {
            "High: Comparable methods are used": 1,
            "Medium: Different methods are used but the culture results are still considered comparable": 0.7,
            "Low: Large differences in methods makes the culture results hard to compare": 0.3,
            "Do not know": "null",
            "No data submitted": "null"
        },
        "actual_answers": {
            "Spain": "No data submitted",
            "Austria": "Do not know",
            "Lithuania": "Medium: Different methods are used but the culture results are still considered comparable",
            "Croatia": "No data submitted",
            "Netherlands": "High: Comparable methods are used",
            "Ireland": "High: Comparable methods are used",
            "Germany": "Medium: Different methods are used but the culture results are still considered comparable",
            "Poland": "No data submitted",
            "Italy": "No data submitted",
            "Greece": "Medium: Different methods are used but the culture results are still considered comparable",
            "France": "High: Comparable methods are used",
            "Czechia": "Medium: Different methods are used but the culture results are still considered comparable",
            "Belgium": "High: Comparable methods are used",
            "Hungary": "No data submitted",
            "Finland": "Medium: Different methods are used but the culture results are still considered comparable",
            "Luxembourg": "High: Comparable methods are used",
            "Malta": "High: Comparable methods are used",
            "Portugal": "High: Comparable methods are used",
            "Norway": "Medium: Different methods are used but the culture results are still considered comparable",
            "Slovenia": "No data submitted",
            "Estonia": "High: Comparable methods are used",
            "Sweden": "High: Comparable methods are used",
            "Ukraine": "No data submitted",
            "Slovak Republic": "Medium: Different methods are used but the culture results are still considered comparable",
            "Denmark": "High: Comparable methods are used",
            "Latvia": "High: Comparable methods are used",
            "Iceland": "High: Comparable methods are used",
            "Bulgaria": "Do not know"
        }
    },
    "39.6": {
        "title": "How would you estimate the comparability of the microbiological culture results from the different sites that submits data to your national AMR surveillance system(s)?Examples of differences that influence comparability in this context include: different reasons for requesting a test, different numbers of tests per patient and/or the different types of included test (e.g. urine dipstick and rapid tests). : Blood/CSF : Comparability",
        "short_title": "Comparability of culture results from sites that are part of national surveillance? Blood.",
        "type": "SingleChoice",
        "coefficient": 0.167,
        "tags": [
            "National surveillance",
            "Blood"
        ],
        "possible_answers": {
            "High: Comparable methods are used": 1,
            "Medium: Different methods are used but the culture results are still considered comparable": 0.7,
            "Low: Large differences in methods makes the culture results hard to compare": 0.3,
            "Do not know": "null",
            "No data submitted": "null"
        },
        "actual_answers": {
            "Spain": "High: Comparable methods are used",
            "Austria": "High: Comparable methods are used",
            "Lithuania": "High: Comparable methods are used",
            "Croatia": "High: Comparable methods are used",
            "Netherlands": "High: Comparable methods are used",
            "Ireland": "High: Comparable methods are used",
            "Germany": "Medium: Different methods are used but the culture results are still considered comparable",
            "Poland": "High: Comparable methods are used",
            "Italy": "High: Comparable methods are used",
            "Greece": "Medium: Different methods are used but the culture results are still considered comparable",
            "France": "High: Comparable methods are used",
            "Czechia": "High: Comparable methods are used",
            "Belgium": "High: Comparable methods are used",
            "Hungary": "High: Comparable methods are used",
            "Finland": "Medium: Different methods are used but the culture results are still considered comparable",
            "Luxembourg": "High: Comparable methods are used",
            "Malta": "High: Comparable methods are used",
            "Portugal": "High: Comparable methods are used",
            "Norway": "High: Comparable methods are used",
            "Slovenia": "High: Comparable methods are used",
            "Estonia": "High: Comparable methods are used",
            "Sweden": "High: Comparable methods are used",
            "Ukraine": "Medium: Different methods are used but the culture results are still considered comparable",
            "Slovak Republic": "Medium: Different methods are used but the culture results are still considered comparable",
            "Denmark": "High: Comparable methods are used",
            "Latvia": "High: Comparable methods are used",
            "Iceland": "High: Comparable methods are used",
            "Bulgaria": "Medium: Different methods are used but the culture results are still considered comparable"
        }
    },
    "40": {
        "title": "For the pathogens that are under national surveillance, is some patient/case data available in your national AMR surveillance system(s)?",
        "short_title": "Is some patient/case data available in your national AMR surveillance system(s)?",
        "type": "SingleChoice",
        "coefficient": 1,
        "tags": [
            "National surveillance"
        ],
        "possible_answers": {
            "Yes": 1,
            "No": 0,
            "Do not know": "null"
        },
        "actual_answers": {
            "Spain": "Yes",
            "Austria": "Yes",
            "Lithuania": "Yes",
            "Croatia": "Yes",
            "Netherlands": "Yes",
            "Ireland": "Yes",
            "Germany": "Yes",
            "Poland": "Yes",
            "Italy": "Yes",
            "Greece": "Yes",
            "France": "Yes",
            "Czechia": "Yes",
            "Belgium": "Yes",
            "Hungary": "Yes",
            "Finland": "Yes",
            "Luxembourg": "Yes",
            "Malta": "Yes",
            "Portugal": "No",
            "Norway": "Yes",
            "Slovenia": "Yes",
            "Estonia": "Yes",
            "Sweden": "Yes",
            "Ukraine": "Yes",
            "Slovak Republic": "No",
            "Denmark": "Yes",
            "Latvia": "No",
            "Iceland": "Yes",
            "Bulgaria": "No"
        }
    },
    "41.1": {
        "title": "You answered \u201cyes to some patient/case information is available\u201d in the question above.  Which of the following patient/case information is available in your national AMR surveillance system(s)?  Please also select available if the data are in separate systems but regularly linked with the AMR data. Community-associated: Infections that are contracted in the community, i.e. outside of a healthcare facility. Healthcare-associated: An infection occurring in a patient during the process of care in a hospital or other healthcare facility, which was not present or incubating at the time of admission. Healthcare-associated infections can also appear after discharge. Long-Term Care Facility (LTCF)-associated: An infection in a patient who is a resident at a LTCF. : Blood/CSF E. coli (3GC- R and/or P) : Patient/case data available",
        "short_title": "Patient data available at national level. 3rd-generation cephalosporins resistant E. coli - blood.",
        "type": "MultipleChoice",
        "coefficient": 0.02,
        "tags": [
            "National surveillance",
            "E. coli",
            "Blood",
            "3rd-generation Cephalosporin"
        ],
        "possible_answers": {
            "Age": 0.2,
            "Sex": 0.2,
            "Sample date": 0.2,
            "Geographic location of patent": 0.2,
            "Antibiotics administered /prescribed": 0.2,
            "Patient outcome (mortality)": 0.2,
            "Travel connection": 0.2,
            "Community-associated": 0.2,
            "Healthcare-associated": 0.2,
            "LTCF-associated": 0.2,
            "None of the listed patient/case data available": "null"
        },
        "actual_answers": {
            "Spain": [
                "None of the listed patient/case data available"
            ],
            "Austria": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Lithuania": [
                "Age",
                "Sample date",
                "Geographic location of patent"
            ],
            "Croatia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Netherlands": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Ireland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Germany": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Poland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Italy": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Greece": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "France": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Community-associated",
                "Healthcare-associated",
                "LTCF-associated"
            ],
            "Czechia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Belgium": [
                "Age",
                "Sex",
                "Sample date"
            ],
            "Hungary": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Finland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Luxembourg": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Malta": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Portugal": [
                ""
            ],
            "Norway": [
                "None of the listed patient/case data available"
            ],
            "Slovenia": [
                "Age",
                "Sex",
                "Sample date"
            ],
            "Estonia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Sweden": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Ukraine": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Latvia": [
                ""
            ],
            "Iceland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Bulgaria": [
                ""
            ]
        }
    },
    "41.2": {
        "title": "You answered \u201cyes to some patient/case information is available\u201d in the question above.  Which of the following patient/case information is available in your national AMR surveillance system(s)?  Please also select available if the data are in separate systems but regularly linked with the AMR data. Community-associated: Infections that are contracted in the community, i.e. outside of a healthcare facility. Healthcare-associated: An infection occurring in a patient during the process of care in a hospital or other healthcare facility, which was not present or incubating at the time of admission. Healthcare-associated infections can also appear after discharge. Long-Term Care Facility (LTCF)-associated: An infection in a patient who is a resident at a LTCF. : Blood/CSF E. coli (colistin R) : Patient/case data available",
        "short_title": "Patient data available at national level. Colistin resistant E. coli - blood.",
        "type": "MultipleChoice",
        "coefficient": 0.02,
        "tags": [
            "National surveillance",
            "E. coli",
            "Blood",
            "Colistin"
        ],
        "possible_answers": {
            "Age": 0.2,
            "Sex": 0.2,
            "Sample date": 0.2,
            "Geographic location of patent": 0.2,
            "Antibiotics administered /prescribed": 0.2,
            "Patient outcome (mortality)": 0.2,
            "Travel connection": 0.2,
            "Community-associated": 0.2,
            "Healthcare-associated": 0.2,
            "LTCF-associated": 0.2,
            "None of the listed patient/case data available": "null"
        },
        "actual_answers": {
            "Spain": [
                "None of the listed patient/case data available"
            ],
            "Austria": [
                "Age",
                "Sex",
                "Sample date",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Lithuania": [
                "Age",
                "Sample date",
                "Geographic location of patent"
            ],
            "Croatia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Netherlands": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Ireland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Germany": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Poland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Italy": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Greece": [
                "None of the listed patient/case data available"
            ],
            "France": [
                "Age",
                "Sample date",
                "Geographic location of patent",
                "Healthcare-associated",
                "LTCF-associated"
            ],
            "Czechia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Belgium": [
                "Age",
                "Sex",
                "Sample date"
            ],
            "Hungary": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Finland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Luxembourg": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Malta": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Portugal": [
                ""
            ],
            "Norway": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Slovenia": [
                "Age",
                "Sex",
                "Sample date"
            ],
            "Estonia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Sweden": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Ukraine": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Latvia": [
                ""
            ],
            "Iceland": [
                "None of the listed patient/case data available"
            ],
            "Bulgaria": [
                ""
            ]
        }
    },
    "41.3": {
        "title": "You answered \u201cyes to some patient/case information is available\u201d in the question above.  Which of the following patient/case information is available in your national AMR surveillance system(s)?  Please also select available if the data are in separate systems but regularly linked with the AMR data. Community-associated: Infections that are contracted in the community, i.e. outside of a healthcare facility. Healthcare-associated: An infection occurring in a patient during the process of care in a hospital or other healthcare facility, which was not present or incubating at the time of admission. Healthcare-associated infections can also appear after discharge. Long-Term Care Facility (LTCF)-associated: An infection in a patient who is a resident at a LTCF. : Blood/CSF K. pneumoniae (colistin R) : Patient/case data available",
        "short_title": "Patient data available at national level. Colistin resistant K. pneumoniae - blood.",
        "type": "MultipleChoice",
        "coefficient": 0.02,
        "tags": [
            "National surveillance",
            "K. pneumoniae",
            "Blood",
            "Colistin"
        ],
        "possible_answers": {
            "Age": 0.2,
            "Sex": 0.2,
            "Sample date": 0.2,
            "Geographic location of patent": 0.2,
            "Antibiotics administered /prescribed": 0.2,
            "Patient outcome (mortality)": 0.2,
            "Travel connection": 0.2,
            "Community-associated": 0.2,
            "Healthcare-associated": 0.2,
            "LTCF-associated": 0.2,
            "None of the listed patient/case data available": "null"
        },
        "actual_answers": {
            "Spain": [
                "None of the listed patient/case data available"
            ],
            "Austria": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Lithuania": [
                "Age",
                "Sample date",
                "Geographic location of patent"
            ],
            "Croatia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Netherlands": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Ireland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Germany": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Poland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Italy": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Greece": [
                "None of the listed patient/case data available"
            ],
            "France": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Community-associated",
                "Healthcare-associated",
                "LTCF-associated"
            ],
            "Czechia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Belgium": [
                "Age",
                "Sex",
                "Sample date"
            ],
            "Hungary": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Finland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Luxembourg": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Malta": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Portugal": [
                ""
            ],
            "Norway": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Slovenia": [
                "Age",
                "Sex",
                "Sample date"
            ],
            "Estonia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Sweden": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Ukraine": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Latvia": [
                ""
            ],
            "Iceland": [
                "None of the listed patient/case data available"
            ],
            "Bulgaria": [
                ""
            ]
        }
    },
    "41.4": {
        "title": "You answered \u201cyes to some patient/case information is available\u201d in the question above.  Which of the following patient/case information is available in your national AMR surveillance system(s)?  Please also select available if the data are in separate systems but regularly linked with the AMR data. Community-associated: Infections that are contracted in the community, i.e. outside of a healthcare facility. Healthcare-associated: An infection occurring in a patient during the process of care in a hospital or other healthcare facility, which was not present or incubating at the time of admission. Healthcare-associated infections can also appear after discharge. Long-Term Care Facility (LTCF)-associated: An infection in a patient who is a resident at a LTCF. : Blood/CSF K. pneumoniae (carbapenem R and/or P) : Patient/case data available",
        "short_title": "Patient data available at national level. Carbapenem resistant K. pneumoniae - blood.",
        "type": "MultipleChoice",
        "coefficient": 0.02,
        "tags": [
            "National surveillance",
            "K. pneumoniae",
            "Blood",
            "Carbapenem"
        ],
        "possible_answers": {
            "Age": 0.2,
            "Sex": 0.2,
            "Sample date": 0.2,
            "Geographic location of patent": 0.2,
            "Antibiotics administered /prescribed": 0.2,
            "Patient outcome (mortality)": 0.2,
            "Travel connection": 0.2,
            "Community-associated": 0.2,
            "Healthcare-associated": 0.2,
            "LTCF-associated": 0.2,
            "None of the listed patient/case data available": "null"
        },
        "actual_answers": {
            "Spain": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Austria": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Lithuania": [
                "Age",
                "Sample date",
                "Geographic location of patent"
            ],
            "Croatia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Netherlands": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Healthcare-associated"
            ],
            "Ireland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Germany": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)",
                "Travel connection"
            ],
            "Poland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Italy": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Greece": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)",
                "Healthcare-associated"
            ],
            "France": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Community-associated",
                "Healthcare-associated",
                "LTCF-associated"
            ],
            "Czechia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Belgium": [
                "Age",
                "Sex",
                "Sample date"
            ],
            "Hungary": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Finland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Luxembourg": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Malta": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Portugal": [
                ""
            ],
            "Norway": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Slovenia": [
                "Age",
                "Sex",
                "Sample date"
            ],
            "Estonia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Sweden": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated",
                "LTCF-associated"
            ],
            "Ukraine": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Latvia": [
                ""
            ],
            "Iceland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Bulgaria": [
                ""
            ]
        }
    },
    "41.5": {
        "title": "You answered \u201cyes to some patient/case information is available\u201d in the question above.  Which of the following patient/case information is available in your national AMR surveillance system(s)?  Please also select available if the data are in separate systems but regularly linked with the AMR data. Community-associated: Infections that are contracted in the community, i.e. outside of a healthcare facility. Healthcare-associated: An infection occurring in a patient during the process of care in a hospital or other healthcare facility, which was not present or incubating at the time of admission. Healthcare-associated infections can also appear after discharge. Long-Term Care Facility (LTCF)-associated: An infection in a patient who is a resident at a LTCF. : Blood/CSF K. pneumoniae (3GC- R and/or P) : Patient/case data available",
        "short_title": "Patient data available at national level. 3rd-generation cephalosporins resistant K. pneumoniae - blood.",
        "type": "MultipleChoice",
        "coefficient": 0.02,
        "tags": [
            "National surveillance",
            "K. pneumoniae",
            "Blood",
            "3rd-generation Cephalosporin"
        ],
        "possible_answers": {
            "Age": 0.2,
            "Sex": 0.2,
            "Sample date": 0.2,
            "Geographic location of patent": 0.2,
            "Antibiotics administered /prescribed": 0.2,
            "Patient outcome (mortality)": 0.2,
            "Travel connection": 0.2,
            "Community-associated": 0.2,
            "Healthcare-associated": 0.2,
            "LTCF-associated": 0.2,
            "None of the listed patient/case data available": "null"
        },
        "actual_answers": {
            "Spain": [
                "None of the listed patient/case data available"
            ],
            "Austria": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Lithuania": [
                "Age",
                "Sample date",
                "Geographic location of patent"
            ],
            "Croatia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Netherlands": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Ireland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Germany": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Poland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Italy": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Greece": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)",
                "Healthcare-associated"
            ],
            "France": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Community-associated",
                "Healthcare-associated",
                "LTCF-associated"
            ],
            "Czechia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Belgium": [
                "Age",
                "Sex",
                "Sample date"
            ],
            "Hungary": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Finland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Luxembourg": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Malta": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Portugal": [
                ""
            ],
            "Norway": [
                "None of the listed patient/case data available"
            ],
            "Slovenia": [
                "Age",
                "Sex",
                "Sample date"
            ],
            "Estonia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Sweden": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Ukraine": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Latvia": [
                ""
            ],
            "Iceland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Bulgaria": [
                ""
            ]
        }
    },
    "41.6": {
        "title": "You answered \u201cyes to some patient/case information is available\u201d in the question above.  Which of the following patient/case information is available in your national AMR surveillance system(s)?  Please also select available if the data are in separate systems but regularly linked with the AMR data. Community-associated: Infections that are contracted in the community, i.e. outside of a healthcare facility. Healthcare-associated: An infection occurring in a patient during the process of care in a hospital or other healthcare facility, which was not present or incubating at the time of admission. Healthcare-associated infections can also appear after discharge. Long-Term Care Facility (LTCF)-associated: An infection in a patient who is a resident at a LTCF. : Blood/CSF P. aeruginosa (carbapenem R and/or P) : Patient/case data available",
        "short_title": "Patient data available at national level. Carbapenem resistant P. aeruginosa - blood.",
        "type": "MultipleChoice",
        "coefficient": 0.02,
        "tags": [
            "National surveillance",
            "P. aeruginosa",
            "Blood",
            "Carbapenem"
        ],
        "possible_answers": {
            "Age": 0.2,
            "Sex": 0.2,
            "Sample date": 0.2,
            "Geographic location of patent": 0.2,
            "Antibiotics administered /prescribed": 0.2,
            "Patient outcome (mortality)": 0.2,
            "Travel connection": 0.2,
            "Community-associated": 0.2,
            "Healthcare-associated": 0.2,
            "LTCF-associated": 0.2,
            "None of the listed patient/case data available": "null"
        },
        "actual_answers": {
            "Spain": [
                "None of the listed patient/case data available"
            ],
            "Austria": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Lithuania": [
                "Age",
                "Sample date",
                "Geographic location of patent"
            ],
            "Croatia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Netherlands": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Antibiotics administered /prescribed",
                "Travel connection",
                "Healthcare-associated"
            ],
            "Ireland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Germany": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Poland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Italy": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Greece": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)",
                "Healthcare-associated"
            ],
            "France": [
                "Age",
                "Sample date",
                "Geographic location of patent",
                "Healthcare-associated",
                "LTCF-associated"
            ],
            "Czechia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Belgium": [
                "Age",
                "Sex",
                "Sample date"
            ],
            "Hungary": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Finland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Luxembourg": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Malta": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Portugal": [
                ""
            ],
            "Norway": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Slovenia": [
                "Age",
                "Sex",
                "Sample date"
            ],
            "Estonia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Sweden": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Ukraine": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Latvia": [
                ""
            ],
            "Iceland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Bulgaria": [
                ""
            ]
        }
    },
    "41.7": {
        "title": "You answered \u201cyes to some patient/case information is available\u201d in the question above.  Which of the following patient/case information is available in your national AMR surveillance system(s)?  Please also select available if the data are in separate systems but regularly linked with the AMR data. Community-associated: Infections that are contracted in the community, i.e. outside of a healthcare facility. Healthcare-associated: An infection occurring in a patient during the process of care in a hospital or other healthcare facility, which was not present or incubating at the time of admission. Healthcare-associated infections can also appear after discharge. Long-Term Care Facility (LTCF)-associated: An infection in a patient who is a resident at a LTCF. : Blood/CSF A. baumanii (carbapenem R and/or P) : Patient/case data available",
        "short_title": "Patient data available at national level. Carbapenem resistant A. baumanii - blood.",
        "type": "MultipleChoice",
        "coefficient": 0.02,
        "tags": [
            "National surveillance",
            "A. baumanii",
            "Blood",
            "Carbapenem"
        ],
        "possible_answers": {
            "Age": 0.2,
            "Sex": 0.2,
            "Sample date": 0.2,
            "Geographic location of patent": 0.2,
            "Antibiotics administered /prescribed": 0.2,
            "Patient outcome (mortality)": 0.2,
            "Travel connection": 0.2,
            "Community-associated": 0.2,
            "Healthcare-associated": 0.2,
            "LTCF-associated": 0.2,
            "None of the listed patient/case data available": "null"
        },
        "actual_answers": {
            "Spain": [
                "None of the listed patient/case data available"
            ],
            "Austria": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Lithuania": [
                "Age",
                "Sample date",
                "Geographic location of patent"
            ],
            "Croatia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Netherlands": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Antibiotics administered /prescribed",
                "Travel connection",
                "Healthcare-associated"
            ],
            "Ireland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Germany": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)",
                "Travel connection"
            ],
            "Poland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Italy": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Greece": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)",
                "Healthcare-associated"
            ],
            "France": [
                "Age",
                "Sample date",
                "Geographic location of patent",
                "Healthcare-associated",
                "LTCF-associated"
            ],
            "Czechia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Belgium": [
                "Age",
                "Sex",
                "Sample date"
            ],
            "Hungary": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Finland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Luxembourg": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Malta": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Portugal": [
                ""
            ],
            "Norway": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Slovenia": [
                "Age",
                "Sex",
                "Sample date"
            ],
            "Estonia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Sweden": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Ukraine": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Latvia": [
                ""
            ],
            "Iceland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Bulgaria": [
                ""
            ]
        }
    },
    "41.8": {
        "title": "You answered \u201cyes to some patient/case information is available\u201d in the question above.  Which of the following patient/case information is available in your national AMR surveillance system(s)?  Please also select available if the data are in separate systems but regularly linked with the AMR data. Community-associated: Infections that are contracted in the community, i.e. outside of a healthcare facility. Healthcare-associated: An infection occurring in a patient during the process of care in a hospital or other healthcare facility, which was not present or incubating at the time of admission. Healthcare-associated infections can also appear after discharge. Long-Term Care Facility (LTCF)-associated: An infection in a patient who is a resident at a LTCF. : Blood/CSF S. aureus (methicillin R) : Patient/case data available",
        "short_title": "Patient data available at national level. Methicillin resistant S. aureus - blood.",
        "type": "MultipleChoice",
        "coefficient": 0.02,
        "tags": [
            "National surveillance",
            "S. aureus",
            "Blood",
            "Methicillin"
        ],
        "possible_answers": {
            "Age": 0.2,
            "Sex": 0.2,
            "Sample date": 0.2,
            "Geographic location of patent": 0.2,
            "Antibiotics administered /prescribed": 0.2,
            "Patient outcome (mortality)": 0.2,
            "Travel connection": 0.2,
            "Community-associated": 0.2,
            "Healthcare-associated": 0.2,
            "LTCF-associated": 0.2,
            "None of the listed patient/case data available": "null"
        },
        "actual_answers": {
            "Spain": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Austria": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Lithuania": [
                "Age",
                "Sample date",
                "Geographic location of patent"
            ],
            "Croatia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Netherlands": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Ireland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Germany": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Poland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Italy": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Greece": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)",
                "Healthcare-associated"
            ],
            "France": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Community-associated",
                "Healthcare-associated",
                "LTCF-associated"
            ],
            "Czechia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Belgium": [
                "Age",
                "Sex",
                "Sample date"
            ],
            "Hungary": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Finland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Luxembourg": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Malta": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Portugal": [
                ""
            ],
            "Norway": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Slovenia": [
                "Age",
                "Sex",
                "Sample date"
            ],
            "Estonia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Sweden": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated",
                "LTCF-associated"
            ],
            "Ukraine": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated",
                "LTCF-associated"
            ],
            "Latvia": [
                ""
            ],
            "Iceland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Bulgaria": [
                ""
            ]
        }
    },
    "41.9": {
        "title": "You answered \u201cyes to some patient/case information is available\u201d in the question above.  Which of the following patient/case information is available in your national AMR surveillance system(s)?  Please also select available if the data are in separate systems but regularly linked with the AMR data. Community-associated: Infections that are contracted in the community, i.e. outside of a healthcare facility. Healthcare-associated: An infection occurring in a patient during the process of care in a hospital or other healthcare facility, which was not present or incubating at the time of admission. Healthcare-associated infections can also appear after discharge. Long-Term Care Facility (LTCF)-associated: An infection in a patient who is a resident at a LTCF. : Blood/CSF S. pneumoniae (penicillin and macrolide R) : Patient/case data available",
        "short_title": "Patient data available at national level. Penicillin resistant S. pneumoniae - blood.",
        "type": "MultipleChoice",
        "coefficient": 0.02,
        "tags": [
            "National surveillance",
            "S. pneumoniae",
            "Blood",
            "Penicillin"
        ],
        "possible_answers": {
            "Age": 0.2,
            "Sex": 0.2,
            "Sample date": 0.2,
            "Geographic location of patent": 0.2,
            "Antibiotics administered /prescribed": 0.2,
            "Patient outcome (mortality)": 0.2,
            "Travel connection": 0.2,
            "Community-associated": 0.2,
            "Healthcare-associated": 0.2,
            "LTCF-associated": 0.2,
            "None of the listed patient/case data available": "null"
        },
        "actual_answers": {
            "Spain": [
                "None of the listed patient/case data available"
            ],
            "Austria": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Lithuania": [
                "Age",
                "Sample date",
                "Geographic location of patent"
            ],
            "Croatia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Netherlands": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Ireland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Germany": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Poland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Antibiotics administered /prescribed",
                "Patient outcome (mortality)"
            ],
            "Italy": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Greece": [
                "None of the listed patient/case data available"
            ],
            "France": [
                "Age",
                "Sample date",
                "Geographic location of patent"
            ],
            "Czechia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Belgium": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Hungary": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Finland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Luxembourg": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Malta": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Portugal": [
                ""
            ],
            "Norway": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Slovenia": [
                "Age",
                "Sex",
                "Sample date"
            ],
            "Estonia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Sweden": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Ukraine": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Latvia": [
                ""
            ],
            "Iceland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Bulgaria": [
                ""
            ]
        }
    },
    "41.10": {
        "title": "You answered \u201cyes to some patient/case information is available\u201d in the question above.  Which of the following patient/case information is available in your national AMR surveillance system(s)?  Please also select available if the data are in separate systems but regularly linked with the AMR data. Community-associated: Infections that are contracted in the community, i.e. outside of a healthcare facility. Healthcare-associated: An infection occurring in a patient during the process of care in a hospital or other healthcare facility, which was not present or incubating at the time of admission. Healthcare-associated infections can also appear after discharge. Long-Term Care Facility (LTCF)-associated: An infection in a patient who is a resident at a LTCF. : Blood/CSF H. influenzae (ampicillin- R) : Patient/case data available",
        "short_title": "Patient data available at national level. Ampicillin resistant H. influenzae - blood.",
        "type": "MultipleChoice",
        "coefficient": 0.02,
        "tags": [
            "National surveillance",
            "H. influenzae",
            "Blood",
            "Ampicillin"
        ],
        "possible_answers": {
            "Age": 0.2,
            "Sex": 0.2,
            "Sample date": 0.2,
            "Geographic location of patent": 0.2,
            "Antibiotics administered /prescribed": 0.2,
            "Patient outcome (mortality)": 0.2,
            "Travel connection": 0.2,
            "Community-associated": 0.2,
            "Healthcare-associated": 0.2,
            "LTCF-associated": 0.2,
            "None of the listed patient/case data available": "null"
        },
        "actual_answers": {
            "Spain": [
                "None of the listed patient/case data available"
            ],
            "Austria": [
                "None of the listed patient/case data available"
            ],
            "Lithuania": [
                "Age",
                "Sample date",
                "Geographic location of patent"
            ],
            "Croatia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Netherlands": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Ireland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Germany": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Poland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Antibiotics administered /prescribed",
                "Patient outcome (mortality)"
            ],
            "Italy": [
                "None of the listed patient/case data available"
            ],
            "Greece": [
                "None of the listed patient/case data available"
            ],
            "France": [
                "None of the listed patient/case data available"
            ],
            "Czechia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)",
                "Community-associated"
            ],
            "Belgium": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)",
                "Travel connection"
            ],
            "Hungary": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Finland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Luxembourg": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Malta": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Portugal": [
                ""
            ],
            "Norway": [
                "None of the listed patient/case data available"
            ],
            "Slovenia": [
                "Age",
                "Sex",
                "Sample date"
            ],
            "Estonia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Sweden": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Ukraine": [
                "None of the listed patient/case data available"
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Latvia": [
                ""
            ],
            "Iceland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Bulgaria": [
                ""
            ]
        }
    },
    "41.11": {
        "title": "You answered \u201cyes to some patient/case information is available\u201d in the question above.  Which of the following patient/case information is available in your national AMR surveillance system(s)?  Please also select available if the data are in separate systems but regularly linked with the AMR data. Community-associated: Infections that are contracted in the community, i.e. outside of a healthcare facility. Healthcare-associated: An infection occurring in a patient during the process of care in a hospital or other healthcare facility, which was not present or incubating at the time of admission. Healthcare-associated infections can also appear after discharge. Long-Term Care Facility (LTCF)-associated: An infection in a patient who is a resident at a LTCF. : Urine E. coli (carbapenem R and/or P) : Patient/case data available",
        "short_title": "Patient data available at national level. Carbapenem resistant E. coli - urine.",
        "type": "MultipleChoice",
        "coefficient": 0.02,
        "tags": [
            "National surveillance",
            "E. coli",
            "Urine",
            "Carbapenem"
        ],
        "possible_answers": {
            "Age": 0.2,
            "Sex": 0.2,
            "Sample date": 0.2,
            "Geographic location of patent": 0.2,
            "Antibiotics administered /prescribed": 0.2,
            "Patient outcome (mortality)": 0.2,
            "Travel connection": 0.2,
            "Community-associated": 0.2,
            "Healthcare-associated": 0.2,
            "LTCF-associated": 0.2,
            "None of the listed patient/case data available": "null"
        },
        "actual_answers": {
            "Spain": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Austria": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Lithuania": [
                "Age",
                "Sample date",
                "Geographic location of patent"
            ],
            "Croatia": [
                "None of the listed patient/case data available"
            ],
            "Netherlands": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Healthcare-associated"
            ],
            "Ireland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Germany": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Poland": [
                "None of the listed patient/case data available"
            ],
            "Italy": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Greece": [
                "None of the listed patient/case data available"
            ],
            "France": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Community-associated",
                "Healthcare-associated",
                "LTCF-associated"
            ],
            "Czechia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Belgium": [
                "Age",
                "Sex",
                "Sample date"
            ],
            "Hungary": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Finland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Luxembourg": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Malta": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Portugal": [
                ""
            ],
            "Norway": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Slovenia": [
                "None of the listed patient/case data available"
            ],
            "Estonia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Sweden": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated",
                "LTCF-associated"
            ],
            "Ukraine": [
                "None of the listed patient/case data available"
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Latvia": [
                ""
            ],
            "Iceland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Bulgaria": [
                ""
            ]
        }
    },
    "41.12": {
        "title": "You answered \u201cyes to some patient/case information is available\u201d in the question above.  Which of the following patient/case information is available in your national AMR surveillance system(s)?  Please also select available if the data are in separate systems but regularly linked with the AMR data. Community-associated: Infections that are contracted in the community, i.e. outside of a healthcare facility. Healthcare-associated: An infection occurring in a patient during the process of care in a hospital or other healthcare facility, which was not present or incubating at the time of admission. Healthcare-associated infections can also appear after discharge. Long-Term Care Facility (LTCF)-associated: An infection in a patient who is a resident at a LTCF. : Urine E. coli (colistin R) : Patient/case data available",
        "short_title": "Patient data available at national level. Colistin resistant E. coli - urine.",
        "type": "MultipleChoice",
        "coefficient": 0.02,
        "tags": [
            "National surveillance",
            "E. coli",
            "Urine",
            "Colistin"
        ],
        "possible_answers": {
            "Age": 0.2,
            "Sex": 0.2,
            "Sample date": 0.2,
            "Geographic location of patent": 0.2,
            "Antibiotics administered /prescribed": 0.2,
            "Patient outcome (mortality)": 0.2,
            "Travel connection": 0.2,
            "Community-associated": 0.2,
            "Healthcare-associated": 0.2,
            "LTCF-associated": 0.2,
            "None of the listed patient/case data available": "null"
        },
        "actual_answers": {
            "Spain": [
                "None of the listed patient/case data available"
            ],
            "Austria": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Lithuania": [
                "Age",
                "Sex",
                "Sample date"
            ],
            "Croatia": [
                "None of the listed patient/case data available"
            ],
            "Netherlands": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Ireland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Germany": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Poland": [
                "None of the listed patient/case data available"
            ],
            "Italy": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Greece": [
                "None of the listed patient/case data available"
            ],
            "France": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Community-associated",
                "Healthcare-associated",
                "LTCF-associated"
            ],
            "Czechia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Belgium": [
                "Age",
                "Sex",
                "Sample date"
            ],
            "Hungary": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Finland": [
                "None of the listed patient/case data available"
            ],
            "Luxembourg": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Malta": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Portugal": [
                ""
            ],
            "Norway": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Slovenia": [
                "None of the listed patient/case data available"
            ],
            "Estonia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Sweden": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Ukraine": [
                "None of the listed patient/case data available"
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Latvia": [
                ""
            ],
            "Iceland": [
                "None of the listed patient/case data available"
            ],
            "Bulgaria": [
                ""
            ]
        }
    },
    "41.13": {
        "title": "You answered \u201cyes to some patient/case information is available\u201d in the question above.  Which of the following patient/case information is available in your national AMR surveillance system(s)?  Please also select available if the data are in separate systems but regularly linked with the AMR data. Community-associated: Infections that are contracted in the community, i.e. outside of a healthcare facility. Healthcare-associated: An infection occurring in a patient during the process of care in a hospital or other healthcare facility, which was not present or incubating at the time of admission. Healthcare-associated infections can also appear after discharge. Long-Term Care Facility (LTCF)-associated: An infection in a patient who is a resident at a LTCF. : Urine K. pneumoniae (carbapenem R and/or P) : Patient/case data available",
        "short_title": "Patient data available at national level. Carbapenem resistant K. pneumoniae - urine.",
        "type": "MultipleChoice",
        "coefficient": 0.02,
        "tags": [
            "National surveillance",
            "K. pneumoniae",
            "Urine",
            "Carbapenem"
        ],
        "possible_answers": {
            "Age": 0.2,
            "Sex": 0.2,
            "Sample date": 0.2,
            "Geographic location of patent": 0.2,
            "Antibiotics administered /prescribed": 0.2,
            "Patient outcome (mortality)": 0.2,
            "Travel connection": 0.2,
            "Community-associated": 0.2,
            "Healthcare-associated": 0.2,
            "LTCF-associated": 0.2,
            "None of the listed patient/case data available": "null"
        },
        "actual_answers": {
            "Spain": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Austria": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Lithuania": [
                "Age",
                "Sample date",
                "Geographic location of patent"
            ],
            "Croatia": [
                "None of the listed patient/case data available"
            ],
            "Netherlands": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Healthcare-associated"
            ],
            "Ireland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Germany": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Poland": [
                "None of the listed patient/case data available"
            ],
            "Italy": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Greece": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "France": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Community-associated",
                "Healthcare-associated",
                "LTCF-associated"
            ],
            "Czechia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Belgium": [
                "Age",
                "Sex",
                "Sample date"
            ],
            "Hungary": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Finland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Luxembourg": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Malta": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Portugal": [
                ""
            ],
            "Norway": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Slovenia": [
                "None of the listed patient/case data available"
            ],
            "Estonia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Sweden": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated",
                "LTCF-associated"
            ],
            "Ukraine": [
                "None of the listed patient/case data available"
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated",
                "LTCF-associated"
            ],
            "Latvia": [
                ""
            ],
            "Iceland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Bulgaria": [
                ""
            ]
        }
    },
    "41.14": {
        "title": "You answered \u201cyes to some patient/case information is available\u201d in the question above.  Which of the following patient/case information is available in your national AMR surveillance system(s)?  Please also select available if the data are in separate systems but regularly linked with the AMR data. Community-associated: Infections that are contracted in the community, i.e. outside of a healthcare facility. Healthcare-associated: An infection occurring in a patient during the process of care in a hospital or other healthcare facility, which was not present or incubating at the time of admission. Healthcare-associated infections can also appear after discharge. Long-Term Care Facility (LTCF)-associated: An infection in a patient who is a resident at a LTCF. : Urine K. pneumoniae (3GC- R and/or P) : Patient/case data available",
        "short_title": "Patient data available at national level. 3rd-generation cephalosporins resistant K. pneumoniae - urine.",
        "type": "MultipleChoice",
        "coefficient": 0.02,
        "tags": [
            "National surveillance",
            "K. pneumoniae",
            "Urine",
            "3rd-generation Cephalosporin"
        ],
        "possible_answers": {
            "Age": 0.2,
            "Sex": 0.2,
            "Sample date": 0.2,
            "Geographic location of patent": 0.2,
            "Antibiotics administered /prescribed": 0.2,
            "Patient outcome (mortality)": 0.2,
            "Travel connection": 0.2,
            "Community-associated": 0.2,
            "Healthcare-associated": 0.2,
            "LTCF-associated": 0.2,
            "None of the listed patient/case data available": "null"
        },
        "actual_answers": {
            "Spain": [
                "None of the listed patient/case data available"
            ],
            "Austria": [
                "None of the listed patient/case data available"
            ],
            "Lithuania": [
                "Age",
                "Sample date",
                "Geographic location of patent"
            ],
            "Croatia": [
                "None of the listed patient/case data available"
            ],
            "Netherlands": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Ireland": [
                "None of the listed patient/case data available"
            ],
            "Germany": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Poland": [
                "None of the listed patient/case data available"
            ],
            "Italy": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Greece": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "France": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Community-associated",
                "Healthcare-associated",
                "LTCF-associated"
            ],
            "Czechia": [
                "None of the listed patient/case data available"
            ],
            "Belgium": [
                "Age",
                "Sex",
                "Sample date"
            ],
            "Hungary": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Finland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Luxembourg": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Malta": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Portugal": [
                ""
            ],
            "Norway": [
                "None of the listed patient/case data available"
            ],
            "Slovenia": [
                "None of the listed patient/case data available"
            ],
            "Estonia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Sweden": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Ukraine": [
                "None of the listed patient/case data available"
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Latvia": [
                ""
            ],
            "Iceland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Bulgaria": [
                ""
            ]
        }
    },
    "41.15": {
        "title": "You answered \u201cyes to some patient/case information is available\u201d in the question above.  Which of the following patient/case information is available in your national AMR surveillance system(s)?  Please also select available if the data are in separate systems but regularly linked with the AMR data. Community-associated: Infections that are contracted in the community, i.e. outside of a healthcare facility. Healthcare-associated: An infection occurring in a patient during the process of care in a hospital or other healthcare facility, which was not present or incubating at the time of admission. Healthcare-associated infections can also appear after discharge. Long-Term Care Facility (LTCF)-associated: An infection in a patient who is a resident at a LTCF. : Urine K. pneumoniae (colistin R) : Patient/case data available",
        "short_title": "Patient data available at national level. Colistin resistant K. pneumoniae - urine.",
        "type": "MultipleChoice",
        "coefficient": 0.02,
        "tags": [
            "National surveillance",
            "K. pneumoniae",
            "Urine",
            "Colistin"
        ],
        "possible_answers": {
            "Age": 0.2,
            "Sex": 0.2,
            "Sample date": 0.2,
            "Geographic location of patent": 0.2,
            "Antibiotics administered /prescribed": 0.2,
            "Patient outcome (mortality)": 0.2,
            "Travel connection": 0.2,
            "Community-associated": 0.2,
            "Healthcare-associated": 0.2,
            "LTCF-associated": 0.2,
            "None of the listed patient/case data available": "null"
        },
        "actual_answers": {
            "Spain": [
                "None of the listed patient/case data available"
            ],
            "Austria": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Lithuania": [
                "Age",
                "Sample date",
                "Geographic location of patent"
            ],
            "Croatia": [
                "None of the listed patient/case data available"
            ],
            "Netherlands": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Ireland": [
                "None of the listed patient/case data available"
            ],
            "Germany": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Poland": [
                "None of the listed patient/case data available"
            ],
            "Italy": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Greece": [
                "None of the listed patient/case data available"
            ],
            "France": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Community-associated",
                "Healthcare-associated",
                "LTCF-associated"
            ],
            "Czechia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Belgium": [
                "Age",
                "Sex",
                "Sample date"
            ],
            "Hungary": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Finland": [
                "None of the listed patient/case data available"
            ],
            "Luxembourg": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Malta": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Portugal": [
                ""
            ],
            "Norway": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Slovenia": [
                "None of the listed patient/case data available"
            ],
            "Estonia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Sweden": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Ukraine": [
                "None of the listed patient/case data available"
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)",
                "Travel connection"
            ],
            "Latvia": [
                ""
            ],
            "Iceland": [
                "None of the listed patient/case data available"
            ],
            "Bulgaria": [
                ""
            ]
        }
    },
    "41.16": {
        "title": "You answered \u201cyes to some patient/case information is available\u201d in the question above.  Which of the following patient/case information is available in your national AMR surveillance system(s)?  Please also select available if the data are in separate systems but regularly linked with the AMR data. Community-associated: Infections that are contracted in the community, i.e. outside of a healthcare facility. Healthcare-associated: An infection occurring in a patient during the process of care in a hospital or other healthcare facility, which was not present or incubating at the time of admission. Healthcare-associated infections can also appear after discharge. Long-Term Care Facility (LTCF)-associated: An infection in a patient who is a resident at a LTCF. : Urine P. aeruginosa (carbapenem R and/or P) : Patient/case data available",
        "short_title": "Patient data available at national level. Carbapenem resistant P. aeruginosa - urine.",
        "type": "MultipleChoice",
        "coefficient": 0.02,
        "tags": [
            "National surveillance",
            "P. aeruginosa",
            "Urine",
            "Carbapenem"
        ],
        "possible_answers": {
            "Age": 0.2,
            "Sex": 0.2,
            "Sample date": 0.2,
            "Geographic location of patent": 0.2,
            "Antibiotics administered /prescribed": 0.2,
            "Patient outcome (mortality)": 0.2,
            "Travel connection": 0.2,
            "Community-associated": 0.2,
            "Healthcare-associated": 0.2,
            "LTCF-associated": 0.2,
            "None of the listed patient/case data available": "null"
        },
        "actual_answers": {
            "Spain": [
                "None of the listed patient/case data available"
            ],
            "Austria": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Lithuania": [
                "None of the listed patient/case data available"
            ],
            "Croatia": [
                "None of the listed patient/case data available"
            ],
            "Netherlands": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Antibiotics administered /prescribed",
                "Travel connection",
                "Healthcare-associated"
            ],
            "Ireland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Germany": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Poland": [
                "None of the listed patient/case data available"
            ],
            "Italy": [
                "None of the listed patient/case data available"
            ],
            "Greece": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "France": [
                "Age",
                "Sample date",
                "Geographic location of patent",
                "Healthcare-associated"
            ],
            "Czechia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Belgium": [
                "Age",
                "Sex",
                "Sample date"
            ],
            "Hungary": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Finland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Luxembourg": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Malta": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Portugal": [
                ""
            ],
            "Norway": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Slovenia": [
                "None of the listed patient/case data available"
            ],
            "Estonia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Sweden": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Ukraine": [
                "None of the listed patient/case data available"
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)",
                "Travel connection"
            ],
            "Latvia": [
                ""
            ],
            "Iceland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Bulgaria": [
                ""
            ]
        }
    },
    "41.17": {
        "title": "You answered \u201cyes to some patient/case information is available\u201d in the question above.  Which of the following patient/case information is available in your national AMR surveillance system(s)?  Please also select available if the data are in separate systems but regularly linked with the AMR data. Community-associated: Infections that are contracted in the community, i.e. outside of a healthcare facility. Healthcare-associated: An infection occurring in a patient during the process of care in a hospital or other healthcare facility, which was not present or incubating at the time of admission. Healthcare-associated infections can also appear after discharge. Long-Term Care Facility (LTCF)-associated: An infection in a patient who is a resident at a LTCF. : Urine A. baumanii (carbapenem R and/or P) : Patient/case data available",
        "short_title": "Patient data available at national level. Carbapenem resistant A. baumanii - urine.",
        "type": "MultipleChoice",
        "coefficient": 0.02,
        "tags": [
            "National surveillance",
            "A. baumanii",
            "Urine",
            "Carbapenem"
        ],
        "possible_answers": {
            "Age": 0.2,
            "Sex": 0.2,
            "Sample date": 0.2,
            "Geographic location of patent": 0.2,
            "Antibiotics administered /prescribed": 0.2,
            "Patient outcome (mortality)": 0.2,
            "Travel connection": 0.2,
            "Community-associated": 0.2,
            "Healthcare-associated": 0.2,
            "LTCF-associated": 0.2,
            "None of the listed patient/case data available": "null"
        },
        "actual_answers": {
            "Spain": [
                "None of the listed patient/case data available"
            ],
            "Austria": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Lithuania": [
                "None of the listed patient/case data available"
            ],
            "Croatia": [
                "None of the listed patient/case data available"
            ],
            "Netherlands": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Antibiotics administered /prescribed",
                "Travel connection",
                "Healthcare-associated"
            ],
            "Ireland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Germany": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Poland": [
                "None of the listed patient/case data available"
            ],
            "Italy": [
                "None of the listed patient/case data available"
            ],
            "Greece": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "France": [
                "Age",
                "Sample date",
                "Geographic location of patent",
                "Healthcare-associated"
            ],
            "Czechia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Belgium": [
                "None of the listed patient/case data available"
            ],
            "Hungary": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Finland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Luxembourg": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Malta": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Portugal": [
                ""
            ],
            "Norway": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Slovenia": [
                "None of the listed patient/case data available"
            ],
            "Estonia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Sweden": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Ukraine": [
                "None of the listed patient/case data available"
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)",
                "Travel connection"
            ],
            "Latvia": [
                ""
            ],
            "Iceland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Bulgaria": [
                ""
            ]
        }
    },
    "41.18": {
        "title": "You answered \u201cyes to some patient/case information is available\u201d in the question above.  Which of the following patient/case information is available in your national AMR surveillance system(s)?  Please also select available if the data are in separate systems but regularly linked with the AMR data. Community-associated: Infections that are contracted in the community, i.e. outside of a healthcare facility. Healthcare-associated: An infection occurring in a patient during the process of care in a hospital or other healthcare facility, which was not present or incubating at the time of admission. Healthcare-associated infections can also appear after discharge. Long-Term Care Facility (LTCF)-associated: An infection in a patient who is a resident at a LTCF. : Urine S. aureus (methicillin R) : Patient/case data available",
        "short_title": "Patient data available at national level. Methicillin resistant S. aureus - urine.",
        "type": "MultipleChoice",
        "coefficient": 0.02,
        "tags": [
            "National surveillance",
            "S. aureus",
            "Urine",
            "Methicillin"
        ],
        "possible_answers": {
            "Age": 0.2,
            "Sex": 0.2,
            "Sample date": 0.2,
            "Geographic location of patent": 0.2,
            "Antibiotics administered /prescribed": 0.2,
            "Patient outcome (mortality)": 0.2,
            "Travel connection": 0.2,
            "Community-associated": 0.2,
            "Healthcare-associated": 0.2,
            "LTCF-associated": 0.2,
            "None of the listed patient/case data available": "null"
        },
        "actual_answers": {
            "Spain": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Austria": [
                "None of the listed patient/case data available"
            ],
            "Lithuania": [
                "None of the listed patient/case data available"
            ],
            "Croatia": [
                "None of the listed patient/case data available"
            ],
            "Netherlands": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Ireland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Germany": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Poland": [
                "None of the listed patient/case data available"
            ],
            "Italy": [
                "None of the listed patient/case data available"
            ],
            "Greece": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "France": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Community-associated",
                "Healthcare-associated",
                "LTCF-associated"
            ],
            "Czechia": [
                "None of the listed patient/case data available"
            ],
            "Belgium": [
                "None of the listed patient/case data available"
            ],
            "Hungary": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Finland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Luxembourg": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Malta": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Portugal": [
                ""
            ],
            "Norway": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Slovenia": [
                "None of the listed patient/case data available"
            ],
            "Estonia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Sweden": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated",
                "LTCF-associated"
            ],
            "Ukraine": [
                "None of the listed patient/case data available"
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated",
                "LTCF-associated"
            ],
            "Latvia": [
                ""
            ],
            "Iceland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Bulgaria": [
                ""
            ]
        }
    },
    "41.19": {
        "title": "You answered \u201cyes to some patient/case information is available\u201d in the question above.  Which of the following patient/case information is available in your national AMR surveillance system(s)?  Please also select available if the data are in separate systems but regularly linked with the AMR data. Community-associated: Infections that are contracted in the community, i.e. outside of a healthcare facility. Healthcare-associated: An infection occurring in a patient during the process of care in a hospital or other healthcare facility, which was not present or incubating at the time of admission. Healthcare-associated infections can also appear after discharge. Long-Term Care Facility (LTCF)-associated: An infection in a patient who is a resident at a LTCF. : Urine E. faecium and/or E. faecalis (vancomycin R) : Patient/case data available",
        "short_title": "Patient data available at national level. Vancomycin resistant Enterococci - urine.",
        "type": "MultipleChoice",
        "coefficient": 0.02,
        "tags": [
            "National surveillance",
            "E. faecium/faecalis",
            "Urine",
            "Vancomycin"
        ],
        "possible_answers": {
            "Age": 0.2,
            "Sex": 0.2,
            "Sample date": 0.2,
            "Geographic location of patent": 0.2,
            "Antibiotics administered /prescribed": 0.2,
            "Patient outcome (mortality)": 0.2,
            "Travel connection": 0.2,
            "Community-associated": 0.2,
            "Healthcare-associated": 0.2,
            "LTCF-associated": 0.2,
            "None of the listed patient/case data available": "null"
        },
        "actual_answers": {
            "Spain": [
                "None of the listed patient/case data available"
            ],
            "Austria": [
                "None of the listed patient/case data available"
            ],
            "Lithuania": [
                "None of the listed patient/case data available"
            ],
            "Croatia": [
                "None of the listed patient/case data available"
            ],
            "Netherlands": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Ireland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Germany": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Poland": [
                "None of the listed patient/case data available"
            ],
            "Italy": [
                "None of the listed patient/case data available"
            ],
            "Greece": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "France": [
                "Age",
                "Sample date",
                "Geographic location of patent",
                "Healthcare-associated"
            ],
            "Czechia": [
                "None of the listed patient/case data available"
            ],
            "Belgium": [
                "Age",
                "Sex",
                "Sample date"
            ],
            "Hungary": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Finland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Luxembourg": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Malta": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Portugal": [
                ""
            ],
            "Norway": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Slovenia": [
                "None of the listed patient/case data available"
            ],
            "Estonia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Sweden": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated",
                "LTCF-associated"
            ],
            "Ukraine": [
                "None of the listed patient/case data available"
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Latvia": [
                ""
            ],
            "Iceland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Bulgaria": [
                ""
            ]
        }
    },
    "41.20": {
        "title": "You answered \u201cyes to some patient/case information is available\u201d in the question above.  Which of the following patient/case information is available in your national AMR surveillance system(s)?  Please also select available if the data are in separate systems but regularly linked with the AMR data. Community-associated: Infections that are contracted in the community, i.e. outside of a healthcare facility. Healthcare-associated: An infection occurring in a patient during the process of care in a hospital or other healthcare facility, which was not present or incubating at the time of admission. Healthcare-associated infections can also appear after discharge. Long-Term Care Facility (LTCF)-associated: An infection in a patient who is a resident at a LTCF. : Wound/tissue swab P. aeruginosa (carbapenem R and/or P) : Patient/case data available",
        "short_title": "Patient data available at national level. Carbapenem resistant P. aeruginosa - soft tisse.",
        "type": "MultipleChoice",
        "coefficient": 0.02,
        "tags": [
            "National surveillance",
            "P. aeruginosa",
            "soft tisse",
            "Carbapenem"
        ],
        "possible_answers": {
            "Age": 0.2,
            "Sex": 0.2,
            "Sample date": 0.2,
            "Geographic location of patent": 0.2,
            "Antibiotics administered /prescribed": 0.2,
            "Patient outcome (mortality)": 0.2,
            "Travel connection": 0.2,
            "Community-associated": 0.2,
            "Healthcare-associated": 0.2,
            "LTCF-associated": 0.2,
            "None of the listed patient/case data available": "null"
        },
        "actual_answers": {
            "Spain": [
                "None of the listed patient/case data available"
            ],
            "Austria": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Lithuania": [
                "None of the listed patient/case data available"
            ],
            "Croatia": [
                "None of the listed patient/case data available"
            ],
            "Netherlands": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Antibiotics administered /prescribed",
                "Travel connection",
                "Healthcare-associated"
            ],
            "Ireland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Germany": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Poland": [
                "None of the listed patient/case data available"
            ],
            "Italy": [
                "None of the listed patient/case data available"
            ],
            "Greece": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "France": [
                "Age",
                "Sample date",
                "Geographic location of patent",
                "Healthcare-associated"
            ],
            "Czechia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Belgium": [
                "None of the listed patient/case data available"
            ],
            "Hungary": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Finland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Luxembourg": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Malta": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Portugal": [
                ""
            ],
            "Norway": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Slovenia": [
                "None of the listed patient/case data available"
            ],
            "Estonia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Sweden": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Ukraine": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)",
                "Travel connection"
            ],
            "Latvia": [
                ""
            ],
            "Iceland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Bulgaria": [
                ""
            ]
        }
    },
    "41.21": {
        "title": "You answered \u201cyes to some patient/case information is available\u201d in the question above.  Which of the following patient/case information is available in your national AMR surveillance system(s)?  Please also select available if the data are in separate systems but regularly linked with the AMR data. Community-associated: Infections that are contracted in the community, i.e. outside of a healthcare facility. Healthcare-associated: An infection occurring in a patient during the process of care in a hospital or other healthcare facility, which was not present or incubating at the time of admission. Healthcare-associated infections can also appear after discharge. Long-Term Care Facility (LTCF)-associated: An infection in a patient who is a resident at a LTCF. : Wound/tissue swab A. baumanii (carbapenem R and/or P) : Patient/case data available",
        "short_title": "Patient data available at national level. Carbapenem resistant A. baumanii - soft tissue.",
        "type": "MultipleChoice",
        "coefficient": 0.02,
        "tags": [
            "National surveillance",
            "A. baumanii",
            "Soft tissue",
            "Carbapenem"
        ],
        "possible_answers": {
            "Age": 0.2,
            "Sex": 0.2,
            "Sample date": 0.2,
            "Geographic location of patent": 0.2,
            "Antibiotics administered /prescribed": 0.2,
            "Patient outcome (mortality)": 0.2,
            "Travel connection": 0.2,
            "Community-associated": 0.2,
            "Healthcare-associated": 0.2,
            "LTCF-associated": 0.2,
            "None of the listed patient/case data available": "null"
        },
        "actual_answers": {
            "Spain": [
                "None of the listed patient/case data available"
            ],
            "Austria": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Lithuania": [
                "None of the listed patient/case data available"
            ],
            "Croatia": [
                "None of the listed patient/case data available"
            ],
            "Netherlands": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Antibiotics administered /prescribed",
                "Travel connection",
                "Healthcare-associated"
            ],
            "Ireland": [
                "None of the listed patient/case data available"
            ],
            "Germany": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Poland": [
                "None of the listed patient/case data available"
            ],
            "Italy": [
                "None of the listed patient/case data available"
            ],
            "Greece": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "France": [
                "Age",
                "Sample date",
                "Geographic location of patent",
                "Healthcare-associated"
            ],
            "Czechia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Belgium": [
                "None of the listed patient/case data available"
            ],
            "Hungary": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Finland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Luxembourg": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Malta": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Portugal": [
                ""
            ],
            "Norway": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Slovenia": [
                "None of the listed patient/case data available"
            ],
            "Estonia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Sweden": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Ukraine": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Latvia": [
                ""
            ],
            "Iceland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Bulgaria": [
                ""
            ]
        }
    },
    "41.22": {
        "title": "You answered \u201cyes to some patient/case information is available\u201d in the question above.  Which of the following patient/case information is available in your national AMR surveillance system(s)?  Please also select available if the data are in separate systems but regularly linked with the AMR data. Community-associated: Infections that are contracted in the community, i.e. outside of a healthcare facility. Healthcare-associated: An infection occurring in a patient during the process of care in a hospital or other healthcare facility, which was not present or incubating at the time of admission. Healthcare-associated infections can also appear after discharge. Long-Term Care Facility (LTCF)-associated: An infection in a patient who is a resident at a LTCF. : Wound/tissue swab S. aureus (methicillin R) : Patient/case data available",
        "short_title": "Patient data available at national level. Methicillin resistant S. aureus - soft tissue.",
        "type": "MultipleChoice",
        "coefficient": 0.02,
        "tags": [
            "National surveillance",
            "S. aureus",
            "Soft tissue",
            "Methicillin"
        ],
        "possible_answers": {
            "Age": 0.2,
            "Sex": 0.2,
            "Sample date": 0.2,
            "Geographic location of patent": 0.2,
            "Antibiotics administered /prescribed": 0.2,
            "Patient outcome (mortality)": 0.2,
            "Travel connection": 0.2,
            "Community-associated": 0.2,
            "Healthcare-associated": 0.2,
            "LTCF-associated": 0.2,
            "None of the listed patient/case data available": "null"
        },
        "actual_answers": {
            "Spain": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Austria": [
                "None of the listed patient/case data available"
            ],
            "Lithuania": [
                "None of the listed patient/case data available"
            ],
            "Croatia": [
                "None of the listed patient/case data available"
            ],
            "Netherlands": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Ireland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Germany": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Poland": [
                "None of the listed patient/case data available"
            ],
            "Italy": [
                "None of the listed patient/case data available"
            ],
            "Greece": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "France": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Community-associated",
                "Healthcare-associated",
                "LTCF-associated"
            ],
            "Czechia": [
                "None of the listed patient/case data available"
            ],
            "Belgium": [
                "None of the listed patient/case data available"
            ],
            "Hungary": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Finland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Luxembourg": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Malta": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Portugal": [
                ""
            ],
            "Norway": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Slovenia": [
                "None of the listed patient/case data available"
            ],
            "Estonia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Sweden": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated",
                "LTCF-associated"
            ],
            "Ukraine": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated",
                "LTCF-associated"
            ],
            "Latvia": [
                ""
            ],
            "Iceland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Bulgaria": [
                ""
            ]
        }
    },
    "41.23": {
        "title": "You answered \u201cyes to some patient/case information is available\u201d in the question above.  Which of the following patient/case information is available in your national AMR surveillance system(s)?  Please also select available if the data are in separate systems but regularly linked with the AMR data. Community-associated: Infections that are contracted in the community, i.e. outside of a healthcare facility. Healthcare-associated: An infection occurring in a patient during the process of care in a hospital or other healthcare facility, which was not present or incubating at the time of admission. Healthcare-associated infections can also appear after discharge. Long-Term Care Facility (LTCF)-associated: An infection in a patient who is a resident at a LTCF. : Upper respiratory tract S. aureus (methicillin R) : Patient/case data available",
        "short_title": "Patient data available at national level. Methicillin resistant S. aureus - upper respiratory tract.",
        "type": "MultipleChoice",
        "coefficient": 0.02,
        "tags": [
            "National surveillance",
            "S. aureus",
            "Respiratory tract",
            "Methicillin"
        ],
        "possible_answers": {
            "Age": 0.2,
            "Sex": 0.2,
            "Sample date": 0.2,
            "Geographic location of patent": 0.2,
            "Antibiotics administered /prescribed": 0.2,
            "Patient outcome (mortality)": 0.2,
            "Travel connection": 0.2,
            "Community-associated": 0.2,
            "Healthcare-associated": 0.2,
            "LTCF-associated": 0.2,
            "None of the listed patient/case data available": "null"
        },
        "actual_answers": {
            "Spain": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Austria": [
                "None of the listed patient/case data available"
            ],
            "Lithuania": [
                "None of the listed patient/case data available"
            ],
            "Croatia": [
                "None of the listed patient/case data available"
            ],
            "Netherlands": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Ireland": [
                "None of the listed patient/case data available"
            ],
            "Germany": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Poland": [
                "None of the listed patient/case data available"
            ],
            "Italy": [
                "None of the listed patient/case data available"
            ],
            "Greece": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "France": [
                "Age",
                "Sample date",
                "Geographic location of patent",
                "Healthcare-associated"
            ],
            "Czechia": [
                "None of the listed patient/case data available"
            ],
            "Belgium": [
                "None of the listed patient/case data available"
            ],
            "Hungary": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Finland": [
                "Age",
                "Sex",
                "Sample date",
                "Travel connection"
            ],
            "Luxembourg": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Malta": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Portugal": [
                ""
            ],
            "Norway": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Slovenia": [
                "None of the listed patient/case data available"
            ],
            "Estonia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Sweden": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated",
                "LTCF-associated"
            ],
            "Ukraine": [
                "None of the listed patient/case data available"
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated",
                "LTCF-associated"
            ],
            "Latvia": [
                ""
            ],
            "Iceland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Bulgaria": [
                ""
            ]
        }
    },
    "41.24": {
        "title": "You answered \u201cyes to some patient/case information is available\u201d in the question above.  Which of the following patient/case information is available in your national AMR surveillance system(s)?  Please also select available if the data are in separate systems but regularly linked with the AMR data. Community-associated: Infections that are contracted in the community, i.e. outside of a healthcare facility. Healthcare-associated: An infection occurring in a patient during the process of care in a hospital or other healthcare facility, which was not present or incubating at the time of admission. Healthcare-associated infections can also appear after discharge. Long-Term Care Facility (LTCF)-associated: An infection in a patient who is a resident at a LTCF. : Upper respiratory tract S. pneumoniae (penicillin and macrolide R) : Patient/case data available",
        "short_title": "Patient data available at national level. Penicillin resistant S. pneumoniae - upper respiratory tract.",
        "type": "MultipleChoice",
        "coefficient": 0.02,
        "tags": [
            "National surveillance",
            "S. pneumoniae",
            "Respiratory tract",
            "Penicillin"
        ],
        "possible_answers": {
            "Age": 0.2,
            "Sex": 0.2,
            "Sample date": 0.2,
            "Geographic location of patent": 0.2,
            "Antibiotics administered /prescribed": 0.2,
            "Patient outcome (mortality)": 0.2,
            "Travel connection": 0.2,
            "Community-associated": 0.2,
            "Healthcare-associated": 0.2,
            "LTCF-associated": 0.2,
            "None of the listed patient/case data available": "null"
        },
        "actual_answers": {
            "Spain": [
                "None of the listed patient/case data available"
            ],
            "Austria": [
                "None of the listed patient/case data available"
            ],
            "Lithuania": [
                "None of the listed patient/case data available"
            ],
            "Croatia": [
                "None of the listed patient/case data available"
            ],
            "Netherlands": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Ireland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Germany": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Poland": [
                "None of the listed patient/case data available"
            ],
            "Italy": [
                "None of the listed patient/case data available"
            ],
            "Greece": [
                "None of the listed patient/case data available"
            ],
            "France": [
                "Age",
                "Sample date",
                "Geographic location of patent",
                "Healthcare-associated"
            ],
            "Czechia": [
                "Age",
                "Geographic location of patent",
                "Community-associated"
            ],
            "Belgium": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Hungary": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Finland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Luxembourg": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Malta": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Portugal": [
                ""
            ],
            "Norway": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Slovenia": [
                "None of the listed patient/case data available"
            ],
            "Estonia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Sweden": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Ukraine": [
                "None of the listed patient/case data available"
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Latvia": [
                ""
            ],
            "Iceland": [
                "None of the listed patient/case data available"
            ],
            "Bulgaria": [
                ""
            ]
        }
    },
    "41.25": {
        "title": "You answered \u201cyes to some patient/case information is available\u201d in the question above.  Which of the following patient/case information is available in your national AMR surveillance system(s)?  Please also select available if the data are in separate systems but regularly linked with the AMR data. Community-associated: Infections that are contracted in the community, i.e. outside of a healthcare facility. Healthcare-associated: An infection occurring in a patient during the process of care in a hospital or other healthcare facility, which was not present or incubating at the time of admission. Healthcare-associated infections can also appear after discharge. Long-Term Care Facility (LTCF)-associated: An infection in a patient who is a resident at a LTCF. : Upper respiratory tract H. influenzae (ampicillin- R) : Patient/case data available",
        "short_title": "Patient data available at national level. Ampicillin resistant H. influenzae - upper respiratory tract.",
        "type": "MultipleChoice",
        "coefficient": 0.02,
        "tags": [
            "National surveillance",
            "H. influenzae",
            "Respiratory tract",
            "Ampicillin"
        ],
        "possible_answers": {
            "Age": 0.2,
            "Sex": 0.2,
            "Sample date": 0.2,
            "Geographic location of patent": 0.2,
            "Antibiotics administered /prescribed": 0.2,
            "Patient outcome (mortality)": 0.2,
            "Travel connection": 0.2,
            "Community-associated": 0.2,
            "Healthcare-associated": 0.2,
            "LTCF-associated": 0.2,
            "None of the listed patient/case data available": "null"
        },
        "actual_answers": {
            "Spain": [
                "None of the listed patient/case data available"
            ],
            "Austria": [
                "None of the listed patient/case data available"
            ],
            "Lithuania": [
                "None of the listed patient/case data available"
            ],
            "Croatia": [
                "None of the listed patient/case data available"
            ],
            "Netherlands": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Ireland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Germany": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Poland": [
                "None of the listed patient/case data available"
            ],
            "Italy": [
                "None of the listed patient/case data available"
            ],
            "Greece": [
                "None of the listed patient/case data available"
            ],
            "France": [
                "None of the listed patient/case data available"
            ],
            "Czechia": [
                "Age",
                "Geographic location of patent",
                "Community-associated"
            ],
            "Belgium": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)",
                "Travel connection"
            ],
            "Hungary": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Finland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Luxembourg": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Malta": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Portugal": [
                ""
            ],
            "Norway": [
                "None of the listed patient/case data available"
            ],
            "Slovenia": [
                "None of the listed patient/case data available"
            ],
            "Estonia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Sweden": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Ukraine": [
                "None of the listed patient/case data available"
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Latvia": [
                ""
            ],
            "Iceland": [
                "None of the listed patient/case data available"
            ],
            "Bulgaria": [
                ""
            ]
        }
    },
    "41.26": {
        "title": "You answered \u201cyes to some patient/case information is available\u201d in the question above.  Which of the following patient/case information is available in your national AMR surveillance system(s)?  Please also select available if the data are in separate systems but regularly linked with the AMR data. Community-associated: Infections that are contracted in the community, i.e. outside of a healthcare facility. Healthcare-associated: An infection occurring in a patient during the process of care in a hospital or other healthcare facility, which was not present or incubating at the time of admission. Healthcare-associated infections can also appear after discharge. Long-Term Care Facility (LTCF)-associated: An infection in a patient who is a resident at a LTCF. : Lower respiratory tract E. coli (carbapenem R and/or P) : Patient/case data available",
        "short_title": "Patient data available at national level. Carbapenem resistant E. coli - lower respiratory tract.",
        "type": "MultipleChoice",
        "coefficient": 0.02,
        "tags": [
            "National surveillance",
            "E. coli",
            "Respiratory tract",
            "Carbapenem"
        ],
        "possible_answers": {
            "Age": 0.2,
            "Sex": 0.2,
            "Sample date": 0.2,
            "Geographic location of patent": 0.2,
            "Antibiotics administered /prescribed": 0.2,
            "Patient outcome (mortality)": 0.2,
            "Travel connection": 0.2,
            "Community-associated": 0.2,
            "Healthcare-associated": 0.2,
            "LTCF-associated": 0.2,
            "None of the listed patient/case data available": "null"
        },
        "actual_answers": {
            "Spain": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Austria": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Lithuania": [
                "None of the listed patient/case data available"
            ],
            "Croatia": [
                "None of the listed patient/case data available"
            ],
            "Netherlands": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Healthcare-associated"
            ],
            "Ireland": [
                "None of the listed patient/case data available"
            ],
            "Germany": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Poland": [
                "None of the listed patient/case data available"
            ],
            "Italy": [
                "None of the listed patient/case data available"
            ],
            "Greece": [
                "None of the listed patient/case data available"
            ],
            "France": [
                "Age",
                "Sample date",
                "Geographic location of patent",
                "Healthcare-associated"
            ],
            "Czechia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Belgium": [
                "None of the listed patient/case data available"
            ],
            "Hungary": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Finland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Luxembourg": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Malta": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Portugal": [
                ""
            ],
            "Norway": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Slovenia": [
                "None of the listed patient/case data available"
            ],
            "Estonia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Sweden": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated",
                "LTCF-associated"
            ],
            "Ukraine": [
                "None of the listed patient/case data available"
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Latvia": [
                ""
            ],
            "Iceland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Bulgaria": [
                ""
            ]
        }
    },
    "41.27": {
        "title": "You answered \u201cyes to some patient/case information is available\u201d in the question above.  Which of the following patient/case information is available in your national AMR surveillance system(s)?  Please also select available if the data are in separate systems but regularly linked with the AMR data. Community-associated: Infections that are contracted in the community, i.e. outside of a healthcare facility. Healthcare-associated: An infection occurring in a patient during the process of care in a hospital or other healthcare facility, which was not present or incubating at the time of admission. Healthcare-associated infections can also appear after discharge. Long-Term Care Facility (LTCF)-associated: An infection in a patient who is a resident at a LTCF. : Lower respiratory tract E. coli (3GC- R and/or P) : Patient/case data available",
        "short_title": "Patient data available at national level. 3rd-generation cephalosporins resistant E. coli - lower respiratory tract.",
        "type": "MultipleChoice",
        "coefficient": 0.02,
        "tags": [
            "National surveillance",
            "E. coli",
            "Respiratory tract",
            "3rd-generation Cephalosporin"
        ],
        "possible_answers": {
            "Age": 0.2,
            "Sex": 0.2,
            "Sample date": 0.2,
            "Geographic location of patent": 0.2,
            "Antibiotics administered /prescribed": 0.2,
            "Patient outcome (mortality)": 0.2,
            "Travel connection": 0.2,
            "Community-associated": 0.2,
            "Healthcare-associated": 0.2,
            "LTCF-associated": 0.2,
            "None of the listed patient/case data available": "null"
        },
        "actual_answers": {
            "Spain": [
                "None of the listed patient/case data available"
            ],
            "Austria": [
                "None of the listed patient/case data available"
            ],
            "Lithuania": [
                "None of the listed patient/case data available"
            ],
            "Croatia": [
                "None of the listed patient/case data available"
            ],
            "Netherlands": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Ireland": [
                "None of the listed patient/case data available"
            ],
            "Germany": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Poland": [
                "None of the listed patient/case data available"
            ],
            "Italy": [
                "None of the listed patient/case data available"
            ],
            "Greece": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "France": [
                "Age",
                "Sample date",
                "Geographic location of patent",
                "Healthcare-associated"
            ],
            "Czechia": [
                "None of the listed patient/case data available"
            ],
            "Belgium": [
                "None of the listed patient/case data available"
            ],
            "Hungary": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Finland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Luxembourg": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Malta": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Portugal": [
                ""
            ],
            "Norway": [
                "None of the listed patient/case data available"
            ],
            "Slovenia": [
                "None of the listed patient/case data available"
            ],
            "Estonia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Sweden": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Ukraine": [
                "None of the listed patient/case data available"
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Latvia": [
                ""
            ],
            "Iceland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Bulgaria": [
                ""
            ]
        }
    },
    "41.28": {
        "title": "You answered \u201cyes to some patient/case information is available\u201d in the question above.  Which of the following patient/case information is available in your national AMR surveillance system(s)?  Please also select available if the data are in separate systems but regularly linked with the AMR data. Community-associated: Infections that are contracted in the community, i.e. outside of a healthcare facility. Healthcare-associated: An infection occurring in a patient during the process of care in a hospital or other healthcare facility, which was not present or incubating at the time of admission. Healthcare-associated infections can also appear after discharge. Long-Term Care Facility (LTCF)-associated: An infection in a patient who is a resident at a LTCF. : Lower respiratory tract E. coli (colistin R) : Patient/case data available",
        "short_title": "Patient data available at national level. Colistin resistant E. coli - lower respiratory tract.",
        "type": "MultipleChoice",
        "coefficient": 0.02,
        "tags": [
            "National surveillance",
            "E. coli",
            "Respiratory tract",
            "Colistin"
        ],
        "possible_answers": {
            "Age": 0.2,
            "Sex": 0.2,
            "Sample date": 0.2,
            "Geographic location of patent": 0.2,
            "Antibiotics administered /prescribed": 0.2,
            "Patient outcome (mortality)": 0.2,
            "Travel connection": 0.2,
            "Community-associated": 0.2,
            "Healthcare-associated": 0.2,
            "LTCF-associated": 0.2,
            "None of the listed patient/case data available": "null"
        },
        "actual_answers": {
            "Spain": [
                "None of the listed patient/case data available"
            ],
            "Austria": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Lithuania": [
                "None of the listed patient/case data available"
            ],
            "Croatia": [
                "None of the listed patient/case data available"
            ],
            "Netherlands": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Ireland": [
                "None of the listed patient/case data available"
            ],
            "Germany": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Poland": [
                "None of the listed patient/case data available"
            ],
            "Italy": [
                "None of the listed patient/case data available"
            ],
            "Greece": [
                "None of the listed patient/case data available"
            ],
            "France": [
                "Age",
                "Sample date",
                "Geographic location of patent",
                "Healthcare-associated"
            ],
            "Czechia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Belgium": [
                "None of the listed patient/case data available"
            ],
            "Hungary": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Finland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Luxembourg": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Malta": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Portugal": [
                ""
            ],
            "Norway": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Antibiotics administered /prescribed",
                "Travel connection"
            ],
            "Slovenia": [
                "None of the listed patient/case data available"
            ],
            "Estonia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Sweden": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Ukraine": [
                "None of the listed patient/case data available"
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Latvia": [
                ""
            ],
            "Iceland": [
                "None of the listed patient/case data available"
            ],
            "Bulgaria": [
                ""
            ]
        }
    },
    "41.29": {
        "title": "You answered \u201cyes to some patient/case information is available\u201d in the question above.  Which of the following patient/case information is available in your national AMR surveillance system(s)?  Please also select available if the data are in separate systems but regularly linked with the AMR data. Community-associated: Infections that are contracted in the community, i.e. outside of a healthcare facility. Healthcare-associated: An infection occurring in a patient during the process of care in a hospital or other healthcare facility, which was not present or incubating at the time of admission. Healthcare-associated infections can also appear after discharge. Long-Term Care Facility (LTCF)-associated: An infection in a patient who is a resident at a LTCF. : Lower respiratory tract K. pneumoniae (carbapenem R and/or P) : Patient/case data available",
        "short_title": "Patient data available at national level. Carbapenem resistant K. pneumoniae - lower respiratory tract.",
        "type": "MultipleChoice",
        "coefficient": 0.02,
        "tags": [
            "National surveillance",
            "K. pneumoniae",
            "Respiratory tract",
            "Carbapenem"
        ],
        "possible_answers": {
            "Age": 0.2,
            "Sex": 0.2,
            "Sample date": 0.2,
            "Geographic location of patent": 0.2,
            "Antibiotics administered /prescribed": 0.2,
            "Patient outcome (mortality)": 0.2,
            "Travel connection": 0.2,
            "Community-associated": 0.2,
            "Healthcare-associated": 0.2,
            "LTCF-associated": 0.2,
            "None of the listed patient/case data available": "null"
        },
        "actual_answers": {
            "Spain": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Austria": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Lithuania": [
                "None of the listed patient/case data available"
            ],
            "Croatia": [
                "None of the listed patient/case data available"
            ],
            "Netherlands": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Healthcare-associated"
            ],
            "Ireland": [
                "None of the listed patient/case data available"
            ],
            "Germany": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Poland": [
                "None of the listed patient/case data available"
            ],
            "Italy": [
                "None of the listed patient/case data available"
            ],
            "Greece": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "France": [
                "Age",
                "Sample date",
                "Geographic location of patent",
                "Healthcare-associated"
            ],
            "Czechia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Belgium": [
                "None of the listed patient/case data available"
            ],
            "Hungary": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Finland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Luxembourg": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Malta": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Portugal": [
                ""
            ],
            "Norway": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Slovenia": [
                "None of the listed patient/case data available"
            ],
            "Estonia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Sweden": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated",
                "LTCF-associated"
            ],
            "Ukraine": [
                "None of the listed patient/case data available"
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Latvia": [
                ""
            ],
            "Iceland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Bulgaria": [
                ""
            ]
        }
    },
    "41.30": {
        "title": "You answered \u201cyes to some patient/case information is available\u201d in the question above.  Which of the following patient/case information is available in your national AMR surveillance system(s)?  Please also select available if the data are in separate systems but regularly linked with the AMR data. Community-associated: Infections that are contracted in the community, i.e. outside of a healthcare facility. Healthcare-associated: An infection occurring in a patient during the process of care in a hospital or other healthcare facility, which was not present or incubating at the time of admission. Healthcare-associated infections can also appear after discharge. Long-Term Care Facility (LTCF)-associated: An infection in a patient who is a resident at a LTCF. : Lower respiratory tract K. pneumoniae (3GC- R and/or P) : Patient/case data available",
        "short_title": "Patient data available at national level. 3rd-generation cephalosporins resistant K. pneumoniae - lower respiratory tract.",
        "type": "MultipleChoice",
        "coefficient": 0.02,
        "tags": [
            "National surveillance",
            "K. pneumoniae",
            "Respiratory tract",
            "3rd-generation Cephalosporin"
        ],
        "possible_answers": {
            "Age": 0.2,
            "Sex": 0.2,
            "Sample date": 0.2,
            "Geographic location of patent": 0.2,
            "Antibiotics administered /prescribed": 0.2,
            "Patient outcome (mortality)": 0.2,
            "Travel connection": 0.2,
            "Community-associated": 0.2,
            "Healthcare-associated": 0.2,
            "LTCF-associated": 0.2,
            "None of the listed patient/case data available": "null"
        },
        "actual_answers": {
            "Spain": [
                "None of the listed patient/case data available"
            ],
            "Austria": [
                "None of the listed patient/case data available"
            ],
            "Lithuania": [
                "None of the listed patient/case data available"
            ],
            "Croatia": [
                "None of the listed patient/case data available"
            ],
            "Netherlands": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Ireland": [
                "None of the listed patient/case data available"
            ],
            "Germany": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Poland": [
                "None of the listed patient/case data available"
            ],
            "Italy": [
                "None of the listed patient/case data available"
            ],
            "Greece": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "France": [
                "Age",
                "Sample date",
                "Geographic location of patent",
                "Healthcare-associated"
            ],
            "Czechia": [
                "None of the listed patient/case data available"
            ],
            "Belgium": [
                "None of the listed patient/case data available"
            ],
            "Hungary": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Finland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Luxembourg": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Malta": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Portugal": [
                ""
            ],
            "Norway": [
                "None of the listed patient/case data available"
            ],
            "Slovenia": [
                "None of the listed patient/case data available"
            ],
            "Estonia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Sweden": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Ukraine": [
                "None of the listed patient/case data available"
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Latvia": [
                ""
            ],
            "Iceland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Bulgaria": [
                ""
            ]
        }
    },
    "41.31": {
        "title": "You answered \u201cyes to some patient/case information is available\u201d in the question above.  Which of the following patient/case information is available in your national AMR surveillance system(s)?  Please also select available if the data are in separate systems but regularly linked with the AMR data. Community-associated: Infections that are contracted in the community, i.e. outside of a healthcare facility. Healthcare-associated: An infection occurring in a patient during the process of care in a hospital or other healthcare facility, which was not present or incubating at the time of admission. Healthcare-associated infections can also appear after discharge. Long-Term Care Facility (LTCF)-associated: An infection in a patient who is a resident at a LTCF. : Lower respiratory tract K. pneumoniae (colistin R) : Patient/case data available",
        "short_title": "Patient data available at national level. Colistin resistant K. pneumoniae - lower respiratory tract.",
        "type": "MultipleChoice",
        "coefficient": 0.02,
        "tags": [
            "National surveillance",
            "K. pneumoniae",
            "Respiratory tract",
            "Colistin"
        ],
        "possible_answers": {
            "Age": 0.2,
            "Sex": 0.2,
            "Sample date": 0.2,
            "Geographic location of patent": 0.2,
            "Antibiotics administered /prescribed": 0.2,
            "Patient outcome (mortality)": 0.2,
            "Travel connection": 0.2,
            "Community-associated": 0.2,
            "Healthcare-associated": 0.2,
            "LTCF-associated": 0.2,
            "None of the listed patient/case data available": "null"
        },
        "actual_answers": {
            "Spain": [
                "None of the listed patient/case data available"
            ],
            "Austria": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Lithuania": [
                "None of the listed patient/case data available"
            ],
            "Croatia": [
                "None of the listed patient/case data available"
            ],
            "Netherlands": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Ireland": [
                "None of the listed patient/case data available"
            ],
            "Germany": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Poland": [
                "None of the listed patient/case data available"
            ],
            "Italy": [
                "None of the listed patient/case data available"
            ],
            "Greece": [
                "None of the listed patient/case data available"
            ],
            "France": [
                "Age",
                "Sample date",
                "Geographic location of patent",
                "Healthcare-associated"
            ],
            "Czechia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Belgium": [
                "None of the listed patient/case data available"
            ],
            "Hungary": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Finland": [
                "None of the listed patient/case data available"
            ],
            "Luxembourg": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Malta": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Portugal": [
                ""
            ],
            "Norway": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Slovenia": [
                "None of the listed patient/case data available"
            ],
            "Estonia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Sweden": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Ukraine": [
                "None of the listed patient/case data available"
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Latvia": [
                ""
            ],
            "Iceland": [
                "None of the listed patient/case data available"
            ],
            "Bulgaria": [
                ""
            ]
        }
    },
    "41.32": {
        "title": "You answered \u201cyes to some patient/case information is available\u201d in the question above.  Which of the following patient/case information is available in your national AMR surveillance system(s)?  Please also select available if the data are in separate systems but regularly linked with the AMR data. Community-associated: Infections that are contracted in the community, i.e. outside of a healthcare facility. Healthcare-associated: An infection occurring in a patient during the process of care in a hospital or other healthcare facility, which was not present or incubating at the time of admission. Healthcare-associated infections can also appear after discharge. Long-Term Care Facility (LTCF)-associated: An infection in a patient who is a resident at a LTCF. : Lower respiratory tract P. aeruginosa (carbapenem R and/or P) : Patient/case data available",
        "short_title": "Patient data available at national level. Carbapenem resistant P. aeruginosa - lower respiratory tract.",
        "type": "MultipleChoice",
        "coefficient": 0.02,
        "tags": [
            "National surveillance",
            "P. aeruginosa",
            "Respiratory tract",
            "Carbapenem"
        ],
        "possible_answers": {
            "Age": 0.2,
            "Sex": 0.2,
            "Sample date": 0.2,
            "Geographic location of patent": 0.2,
            "Antibiotics administered /prescribed": 0.2,
            "Patient outcome (mortality)": 0.2,
            "Travel connection": 0.2,
            "Community-associated": 0.2,
            "Healthcare-associated": 0.2,
            "LTCF-associated": 0.2,
            "None of the listed patient/case data available": "null"
        },
        "actual_answers": {
            "Spain": [
                "None of the listed patient/case data available"
            ],
            "Austria": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Lithuania": [
                "None of the listed patient/case data available"
            ],
            "Croatia": [
                "None of the listed patient/case data available"
            ],
            "Netherlands": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Antibiotics administered /prescribed",
                "Travel connection",
                "Healthcare-associated"
            ],
            "Ireland": [
                "None of the listed patient/case data available"
            ],
            "Germany": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Poland": [
                "None of the listed patient/case data available"
            ],
            "Italy": [
                "None of the listed patient/case data available"
            ],
            "Greece": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "France": [
                "Age",
                "Sample date",
                "Geographic location of patent",
                "Healthcare-associated"
            ],
            "Czechia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Belgium": [
                "None of the listed patient/case data available"
            ],
            "Hungary": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Finland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Luxembourg": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Malta": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Portugal": [
                ""
            ],
            "Norway": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Slovenia": [
                "None of the listed patient/case data available"
            ],
            "Estonia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Sweden": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Ukraine": [
                "None of the listed patient/case data available"
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Latvia": [
                ""
            ],
            "Iceland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Bulgaria": [
                ""
            ]
        }
    },
    "41.33": {
        "title": "You answered \u201cyes to some patient/case information is available\u201d in the question above.  Which of the following patient/case information is available in your national AMR surveillance system(s)?  Please also select available if the data are in separate systems but regularly linked with the AMR data. Community-associated: Infections that are contracted in the community, i.e. outside of a healthcare facility. Healthcare-associated: An infection occurring in a patient during the process of care in a hospital or other healthcare facility, which was not present or incubating at the time of admission. Healthcare-associated infections can also appear after discharge. Long-Term Care Facility (LTCF)-associated: An infection in a patient who is a resident at a LTCF. : Lower respiratory tract S. aureus (methicillin R) : Patient/case data available",
        "short_title": "Patient data available at national level. Methicillin resistant S. aureus - lower respiratory tract.",
        "type": "MultipleChoice",
        "coefficient": 0.02,
        "tags": [
            "National surveillance",
            "S. aureus",
            "Respiratory tract",
            "Methicillin"
        ],
        "possible_answers": {
            "Age": 0.2,
            "Sex": 0.2,
            "Sample date": 0.2,
            "Geographic location of patent": 0.2,
            "Antibiotics administered /prescribed": 0.2,
            "Patient outcome (mortality)": 0.2,
            "Travel connection": 0.2,
            "Community-associated": 0.2,
            "Healthcare-associated": 0.2,
            "LTCF-associated": 0.2,
            "None of the listed patient/case data available": "null"
        },
        "actual_answers": {
            "Spain": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Austria": [
                "None of the listed patient/case data available"
            ],
            "Lithuania": [
                "None of the listed patient/case data available"
            ],
            "Croatia": [
                "None of the listed patient/case data available"
            ],
            "Netherlands": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Ireland": [
                "None of the listed patient/case data available"
            ],
            "Germany": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Poland": [
                "None of the listed patient/case data available"
            ],
            "Italy": [
                "None of the listed patient/case data available"
            ],
            "Greece": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "France": [
                "Age",
                "Sample date",
                "Geographic location of patent",
                "Healthcare-associated"
            ],
            "Czechia": [
                "None of the listed patient/case data available"
            ],
            "Belgium": [
                "None of the listed patient/case data available"
            ],
            "Hungary": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Finland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Luxembourg": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Malta": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Portugal": [
                ""
            ],
            "Norway": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Slovenia": [
                "None of the listed patient/case data available"
            ],
            "Estonia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Sweden": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated",
                "LTCF-associated"
            ],
            "Ukraine": [
                "None of the listed patient/case data available"
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated",
                "LTCF-associated"
            ],
            "Latvia": [
                ""
            ],
            "Iceland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Bulgaria": [
                ""
            ]
        }
    },
    "41.34": {
        "title": "You answered \u201cyes to some patient/case information is available\u201d in the question above.  Which of the following patient/case information is available in your national AMR surveillance system(s)?  Please also select available if the data are in separate systems but regularly linked with the AMR data. Community-associated: Infections that are contracted in the community, i.e. outside of a healthcare facility. Healthcare-associated: An infection occurring in a patient during the process of care in a hospital or other healthcare facility, which was not present or incubating at the time of admission. Healthcare-associated infections can also appear after discharge. Long-Term Care Facility (LTCF)-associated: An infection in a patient who is a resident at a LTCF. : Lower respiratory tract S. pneumoniae (penicillin and macrolide R) : Patient/case data available",
        "short_title": "Patient data available at national level. Penicillin resistant S. pneumoniae - lower respiratory tract.",
        "type": "MultipleChoice",
        "coefficient": 0.02,
        "tags": [
            "National surveillance",
            "S. pneumoniae",
            "Respiratory tract",
            "Penicillin"
        ],
        "possible_answers": {
            "Age": 0.2,
            "Sex": 0.2,
            "Sample date": 0.2,
            "Geographic location of patent": 0.2,
            "Antibiotics administered /prescribed": 0.2,
            "Patient outcome (mortality)": 0.2,
            "Travel connection": 0.2,
            "Community-associated": 0.2,
            "Healthcare-associated": 0.2,
            "LTCF-associated": 0.2,
            "None of the listed patient/case data available": "null"
        },
        "actual_answers": {
            "Spain": [
                "None of the listed patient/case data available"
            ],
            "Austria": [
                "None of the listed patient/case data available"
            ],
            "Lithuania": [
                "None of the listed patient/case data available"
            ],
            "Croatia": [
                "None of the listed patient/case data available"
            ],
            "Netherlands": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Ireland": [
                "None of the listed patient/case data available"
            ],
            "Germany": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Poland": [
                "None of the listed patient/case data available"
            ],
            "Italy": [
                "None of the listed patient/case data available"
            ],
            "Greece": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "France": [
                "Age",
                "Sample date",
                "Geographic location of patent"
            ],
            "Czechia": [
                "Age",
                "Geographic location of patent",
                "Community-associated"
            ],
            "Belgium": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Hungary": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Finland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Luxembourg": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Malta": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Portugal": [
                ""
            ],
            "Norway": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Slovenia": [
                "None of the listed patient/case data available"
            ],
            "Estonia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Sweden": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Ukraine": [
                "None of the listed patient/case data available"
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Latvia": [
                ""
            ],
            "Iceland": [
                "None of the listed patient/case data available"
            ],
            "Bulgaria": [
                ""
            ]
        }
    },
    "41.35": {
        "title": "You answered \u201cyes to some patient/case information is available\u201d in the question above.  Which of the following patient/case information is available in your national AMR surveillance system(s)?  Please also select available if the data are in separate systems but regularly linked with the AMR data. Community-associated: Infections that are contracted in the community, i.e. outside of a healthcare facility. Healthcare-associated: An infection occurring in a patient during the process of care in a hospital or other healthcare facility, which was not present or incubating at the time of admission. Healthcare-associated infections can also appear after discharge. Long-Term Care Facility (LTCF)-associated: An infection in a patient who is a resident at a LTCF. : Lower respiratory tract H. influenzae (ampicillin- R) : Patient/case data available",
        "short_title": "Patient data available at national level. Ampicillin resistant H. influenzae - lower respiratory tract.",
        "type": "MultipleChoice",
        "coefficient": 0.02,
        "tags": [
            "National surveillance",
            "H. influenzae",
            "Respiratory tract",
            "Ampicillin"
        ],
        "possible_answers": {
            "Age": 0.2,
            "Sex": 0.2,
            "Sample date": 0.2,
            "Geographic location of patent": 0.2,
            "Antibiotics administered /prescribed": 0.2,
            "Patient outcome (mortality)": 0.2,
            "Travel connection": 0.2,
            "Community-associated": 0.2,
            "Healthcare-associated": 0.2,
            "LTCF-associated": 0.2,
            "None of the listed patient/case data available": "null"
        },
        "actual_answers": {
            "Spain": [
                "None of the listed patient/case data available"
            ],
            "Austria": [
                "None of the listed patient/case data available"
            ],
            "Lithuania": [
                "None of the listed patient/case data available"
            ],
            "Croatia": [
                "None of the listed patient/case data available"
            ],
            "Netherlands": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Ireland": [
                "None of the listed patient/case data available"
            ],
            "Germany": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Poland": [
                "None of the listed patient/case data available"
            ],
            "Italy": [
                "None of the listed patient/case data available"
            ],
            "Greece": [
                "None of the listed patient/case data available"
            ],
            "France": [
                "None of the listed patient/case data available"
            ],
            "Czechia": [
                "Age",
                "Geographic location of patent",
                "Community-associated"
            ],
            "Belgium": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)",
                "Travel connection"
            ],
            "Hungary": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Finland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Luxembourg": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Malta": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Portugal": [
                ""
            ],
            "Norway": [
                "None of the listed patient/case data available"
            ],
            "Slovenia": [
                "None of the listed patient/case data available"
            ],
            "Estonia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Sweden": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Ukraine": [
                "None of the listed patient/case data available"
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Latvia": [
                ""
            ],
            "Iceland": [
                "None of the listed patient/case data available"
            ],
            "Bulgaria": [
                ""
            ]
        }
    },
    "41.36": {
        "title": "You answered \u201cyes to some patient/case information is available\u201d in the question above.  Which of the following patient/case information is available in your national AMR surveillance system(s)?  Please also select available if the data are in separate systems but regularly linked with the AMR data. Community-associated: Infections that are contracted in the community, i.e. outside of a healthcare facility. Healthcare-associated: An infection occurring in a patient during the process of care in a hospital or other healthcare facility, which was not present or incubating at the time of admission. Healthcare-associated infections can also appear after discharge. Long-Term Care Facility (LTCF)-associated: An infection in a patient who is a resident at a LTCF. : Diarrhea/stool sample C. difficile : Patient/case data available",
        "short_title": "Patient data available at national level. C. difficile - stool.",
        "type": "MultipleChoice",
        "coefficient": 0.02,
        "tags": [
            "National surveillance",
            "C. difficile",
            "Stool"
        ],
        "possible_answers": {
            "Age": 0.2,
            "Sex": 0.2,
            "Sample date": 0.2,
            "Geographic location of patent": 0.2,
            "Antibiotics administered /prescribed": 0.2,
            "Patient outcome (mortality)": 0.2,
            "Travel connection": 0.2,
            "Community-associated": 0.2,
            "Healthcare-associated": 0.2,
            "LTCF-associated": 0.2,
            "None of the listed patient/case data available": "null"
        },
        "actual_answers": {
            "Spain": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Austria": [
                ""
            ],
            "Lithuania": [
                "Age",
                "Sample date",
                "Geographic location of patent"
            ],
            "Croatia": [
                "None of the listed patient/case data available"
            ],
            "Netherlands": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Antibiotics administered /prescribed",
                "Patient outcome (mortality)",
                "Community-associated",
                "Healthcare-associated",
                "LTCF-associated"
            ],
            "Ireland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Germany": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Poland": [
                "None of the listed patient/case data available"
            ],
            "Italy": [
                "None of the listed patient/case data available"
            ],
            "Greece": [
                "None of the listed patient/case data available"
            ],
            "France": [
                "None of the listed patient/case data available"
            ],
            "Czechia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Antibiotics administered /prescribed",
                "Patient outcome (mortality)",
                "Community-associated",
                "Healthcare-associated",
                "LTCF-associated"
            ],
            "Belgium": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)",
                "Community-associated",
                "Healthcare-associated",
                "LTCF-associated"
            ],
            "Hungary": [
                "None of the listed patient/case data available"
            ],
            "Finland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Luxembourg": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Malta": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Portugal": [
                ""
            ],
            "Norway": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Slovenia": [
                "None of the listed patient/case data available"
            ],
            "Estonia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Sweden": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Ukraine": [
                "None of the listed patient/case data available"
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Latvia": [
                ""
            ],
            "Iceland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Bulgaria": [
                ""
            ]
        }
    },
    "41.37": {
        "title": "You answered \u201cyes to some patient/case information is available\u201d in the question above.  Which of the following patient/case information is available in your national AMR surveillance system(s)?  Please also select available if the data are in separate systems but regularly linked with the AMR data. Community-associated: Infections that are contracted in the community, i.e. outside of a healthcare facility. Healthcare-associated: An infection occurring in a patient during the process of care in a hospital or other healthcare facility, which was not present or incubating at the time of admission. Healthcare-associated infections can also appear after discharge. Long-Term Care Facility (LTCF)-associated: An infection in a patient who is a resident at a LTCF. : Screening E. coli (carbapenem R and/or P) : Patient/case data available",
        "short_title": "Patient data available at national level. Carbapenem resistant E. coli - screening.",
        "type": "MultipleChoice",
        "coefficient": 0.02,
        "tags": [
            "National surveillance",
            "E. coli",
            "Screening",
            "Carbapenem"
        ],
        "possible_answers": {
            "Age": 0.2,
            "Sex": 0.2,
            "Sample date": 0.2,
            "Geographic location of patent": 0.2,
            "Antibiotics administered /prescribed": 0.2,
            "Patient outcome (mortality)": 0.2,
            "Travel connection": 0.2,
            "Community-associated": 0.2,
            "Healthcare-associated": 0.2,
            "LTCF-associated": 0.2,
            "None of the listed patient/case data available": "null"
        },
        "actual_answers": {
            "Spain": [
                "None of the listed patient/case data available"
            ],
            "Austria": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Lithuania": [
                "None of the listed patient/case data available"
            ],
            "Croatia": [
                "None of the listed patient/case data available"
            ],
            "Netherlands": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Healthcare-associated"
            ],
            "Ireland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Germany": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Poland": [
                "None of the listed patient/case data available"
            ],
            "Italy": [
                "None of the listed patient/case data available"
            ],
            "Greece": [
                "None of the listed patient/case data available"
            ],
            "France": [
                "None of the listed patient/case data available"
            ],
            "Czechia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Belgium": [
                "Age",
                "Sex",
                "Sample date"
            ],
            "Hungary": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Finland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Luxembourg": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Malta": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Portugal": [
                ""
            ],
            "Norway": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Slovenia": [
                "None of the listed patient/case data available"
            ],
            "Estonia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Sweden": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated",
                "LTCF-associated"
            ],
            "Ukraine": [
                "None of the listed patient/case data available"
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Latvia": [
                ""
            ],
            "Iceland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Bulgaria": [
                ""
            ]
        }
    },
    "41.38": {
        "title": "You answered \u201cyes to some patient/case information is available\u201d in the question above.  Which of the following patient/case information is available in your national AMR surveillance system(s)?  Please also select available if the data are in separate systems but regularly linked with the AMR data. Community-associated: Infections that are contracted in the community, i.e. outside of a healthcare facility. Healthcare-associated: An infection occurring in a patient during the process of care in a hospital or other healthcare facility, which was not present or incubating at the time of admission. Healthcare-associated infections can also appear after discharge. Long-Term Care Facility (LTCF)-associated: An infection in a patient who is a resident at a LTCF. : Screening E. coli (3GC- R and/or P) : Patient/case data available",
        "short_title": "Patient data available at national level. 3rd-generation cephalosporins resistant E. coli - screening.",
        "type": "MultipleChoice",
        "coefficient": 0.02,
        "tags": [
            "National surveillance",
            "E. coli",
            "Screening",
            "3rd-generation Cephalosporin"
        ],
        "possible_answers": {
            "Age": 0.2,
            "Sex": 0.2,
            "Sample date": 0.2,
            "Geographic location of patent": 0.2,
            "Antibiotics administered /prescribed": 0.2,
            "Patient outcome (mortality)": 0.2,
            "Travel connection": 0.2,
            "Community-associated": 0.2,
            "Healthcare-associated": 0.2,
            "LTCF-associated": 0.2,
            "None of the listed patient/case data available": "null"
        },
        "actual_answers": {
            "Spain": [
                "None of the listed patient/case data available"
            ],
            "Austria": [
                "None of the listed patient/case data available"
            ],
            "Lithuania": [
                "None of the listed patient/case data available"
            ],
            "Croatia": [
                "None of the listed patient/case data available"
            ],
            "Netherlands": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Ireland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Germany": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Poland": [
                "None of the listed patient/case data available"
            ],
            "Italy": [
                "None of the listed patient/case data available"
            ],
            "Greece": [
                "None of the listed patient/case data available"
            ],
            "France": [
                "None of the listed patient/case data available"
            ],
            "Czechia": [
                "None of the listed patient/case data available"
            ],
            "Belgium": [
                "Age",
                "Sex",
                "Sample date"
            ],
            "Hungary": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Finland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Luxembourg": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Malta": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Portugal": [
                ""
            ],
            "Norway": [
                "None of the listed patient/case data available"
            ],
            "Slovenia": [
                "None of the listed patient/case data available"
            ],
            "Estonia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Sweden": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Ukraine": [
                "None of the listed patient/case data available"
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Latvia": [
                ""
            ],
            "Iceland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Bulgaria": [
                ""
            ]
        }
    },
    "41.39": {
        "title": "You answered \u201cyes to some patient/case information is available\u201d in the question above.  Which of the following patient/case information is available in your national AMR surveillance system(s)?  Please also select available if the data are in separate systems but regularly linked with the AMR data. Community-associated: Infections that are contracted in the community, i.e. outside of a healthcare facility. Healthcare-associated: An infection occurring in a patient during the process of care in a hospital or other healthcare facility, which was not present or incubating at the time of admission. Healthcare-associated infections can also appear after discharge. Long-Term Care Facility (LTCF)-associated: An infection in a patient who is a resident at a LTCF. : Screening E. coli (colistin R) : Patient/case data available",
        "short_title": "Patient data available at national level. Colistin resistant E. coli - screening.",
        "type": "MultipleChoice",
        "coefficient": 0.02,
        "tags": [
            "National surveillance",
            "E. coli",
            "Screening",
            "Colistin"
        ],
        "possible_answers": {
            "Age": 0.2,
            "Sex": 0.2,
            "Sample date": 0.2,
            "Geographic location of patent": 0.2,
            "Antibiotics administered /prescribed": 0.2,
            "Patient outcome (mortality)": 0.2,
            "Travel connection": 0.2,
            "Community-associated": 0.2,
            "Healthcare-associated": 0.2,
            "LTCF-associated": 0.2,
            "None of the listed patient/case data available": "null"
        },
        "actual_answers": {
            "Spain": [
                "None of the listed patient/case data available"
            ],
            "Austria": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Lithuania": [
                "None of the listed patient/case data available"
            ],
            "Croatia": [
                "None of the listed patient/case data available"
            ],
            "Netherlands": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Ireland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Germany": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Poland": [
                "None of the listed patient/case data available"
            ],
            "Italy": [
                "None of the listed patient/case data available"
            ],
            "Greece": [
                "None of the listed patient/case data available"
            ],
            "France": [
                "None of the listed patient/case data available"
            ],
            "Czechia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Belgium": [
                "Age",
                "Sex",
                "Sample date"
            ],
            "Hungary": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Finland": [
                "None of the listed patient/case data available"
            ],
            "Luxembourg": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Malta": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Portugal": [
                ""
            ],
            "Norway": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Slovenia": [
                "None of the listed patient/case data available"
            ],
            "Estonia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Sweden": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Ukraine": [
                "None of the listed patient/case data available"
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Latvia": [
                ""
            ],
            "Iceland": [
                "None of the listed patient/case data available"
            ],
            "Bulgaria": [
                ""
            ]
        }
    },
    "41.40": {
        "title": "You answered \u201cyes to some patient/case information is available\u201d in the question above.  Which of the following patient/case information is available in your national AMR surveillance system(s)?  Please also select available if the data are in separate systems but regularly linked with the AMR data. Community-associated: Infections that are contracted in the community, i.e. outside of a healthcare facility. Healthcare-associated: An infection occurring in a patient during the process of care in a hospital or other healthcare facility, which was not present or incubating at the time of admission. Healthcare-associated infections can also appear after discharge. Long-Term Care Facility (LTCF)-associated: An infection in a patient who is a resident at a LTCF. : Screening K. pneumoniae (carbapenem R and/or P) : Patient/case data available",
        "short_title": "Patient data available at national level. Carbapenem resistant K. pneumoniae - screening.",
        "type": "MultipleChoice",
        "coefficient": 0.02,
        "tags": [
            "National surveillance",
            "K. pneumoniae",
            "Screening",
            "Carbapenem"
        ],
        "possible_answers": {
            "Age": 0.2,
            "Sex": 0.2,
            "Sample date": 0.2,
            "Geographic location of patent": 0.2,
            "Antibiotics administered /prescribed": 0.2,
            "Patient outcome (mortality)": 0.2,
            "Travel connection": 0.2,
            "Community-associated": 0.2,
            "Healthcare-associated": 0.2,
            "LTCF-associated": 0.2,
            "None of the listed patient/case data available": "null"
        },
        "actual_answers": {
            "Spain": [
                "None of the listed patient/case data available"
            ],
            "Austria": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Lithuania": [
                "None of the listed patient/case data available"
            ],
            "Croatia": [
                "None of the listed patient/case data available"
            ],
            "Netherlands": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Healthcare-associated"
            ],
            "Ireland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Germany": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Poland": [
                "None of the listed patient/case data available"
            ],
            "Italy": [
                "None of the listed patient/case data available"
            ],
            "Greece": [
                "None of the listed patient/case data available"
            ],
            "France": [
                "None of the listed patient/case data available"
            ],
            "Czechia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Belgium": [
                "Age",
                "Sex",
                "Sample date"
            ],
            "Hungary": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Finland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Luxembourg": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Malta": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Portugal": [
                ""
            ],
            "Norway": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Slovenia": [
                "None of the listed patient/case data available"
            ],
            "Estonia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Sweden": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated",
                "LTCF-associated"
            ],
            "Ukraine": [
                "None of the listed patient/case data available"
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Latvia": [
                ""
            ],
            "Iceland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Bulgaria": [
                ""
            ]
        }
    },
    "41.41": {
        "title": "You answered \u201cyes to some patient/case information is available\u201d in the question above.  Which of the following patient/case information is available in your national AMR surveillance system(s)?  Please also select available if the data are in separate systems but regularly linked with the AMR data. Community-associated: Infections that are contracted in the community, i.e. outside of a healthcare facility. Healthcare-associated: An infection occurring in a patient during the process of care in a hospital or other healthcare facility, which was not present or incubating at the time of admission. Healthcare-associated infections can also appear after discharge. Long-Term Care Facility (LTCF)-associated: An infection in a patient who is a resident at a LTCF. : Screening P. aeruginosa (carbapenem R and/or P) : Patient/case data available",
        "short_title": "Patient data available at national level. Carbapenem resistant P. aeruginosa - screening.",
        "type": "MultipleChoice",
        "coefficient": 0.02,
        "tags": [
            "National surveillance",
            "P. aeruginosa",
            "Screening",
            "Carbapenem"
        ],
        "possible_answers": {
            "Age": 0.2,
            "Sex": 0.2,
            "Sample date": 0.2,
            "Geographic location of patent": 0.2,
            "Antibiotics administered /prescribed": 0.2,
            "Patient outcome (mortality)": 0.2,
            "Travel connection": 0.2,
            "Community-associated": 0.2,
            "Healthcare-associated": 0.2,
            "LTCF-associated": 0.2,
            "None of the listed patient/case data available": "null"
        },
        "actual_answers": {
            "Spain": [
                "None of the listed patient/case data available"
            ],
            "Austria": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Lithuania": [
                "None of the listed patient/case data available"
            ],
            "Croatia": [
                "None of the listed patient/case data available"
            ],
            "Netherlands": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Antibiotics administered /prescribed",
                "Travel connection",
                "Healthcare-associated"
            ],
            "Ireland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Germany": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Poland": [
                "None of the listed patient/case data available"
            ],
            "Italy": [
                "None of the listed patient/case data available"
            ],
            "Greece": [
                "None of the listed patient/case data available"
            ],
            "France": [
                "None of the listed patient/case data available"
            ],
            "Czechia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Belgium": [
                "Age",
                "Sex",
                "Sample date"
            ],
            "Hungary": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Finland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Luxembourg": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Malta": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Portugal": [
                ""
            ],
            "Norway": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Slovenia": [
                "None of the listed patient/case data available"
            ],
            "Estonia": [
                "Age",
                "Sex",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Sweden": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Ukraine": [
                "None of the listed patient/case data available"
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Latvia": [
                ""
            ],
            "Iceland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Bulgaria": [
                ""
            ]
        }
    },
    "41.42": {
        "title": "You answered \u201cyes to some patient/case information is available\u201d in the question above.  Which of the following patient/case information is available in your national AMR surveillance system(s)?  Please also select available if the data are in separate systems but regularly linked with the AMR data. Community-associated: Infections that are contracted in the community, i.e. outside of a healthcare facility. Healthcare-associated: An infection occurring in a patient during the process of care in a hospital or other healthcare facility, which was not present or incubating at the time of admission. Healthcare-associated infections can also appear after discharge. Long-Term Care Facility (LTCF)-associated: An infection in a patient who is a resident at a LTCF. : Screening S. aureus (methicillin R) : Patient/case data available",
        "short_title": "Patient data available at national level. Methicillin resistant S. aureus - screening.",
        "type": "MultipleChoice",
        "coefficient": 0.02,
        "tags": [
            "National surveillance",
            "S. aureus",
            "Screening",
            "Methicillin"
        ],
        "possible_answers": {
            "Age": 0.2,
            "Sex": 0.2,
            "Sample date": 0.2,
            "Geographic location of patent": 0.2,
            "Antibiotics administered /prescribed": 0.2,
            "Patient outcome (mortality)": 0.2,
            "Travel connection": 0.2,
            "Community-associated": 0.2,
            "Healthcare-associated": 0.2,
            "LTCF-associated": 0.2,
            "None of the listed patient/case data available": "null"
        },
        "actual_answers": {
            "Spain": [
                "None of the listed patient/case data available"
            ],
            "Austria": [
                "None of the listed patient/case data available"
            ],
            "Lithuania": [
                "None of the listed patient/case data available"
            ],
            "Croatia": [
                "None of the listed patient/case data available"
            ],
            "Netherlands": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Ireland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Germany": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Poland": [
                "None of the listed patient/case data available"
            ],
            "Italy": [
                "None of the listed patient/case data available"
            ],
            "Greece": [
                "None of the listed patient/case data available"
            ],
            "France": [
                "None of the listed patient/case data available"
            ],
            "Czechia": [
                "None of the listed patient/case data available"
            ],
            "Belgium": [
                "Age",
                "Sex",
                "Sample date"
            ],
            "Hungary": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Finland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Luxembourg": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Malta": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Portugal": [
                ""
            ],
            "Norway": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Slovenia": [
                "None of the listed patient/case data available"
            ],
            "Estonia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Sweden": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated",
                "LTCF-associated"
            ],
            "Ukraine": [
                "None of the listed patient/case data available"
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated",
                "LTCF-associated"
            ],
            "Latvia": [
                ""
            ],
            "Iceland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Bulgaria": [
                ""
            ]
        }
    },
    "41.43": {
        "title": "You answered \u201cyes to some patient/case information is available\u201d in the question above.  Which of the following patient/case information is available in your national AMR surveillance system(s)?  Please also select available if the data are in separate systems but regularly linked with the AMR data. Community-associated: Infections that are contracted in the community, i.e. outside of a healthcare facility. Healthcare-associated: An infection occurring in a patient during the process of care in a hospital or other healthcare facility, which was not present or incubating at the time of admission. Healthcare-associated infections can also appear after discharge. Long-Term Care Facility (LTCF)-associated: An infection in a patient who is a resident at a LTCF. : Screening E. faecium and/or E. faecalis (vancomycin R) : Patient/case data available",
        "short_title": "Patient data available at national level. Vancomycin resistant Enterococci - screening.",
        "type": "MultipleChoice",
        "coefficient": 0.02,
        "tags": [
            "National surveillance",
            "E. faecium/faecalis",
            "Screening",
            "Vancomycin"
        ],
        "possible_answers": {
            "Age": 0.2,
            "Sex": 0.2,
            "Sample date": 0.2,
            "Geographic location of patent": 0.2,
            "Antibiotics administered /prescribed": 0.2,
            "Patient outcome (mortality)": 0.2,
            "Travel connection": 0.2,
            "Community-associated": 0.2,
            "Healthcare-associated": 0.2,
            "LTCF-associated": 0.2,
            "None of the listed patient/case data available": "null"
        },
        "actual_answers": {
            "Spain": [
                "None of the listed patient/case data available"
            ],
            "Austria": [
                "None of the listed patient/case data available"
            ],
            "Lithuania": [
                "None of the listed patient/case data available"
            ],
            "Croatia": [
                "None of the listed patient/case data available"
            ],
            "Netherlands": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Ireland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Germany": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Poland": [
                "None of the listed patient/case data available"
            ],
            "Italy": [
                "None of the listed patient/case data available"
            ],
            "Greece": [
                "None of the listed patient/case data available"
            ],
            "France": [
                "None of the listed patient/case data available"
            ],
            "Czechia": [
                "None of the listed patient/case data available"
            ],
            "Belgium": [
                "Age",
                "Sex",
                "Sample date"
            ],
            "Hungary": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Finland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Luxembourg": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Malta": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Portugal": [
                ""
            ],
            "Norway": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Slovenia": [
                "None of the listed patient/case data available"
            ],
            "Estonia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Sweden": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated",
                "LTCF-associated"
            ],
            "Ukraine": [
                "None of the listed patient/case data available"
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Latvia": [
                ""
            ],
            "Iceland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Bulgaria": [
                ""
            ]
        }
    },
    "41.44": {
        "title": "You answered \u201cyes to some patient/case information is available\u201d in the question above.  Which of the following patient/case information is available in your national AMR surveillance system(s)?  Please also select available if the data are in separate systems but regularly linked with the AMR data. Community-associated: Infections that are contracted in the community, i.e. outside of a healthcare facility. Healthcare-associated: An infection occurring in a patient during the process of care in a hospital or other healthcare facility, which was not present or incubating at the time of admission. Healthcare-associated infections can also appear after discharge. Long-Term Care Facility (LTCF)-associated: An infection in a patient who is a resident at a LTCF. : Blood/CSF E. coli (carbapenem R and/or P) : Patient/case data available",
        "short_title": "Patient data available at national level. Carbapenem resistant E. coli - blood.",
        "type": "MultipleChoice",
        "coefficient": 0.02,
        "tags": [
            "National surveillance",
            "E. coli",
            "Blood",
            "Carbapenem"
        ],
        "possible_answers": {
            "Age": 0.2,
            "Sex": 0.2,
            "Sample date": 0.2,
            "Geographic location of patent": 0.2,
            "Antibiotics administered /prescribed": 0.2,
            "Patient outcome (mortality)": 0.2,
            "Travel connection": 0.2,
            "Community-associated": 0.2,
            "Healthcare-associated": 0.2,
            "LTCF-associated": 0.2,
            "None of the listed patient/case data available": "null"
        },
        "actual_answers": {
            "Spain": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Austria": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Lithuania": [
                "Age",
                "Sample date",
                "Geographic location of patent"
            ],
            "Croatia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Netherlands": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Healthcare-associated"
            ],
            "Ireland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Germany": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)",
                "Travel connection"
            ],
            "Poland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Italy": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Greece": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "France": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Community-associated",
                "Healthcare-associated",
                "LTCF-associated"
            ],
            "Czechia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Belgium": [
                "Age",
                "Sex",
                "Sample date"
            ],
            "Hungary": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Finland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Luxembourg": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Malta": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Portugal": [
                ""
            ],
            "Norway": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Slovenia": [
                "Age",
                "Sex",
                "Sample date"
            ],
            "Estonia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Sweden": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated",
                "LTCF-associated"
            ],
            "Ukraine": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Latvia": [
                ""
            ],
            "Iceland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Bulgaria": [
                ""
            ]
        }
    },
    "41.45": {
        "title": "You answered \u201cyes to some patient/case information is available\u201d in the question above.  Which of the following patient/case information is available in your national AMR surveillance system(s)?  Please also select available if the data are in separate systems but regularly linked with the AMR data. Community-associated: Infections that are contracted in the community, i.e. outside of a healthcare facility. Healthcare-associated: An infection occurring in a patient during the process of care in a hospital or other healthcare facility, which was not present or incubating at the time of admission. Healthcare-associated infections can also appear after discharge. Long-Term Care Facility (LTCF)-associated: An infection in a patient who is a resident at a LTCF. : Screening K. pneumoniae (3GC- R and/or P) : Patient/case data available",
        "short_title": "Patient data available at national level. 3rd-generation cephalosporins resistant K. pneumoniae - screening.",
        "type": "MultipleChoice",
        "coefficient": 0.02,
        "tags": [
            "National surveillance",
            "K. pneumoniae",
            "Screening",
            "3rd-generation Cephalosporin"
        ],
        "possible_answers": {
            "Age": 0.2,
            "Sex": 0.2,
            "Sample date": 0.2,
            "Geographic location of patent": 0.2,
            "Antibiotics administered /prescribed": 0.2,
            "Patient outcome (mortality)": 0.2,
            "Travel connection": 0.2,
            "Community-associated": 0.2,
            "Healthcare-associated": 0.2,
            "LTCF-associated": 0.2,
            "None of the listed patient/case data available": "null"
        },
        "actual_answers": {
            "Spain": [
                "None of the listed patient/case data available"
            ],
            "Austria": [
                "None of the listed patient/case data available"
            ],
            "Lithuania": [
                "None of the listed patient/case data available"
            ],
            "Croatia": [
                "None of the listed patient/case data available"
            ],
            "Netherlands": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Ireland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Germany": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Poland": [
                "None of the listed patient/case data available"
            ],
            "Italy": [
                "None of the listed patient/case data available"
            ],
            "Greece": [
                "None of the listed patient/case data available"
            ],
            "France": [
                "None of the listed patient/case data available"
            ],
            "Czechia": [
                "None of the listed patient/case data available"
            ],
            "Belgium": [
                "Age",
                "Sex",
                "Sample date"
            ],
            "Hungary": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Finland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Luxembourg": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Malta": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Portugal": [
                ""
            ],
            "Norway": [
                "None of the listed patient/case data available"
            ],
            "Slovenia": [
                "None of the listed patient/case data available"
            ],
            "Estonia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Sweden": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Ukraine": [
                "None of the listed patient/case data available"
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Latvia": [
                ""
            ],
            "Iceland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Bulgaria": [
                ""
            ]
        }
    },
    "41.46": {
        "title": "You answered \u201cyes to some patient/case information is available\u201d in the question above.  Which of the following patient/case information is available in your national AMR surveillance system(s)?  Please also select available if the data are in separate systems but regularly linked with the AMR data. Community-associated: Infections that are contracted in the community, i.e. outside of a healthcare facility. Healthcare-associated: An infection occurring in a patient during the process of care in a hospital or other healthcare facility, which was not present or incubating at the time of admission. Healthcare-associated infections can also appear after discharge. Long-Term Care Facility (LTCF)-associated: An infection in a patient who is a resident at a LTCF. : Urine E. coli (3GC-R and/or P) : Patient/case data available",
        "short_title": "Patient data available at national level. 3rd-generation cephalosporins resistant E. coli - urine.",
        "type": "MultipleChoice",
        "coefficient": 0.02,
        "tags": [
            "National surveillance",
            "E. coli",
            "Urine",
            "3rd-generation Cephalosporin"
        ],
        "possible_answers": {
            "Age": 0.2,
            "Sex": 0.2,
            "Sample date": 0.2,
            "Geographic location of patent": 0.2,
            "Antibiotics administered /prescribed": 0.2,
            "Patient outcome (mortality)": 0.2,
            "Travel connection": 0.2,
            "Community-associated": 0.2,
            "Healthcare-associated": 0.2,
            "LTCF-associated": 0.2,
            "None of the listed patient/case data available": "null"
        },
        "actual_answers": {
            "Spain": [
                "None of the listed patient/case data available"
            ],
            "Austria": [
                "None of the listed patient/case data available"
            ],
            "Lithuania": [
                "Age",
                "Sample date",
                "Geographic location of patent"
            ],
            "Croatia": [
                "None of the listed patient/case data available"
            ],
            "Netherlands": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Ireland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Germany": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Poland": [
                "None of the listed patient/case data available"
            ],
            "Italy": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Greece": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "France": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Community-associated",
                "Healthcare-associated",
                "LTCF-associated"
            ],
            "Czechia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Community-associated"
            ],
            "Belgium": [
                "Age",
                "Sex",
                "Sample date"
            ],
            "Hungary": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Finland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Luxembourg": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Malta": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Portugal": [
                ""
            ],
            "Norway": [
                "None of the listed patient/case data available"
            ],
            "Slovenia": [
                "None of the listed patient/case data available"
            ],
            "Estonia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Sweden": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Ukraine": [
                "None of the listed patient/case data available"
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Latvia": [
                ""
            ],
            "Iceland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Bulgaria": [
                ""
            ]
        }
    },
    "41.47": {
        "title": "You answered \u201cyes to some patient/case information is available\u201d in the question above.  Which of the following patient/case information is available in your national AMR surveillance system(s)?  Please also select available if the data are in separate systems but regularly linked with the AMR data. Community-associated: Infections that are contracted in the community, i.e. outside of a healthcare facility. Healthcare-associated: An infection occurring in a patient during the process of care in a hospital or other healthcare facility, which was not present or incubating at the time of admission. Healthcare-associated infections can also appear after discharge. Long-Term Care Facility (LTCF)-associated: An infection in a patient who is a resident at a LTCF. : Blood/CSF E. faecium and/or faecalis (vancomycin R) : Patient/case data available",
        "short_title": "Patient data available at national level. Vancomycin resistant Enterococci - blood.",
        "type": "MultipleChoice",
        "coefficient": 0.02,
        "tags": [
            "National surveillance",
            "E. faecium/faecalis",
            "Blood",
            "Vancomycin"
        ],
        "possible_answers": {
            "Age": 0.2,
            "Sex": 0.2,
            "Sample date": 0.2,
            "Geographic location of patent": 0.2,
            "Antibiotics administered /prescribed": 0.2,
            "Patient outcome (mortality)": 0.2,
            "Travel connection": 0.2,
            "Community-associated": 0.2,
            "Healthcare-associated": 0.2,
            "LTCF-associated": 0.2,
            "None of the listed patient/case data available": "null"
        },
        "actual_answers": {
            "Spain": [
                "None of the listed patient/case data available"
            ],
            "Austria": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Lithuania": [
                "Age",
                "Sample date",
                "Geographic location of patent"
            ],
            "Croatia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Netherlands": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Ireland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Germany": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Poland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Italy": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Greece": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)",
                "Healthcare-associated"
            ],
            "France": [
                "Age",
                "Sample date",
                "Geographic location of patent",
                "Healthcare-associated",
                "LTCF-associated"
            ],
            "Czechia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Belgium": [
                "Age",
                "Sex",
                "Sample date"
            ],
            "Hungary": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Finland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Luxembourg": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Malta": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Portugal": [
                ""
            ],
            "Norway": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Slovenia": [
                "Age",
                "Sex",
                "Sample date"
            ],
            "Estonia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Sweden": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated",
                "LTCF-associated"
            ],
            "Ukraine": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Latvia": [
                ""
            ],
            "Iceland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Bulgaria": [
                ""
            ]
        }
    },
    "41.48": {
        "title": "You answered \u201cyes to some patient/case information is available\u201d in the question above.  Which of the following patient/case information is available in your national AMR surveillance system(s)?  Please also select available if the data are in separate systems but regularly linked with the AMR data. Community-associated: Infections that are contracted in the community, i.e. outside of a healthcare facility. Healthcare-associated: An infection occurring in a patient during the process of care in a hospital or other healthcare facility, which was not present or incubating at the time of admission. Healthcare-associated infections can also appear after discharge. Long-Term Care Facility (LTCF)-associated: An infection in a patient who is a resident at a LTCF. : Lower respiratory tract A. baumanii (carbapenem R and/or P) : Patient/case data available",
        "short_title": "Patient data available at national level. Carbapenem resistant A. baumanii - lower respiratory tract.",
        "type": "MultipleChoice",
        "coefficient": 0.02,
        "tags": [
            "National surveillance",
            "A. baumanii",
            "Respiratory tract",
            "Carbapenem"
        ],
        "possible_answers": {
            "Age": 0.2,
            "Sex": 0.2,
            "Sample date": 0.2,
            "Geographic location of patent": 0.2,
            "Antibiotics administered /prescribed": 0.2,
            "Patient outcome (mortality)": 0.2,
            "Travel connection": 0.2,
            "Community-associated": 0.2,
            "Healthcare-associated": 0.2,
            "LTCF-associated": 0.2,
            "None of the listed patient/case data available": "null"
        },
        "actual_answers": {
            "Spain": [
                "None of the listed patient/case data available"
            ],
            "Austria": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Lithuania": [
                "None of the listed patient/case data available"
            ],
            "Croatia": [
                "None of the listed patient/case data available"
            ],
            "Netherlands": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Antibiotics administered /prescribed",
                "Travel connection",
                "Healthcare-associated"
            ],
            "Ireland": [
                "None of the listed patient/case data available"
            ],
            "Germany": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Poland": [
                "None of the listed patient/case data available"
            ],
            "Italy": [
                "None of the listed patient/case data available"
            ],
            "Greece": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "France": [
                "Age",
                "Sample date",
                "Geographic location of patent",
                "Healthcare-associated"
            ],
            "Czechia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Belgium": [
                "None of the listed patient/case data available"
            ],
            "Hungary": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Finland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Luxembourg": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Malta": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Portugal": [
                ""
            ],
            "Norway": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Slovenia": [
                "None of the listed patient/case data available"
            ],
            "Estonia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Sweden": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Ukraine": [
                "None of the listed patient/case data available"
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Latvia": [
                ""
            ],
            "Iceland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Bulgaria": [
                ""
            ]
        }
    },
    "41.49": {
        "title": "You answered \u201cyes to some patient/case information is available\u201d in the question above.  Which of the following patient/case information is available in your national AMR surveillance system(s)?  Please also select available if the data are in separate systems but regularly linked with the AMR data. Community-associated: Infections that are contracted in the community, i.e. outside of a healthcare facility. Healthcare-associated: An infection occurring in a patient during the process of care in a hospital or other healthcare facility, which was not present or incubating at the time of admission. Healthcare-associated infections can also appear after discharge. Long-Term Care Facility (LTCF)-associated: An infection in a patient who is a resident at a LTCF. : Screening K. pneumoniae (colistin R) : Patient/case data available",
        "short_title": "Patient data available at national level. Colistin resistant K. pneumoniae - screening.",
        "type": "MultipleChoice",
        "coefficient": 0.02,
        "tags": [
            "National surveillance",
            "K. pneumoniae",
            "Screening",
            "Colistin"
        ],
        "possible_answers": {
            "Age": 0.2,
            "Sex": 0.2,
            "Sample date": 0.2,
            "Geographic location of patent": 0.2,
            "Antibiotics administered /prescribed": 0.2,
            "Patient outcome (mortality)": 0.2,
            "Travel connection": 0.2,
            "Community-associated": 0.2,
            "Healthcare-associated": 0.2,
            "LTCF-associated": 0.2,
            "None of the listed patient/case data available": "null"
        },
        "actual_answers": {
            "Spain": [
                "None of the listed patient/case data available"
            ],
            "Austria": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Lithuania": [
                "None of the listed patient/case data available"
            ],
            "Croatia": [
                "None of the listed patient/case data available"
            ],
            "Netherlands": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Ireland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Germany": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Poland": [
                "None of the listed patient/case data available"
            ],
            "Italy": [
                "None of the listed patient/case data available"
            ],
            "Greece": [
                "None of the listed patient/case data available"
            ],
            "France": [
                "None of the listed patient/case data available"
            ],
            "Czechia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Belgium": [
                "Age",
                "Sex",
                "Sample date"
            ],
            "Hungary": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Finland": [
                "None of the listed patient/case data available"
            ],
            "Luxembourg": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Malta": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Portugal": [
                ""
            ],
            "Norway": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Slovenia": [
                "None of the listed patient/case data available"
            ],
            "Estonia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Sweden": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Ukraine": [
                "None of the listed patient/case data available"
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Latvia": [
                ""
            ],
            "Iceland": [
                "None of the listed patient/case data available"
            ],
            "Bulgaria": [
                ""
            ]
        }
    },
    "41.50": {
        "title": "You answered \u201cyes to some patient/case information is available\u201d in the question above.  Which of the following patient/case information is available in your national AMR surveillance system(s)?  Please also select available if the data are in separate systems but regularly linked with the AMR data. Community-associated: Infections that are contracted in the community, i.e. outside of a healthcare facility. Healthcare-associated: An infection occurring in a patient during the process of care in a hospital or other healthcare facility, which was not present or incubating at the time of admission. Healthcare-associated infections can also appear after discharge. Long-Term Care Facility (LTCF)-associated: An infection in a patient who is a resident at a LTCF. : Screening A. baumanii (carbapenem R and/or P) : Patient/case data available",
        "short_title": "Patient data available at national level. Carbapenem resistant A. baumanii - screening.",
        "type": "MultipleChoice",
        "coefficient": 0.02,
        "tags": [
            "National surveillance",
            "A. baumanii",
            "Screening",
            "Carbapenem"
        ],
        "possible_answers": {
            "Age": 0.2,
            "Sex": 0.2,
            "Sample date": 0.2,
            "Geographic location of patent": 0.2,
            "Antibiotics administered /prescribed": 0.2,
            "Patient outcome (mortality)": 0.2,
            "Travel connection": 0.2,
            "Community-associated": 0.2,
            "Healthcare-associated": 0.2,
            "LTCF-associated": 0.2,
            "None of the listed patient/case data available": "null"
        },
        "actual_answers": {
            "Spain": [
                "None of the listed patient/case data available"
            ],
            "Austria": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Lithuania": [
                "None of the listed patient/case data available"
            ],
            "Croatia": [
                "None of the listed patient/case data available"
            ],
            "Netherlands": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Antibiotics administered /prescribed",
                "Travel connection",
                "Healthcare-associated"
            ],
            "Ireland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Germany": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Poland": [
                "None of the listed patient/case data available"
            ],
            "Italy": [
                "None of the listed patient/case data available"
            ],
            "Greece": [
                "None of the listed patient/case data available"
            ],
            "France": [
                "None of the listed patient/case data available"
            ],
            "Czechia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Belgium": [
                "Age",
                "Sex",
                "Sample date"
            ],
            "Hungary": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Finland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Luxembourg": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Malta": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Portugal": [
                ""
            ],
            "Norway": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Slovenia": [
                "None of the listed patient/case data available"
            ],
            "Estonia": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Patient outcome (mortality)"
            ],
            "Sweden": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent"
            ],
            "Ukraine": [
                "None of the listed patient/case data available"
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection"
            ],
            "Latvia": [
                ""
            ],
            "Iceland": [
                "Age",
                "Sex",
                "Sample date",
                "Geographic location of patent",
                "Travel connection",
                "Community-associated",
                "Healthcare-associated"
            ],
            "Bulgaria": [
                ""
            ]
        }
    },
    "42.1": {
        "title": "Which of the following types of surveillance systems are in place nationally and used for AMR surveillance? (Tick all that apply) CML: Clinical Microbiological Laboratory NRL: National Reference or Expert Laboratory The focus of this question is on what type of systems are in place and used for AMR surveillance for at least one of the included pathogens. The focus should not be on the coverage of the submitted data in this question, (i.e. how many laboratories or hospitals contribute data to a particular system). : Laboratory isolate based: CMLs can submit data on pathogens under surveillance. Data is structured in one row per isolate. : In place",
        "short_title": "Laboratories can submit data on pathogens under surveillance - In place",
        "type": "SingleChoice",
        "coefficient": 0.5,
        "tags": [
            "National surveillance"
        ],
        "possible_answers": {
            "Yes": 1,
            "No": 0
        },
        "actual_answers": {
            "Spain": "Yes",
            "Austria": "Yes",
            "Lithuania": "Yes",
            "Croatia": "Yes",
            "Netherlands": "Yes",
            "Ireland": "Yes",
            "Germany": "Yes",
            "Poland": "Yes",
            "Italy": "Yes",
            "Greece": "Yes",
            "France": "Yes",
            "Czechia": "No",
            "Belgium": "Yes",
            "Hungary": "Yes",
            "Finland": "Yes",
            "Luxembourg": "Yes",
            "Malta": "Yes",
            "Portugal": "Yes",
            "Norway": "Yes",
            "Slovenia": "Yes",
            "Estonia": "Yes",
            "Sweden": "Yes",
            "Ukraine": "Yes",
            "Slovak Republic": "Yes",
            "Denmark": "Yes",
            "Latvia": "Yes",
            "Iceland": "Yes",
            "Bulgaria": "No"
        }
    },
    "42.2": {
        "title": "Which of the following types of surveillance systems are in place nationally and used for AMR surveillance? (Tick all that apply) CML: Clinical Microbiological Laboratory NRL: National Reference or Expert Laboratory The focus of this question is on what type of systems are in place and used for AMR surveillance for at least one of the included pathogens. The focus should not be on the coverage of the submitted data in this question, (i.e. how many laboratories or hospitals contribute data to a particular system). : Laboratory Real-time resistance data: CMLs can submit data for tested isolates continuously (semi-automatic or automatic) : In place",
        "short_title": "Laboratories can submit data for tested isolates in real-time - In place",
        "type": "SingleChoice",
        "coefficient": 0,
        "tags": [
            "National surveillance"
        ],
        "possible_answers": {
            "Yes": "null",
            "No": "null"
        },
        "actual_answers": {
            "Spain": "Yes",
            "Austria": "No",
            "Lithuania": "No",
            "Croatia": "Yes",
            "Netherlands": "Yes",
            "Ireland": "No",
            "Germany": "Yes",
            "Poland": "No",
            "Italy": "No",
            "Greece": "Yes",
            "France": "No",
            "Czechia": "No",
            "Belgium": "Yes",
            "Hungary": "Yes",
            "Finland": "Yes",
            "Luxembourg": "No",
            "Malta": "Yes",
            "Portugal": "Yes",
            "Norway": "Yes",
            "Slovenia": "No",
            "Estonia": "Yes",
            "Sweden": "Yes",
            "Ukraine": "No",
            "Slovak Republic": "No",
            "Denmark": "Yes",
            "Latvia": "No",
            "Iceland": "Yes",
            "Bulgaria": "No"
        }
    },
    "42.3": {
        "title": "Which of the following types of surveillance systems are in place nationally and used for AMR surveillance? (Tick all that apply) CML: Clinical Microbiological Laboratory NRL: National Reference or Expert Laboratory The focus of this question is on what type of systems are in place and used for AMR surveillance for at least one of the included pathogens. The focus should not be on the coverage of the submitted data in this question, (i.e. how many laboratories or hospitals contribute data to a particular system). : Laboratory statistics aggregated data: CMLs can submit data on pathogens under surveillance in aggregated form. : In place",
        "short_title": "Laboratories can submit data on pathogens under surveillance in aggregated form - In place",
        "type": "SingleChoice",
        "coefficient": 0,
        "tags": [
            "National surveillance"
        ],
        "possible_answers": {
            "Yes": "null",
            "No": "null"
        },
        "actual_answers": {}
    },
    "42.4": {
        "title": "Which of the following types of surveillance systems are in place nationally and used for AMR surveillance? (Tick all that apply) CML: Clinical Microbiological Laboratory NRL: National Reference or Expert Laboratory The focus of this question is on what type of systems are in place and used for AMR surveillance for at least one of the included pathogens. The focus should not be on the coverage of the submitted data in this question, (i.e. how many laboratories or hospitals contribute data to a particular system). : Laboratory periodic isolates: CMLs can submit data for pathogens under surveillance during a specific time period. : In place",
        "short_title": "Laboratories can submit data for pathogens under surveillance during a specific time period.  - In place",
        "type": "SingleChoice",
        "coefficient": 0,
        "tags": [
            "National surveillance"
        ],
        "possible_answers": {
            "Yes": "null",
            "No": "null"
        },
        "actual_answers": {
            "Spain": "Yes",
            "Austria": "Yes",
            "Lithuania": "Yes",
            "Croatia": "Yes",
            "Netherlands": "No",
            "Ireland": "No",
            "Germany": "Yes",
            "Poland": "No",
            "Italy": "Yes",
            "Greece": "Yes",
            "France": "No",
            "Czechia": "Yes",
            "Belgium": "Yes",
            "Hungary": "Yes",
            "Finland": "Yes",
            "Luxembourg": "No",
            "Malta": "No",
            "Portugal": "Yes",
            "Norway": "Yes",
            "Slovenia": "Yes",
            "Estonia": "No",
            "Sweden": "No",
            "Ukraine": "No",
            "Slovak Republic": "No",
            "Denmark": "Yes",
            "Latvia": "Yes",
            "Iceland": "Yes",
            "Bulgaria": "No"
        }
    },
    "42.5": {
        "title": "Which of the following types of surveillance systems are in place nationally and used for AMR surveillance? (Tick all that apply) CML: Clinical Microbiological Laboratory NRL: National Reference or Expert Laboratory The focus of this question is on what type of systems are in place and used for AMR surveillance for at least one of the included pathogens. The focus should not be on the coverage of the submitted data in this question, (i.e. how many laboratories or hospitals contribute data to a particular system). : Laboratory number of isolates: CMLs can submit data for a specific number of pathogens under surveillance : In place",
        "short_title": "Laboratories can submit data for a specific number of pathogens under surveillance.  - In place",
        "type": "SingleChoice",
        "coefficient": 0,
        "tags": [
            "National surveillance"
        ],
        "possible_answers": {
            "Yes": "null",
            "No": "null"
        },
        "actual_answers": {
            "Spain": "Yes",
            "Austria": "No",
            "Lithuania": "No",
            "Croatia": "Yes",
            "Netherlands": "No",
            "Ireland": "Yes",
            "Germany": "Yes",
            "Poland": "Yes",
            "Italy": "Yes",
            "Greece": "Yes",
            "France": "No",
            "Czechia": "Yes",
            "Belgium": "Yes",
            "Hungary": "No",
            "Finland": "Yes",
            "Luxembourg": "No",
            "Malta": "No",
            "Portugal": "Yes",
            "Norway": "Yes",
            "Slovenia": "Yes",
            "Estonia": "No",
            "Sweden": "No",
            "Ukraine": "Yes",
            "Slovak Republic": "No",
            "Denmark": "Yes",
            "Latvia": "Yes",
            "Iceland": "Yes",
            "Bulgaria": "Yes"
        }
    },
    "42.6": {
        "title": "Which of the following types of surveillance systems are in place nationally and used for AMR surveillance? (Tick all that apply) CML: Clinical Microbiological Laboratory NRL: National Reference or Expert Laboratory The focus of this question is on what type of systems are in place and used for AMR surveillance for at least one of the included pathogens. The focus should not be on the coverage of the submitted data in this question, (i.e. how many laboratories or hospitals contribute data to a particular system). : Patient/case based: Hospitals/treating physicians (or equivalent) can submit data for cases with pathogens under surveillance. Data is structured in one row per case. : In place",
        "short_title": "Hospitals/treating physicians can submit data for cases with pathogens under surveillance - In place",
        "type": "SingleChoice",
        "coefficient": 0,
        "tags": [
            "National surveillance"
        ],
        "possible_answers": {
            "Yes": "null",
            "No": "null"
        },
        "actual_answers": {
            "Spain": "Yes",
            "Austria": "No",
            "Lithuania": "No",
            "Croatia": "No",
            "Netherlands": "Yes",
            "Ireland": "No",
            "Germany": "Yes",
            "Poland": "Yes",
            "Italy": "Yes",
            "Greece": "Yes",
            "France": "No",
            "Czechia": "Yes",
            "Belgium": "Yes",
            "Hungary": "No",
            "Finland": "Yes",
            "Luxembourg": "No",
            "Malta": "No",
            "Portugal": "Yes",
            "Norway": "Yes",
            "Slovenia": "No",
            "Estonia": "Yes",
            "Sweden": "Yes",
            "Ukraine": "No",
            "Slovak Republic": "No",
            "Denmark": "Yes",
            "Latvia": "No",
            "Iceland": "Yes",
            "Bulgaria": "No"
        }
    },
    "42.7": {
        "title": "Which of the following types of surveillance systems are in place nationally and used for AMR surveillance? (Tick all that apply) CML: Clinical Microbiological Laboratory NRL: National Reference or Expert Laboratory The focus of this question is on what type of systems are in place and used for AMR surveillance for at least one of the included pathogens. The focus should not be on the coverage of the submitted data in this question, (i.e. how many laboratories or hospitals contribute data to a particular system). : Hospital patient aggregated data:  Hospitals can submit aggregated data with information about the cases. : In place",
        "short_title": "Hospitals can submit aggregated data with information about the cases - In place",
        "type": "SingleChoice",
        "coefficient": 0,
        "tags": [
            "National surveillance"
        ],
        "possible_answers": {
            "Yes": "null",
            "No": "null"
        },
        "actual_answers": {
            "Spain": "No",
            "Austria": "No",
            "Lithuania": "No",
            "Croatia": "Yes",
            "Netherlands": "No",
            "Ireland": "No",
            "Germany": "No",
            "Poland": "Yes",
            "Italy": "Yes",
            "Greece": "Yes",
            "France": "No",
            "Czechia": "No",
            "Belgium": "Yes",
            "Hungary": "No",
            "Finland": "No",
            "Luxembourg": "No",
            "Malta": "No",
            "Portugal": "Yes",
            "Norway": "No",
            "Slovenia": "No",
            "Estonia": "No",
            "Sweden": "No",
            "Ukraine": "No",
            "Slovak Republic": "No",
            "Denmark": "Yes",
            "Latvia": "No",
            "Iceland": "No",
            "Bulgaria": "No"
        }
    },
    "42.8": {
        "title": "Which of the following types of surveillance systems are in place nationally and used for AMR surveillance? (Tick all that apply) CML: Clinical Microbiological Laboratory NRL: National Reference or Expert Laboratory The focus of this question is on what type of systems are in place and used for AMR surveillance for at least one of the included pathogens. The focus should not be on the coverage of the submitted data in this question, (i.e. how many laboratories or hospitals contribute data to a particular system). : Laboratory isolate based: CMLs can submit data on pathogens under surveillance. Data is structured in one row per isolate. : Frequency of submission",
        "short_title": "Laboratories can submit data on pathogens under surveillance - Frequency of submission ",
        "type": "MultipleChoice",
        "coefficient": 0,
        "tags": [
            "National surveillance"
        ],
        "possible_answers": {
            "Data is submitted\u00a0continuously or with close regular intervals (at least once a month)": "null",
            "Data is submitted once a year": "null",
            "Other": "null"
        },
        "actual_answers": {
            "Spain": [
                "Data is submitted continuously or with close regular intervals (at least once a month)"
            ],
            "Austria": [
                "Data is submitted continuously or with close regular intervals (at least once a month)",
                "Data is submitted once a year"
            ],
            "Lithuania": [
                "Data is submitted continuously or with close regular intervals (at least once a month)",
                "Data is submitted once a year"
            ],
            "Croatia": [
                "Data is submitted once a year"
            ],
            "Netherlands": [
                "Data is submitted continuously or with close regular intervals (at least once a month)"
            ],
            "Ireland": [
                "Data is submitted once a year"
            ],
            "Germany": [
                "Data is submitted continuously or with close regular intervals (at least once a month)"
            ],
            "Poland": [
                "Data is submitted once a year"
            ],
            "Italy": [
                "Data is submitted once a year"
            ],
            "Greece": [
                "Data is submitted continuously or with close regular intervals (at least once a month)"
            ],
            "France": [
                "Data is submitted continuously or with close regular intervals (at least once a month)",
                "Data is submitted once a year"
            ],
            "Czechia": [
                ""
            ],
            "Belgium": [
                "Data is submitted once a year"
            ],
            "Hungary": [
                "Data is submitted continuously or with close regular intervals (at least once a month)",
                "Data is submitted once a year"
            ],
            "Finland": [
                "Data is submitted continuously or with close regular intervals (at least once a month)",
                "Data is submitted once a year"
            ],
            "Luxembourg": [
                "Other"
            ],
            "Malta": [
                "Data is submitted continuously or with close regular intervals (at least once a month)"
            ],
            "Portugal": [
                "Data is submitted continuously or with close regular intervals (at least once a month)",
                "Data is submitted once a year"
            ],
            "Norway": [
                "Data is submitted continuously or with close regular intervals (at least once a month)"
            ],
            "Slovenia": [
                "Data is submitted once a year"
            ],
            "Estonia": [
                "Data is submitted continuously or with close regular intervals (at least once a month)"
            ],
            "Sweden": [
                "Data is submitted continuously or with close regular intervals (at least once a month)"
            ],
            "Ukraine": [
                "Data is submitted once a year"
            ],
            "Slovak Republic": [
                "Other"
            ],
            "Denmark": [
                "Data is submitted continuously or with close regular intervals (at least once a month)"
            ],
            "Latvia": [
                "Data is submitted once a year"
            ],
            "Iceland": [
                "Data is submitted continuously or with close regular intervals (at least once a month)"
            ],
            "Bulgaria": [
                "Other"
            ]
        }
    },
    "42.9": {
        "title": "Which of the following types of surveillance systems are in place nationally and used for AMR surveillance? (Tick all that apply) CML: Clinical Microbiological Laboratory NRL: National Reference or Expert Laboratory The focus of this question is on what type of systems are in place and used for AMR surveillance for at least one of the included pathogens. The focus should not be on the coverage of the submitted data in this question, (i.e. how many laboratories or hospitals contribute data to a particular system). : Laboratory statistics aggregated data: CMLs can submit data on pathogens under surveillance in aggregated form. : Frequency of submission",
        "short_title": "Laboratories can submit data on pathogens under surveillance in aggregated form - Frequency of submission ",
        "type": "MultipleChoice",
        "coefficient": 0,
        "tags": [
            "National surveillance"
        ],
        "possible_answers": {
            "Data is submitted continuously or with close regular intervals (at least once a month)": "null",
            "Data is submitted once a year": "null",
            "Other": "null"
        },
        "actual_answers": {
            "Spain": [
                "Data is submitted once a year"
            ],
            "Austria": [
                "Data is submitted once a year"
            ],
            "Lithuania": [
                ""
            ],
            "Croatia": [
                "Data is submitted once a year"
            ],
            "Netherlands": [
                ""
            ],
            "Ireland": [
                ""
            ],
            "Germany": [
                "Which of the following types of surveillance systems are in place nationally and used for AMR surveillance? (Tick all that apply) CML: Clinical Microbiological Laboratory NRL: National Reference or Expert Laboratory The focus of this question is on what type of systems are in place and used for AMR surveillance for at least one of the included pathogens. The focus should not be on the coverage of the submitted data in this question, (i.e. how many laboratories or hospitals contribute data to a particular system). : Laboratory isolate based: CMLs can submit data on pathogens under surveillance. Data is structured in one row per isolate. : In place"
            ],
            "Poland": [
                "Data is submitted once a year"
            ],
            "Italy": [
                ""
            ],
            "Greece": [
                "Data is submitted continuously or with close regular intervals (at least once a month)"
            ],
            "France": [
                ""
            ],
            "Czechia": [
                "Data is submitted once a year"
            ],
            "Belgium": [
                "Data is submitted once a year"
            ],
            "Hungary": [
                ""
            ],
            "Finland": [
                ""
            ],
            "Luxembourg": [
                ""
            ],
            "Malta": [
                ""
            ],
            "Portugal": [
                "Data is submitted continuously or with close regular intervals (at least once a month)",
                "Data is submitted once a year"
            ],
            "Norway": [
                ""
            ],
            "Slovenia": [
                "Data is submitted once a year"
            ],
            "Estonia": [
                ""
            ],
            "Sweden": [
                ""
            ],
            "Ukraine": [
                "Other"
            ],
            "Slovak Republic": [
                "Other"
            ],
            "Denmark": [
                "Data is submitted continuously or with close regular intervals (at least once a month)"
            ],
            "Latvia": [
                "Data is submitted once a year"
            ],
            "Iceland": [
                "Other"
            ],
            "Bulgaria": [
                "Data is submitted once a year"
            ]
        }
    },
    "42.10": {
        "title": "Which of the following types of surveillance systems are in place nationally and used for AMR surveillance? (Tick all that apply) CML: Clinical Microbiological Laboratory NRL: National Reference or Expert Laboratory The focus of this question is on what type of systems are in place and used for AMR surveillance for at least one of the included pathogens. The focus should not be on the coverage of the submitted data in this question, (i.e. how many laboratories or hospitals contribute data to a particular system). : Laboratory number of isolates: CMLs can submit data for a specific number of pathogens under surveillance : Frequency of submission",
        "short_title": "Laboratories can submit data for a specific number of pathogens under surveillance - Frequency of submission ",
        "type": "MultipleChoice",
        "coefficient": 0,
        "tags": [
            "National surveillance"
        ],
        "possible_answers": {
            "Data is submitted continuously or with close regular intervals (at least once a month)": "null",
            "Data is submitted once a year": "null",
            "Other": "null"
        },
        "actual_answers": {
            "Spain": [
                "Data is submitted continuously or with close regular intervals (at least once a month)"
            ],
            "Austria": [
                ""
            ],
            "Lithuania": [
                ""
            ],
            "Croatia": [
                "Data is submitted once a year"
            ],
            "Netherlands": [
                ""
            ],
            "Ireland": [
                "Data is submitted once a year"
            ],
            "Germany": [
                ""
            ],
            "Poland": [
                "Data is submitted once a year"
            ],
            "Italy": [
                "Other"
            ],
            "Greece": [
                "Data is submitted continuously or with close regular intervals (at least once a month)"
            ],
            "France": [
                ""
            ],
            "Czechia": [
                "Data is submitted continuously or with close regular intervals (at least once a month)",
                "Data is submitted once a year"
            ],
            "Belgium": [
                "Data is submitted once a year",
                "Other"
            ],
            "Hungary": [
                "Data is submitted once a year"
            ],
            "Finland": [
                "Data is submitted once a year"
            ],
            "Luxembourg": [
                ""
            ],
            "Malta": [
                ""
            ],
            "Portugal": [
                "Data is submitted continuously or with close regular intervals (at least once a month)"
            ],
            "Norway": [
                "Data is submitted once a year"
            ],
            "Slovenia": [
                ""
            ],
            "Estonia": [
                ""
            ],
            "Sweden": [
                ""
            ],
            "Ukraine": [
                "Other"
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Data is submitted continuously or with close regular intervals (at least once a month)"
            ],
            "Latvia": [
                "Data is submitted once a year"
            ],
            "Iceland": [
                "Other"
            ],
            "Bulgaria": [
                "Data is submitted once a year"
            ]
        }
    },
    "42.11": {
        "title": "Which of the following types of surveillance systems are in place nationally and used for AMR surveillance? (Tick all that apply) CML: Clinical Microbiological Laboratory NRL: National Reference or Expert Laboratory The focus of this question is on what type of systems are in place and used for AMR surveillance for at least one of the included pathogens. The focus should not be on the coverage of the submitted data in this question, (i.e. how many laboratories or hospitals contribute data to a particular system). : Patient/case based: Hospitals/treating physicians (or equivalent) can submit data for cases with pathogens under surveillance. Data is structured in one row per case. : Frequency of submission",
        "short_title": "Hospitals/treating physicians can submit data for cases with pathogens under surveillance - Frequency of submission ",
        "type": "MultipleChoice",
        "coefficient": 0,
        "tags": [
            "National surveillance"
        ],
        "possible_answers": {
            "Data is submitted continuously or with close regular intervals (at least once a month)": "null",
            "Data is submitted once a year": "null",
            "Other": "null"
        },
        "actual_answers": {
            "Spain": [
                "Data is submitted once a year"
            ],
            "Austria": [
                ""
            ],
            "Lithuania": [
                ""
            ],
            "Croatia": [
                ""
            ],
            "Netherlands": [
                "Data is submitted continuously or with close regular intervals (at least once a month)"
            ],
            "Ireland": [
                ""
            ],
            "Germany": [
                "Data is submitted continuously or with close regular intervals (at least once a month)"
            ],
            "Poland": [
                "Data is submitted continuously or with close regular intervals (at least once a month)"
            ],
            "Italy": [
                "Data is submitted continuously or with close regular intervals (at least once a month)",
                "Data is submitted once a year"
            ],
            "Greece": [
                "Data is submitted continuously or with close regular intervals (at least once a month)"
            ],
            "France": [
                ""
            ],
            "Czechia": [
                "Data is submitted continuously or with close regular intervals (at least once a month)"
            ],
            "Belgium": [
                "Data is submitted once a year"
            ],
            "Hungary": [
                "Data is submitted continuously or with close regular intervals (at least once a month)"
            ],
            "Finland": [
                "Data is submitted continuously or with close regular intervals (at least once a month)"
            ],
            "Luxembourg": [
                ""
            ],
            "Malta": [
                ""
            ],
            "Portugal": [
                "Other"
            ],
            "Norway": [
                "Data is submitted continuously or with close regular intervals (at least once a month)"
            ],
            "Slovenia": [
                ""
            ],
            "Estonia": [
                ""
            ],
            "Sweden": [
                "Data is submitted continuously or with close regular intervals (at least once a month)"
            ],
            "Ukraine": [
                ""
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Data is submitted continuously or with close regular intervals (at least once a month)"
            ],
            "Latvia": [
                "Other"
            ],
            "Iceland": [
                "Data is submitted continuously or with close regular intervals (at least once a month)"
            ],
            "Bulgaria": [
                ""
            ]
        }
    },
    "42.12": {
        "title": "Which of the following types of surveillance systems are in place nationally and used for AMR surveillance? (Tick all that apply) CML: Clinical Microbiological Laboratory NRL: National Reference or Expert Laboratory The focus of this question is on what type of systems are in place and used for AMR surveillance for at least one of the included pathogens. The focus should not be on the coverage of the submitted data in this question, (i.e. how many laboratories or hospitals contribute data to a particular system). : Hospital patient aggregated data:  Hospitals can submit aggregated data with information about the cases. : Frequency of submission",
        "short_title": "Hospitals can submit aggregated data with information about the cases - Frequency of submission ",
        "type": "MultipleChoice",
        "coefficient": 0,
        "tags": [
            "National surveillance"
        ],
        "possible_answers": {
            "Data is submitted continuously or with close regular intervals (at least once a month)": "null",
            "Data is submitted once a year": "null",
            "Other": "null"
        },
        "actual_answers": {
            "Spain": [
                ""
            ],
            "Austria": [
                ""
            ],
            "Lithuania": [
                ""
            ],
            "Croatia": [
                "Data is submitted once a year"
            ],
            "Netherlands": [
                ""
            ],
            "Ireland": [
                ""
            ],
            "Germany": [
                ""
            ],
            "Poland": [
                "Data is submitted continuously or with close regular intervals (at least once a month)"
            ],
            "Italy": [
                "Other"
            ],
            "Greece": [
                "Data is submitted continuously or with close regular intervals (at least once a month)"
            ],
            "France": [
                ""
            ],
            "Czechia": [
                ""
            ],
            "Belgium": [
                "Data is submitted once a year"
            ],
            "Hungary": [
                ""
            ],
            "Finland": [
                ""
            ],
            "Luxembourg": [
                ""
            ],
            "Malta": [
                ""
            ],
            "Portugal": [
                "Other"
            ],
            "Norway": [
                ""
            ],
            "Slovenia": [
                ""
            ],
            "Estonia": [
                ""
            ],
            "Sweden": [
                ""
            ],
            "Ukraine": [
                ""
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Data is submitted continuously or with close regular intervals (at least once a month)"
            ],
            "Latvia": [
                "Data is submitted once a year"
            ],
            "Iceland": [
                ""
            ],
            "Bulgaria": [
                ""
            ]
        }
    },
    "42.13": {
        "title": "Which of the following types of surveillance systems are in place nationally and used for AMR surveillance? (Tick all that apply) CML: Clinical Microbiological Laboratory NRL: National Reference or Expert Laboratory The focus of this question is on what type of systems are in place and used for AMR surveillance for at least one of the included pathogens. The focus should not be on the coverage of the submitted data in this question, (i.e. how many laboratories or hospitals contribute data to a particular system). : Laboratory isolate based: CMLs can submit data on pathogens under surveillance. Data is structured in one row per isolate. : Format for submission",
        "short_title": "Laboratories can submit data on pathogens under surveillance - Format for submission",
        "type": "MultipleChoice",
        "coefficient": 0,
        "tags": [
            "National surveillance"
        ],
        "possible_answers": {
            "Data is submitted automatically/semi-automatically via direct integrations": "null",
            "Data is submitted manually directly into digital system/database": "null",
            "Data is reported digitally in electronic files (e.g., spread sheets or text)": "null",
            "Data is reported in paper format": "null",
            "Other": "null"
        },
        "actual_answers": {
            "Spain": [
                "Data is submitted manually directly into digital system/database"
            ],
            "Austria": [
                "Data is reported digitally in electronic files (e.g., spread sheets or text)",
                "Data is reported in paper format"
            ],
            "Lithuania": [
                "Data is reported digitally in electronic files (e.g., spread sheets or text)",
                "Data is reported in paper format"
            ],
            "Croatia": [
                "Data is submitted automatically/semi-automatically via direct integrations",
                "Data is submitted manually directly into digital system/database"
            ],
            "Netherlands": [
                "Data is submitted automatically/semi-automatically via direct integrations",
                "Data is submitted manually directly into digital system/database",
                "Data is reported digitally in electronic files (e.g., spread sheets or text)"
            ],
            "Ireland": [
                "Data is reported digitally in electronic files (e.g., spread sheets or text)"
            ],
            "Germany": [
                "Data is submitted automatically/semi-automatically via direct integrations"
            ],
            "Poland": [
                "Data is reported digitally in electronic files (e.g., spread sheets or text)"
            ],
            "Italy": [
                "Data is reported digitally in electronic files (e.g., spread sheets or text)"
            ],
            "Greece": [
                "Data is submitted automatically/semi-automatically via direct integrations",
                "Data is reported in paper format"
            ],
            "France": [
                "Data is submitted manually directly into digital system/database",
                "Data is reported digitally in electronic files (e.g., spread sheets or text)"
            ],
            "Czechia": [
                ""
            ],
            "Belgium": [
                "Data is submitted manually directly into digital system/database",
                "Data is reported digitally in electronic files (e.g., spread sheets or text)"
            ],
            "Hungary": [
                "Data is submitted automatically/semi-automatically via direct integrations",
                "Data is reported digitally in electronic files (e.g., spread sheets or text)"
            ],
            "Finland": [
                "Data is submitted automatically/semi-automatically via direct integrations",
                "Data is reported digitally in electronic files (e.g., spread sheets or text)"
            ],
            "Luxembourg": [
                "Data is reported digitally in electronic files (e.g., spread sheets or text)"
            ],
            "Malta": [
                "Data is submitted automatically/semi-automatically via direct integrations",
                "Data is reported digitally in electronic files (e.g., spread sheets or text)"
            ],
            "Portugal": [
                "Data is reported digitally in electronic files (e.g., spread sheets or text)"
            ],
            "Norway": [
                "Data is submitted automatically/semi-automatically via direct integrations",
                "Data is submitted manually directly into digital system/database"
            ],
            "Slovenia": [
                "Data is reported digitally in electronic files (e.g., spread sheets or text)"
            ],
            "Estonia": [
                "Data is submitted automatically/semi-automatically via direct integrations"
            ],
            "Sweden": [
                "Data is submitted automatically/semi-automatically via direct integrations",
                "Data is submitted manually directly into digital system/database"
            ],
            "Ukraine": [
                "Data is reported digitally in electronic files (e.g., spread sheets or text)"
            ],
            "Slovak Republic": [
                "Data is reported digitally in electronic files (e.g., spread sheets or text)"
            ],
            "Denmark": [
                ""
            ],
            "Latvia": [
                "Data is reported digitally in electronic files (e.g., spread sheets or text)"
            ],
            "Iceland": [
                "Data is submitted automatically/semi-automatically via direct integrations"
            ],
            "Bulgaria": [
                "Other"
            ]
        }
    },
    "42.14": {
        "title": "Which of the following types of surveillance systems are in place nationally and used for AMR surveillance? (Tick all that apply) CML: Clinical Microbiological Laboratory NRL: National Reference or Expert Laboratory The focus of this question is on what type of systems are in place and used for AMR surveillance for at least one of the included pathogens. The focus should not be on the coverage of the submitted data in this question, (i.e. how many laboratories or hospitals contribute data to a particular system). : Laboratory statistics aggregated data: CMLs can submit data on pathogens under surveillance in aggregated form. : Format for submission",
        "short_title": "Laboratories can submit data on pathogens under surveillance in aggregated form - Format for submission",
        "type": "MultipleChoice",
        "coefficient": 0,
        "tags": [
            "National surveillance"
        ],
        "possible_answers": {
            "Data is submitted automatically/semi-automatically via direct integrations": "null",
            "Data is submitted manually directly into digital system/database": "null",
            "Data is reported digitally in electronic files (e.g., spread sheets or text)": "null",
            "Data is reported in paper format": "null",
            "Other": "null"
        },
        "actual_answers": {
            "Spain": [
                "Data is submitted manually directly into digital system/database"
            ],
            "Austria": [
                "Data is reported digitally in electronic files (e.g., spread sheets or text)",
                "Data is reported in paper format"
            ],
            "Lithuania": [
                ""
            ],
            "Croatia": [
                "Data is submitted manually directly into digital system/database"
            ],
            "Netherlands": [
                ""
            ],
            "Ireland": [
                ""
            ],
            "Germany": [
                ""
            ],
            "Poland": [
                "Data is submitted manually directly into digital system/database",
                "Data is reported digitally in electronic files (e.g., spread sheets or text)",
                "Data is reported in paper format"
            ],
            "Italy": [
                ""
            ],
            "Greece": [
                "Data is submitted automatically/semi-automatically via direct integrations",
                "Data is reported in paper format"
            ],
            "France": [
                ""
            ],
            "Czechia": [
                "Data is reported digitally in electronic files (e.g., spread sheets or text)",
                "Data is reported in paper format"
            ],
            "Belgium": [
                "Data is submitted manually directly into digital system/database",
                "Data is reported digitally in electronic files (e.g., spread sheets or text)"
            ],
            "Hungary": [
                ""
            ],
            "Finland": [
                ""
            ],
            "Luxembourg": [
                ""
            ],
            "Malta": [
                ""
            ],
            "Portugal": [
                "Data is reported digitally in electronic files (e.g., spread sheets or text)"
            ],
            "Norway": [
                ""
            ],
            "Slovenia": [
                "Data is reported in paper format"
            ],
            "Estonia": [
                ""
            ],
            "Sweden": [
                ""
            ],
            "Ukraine": [
                "Data is submitted manually directly into digital system/database"
            ],
            "Slovak Republic": [
                "Data is reported digitally in electronic files (e.g., spread sheets or text)"
            ],
            "Denmark": [
                "Data is submitted automatically/semi-automatically via direct integrations"
            ],
            "Latvia": [
                "Data is reported digitally in electronic files (e.g., spread sheets or text)"
            ],
            "Iceland": [
                "Data is reported digitally in electronic files (e.g., spread sheets or text)"
            ],
            "Bulgaria": [
                "Data is reported digitally in electronic files (e.g., spread sheets or text)"
            ]
        }
    },
    "42.15": {
        "title": "Which of the following types of surveillance systems are in place nationally and used for AMR surveillance? (Tick all that apply) CML: Clinical Microbiological Laboratory NRL: National Reference or Expert Laboratory The focus of this question is on what type of systems are in place and used for AMR surveillance for at least one of the included pathogens. The focus should not be on the coverage of the submitted data in this question, (i.e. how many laboratories or hospitals contribute data to a particular system). : Laboratory periodic isolates: CMLs can submit data for pathogens under surveillance during a specific time period. : Format for submission",
        "short_title": "Laboratories can submit data for pathogens under surveillance during a specific time period - Format for submission",
        "type": "MultipleChoice",
        "coefficient": 0,
        "tags": [
            "National surveillance"
        ],
        "possible_answers": {
            "Data is submitted automatically/semi-automatically via direct integrations": "null",
            "Data is submitted manually directly into digital system/database": "null",
            "Data is reported digitally in electronic files (e.g., spread sheets or text)": "null",
            "Data is reported in paper format": "null",
            "Other": "null"
        },
        "actual_answers": {
            "Spain": [
                "Data is submitted manually directly into digital system/database"
            ],
            "Austria": [
                "Data is reported digitally in electronic files (e.g., spread sheets or text)",
                "Data is reported in paper format"
            ],
            "Lithuania": [
                "Data is reported digitally in electronic files (e.g., spread sheets or text)"
            ],
            "Croatia": [
                "Data is reported digitally in electronic files (e.g., spread sheets or text)"
            ],
            "Netherlands": [
                ""
            ],
            "Ireland": [
                ""
            ],
            "Germany": [
                "Data is submitted automatically/semi-automatically via direct integrations"
            ],
            "Poland": [
                ""
            ],
            "Italy": [
                "Data is reported digitally in electronic files (e.g., spread sheets or text)",
                "Other"
            ],
            "Greece": [
                "Data is reported in paper format"
            ],
            "France": [
                ""
            ],
            "Czechia": [
                "Data is reported digitally in electronic files (e.g., spread sheets or text)",
                "Data is reported in paper format"
            ],
            "Belgium": [
                "Data is submitted manually directly into digital system/database",
                "Data is reported digitally in electronic files (e.g., spread sheets or text)"
            ],
            "Hungary": [
                "Data is reported digitally in electronic files (e.g., spread sheets or text)"
            ],
            "Finland": [
                "Data is reported digitally in electronic files (e.g., spread sheets or text)"
            ],
            "Luxembourg": [
                ""
            ],
            "Malta": [
                ""
            ],
            "Portugal": [
                "Data is reported digitally in electronic files (e.g., spread sheets or text)"
            ],
            "Norway": [
                "Data is submitted manually directly into digital system/database"
            ],
            "Slovenia": [
                "Data is reported in paper format"
            ],
            "Estonia": [
                ""
            ],
            "Sweden": [
                ""
            ],
            "Ukraine": [
                ""
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Data is submitted automatically/semi-automatically via direct integrations"
            ],
            "Latvia": [
                "Data is submitted manually directly into digital system/database"
            ],
            "Iceland": [
                "Data is reported digitally in electronic files (e.g., spread sheets or text)"
            ],
            "Bulgaria": [
                "Other"
            ]
        }
    },
    "42.16": {
        "title": "Which of the following types of surveillance systems are in place nationally and used for AMR surveillance? (Tick all that apply) CML: Clinical Microbiological Laboratory NRL: National Reference or Expert Laboratory The focus of this question is on what type of systems are in place and used for AMR surveillance for at least one of the included pathogens. The focus should not be on the coverage of the submitted data in this question, (i.e. how many laboratories or hospitals contribute data to a particular system). : Laboratory number of isolates: CMLs can submit data for a specific number of pathogens under surveillance : Format for submission",
        "short_title": "Laboratories can submit data for a specific number of pathogens under surveillance - Format for submission",
        "type": "MultipleChoice",
        "coefficient": 0,
        "tags": [
            "National surveillance"
        ],
        "possible_answers": {
            "Data is submitted automatically/semi-automatically via direct integrations": "null",
            "Data is submitted manually directly into digital system/database": "null",
            "Data is reported digitally in electronic files (e.g., spread sheets or text)": "null",
            "Data is reported in paper format": "null",
            "Other": "null"
        },
        "actual_answers": {
            "Spain": [
                "Data is submitted manually directly into digital system/database"
            ],
            "Austria": [
                ""
            ],
            "Lithuania": [
                ""
            ],
            "Croatia": [
                "Data is submitted automatically/semi-automatically via direct integrations",
                "Data is submitted manually directly into digital system/database"
            ],
            "Netherlands": [
                ""
            ],
            "Ireland": [
                "Data is reported digitally in electronic files (e.g., spread sheets or text)"
            ],
            "Germany": [
                "Data is submitted automatically/semi-automatically via direct integrations"
            ],
            "Poland": [
                "Data is submitted manually directly into digital system/database",
                "Data is reported digitally in electronic files (e.g., spread sheets or text)",
                "Data is reported in paper format"
            ],
            "Italy": [
                "Data is submitted manually directly into digital system/database",
                "Data is reported digitally in electronic files (e.g., spread sheets or text)"
            ],
            "Greece": [
                "Data is submitted automatically/semi-automatically via direct integrations",
                "Data is reported in paper format"
            ],
            "France": [
                ""
            ],
            "Czechia": [
                "Data is submitted manually directly into digital system/database",
                "Data is reported digitally in electronic files (e.g., spread sheets or text)",
                "Data is reported in paper format"
            ],
            "Belgium": [
                "Data is submitted manually directly into digital system/database",
                "Data is reported digitally in electronic files (e.g., spread sheets or text)"
            ],
            "Hungary": [
                "Data is reported digitally in electronic files (e.g., spread sheets or text)"
            ],
            "Finland": [
                "Data is reported digitally in electronic files (e.g., spread sheets or text)"
            ],
            "Luxembourg": [
                ""
            ],
            "Malta": [
                ""
            ],
            "Portugal": [
                "Data is reported digitally in electronic files (e.g., spread sheets or text)"
            ],
            "Norway": [
                "Data is submitted manually directly into digital system/database"
            ],
            "Slovenia": [
                "Data is reported in paper format"
            ],
            "Estonia": [
                ""
            ],
            "Sweden": [
                ""
            ],
            "Ukraine": [
                "Data is submitted manually directly into digital system/database"
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Data is submitted automatically/semi-automatically via direct integrations"
            ],
            "Latvia": [
                "Data is submitted manually directly into digital system/database"
            ],
            "Iceland": [
                "Data is reported digitally in electronic files (e.g., spread sheets or text)"
            ],
            "Bulgaria": [
                "Data is reported digitally in electronic files (e.g., spread sheets or text)"
            ]
        }
    },
    "42.17": {
        "title": "Which of the following types of surveillance systems are in place nationally and used for AMR surveillance? (Tick all that apply) CML: Clinical Microbiological Laboratory NRL: National Reference or Expert Laboratory The focus of this question is on what type of systems are in place and used for AMR surveillance for at least one of the included pathogens. The focus should not be on the coverage of the submitted data in this question, (i.e. how many laboratories or hospitals contribute data to a particular system). : Patient/case based: Hospitals/treating physicians (or equivalent) can submit data for cases with pathogens under surveillance. Data is structured in one row per case. : Format for submission",
        "short_title": "Hospitals/treating physicians can submit data for cases with pathogens under surveillance - Format for submission",
        "type": "MultipleChoice",
        "coefficient": 0,
        "tags": [
            "National surveillance"
        ],
        "possible_answers": {
            "Data is submitted automatically/semi-automatically via direct integrations": "null",
            "Data is submitted manually directly into digital system/database": "null",
            "Data is reported digitally in electronic files (e.g., spread sheets or text)": "null",
            "Data is reported in paper format": "null",
            "Other": "null"
        },
        "actual_answers": {
            "Spain": [
                "Data is submitted manually directly into digital system/database"
            ],
            "Austria": [
                ""
            ],
            "Lithuania": [
                ""
            ],
            "Croatia": [
                ""
            ],
            "Netherlands": [
                "Data is submitted manually directly into digital system/database"
            ],
            "Ireland": [
                ""
            ],
            "Germany": [
                "Data is submitted automatically/semi-automatically via direct integrations"
            ],
            "Poland": [
                "Data is reported digitally in electronic files (e.g., spread sheets or text)",
                "Data is reported in paper format"
            ],
            "Italy": [
                "Data is submitted manually directly into digital system/database"
            ],
            "Greece": [
                "Data is reported in paper format"
            ],
            "France": [
                ""
            ],
            "Czechia": [
                "Data is reported digitally in electronic files (e.g., spread sheets or text)",
                "Data is reported in paper format"
            ],
            "Belgium": [
                "Data is submitted manually directly into digital system/database",
                "Data is reported digitally in electronic files (e.g., spread sheets or text)"
            ],
            "Hungary": [
                "Data is submitted manually directly into digital system/database"
            ],
            "Finland": [
                "Data is submitted automatically/semi-automatically via direct integrations"
            ],
            "Luxembourg": [
                ""
            ],
            "Malta": [
                ""
            ],
            "Portugal": [
                "Other"
            ],
            "Norway": [
                "Data is submitted automatically/semi-automatically via direct integrations",
                "Data is submitted manually directly into digital system/database"
            ],
            "Slovenia": [
                ""
            ],
            "Estonia": [
                ""
            ],
            "Sweden": [
                "Data is submitted automatically/semi-automatically via direct integrations",
                "Data is submitted manually directly into digital system/database"
            ],
            "Ukraine": [
                ""
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Data is submitted manually directly into digital system/database"
            ],
            "Latvia": [
                "Data is reported digitally in electronic files (e.g., spread sheets or text)"
            ],
            "Iceland": [
                "Data is reported in paper format"
            ],
            "Bulgaria": [
                ""
            ]
        }
    },
    "42.18": {
        "title": "Which of the following types of surveillance systems are in place nationally and used for AMR surveillance? (Tick all that apply) CML: Clinical Microbiological Laboratory NRL: National Reference or Expert Laboratory The focus of this question is on what type of systems are in place and used for AMR surveillance for at least one of the included pathogens. The focus should not be on the coverage of the submitted data in this question, (i.e. how many laboratories or hospitals contribute data to a particular system). : Hospital patient aggregated data:  Hospitals can submit aggregated data with information about the cases. : Format for submission",
        "short_title": "Hospitals can submit aggregated data with information about the cases - Format for submission",
        "type": "MultipleChoice",
        "coefficient": 0,
        "tags": [
            "National surveillance"
        ],
        "possible_answers": {
            "Data is submitted automatically/semi-automatically via direct integrations": "null",
            "Data is submitted manually directly into digital system/database": "null",
            "Data is reported digitally in electronic files (e.g., spread sheets or text)": "null",
            "Data is reported in paper format": "null",
            "Other": "null"
        },
        "actual_answers": {
            "Spain": [
                ""
            ],
            "Austria": [
                ""
            ],
            "Lithuania": [
                ""
            ],
            "Croatia": [
                "Data is submitted manually directly into digital system/database"
            ],
            "Netherlands": [
                ""
            ],
            "Ireland": [
                ""
            ],
            "Germany": [
                ""
            ],
            "Poland": [
                "Data is reported digitally in electronic files (e.g., spread sheets or text)",
                "Data is reported in paper format"
            ],
            "Italy": [
                ""
            ],
            "Greece": [
                "Data is reported in paper format"
            ],
            "France": [
                ""
            ],
            "Czechia": [
                ""
            ],
            "Belgium": [
                "Data is submitted manually directly into digital system/database",
                "Data is reported digitally in electronic files (e.g., spread sheets or text)"
            ],
            "Hungary": [
                ""
            ],
            "Finland": [
                ""
            ],
            "Luxembourg": [
                ""
            ],
            "Malta": [
                ""
            ],
            "Portugal": [
                "Other"
            ],
            "Norway": [
                ""
            ],
            "Slovenia": [
                ""
            ],
            "Estonia": [
                ""
            ],
            "Sweden": [
                ""
            ],
            "Ukraine": [
                ""
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Data is submitted manually directly into digital system/database"
            ],
            "Latvia": [
                "Data is reported digitally in electronic files (e.g., spread sheets or text)"
            ],
            "Iceland": [
                ""
            ],
            "Bulgaria": [
                ""
            ]
        }
    },
    "42.19": {
        "title": "Which of the following types of surveillance systems are in place nationally and used for AMR surveillance? (Tick all that apply) CML: Clinical Microbiological Laboratory NRL: National Reference or Expert Laboratory The focus of this question is on what type of systems are in place and used for AMR surveillance for at least one of the included pathogens. The focus should not be on the coverage of the submitted data in this question, (i.e. how many laboratories or hospitals contribute data to a particular system). : Laboratory NRL data: The NRL can submit data for pathogens under surveillance. : In place",
        "short_title": "The NRL can submit data for pathogens under surveillance - In place",
        "type": "SingleChoice",
        "coefficient": 0.5,
        "tags": [
            "National surveillance"
        ],
        "possible_answers": {
            "Yes": 1,
            "No": 0
        },
        "actual_answers": {
            "Spain": "Yes",
            "Austria": "Yes",
            "Lithuania": "Yes",
            "Croatia": "Yes",
            "Netherlands": "Yes",
            "Ireland": "No",
            "Germany": "Yes",
            "Poland": "Yes",
            "Italy": "Yes",
            "Greece": "Yes",
            "France": "Yes",
            "Czechia": "Yes",
            "Belgium": "Yes",
            "Hungary": "Yes",
            "Finland": "Yes",
            "Luxembourg": "Yes",
            "Malta": "No",
            "Portugal": "Yes",
            "Norway": "Yes",
            "Slovenia": "No",
            "Estonia": "Yes",
            "Sweden": "Yes",
            "Ukraine": "Yes",
            "Slovak Republic": "No",
            "Denmark": "Yes",
            "Latvia": "Yes",
            "Iceland": "Yes",
            "Bulgaria": "No"
        }
    },
    "42.20": {
        "title": "Which of the following types of surveillance systems are in place nationally and used for AMR surveillance? (Tick all that apply) CML: Clinical Microbiological Laboratory NRL: National Reference or Expert Laboratory The focus of this question is on what type of systems are in place and used for AMR surveillance for at least one of the included pathogens. The focus should not be on the coverage of the submitted data in this question, (i.e. how many laboratories or hospitals contribute data to a particular system). : Laboratory NRL data: The NRL can submit data for pathogens under surveillance. : Frequency of submission",
        "short_title": "The NRL can submit data for pathogens under surveillance - Frequency of submission ",
        "type": "MultipleChoice",
        "coefficient": 0,
        "tags": [
            "National surveillance"
        ],
        "possible_answers": {
            "Data is submitted continuously or with close regular intervals (at least once a month)": 0,
            "Data is submitted once a year": "null",
            "Other": "null"
        },
        "actual_answers": {
            "Spain": [
                "Data is submitted continuously or with close regular intervals (at least once a month)"
            ],
            "Austria": [
                "Data is submitted continuously or with close regular intervals (at least once a month)",
                "Data is submitted once a year"
            ],
            "Lithuania": [
                "Data is submitted once a year"
            ],
            "Croatia": [
                "Data is submitted once a year"
            ],
            "Netherlands": [
                "Data is submitted once a year"
            ],
            "Ireland": [
                ""
            ],
            "Germany": [
                "Other"
            ],
            "Poland": [
                "Data is submitted once a year"
            ],
            "Italy": [
                "Data is submitted once a year",
                "Other"
            ],
            "Greece": [
                "Other"
            ],
            "France": [
                "Data is submitted continuously or with close regular intervals (at least once a month)"
            ],
            "Czechia": [
                "Data is submitted continuously or with close regular intervals (at least once a month)",
                "Data is submitted once a year"
            ],
            "Belgium": [
                "Data is submitted continuously or with close regular intervals (at least once a month)",
                "Data is submitted once a year",
                "Other"
            ],
            "Hungary": [
                "Data is submitted continuously or with close regular intervals (at least once a month)"
            ],
            "Finland": [
                "Data is submitted continuously or with close regular intervals (at least once a month)"
            ],
            "Luxembourg": [
                "Data is submitted continuously or with close regular intervals (at least once a month)"
            ],
            "Malta": [
                ""
            ],
            "Portugal": [
                "Data is submitted once a year"
            ],
            "Norway": [
                "Data is submitted continuously or with close regular intervals (at least once a month)"
            ],
            "Slovenia": [
                ""
            ],
            "Estonia": [
                "Data is submitted continuously or with close regular intervals (at least once a month)"
            ],
            "Sweden": [
                "Data is submitted once a year"
            ],
            "Ukraine": [
                "Other"
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Data is submitted once a year"
            ],
            "Latvia": [
                ""
            ],
            "Iceland": [
                "Data is submitted continuously or with close regular intervals (at least once a month)"
            ],
            "Bulgaria": [
                ""
            ]
        }
    },
    "42.21": {
        "title": "Which of the following types of surveillance systems are in place nationally and used for AMR surveillance? (Tick all that apply) CML: Clinical Microbiological Laboratory NRL: National Reference or Expert Laboratory The focus of this question is on what type of systems are in place and used for AMR surveillance for at least one of the included pathogens. The focus should not be on the coverage of the submitted data in this question, (i.e. how many laboratories or hospitals contribute data to a particular system). : Laboratory NRL data: The NRL can submit data for pathogens under surveillance. : Format for submission",
        "short_title": "The NRL can submit data for pathogens under surveillance - Format for submission",
        "type": "MultipleChoice",
        "coefficient": 0,
        "tags": [
            "National surveillance"
        ],
        "possible_answers": {
            "Data is submitted automatically/semi-automatically via direct integrations": "null",
            "Data is submitted manually directly into digital system/database": "null",
            "Data is reported digitally in electronic files (e.g., spread sheets or text)": "null",
            "Data is reported in paper format": "null",
            "Other": "null"
        },
        "actual_answers": {
            "Spain": [
                "Data is submitted manually directly into digital system/database"
            ],
            "Austria": [
                "Data is reported digitally in electronic files (e.g., spread sheets or text)"
            ],
            "Lithuania": [
                "Data is submitted automatically/semi-automatically via direct integrations"
            ],
            "Croatia": [
                "Data is submitted automatically/semi-automatically via direct integrations"
            ],
            "Netherlands": [
                "Data is reported digitally in electronic files (e.g., spread sheets or text)"
            ],
            "Ireland": [
                ""
            ],
            "Germany": [
                "Data is reported digitally in electronic files (e.g., spread sheets or text)",
                "Data is reported in paper format"
            ],
            "Poland": [
                "Data is reported digitally in electronic files (e.g., spread sheets or text)",
                "Data is reported in paper format"
            ],
            "Italy": [
                ""
            ],
            "Greece": [
                "Data is submitted automatically/semi-automatically via direct integrations"
            ],
            "France": [
                "Data is reported digitally in electronic files (e.g., spread sheets or text)"
            ],
            "Czechia": [
                "Data is submitted manually directly into digital system/database",
                "Data is reported digitally in electronic files (e.g., spread sheets or text)"
            ],
            "Belgium": [
                "Data is submitted manually directly into digital system/database",
                "Data is reported digitally in electronic files (e.g., spread sheets or text)"
            ],
            "Hungary": [
                "Data is submitted automatically/semi-automatically via direct integrations"
            ],
            "Finland": [
                "Data is submitted manually directly into digital system/database"
            ],
            "Luxembourg": [
                "Data is reported digitally in electronic files (e.g., spread sheets or text)"
            ],
            "Malta": [
                ""
            ],
            "Portugal": [
                "Data is reported digitally in electronic files (e.g., spread sheets or text)"
            ],
            "Norway": [
                "Data is submitted automatically/semi-automatically via direct integrations",
                "Data is submitted manually directly into digital system/database"
            ],
            "Slovenia": [
                ""
            ],
            "Estonia": [
                "Data is reported digitally in electronic files (e.g., spread sheets or text)"
            ],
            "Sweden": [
                "Data is reported digitally in electronic files (e.g., spread sheets or text)"
            ],
            "Ukraine": [
                "Other"
            ],
            "Slovak Republic": [
                ""
            ],
            "Denmark": [
                "Data is reported digitally in electronic files (e.g., spread sheets or text)"
            ],
            "Latvia": [
                "Data is submitted manually directly into digital system/database"
            ],
            "Iceland": [
                "Data is submitted automatically/semi-automatically via direct integrations"
            ],
            "Bulgaria": [
                ""
            ]
        }
    },
    "43": {
        "title": "If there is more than one surveillance system encompassing the national AMR surveillance, can data from the different systems be linked on case/isolate level nationally? (Tick all that apply) Question refers only to systems on national level that contains data relating to human cases with the included pathogens.",
        "short_title": "Can data from different surveillance systems be linked on case/isolate level nationally?",
        "type": "MultipleChoice",
        "coefficient": 1,
        "tags": [
            "National surveillance"
        ],
        "possible_answers": {
            "There is no need, one system collects all information at national level": 1,
            "Yes, data from all our national AMR surveillance systems can be linked.": 1,
            "Yes, data from some of our national AMR surveillance systems can be linked.": 0.3,
            "Data could be linked but legal issues prohibit the linkage.": 0,
            "No, systems are lacking common identifier to link the data on case/isolate level.": 0,
            "No, other reason.": 0,
            "Do not know.": "null"
        },
        "actual_answers": {
            "Spain": [
                "No, systems are lacking common identifier to link the data on case/isolate level."
            ],
            "Austria": [
                "Do not know."
            ],
            "Lithuania": [
                "There is no need, one system collects all information at national level"
            ],
            "Croatia": [
                "No, systems are lacking common identifier to link the data on case/isolate level."
            ],
            "Netherlands": [
                "Yes, data from some of our national AMR surveillance systems can be linked.",
                "No, systems are lacking common identifier to link the data on case/isolate level.",
                "No, other reason."
            ],
            "Ireland": [
                "Yes, data from all our national AMR surveillance systems can be linked."
            ],
            "Germany": [
                "Yes, data from some of our national AMR surveillance systems can be linked."
            ],
            "Poland": [
                "Yes, data from some of our national AMR surveillance systems can be linked."
            ],
            "Italy": [
                "No, systems are lacking common identifier to link the data on case/isolate level."
            ],
            "Greece": [
                "No, systems are lacking common identifier to link the data on case/isolate level."
            ],
            "France": [
                "No, systems are lacking common identifier to link the data on case/isolate level."
            ],
            "Czechia": [
                "No, systems are lacking common identifier to link the data on case/isolate level.",
                "No, other reason."
            ],
            "Belgium": [
                "Yes, data from some of our national AMR surveillance systems can be linked.",
                "Data could be linked but legal issues prohibit the linkage.",
                "No, systems are lacking common identifier to link the data on case/isolate level."
            ],
            "Hungary": [
                "No, systems are lacking common identifier to link the data on case/isolate level."
            ],
            "Finland": [
                "Yes, data from some of our national AMR surveillance systems can be linked."
            ],
            "Luxembourg": [
                "There is no need, one system collects all information at national level"
            ],
            "Malta": [
                "Yes, data from all our national AMR surveillance systems can be linked."
            ],
            "Portugal": [
                "Data could be linked but legal issues prohibit the linkage.",
                "No, systems are lacking common identifier to link the data on case/isolate level."
            ],
            "Norway": [
                "Yes, data from all our national AMR surveillance systems can be linked."
            ],
            "Slovenia": [
                "There is no need, one system collects all information at national level"
            ],
            "Estonia": [
                "There is no need, one system collects all information at national level"
            ],
            "Sweden": [
                "No, systems are lacking common identifier to link the data on case/isolate level."
            ],
            "Ukraine": [
                "No, systems are lacking common identifier to link the data on case/isolate level."
            ],
            "Slovak Republic": [
                "There is no need, one system collects all information at national level"
            ],
            "Denmark": [
                "There is no need, one system collects all information at national level"
            ],
            "Latvia": [
                "No, systems are lacking common identifier to link the data on case/isolate level."
            ],
            "Iceland": [
                "There is no need, one system collects all information at national level"
            ],
            "Bulgaria": [
                "There is no need, one system collects all information at national level"
            ]
        }
    },
    "44": {
        "title": "You answered \"No, other reason\" to the previous question if data from different systems can be linked on case/isolate level nationally?Please specify the reason.",
        "short_title": "",
        "type": "FreeText",
        "coefficient": 0,
        "tags": [
            "National surveillance"
        ],
        "possible_answers": {},
        "actual_answers": {
            "Spain": "",
            "Austria": "",
            "Lithuania": "",
            "Croatia": "",
            "Netherlands": "The current situation is a combination of 2 answers:\r\nPart of the data can be linked, based on limited patient data, and part of the data can not be linked, because in those cases, the limited patient data is insufficient to link with certainty, and in general systems are lacking a common identifier to link the data on case/isolate level.",
            "Ireland": "",
            "Germany": "",
            "Poland": "",
            "Italy": "",
            "Greece": "",
            "France": "",
            "Czechia": "For example, we only collect aggregate data from some patogenes/specimens. There cannot by linked with sample/patient oriented surveillance.",
            "Belgium": "",
            "Hungary": "",
            "Finland": "",
            "Luxembourg": "",
            "Malta": "",
            "Portugal": "",
            "Norway": "",
            "Slovenia": "",
            "Estonia": "",
            "Sweden": "",
            "Ukraine": "",
            "Slovak Republic": "",
            "Denmark": "",
            "Latvia": "",
            "Iceland": "",
            "Bulgaria": ""
        }
    },
    "45": {
        "title": "How is data from your national AMR surveillance system(s) made publicly available? (Tick all that apply).  Please select the options that best describe your situation.",
        "short_title": "How is data from national AMR surveillance system(s) made publicly available? ",
        "type": "MultipleChoice",
        "coefficient": 1,
        "tags": [
            "National surveillance"
        ],
        "possible_answers": {
            "Data is published automatically in a real-time dashboard via direct integration between the AMR surveillance system and the dashboard.": 1,
            "Data is published in regular intervals in a dashboard after data has been analyzed and processed. Requires manual steps for analysis and data migration.": 1,
            "Data is published in regular intervals, either weekly or monthly, in e.g., tables on a webpage, or a published newsletter or report.": 1,
            "Data is published annually in a non-interactive online and/or printed report format.": 0.5,
            "A national analysis of current trends and possible explanations for increases and decreases for AMR pathogens is published with regular intervals.": 0.5,
            "No publication of national AMR surveillance data.": 0,
            "Other (free text in next question)": 0
        },
        "actual_answers": {
            "Spain": [
                "Data is published annually in a non-interactive online and/or printed report format.",
                "No publication of national AMR surveillance data.",
                "Other (free text in next question)"
            ],
            "Austria": [
                "Data is published annually in a non-interactive online and/or printed report format."
            ],
            "Lithuania": [
                "Data is published annually in a non-interactive online and/or printed report format."
            ],
            "Croatia": [
                "Data is published annually in a non-interactive online and/or printed report format."
            ],
            "Netherlands": [
                "Data is published in regular intervals in a dashboard after data has been analyzed and processed. Requires manual steps for analysis and data migration.",
                "Data is published annually in a non-interactive online and/or printed report format.",
                "A national analysis of current trends and possible explanations for increases and decreases for AMR pathogens is published with regular intervals."
            ],
            "Ireland": [
                "Other (free text in next question)"
            ],
            "Germany": [
                "Data is published annually in a non-interactive online and/or printed report format."
            ],
            "Poland": [
                "Data is published in regular intervals, either weekly or monthly, in e.g., tables on a webpage, or a published newsletter or report.",
                "Data is published annually in a non-interactive online and/or printed report format.",
                "A national analysis of current trends and possible explanations for increases and decreases for AMR pathogens is published with regular intervals."
            ],
            "Italy": [
                "Data is published annually in a non-interactive online and/or printed report format."
            ],
            "Greece": [
                "Other (free text in next question)"
            ],
            "France": [
                "Data is published in regular intervals in a dashboard after data has been analyzed and processed. Requires manual steps for analysis and data migration.",
                "Data is published annually in a non-interactive online and/or printed report format.",
                "A national analysis of current trends and possible explanations for increases and decreases for AMR pathogens is published with regular intervals."
            ],
            "Czechia": [
                "Data is published annually in a non-interactive online and/or printed report format."
            ],
            "Belgium": [
                "Data is published annually in a non-interactive online and/or printed report format."
            ],
            "Hungary": [
                "Data is published annually in a non-interactive online and/or printed report format."
            ],
            "Finland": [
                "Data is published automatically in a real-time dashboard via direct integration between the AMR surveillance system and the dashboard.",
                "Data is published annually in a non-interactive online and/or printed report format.",
                "A national analysis of current trends and possible explanations for increases and decreases for AMR pathogens is published with regular intervals."
            ],
            "Luxembourg": [
                "Data is published annually in a non-interactive online and/or printed report format."
            ],
            "Malta": [
                "A national analysis of current trends and possible explanations for increases and decreases for AMR pathogens is published with regular intervals.",
                "Other (free text in next question)"
            ],
            "Portugal": [
                "Data is published annually in a non-interactive online and/or printed report format."
            ],
            "Norway": [
                "Data is published in regular intervals in a dashboard after data has been analyzed and processed. Requires manual steps for analysis and data migration.",
                "Data is published in regular intervals, either weekly or monthly, in e.g., tables on a webpage, or a published newsletter or report.",
                "Data is published annually in a non-interactive online and/or printed report format.",
                "A national analysis of current trends and possible explanations for increases and decreases for AMR pathogens is published with regular intervals."
            ],
            "Slovenia": [
                "Data is published annually in a non-interactive online and/or printed report format."
            ],
            "Estonia": [
                "Data is published annually in a non-interactive online and/or printed report format."
            ],
            "Sweden": [
                "Data is published automatically in a real-time dashboard via direct integration between the AMR surveillance system and the dashboard.",
                "Data is published annually in a non-interactive online and/or printed report format.",
                "A national analysis of current trends and possible explanations for increases and decreases for AMR pathogens is published with regular intervals."
            ],
            "Ukraine": [
                "No publication of national AMR surveillance data."
            ],
            "Slovak Republic": [
                "Data is published in regular intervals in a dashboard after data has been analyzed and processed. Requires manual steps for analysis and data migration."
            ],
            "Denmark": [
                "Data is published in regular intervals, either weekly or monthly, in e.g., tables on a webpage, or a published newsletter or report.",
                "Data is published annually in a non-interactive online and/or printed report format.",
                "A national analysis of current trends and possible explanations for increases and decreases for AMR pathogens is published with regular intervals."
            ],
            "Latvia": [
                "Data is published annually in a non-interactive online and/or printed report format."
            ],
            "Iceland": [
                "Data is published annually in a non-interactive online and/or printed report format."
            ],
            "Bulgaria": [
                "Data is published annually in a non-interactive online and/or printed report format.",
                "A national analysis of current trends and possible explanations for increases and decreases for AMR pathogens is published with regular intervals."
            ]
        }
    },
    "46": {
        "title": "You answered other in the previous question regarding the publication of AMR surveillance data. Please specify.",
        "short_title": "",
        "type": "FreeText",
        "coefficient": 0,
        "tags": [
            "National surveillance"
        ],
        "possible_answers": {},
        "actual_answers": {
            "Spain": "To understand Spanish national surveillance and the answers to the survey, please note that within RENAVE, which is the National Epidemiological Surveillance Network, coordinated by the CCAES and managed by the CNE, the following are monitored: Carbapenemase-producing enterobacteria, S. aureus meticillin R and C.difficile. Surveillance is carried out based on the patient and clinical samples, not contact tracing. This is mandatory surveillance.\r\nHowever, within Spanish participation in EARS-Net a voluntary surveillance on all the above data is performed. \r\n\r\nThere are also several questions we would like to clarify: \r\n\r\nQ 37: We answered \"others\" because in the national surveillance network for resistant microorganisms, RedLabRA (https://cnm.isciii.es/redlabra) genotypic confirmation of resistance mechanisms is carried out by certain laboratories nominated by each Autonomous Community (CCAA) and also by the NRL (N2)\r\n\r\nQ 45: Annual reports are published that include surveillance data on antimicrobial susceptibility (EARS-Net, https://repisalud.isciii.es/entities/publication/4d4b2e90-c3a2-4b66-9b36-2b97c47f3a57 ) and the analysis of genotypic data (RedLabRA, https://cnm.isciii.es/redlabra; https://repisalud.isciii.es/entities/publication/3593c2bb-3343-4db9-bb1c-c244dc262815).",
            "Austria": "",
            "Lithuania": "",
            "Croatia": "",
            "Netherlands": "",
            "Ireland": "Data are validated and analysed on an annual basis. National reports are prepared for EARS-Net pathogens and CPE (all new cases of CPE, from infection or colonisation, are notifiable in Ireland). Individual laboratory feedback, with latest 5-yearly trends, is also provided. An interactive database on S. aureus/MRSA BSI with data by acute hospital is published on HPSC\u2019s website.",
            "Germany": "",
            "Poland": "",
            "Italy": "",
            "Greece": "Data is published biannually in a non-interactive online format.",
            "France": "",
            "Czechia": "",
            "Belgium": "",
            "Hungary": "",
            "Finland": "",
            "Luxembourg": "",
            "Malta": "in the ECDC atlas online",
            "Portugal": "",
            "Norway": "",
            "Slovenia": "",
            "Estonia": "",
            "Sweden": "",
            "Ukraine": "",
            "Slovak Republic": "",
            "Denmark": "",
            "Latvia": "",
            "Iceland": "",
            "Bulgaria": ""
        }
    },
    "47": {
        "title": "Which are the main factors effecting completeness of the laboratory AST and/or genotypic resistance data in the national AMR surveillance system(s)? (Tick all that apply, max four options)Data completeness in this context refers to aspects such as: Coverage (if the collected data is representative for the population under surveillance) and uniformity (if the data is collected, processed and analyzed in a comparable manner).",
        "short_title": "Main factors effecting completeness of laboratory AST/genotypic resistance data?",
        "type": "MultipleChoice",
        "coefficient": 0,
        "tags": [
            "National surveillance"
        ],
        "possible_answers": {
            "The indicators and/or frequency for when a clinical sample is taken for microbiological culture varies between healthcare facilities \u2013 makes it hard to know if measured resistance levels are representative.": "null",
            "Lack of harmonization of methods at clinical microbiology laboratories \u2013 different methods generate non-comparable data.": "null",
            "Lack of harmonization of what is analyzed at the clinical microbiological laboratories \u2013 different priorities create heterogenous datasets e.g., different antibiotics are included in the routine AST.": "null",
            "Lack of resources to perform additional testing on all isolates with resistant phenotypes under surveillance \u2013 can be applicable for both clinical microbiology laboratories and/or national reference/expert laboratory.": "null",
            "Clinical microbiology laboratories lack resources and/or capacity to connect themselves to the national AMR surveillance system.": "null",
            "It is voluntary for clinical microbiological laboratories to submit data to the national AMR surveillance system(s).": "null",
            "The institution(s) responsible for the national AMR surveillance system(s) are unable to connect new clinical microbiology laboratories.": "null",
            "Decentralized systems make it difficult to build efficient structures.": "null",
            "Lack of digitalization of the national AMR surveillance system(s) makes it difficult to expand surveillance.": "null",
            "Legal obstacle(s) are preventing development of the national AMR surveillance system(s).": "null",
            "Other (free text in next question).": "null"
        },
        "actual_answers": {
            "Spain": [
                "Lack of resources to perform additional testing on all isolates with resistant phenotypes under surveillance \u2013 can be applicable for both clinical microbiology laboratories and/or national reference/expert laboratory.",
                "It is voluntary for clinical microbiological laboratories to submit data to the national AMR surveillance system(s).",
                "Decentralized systems make it difficult to build efficient structures."
            ],
            "Austria": [
                "It is voluntary for clinical microbiological laboratories to submit data to the national AMR surveillance system(s).",
                "Decentralized systems make it difficult to build efficient structures."
            ],
            "Lithuania": [
                "Lack of resources to perform additional testing on all isolates with resistant phenotypes under surveillance \u2013 can be applicable for both clinical microbiology laboratories and/or national reference/expert laboratory.",
                "Lack of digitalization of the national AMR surveillance system(s) makes it difficult to expand surveillance."
            ],
            "Croatia": [
                "Lack of digitalization of the national AMR surveillance system(s) makes it difficult to expand surveillance.;"
            ],
            "Netherlands": [
                "Clinical microbiology laboratories lack resources and/or capacity to connect themselves to the national AMR surveillance system.",
                "It is voluntary for clinical microbiological laboratories to submit data to the national AMR surveillance system(s).",
                "Legal obstacle(s) are preventing development of the national AMR surveillance system(s).",
                "Other (free text in next question)."
            ],
            "Ireland": [
                "Lack of digitalization of the national AMR surveillance system(s) makes it difficult to expand surveillance.",
                "Other (free text in next question)."
            ],
            "Germany": [
                "The indicators and/or frequency for when a clinical sample is taken for microbiological culture varies between healthcare facilities \u2013 makes it hard to know if measured resistance levels are representative.",
                "Lack of harmonization of methods at clinical microbiology laboratories \u2013 different methods generate non-comparable data.",
                "Lack of harmonization of what is analyzed at the clinical microbiological laboratories \u2013 different priorities create heterogenous datasets e.g., different antibiotics are included in the routine AST.",
                "Lack of resources to perform additional testing on all isolates with resistant phenotypes under surveillance \u2013 can be applicable for both clinical microbiology laboratories and/or national reference/expert laboratory."
            ],
            "Poland": [
                "Lack of resources to perform additional testing on all isolates with resistant phenotypes under surveillance \u2013 can be applicable for both clinical microbiology laboratories and/or national reference/expert laboratory.",
                "It is voluntary for clinical microbiological laboratories to submit data to the national AMR surveillance system(s).",
                "Lack of digitalization of the national AMR surveillance system(s) makes it difficult to expand surveillance.",
                "Legal obstacle(s) are preventing development of the national AMR surveillance system(s)."
            ],
            "Italy": [
                "It is voluntary for clinical microbiological laboratories to submit data to the national AMR surveillance system(s).",
                "Legal obstacle(s) are preventing development of the national AMR surveillance system(s).",
                "Other (free text in next question)."
            ],
            "Greece": [
                "The indicators and/or frequency for when a clinical sample is taken for microbiological culture varies between healthcare facilities \u2013 makes it hard to know if measured resistance levels are representative.",
                "Clinical microbiology laboratories lack resources and/or capacity to connect themselves to the national AMR surveillance system.",
                "Lack of digitalization of the national AMR surveillance system(s) makes it difficult to expand surveillance."
            ],
            "France": [
                "It is voluntary for clinical microbiological laboratories to submit data to the national AMR surveillance system(s)."
            ],
            "Czechia": [
                "Lack of harmonization of what is analyzed at the clinical microbiological laboratories \u2013 different priorities create heterogenous datasets e.g., different antibiotics are included in the routine AST.",
                "Clinical microbiology laboratories lack resources and/or capacity to connect themselves to the national AMR surveillance system.",
                "It is voluntary for clinical microbiological laboratories to submit data to the national AMR surveillance system(s).",
                "Lack of digitalization of the national AMR surveillance system(s) makes it difficult to expand surveillance."
            ],
            "Belgium": [
                "It is voluntary for clinical microbiological laboratories to submit data to the national AMR surveillance system(s).",
                "Decentralized systems make it difficult to build efficient structures.",
                "Legal obstacle(s) are preventing development of the national AMR surveillance system(s)."
            ],
            "Hungary": [
                "Lack of resources to perform additional testing on all isolates with resistant phenotypes under surveillance \u2013 can be applicable for both clinical microbiology laboratories and/or national reference/expert laboratory."
            ],
            "Finland": [
                "Clinical microbiology laboratories lack resources and/or capacity to connect themselves to the national AMR surveillance system.",
                "Lack of digitalization of the national AMR surveillance system(s) makes it difficult to expand surveillance.",
                "Legal obstacle(s) are preventing development of the national AMR surveillance system(s)."
            ],
            "Luxembourg": [
                "The indicators and/or frequency for when a clinical sample is taken for microbiological culture varies between healthcare facilities \u2013 makes it hard to know if measured resistance levels are representative.",
                "It is voluntary for clinical microbiological laboratories to submit data to the national AMR surveillance system(s).",
                "Lack of digitalization of the national AMR surveillance system(s) makes it difficult to expand surveillance.",
                "Legal obstacle(s) are preventing development of the national AMR surveillance system(s)."
            ],
            "Malta": [
                "The indicators and/or frequency for when a clinical sample is taken for microbiological culture varies between healthcare facilities \u2013 makes it hard to know if measured resistance levels are representative.",
                "Lack of resources to perform additional testing on all isolates with resistant phenotypes under surveillance \u2013 can be applicable for both clinical microbiology laboratories and/or national reference/expert laboratory.",
                "Other (free text in next question)."
            ],
            "Portugal": [
                "Decentralized systems make it difficult to build efficient structures.",
                "Lack of digitalization of the national AMR surveillance system(s) makes it difficult to expand surveillance.",
                "Legal obstacle(s) are preventing development of the national AMR surveillance system(s)."
            ],
            "Norway": [
                "Lack of digitalization of the national AMR surveillance system(s) makes it difficult to expand surveillance.",
                "",
                "Legal obstacle(s) are preventing development of the national AMR surveillance system(s).;"
            ],
            "Slovenia": [
                "It is voluntary for clinical microbiological laboratories to submit data to the national AMR surveillance system(s).",
                "Lack of digitalization of the national AMR surveillance system(s) makes it difficult to expand surveillance.",
                "Legal obstacle(s) are preventing development of the national AMR surveillance system(s)."
            ],
            "Estonia": [
                "Other (free text in next question)."
            ],
            "Sweden": [
                "Lack of harmonization of what is analyzed at the clinical microbiological laboratories \u2013 different priorities create heterogenous datasets e.g., different antibiotics are included in the routine AST.",
                "It is voluntary for clinical microbiological laboratories to submit data to the national AMR surveillance system(s).",
                "Decentralized systems make it difficult to build efficient structures."
            ],
            "Ukraine": [
                "Lack of resources to perform additional testing on all isolates with resistant phenotypes under surveillance \u2013 can be applicable for both clinical microbiology laboratories and/or national reference/expert laboratory.",
                "Lack of digitalization of the national AMR surveillance system(s) makes it difficult to expand surveillance.",
                "Other (free text in next question)."
            ],
            "Slovak Republic": [
                "Lack of resources to perform additional testing on all isolates with resistant phenotypes under surveillance \u2013 can be applicable for both clinical microbiology laboratories and/or national reference/expert laboratory.",
                "Clinical microbiology laboratories lack resources and/or capacity to connect themselves to the national AMR surveillance system.",
                "Decentralized systems make it difficult to build efficient structures.",
                "Legal obstacle(s) are preventing development of the national AMR surveillance system(s)."
            ],
            "Denmark": [
                "Lack of harmonization of what is analyzed at the clinical microbiological laboratories \u2013 different priorities create heterogenous datasets e.g., different antibiotics are included in the routine AST.",
                "Lack of resources to perform additional testing on all isolates with resistant phenotypes under surveillance \u2013 can be applicable for both clinical microbiology laboratories and/or national reference/expert laboratory."
            ],
            "Latvia": [
                "Lack of resources to perform additional testing on all isolates with resistant phenotypes under surveillance \u2013 can be applicable for both clinical microbiology laboratories and/or national reference/expert laboratory.",
                "Clinical microbiology laboratories lack resources and/or capacity to connect themselves to the national AMR surveillance system.",
                "Decentralized systems make it difficult to build efficient structures.;"
            ],
            "Iceland": [
                "Clinical microbiology laboratories lack resources and/or capacity to connect themselves to the national AMR surveillance system.",
                "It is voluntary for clinical microbiological laboratories to submit data to the national AMR surveillance system(s).",
                "Decentralized systems make it difficult to build efficient structures."
            ],
            "Bulgaria": [
                "The indicators and/or frequency for when a clinical sample is taken for microbiological culture varies between healthcare facilities \u2013 makes it hard to know if measured resistance levels are representative.",
                "Lack of harmonization of what is analyzed at the clinical microbiological laboratories \u2013 different priorities create heterogenous datasets e.g., different antibiotics are included in the routine AST.",
                "Lack of resources to perform additional testing on all isolates with resistant phenotypes under surveillance \u2013 can be applicable for both clinical microbiology laboratories and/or national reference/expert laboratory.",
                "Legal obstacle(s) are preventing development of the national AMR surveillance system(s)."
            ]
        }
    },
    "48": {
        "title": "You answered other in the previous question on factors affecting completeness of laboratory AST data.Please specify.",
        "short_title": "",
        "type": "FreeText",
        "coefficient": 0,
        "tags": [
            "National surveillance"
        ],
        "possible_answers": {},
        "actual_answers": {
            "Spain": "",
            "Austria": "",
            "Lithuania": "",
            "Croatia": "",
            "Netherlands": "I answered 'Legal obstacle(s).....' because most of the systems are lacking a common identifier (citizen service number) as a result of legal obstacles, which makes it more difficult to link data from different sources on case/isolate level.",
            "Ireland": "Despite most EARS-Net pathogens, and CPE, being notifiable in Ireland, staffing and other resources in laboratories mean that labs sometimes are unable to participate in this, and other, surveillance. In terms of automation, there are still a number of obstacles to streamlining data collection at the national level, including the lack of a national patient identifier. A national strategy to address the issues is required.\r\n\r\nPlease note some infections (e.g. H.influenzae, invasive) are notifiable regardless of AMR status and responses here try to capture that information (e.g. lack of AST information collected) accurately. ",
            "Germany": "",
            "Poland": "",
            "Italy": "- Laboratory Information System (LIS) are different among laboratories and it is difficult to aggregate data in real time\r\n- Inability to link with clinical data and hospital discharge records, and genomic data with AMR data\r\n",
            "Greece": "",
            "France": "",
            "Czechia": "",
            "Belgium": "",
            "Hungary": "",
            "Finland": "",
            "Luxembourg": "",
            "Malta": "clinical data is missing. there is the need for an EHR system that can be linked to the LIS and the patient administration system. so far linkage between the last two in manual.",
            "Portugal": "",
            "Norway": "",
            "Slovenia": "",
            "Estonia": "Some part of the data recieved from labs to AMR surveillance systems is structured differently and it makes the time-consuming, manual and complicated to analyze the data.",
            "Sweden": "",
            "Ukraine": "1. Lack of resources, equipment and personnel.\r\n\r\n2. Many small, decentralized laboratories with varying levels of available resources.\r\n\r\nLow level of awareness among clinicians about indications for bacteriological testing (lack of national guidelines), resulting in very low ammount of data for surveillance",
            "Slovak Republic": "",
            "Denmark": "",
            "Latvia": "",
            "Iceland": "",
            "Bulgaria": ""
        }
    }
}
